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INVESTIGATION OF BURSAE IN THE FOREFOOT OF PATIENTS WITH 
RHEUMATOID ARTHRITIS USING MUSCULOSKELETAL ULTRASOUND 
IMAGING PERFORMED BY A PODIATRIST 
 
by Catherine Jane Bowen 
 
Patients with rheumatoid arthritis (RA) frequently present with pain under their feet. 
Forefoot bursae can give rise to such symptoms, but are rarely investigated. The aim of this 
thesis was to use musculoskeletal ultrasound (MSUS) performed by a podiatrist to evaluate 
the prevalence and natural history of bursae in the forefoot in RA patients. 
Once reliability of technique was established, a longitudinal study design was used 
in which a sample of RA patients (N=149) and a comparator group (N=50) of healthy 
individuals were assessed at baseline. A Diasus MSUS system was used to image the 
forefeet of all participants to determine prevalence of bursae. 120 patients (98 female, 22 
male) with RA (24 seronegative, 93 seropositive, 3 unknown) completed the study at 
twelve months: mean age 60.7 (SD 12.1) years and disease duration 12.99 (10.4) years.  
Results confirmed a high prevalence of forefoot bursae (92.6% of patients; mean 
per individual =3.54, range 0-9) and that these were often missed by clinical examination. 
Findings that there could be an association between patient reported foot impact scales of 
impairment/footwear (LFISIF) and activity participation restriction/limitation (LFISAP) and 
presence of bursae (LFISIF β=0.377, p=0.033; LFISAP β=0.762, p=0.013) independent of 
disease activity were unique. On examination of prospective data after one year, 25.8% of 
participants had increases in bursae and 23.3% decreases. There was a significant 
correlation between changes in bursae with changes in LFISIF (PCC=0.216, p=0.018) and 
LFISAP (PCC=0.193, p=0.036) and a significant negative correlation with changes in 
duration of RA (PCC=-0.269, p=0.003).  
The findings imply that MSUS detectable bursae in the forefeet are highly 
prevalent, clinically under-reported and change over time.  The findings suggest that bursae 
within the foot in RA deserve increased clinical attention and that further work is required 
to confirm associations with patient reported foot impact outcome measures.   iii
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1.0. Chapter One: Introduction to the Thesis 
This thesis presents the work carried out to date as a post-graduate research student with the 
School of Health Sciences, University of Southampton. The thesis forms the requirement for 
Doctor of Philosophy. 
 
In my clinical experience as a podiatrist, palpable and often painful swelling, attributed to 
bursae under the forefoot in patients with rheumatoid arthritis (RA) is a common complaint 
that is difficult to treat. Management of this problem is primarily aimed at deflecting 
pressure away from the affected areas. The treatment, however, is based on the notion that 
the aetiology of swollen bursae in the plantar forefoot area is mechanically derived, 
although there is very little research evidence to support this. In fact, patients’ foot status 
and bursal swelling in many observed cases appear to become worse over time and do not 
respond to the intervention.  
 
On questioning this further, it was clear that literature regarding bursae within the forefoot 
was confusing and, inevitably, that treatment was often mis-informed and less likely to be 
successful. At the beginning of the study, musculoskeletal ultrasound (MSUS) was 
emerging as a new diagnostic technique that was reported as superior to clinical 
examination in identifying soft tissue swelling. The technique was largely performed by 
non-radiologists, namely rheumatologists and no podiatrists had developed this within their 
practice. The stages of this doctoral thesis therefore follow a sequential programme of 
original work. A new scope of practice for podiatrists in the use of MSUS has been 
introduced and the prevalence and natural history of bursae within the forefoot in RA have 
subsequently been described using MSUS performed by a podiatrist. 
 
 
1.1. Overview of the research problem 
Foot health providers, such as podiatrists, have a prime role to play in the assessment and 
management of musculoskeletal foot and ankle pathology (ARMA 2008; NICE 2009). 
Rheumatoid Arthritis (RA) commonly affects the feet, causing swelling and pain that reduces 
a person’s mobility (Costa, Rizack et al 2004). There is radiological evidence that the first 
signs of rheumatological disease may appear in the foot in about 20% of patients who have 
RA (Paimela 1992) and that rheumatoid involvement of the feet is as frequent as, or more   2
frequent than, that of the hands (Isomaki, Kaarela et al 1988).   
 
Patients who have RA, however, rarely report foot problems (Williams and Bowden 2004) 
although what is not currently known is why this is the case. It might be possible that, due to 
the global nature of the disease process of RA, feet are not as important as other joints in this 
patient population.  
 
Most evidence of the manifestations of RA disease within the foot is attributable to cross-
sectional analytical data; longitudinal studies of manifestations of RA disease, within the foot 
and ankle, are rare. Accordingly, there remains a limited understanding of the full patho-
physiology of this chronic disease within the foot and thus a relatively inadequate evidence 
base for currently used clinical interventions (Bowen, Burridge and Arden 2005; Farrow, 
Kingsley et al 2005; Clark, Rome et al 2006; van der Leeden, Steultjens et al 2008). Usually 
it is synovitis that is investigated and investigation of changes in disease state may include 
synovitis within the metatarso-phalangeal (MTP) joints, although do not necessarily form the 
main focus of studies (Ejbjerg, Vestergaard et al 2005; Naredo, Bonilla et al 2005; Joshua, 
Lassere et al 2007; van der Heijde, Landewe et al 2008). To our knowledge, no study has 
included forefoot bursae as potential confounding factors with MTP joint synovitis within the 
analyses. 
 
Consequently the roles of inflamed soft tissues, such as bursae, in the process of RA and the 
resulting impact on foot disability and function are undetermined. Olivieri, Scarano et al 
(2004) highlighted that bursitis in the forefoot was poorly documented and emphasised the 
importance of rheumatologists being aware of the existence of numerous small, synovial 
bursae in the forefoot that may be difficult to detect clinically and be the cause of persistent 
pain. The findings from Brown, O’Connor et al (2006) in defining competency within 
musculoskeletal ultrasound (MSUS) concur, suggesting more specifically that the presence of 
bursitis between the metatarsal heads of the forefoot (intermetatarsal bursitis) was classified 
as ‘must know’ by rheumatologists.  
 
Whilst bursae may be an important feature of the forefoot in RA, the terminology of forefoot 
bursitis within the literature is confusing. Some describe all bursae as fibrous sacs filled with 
synovial fluid (Saladin 2004) and others conversely describe the existence of two main types 
of bursa, anatomical bursae and adventitious bursae (Warwick, Williams et al 1973) or   3
convey bursae as being classified according to type (anatomical or adventitious), location, or 
nature (pathological or non pathological) (Hernandez, Hernandez and Hernandez 1991). It is 
possible that the lack of definition of forefoot bursae and consequent lack of identification of 
their aetiology could mean that treatment may be delayed or be inappropriate. 
 
According to Warwick, Williams et al (1973), anatomical bursae are naturally occurring 
bursae that contain a capillary film of synovial fluid that acts as a lubricant and provides the 
cells of their synovial membrane with a wet environment on their free surfaces. Arguably, the 
synovium of anatomical bursae therefore may be susceptible to the pathological processes of 
RA (Palmer 1995; O'Brien, Hart et al 1997; Narvaez, Narvaez et al 2002). Within the plantar 
forefoot area four anatomical bursae are described as existing between the metatarsal heads in 
the intermetatarsal spaces (Theumann, Pfirrmann et al 2001). Adventitious bursae, on the 
other hand, are said to occur within the subcutaneous tissues or the plantar fat pad of the 
plantar forefoot and have no synovial lining (Hernandez, Hernandez and Hernandez 1991; 
Studler et al 2008). Differentiating adventitious bursae formation from anatomical bursae 
formation however is difficult unless confirmed by histology.  
 
As technology has advanced for clinical diagnosis, MRI appears to give good detail on the 
differential diagnosis of swollen bursae from other inflammatory soft tissue pathologies 
that may occur within the forefoot (Bancroft, Peterson and Kransdorf 2008). MSUS is also 
promising in identifying forefoot bursitis (Koski et al 1998). Interestingly, Koski (1998) 
demonstrated a high prevalence of intermetatarsal bursitis within patients with early RA 
that were not clinically apparent (Koski et al 1998). Other work using MSUS has also 
highlighted a high presence of synovitis that was not clinically apparent in patients with RA 
(Brown, Quinn et al 2006) and within patients with oligoarthritis (Wakefield, Green et al 
2004). 
 
It has been suggested that results from MSUS investigations challenge current classifications 
of rheumatological disease (Bresnihan and Kane 2004). The new information revealed by 
MSUS can be attributed to the dramatic advancement in technology that has led to improved 
clinical expertise in performing MSUS (Gibbon 1996; O’Connor and Grainger 2002). MSUS 
imaging has advantages over conventional radiography, computed tomography, radioisotope 
scan and MRI (Magnetic Resonance Imaging) in that it is painless, does not use ionizing 
radiation, is less expensive, can be performed in real time and is clinically readily accessible   4
(Gibbon 1996). 
 
MSUS imaging could be more clinically useful in determining foot status prior to podiatric 
treatment interventions than existing tools such as gait assessment and foot pressure 
measurement, which have emerged as useful outcome measures for interventions associated 
with foot and ankle pain (Budiman-Mak, Conrad et al 1995; Conrad, Budiman-Mak et al 
1996; Fransen and Edmonds 1997; Hodge, Bach et al 1999; Macsween, Brysdon et al 1999; 
Chalmers, Busby et al 2000; Woodburn, Stableford et al 2000; Woodburn, Barker et al 2002; 
Turner, Helliwell et al 2008). Gait analysis and foot pressure measurement techniques are 
based on assessment of biomechanical influences that rely on the bony alignment of the foot 
joints and therapy is aimed at pain and pressure relief from customary clinical observations. 
Further knowledge of the status of soft tissues within the foot, especially within a chronic 
fluctuating disease such as RA, would allow better targeted therapeutic approaches, such as 
localised corticosteroid injection. 
 
There have been a number of studies that have utilised MSUS to diagnose specific soft tissue 
foot pain in a range of different patient groups (Brown, Betts et al 1994; Bygrave, Betts et al 
1998; Irwin, Konstantoulakis et al 2000) and soft tissue problems in RA (Coakley, Samanta 
et al 1994). More specifically for the forefoot, MSUS findings of MTP joint synovitis (Koski 
1990; Szkudlarek, Narvestad et al 2004), plantar flexor tenosynovitis (Koski 1995) and 
plantar bursitis have been described (Koski 1998).  
 
In the discipline of the podiatrist, foot health clinician or foot and ankle surgeon MSUS has, 
however, been deemed to be an under-utilised tool (Rockett 1999, Bowen 2003). Darzi 
(2008) recognises that delivery of modern health care will require crossing of traditional 
professional boundaries. It therefore follows that the ability of a suitably trained podiatrist to 
use and apply the techniques of real time diagnostic MSUS imaging within their consultations 
has great potential for enhancing the current assessment–referral pathways (ARMA 2008).   
 
However, MSUS is affirmed as being highly operator dependent (Grassi and Cervini 1998). 
The procedure itself has no known specific side effects, although mis-diagnosis that may 
result from incorrect acquisition and interpretation of images has been highlighted as a 
potential risk (O’Connor and Grainger 2002). The reported challenges in training for this skill 
are primarily due to the quality and interpretation of the MSUS images, which are   5
acknowledged as being greatly dependent on the expertise and experience of the operator 
(Balint and Sturrock 1997). Knowledge about the basic principles relevant to sound waves 
and a detailed anatomical knowledge of the structures under investigation are therefore 
mandatory (Backhaus, Burmester et al 2001). 
 
Models for the use of MSUS by clinicians other than radiologists, have been demonstrated 
(Filippucci, Unlu et al 2003; Taggart, Filippucci et al 2006) and specific competencies for 
MSUS performed by non radiologists have been rigorously developed (Brown, O’Connor et 
al 2005; Brown, O’Connor et al 2006; Brown, Roberts et al 2007). The most recently 
proposed framework for development of competencies in MSUS scanning techniques 
recognises the challenges of training and recommends that learning is tailored to areas 
directly relevant to a clinician’s discrete field of practice (Brown, Roberts et al 2007). 
 
The use of MSUS assessment of the foot and ankle as a discrete field in podiatric clinical 
practice could thus be beneficial to patients with RA by facilitating more effective timely 
referral and management of foot problems.  Additionally, there are perceived benefits to 
service providers, in lower costs. Robust diagnostic MSUS imaging studies of foot pathology 
will be an essential element in the development of such emerging clinical practices.  
 
According to Bell and McNally (2002) the majority of musculoskeletal structures in the foot 
and ankle are relatively superficial, so they can be effectively imaged by MSUS. However, in 
recent reviews of podiatry interventions for the rheumatoid foot, none of the included studies 
utilised MSUS imaging techniques to assess severity and activity of inflammation within the 
foot joints (Bowen 2005; Farrow, Kingsley et al 2005; Clark, Rome et al 2006). 
 
Using MSUS, Koski (1998) suggested that forefoot bursae in RA could be associated with 
forefoot symptoms but did not prove this within his small cross sectional study. In the 
absence of larger studies and longitudinal data, the relationship between forefoot bursae, 
poor clinical symptoms and foot disability therefore remains speculative. This becomes 
important in considering the clinical implications of forefoot bursae in causing 
metatarsalgia and consequent foot disability. Usually, in longitudinal studies, it is MTP 
joint synovitis or tenosynovitis that has been linked to metatarsalgia in patients with RA 
(Welsing, van Gestel et al 2001; Ødegard, Landewe et al 2006; van der Heijde, Landewe et 
al 2008; van der Leeden, Steultjens et al 2008). The lack of consideration of forefoot bursae   6
as a potential confounding variable in metatarsalgia within these studies may be a 
significant omission.  
 
If non-invasive clinical palpation of the plantar metatarsal area is relatively insensitive for 
swollen forefoot bursae in RA disease, it is likely that diagnosis of foot symptoms may be 
delayed (Koski 1998). However, the evidence that suggests forefoot bursae are highly 
prevalent and clinically important in RA forefoot disease is currently limited. It therefore 
seems fundamental to clearly define the prevalence of forefoot bursae in a large population 
of patients with RA and to investigate the natural history of this over time. There is also a 
reasonable argument that the use of MSUS imaging performed by a podiatrist to achieve 
this has good potential. 
 
1.2. Summary of thesis chapters 
Chapter one has given an overview of the research problem and rationale for the studies. 
Forefoot bursae, as well as MTP joint synovitis and tenosynovitis are implicated as a cause of 
metatarsalgia within the forefoot in patients with RA. The chapter highlights that bursae 
within the forefoot in patients with RA are clinically mis-interpreted and under-investigated. 
MSUS imaging performed by a podiatrist is suggested as being a useful technique to 
investigate this further.  
 
Chapter two of this thesis will seek to explore further the background and literature review 
and will bring together thoughts from the subject material read to date and the important 
issues regarding the confusion in terminology, classification and relevance of bursae in the 
forefoot in patients with rheumatoid arthritis. The potential use of MSUS imaging performed 
by a podiatrist to detect forefoot bursae is considered. The relevance to patient care and 
clinical practice of the use of MSUS performed by a podiatrist is also highlighted. 
 
Chapter three explains the methodological approach for the programme of research study 
and the selection of study design for each phase of the work. The participant samples, MSUS 
protocols, observational outcomes, patient reported outcome measures, and statistical 
analyses are discussed and justified. 
 
Chapter four details the first phase of the programme of research study in which the MSUS   7
technique of a podiatrist is tested for reliability. The prevalence of bursae within the forefoot 
is provisionally explored as well as the ability of MSUS to detect changes in the prevalence 
of forefoot over time following intervention. The results of the investigations are discussed in 
light of current evidence and the investigation of forefoot bursae by MSUS, performed by the 
podiatrist, is justified.    
 
Chapter five presents the baseline cross sectional study of investigation of the prevalence of 
forefoot bursae in RA. The results of the study, detailing the prevalence of forefoot bursae 
detected by MSUS and by clinical examination are presented and their uniqueness discussed 
in light of current evidence. Further analyses of the associations of bursae within the forefoot 
detectable by MSUS but undetected clinically with patient reported foot symptoms are also 
presented and discussed in light of current evidence. 
 
Chapter six presents the twelve month longitudinal prospective study that explores the 
natural history of bursae within the forefoot detectable by MSUS over time. Results from the 
longitudinal data are presented and the association of MSUS detectable forefoot bursae with 
patient reported foot symptoms at baseline and twelve months are compared. Predictors of 
change in MSUS detectable forefoot bursae status over time are also analysed and discussed 
in light of current evidence. 
 
Chapter seven draws the discussions from chapters’ four, five and six together and further 
critiques each of the studies’ designs. Suggestions for improvement and plans for future 
research are proffered along with concluding remarks. 
 
 
 
 
 
 
 
 
 
 
   8
2.0 Chapter Two: Background and Literature Review 
The aim of this chapter is to introduce the background to the research study, explore the 
rationale for the study and discuss the paradigm within which the piece of work is set. The 
literature review considers the various opinions regarding the pathological processes of RA 
and the assessment of musculoskeletal pathology by diagnostic imaging. The main ideas 
behind the need to define bursitis and increase the specificity of clinical diagnosis of forefoot 
pain are also discussed. Ultimately, this review considers the need for podiatrists to perform 
diagnostic MSUS imaging of the foot and ankle in the current climate of reduced service 
provision and low numbers of musculoskeletal radiologists. 
 
2.1. Rheumatoid arthritis 
This section explains the diagnosis and definition of rheumatoid arthritis and the current 
concepts in disease progression and variation.   
2.1.1. Epidemiology 
Musculoskeletal diseases have been conveyed as the commonest cause of work-limiting 
health problems, long standing illness and sickness absence in the UK (Scott, Shipley et al 
1998). Twenty million people in the United Kingdom are reported to experience a rheumatic 
disorder with eight million consulting their General Practitioners (GPs) in 1 year (Spector and 
MacGregor 2001). Musculoskeletal disease reportedly accounts for 23% of all GP 
consultations (Spector and MacGregor 2001) with high medical costs accounting for nearly 
8% of Health Service related expenditure (Scott, Shipley et al 1998). Of the chronic 
inflammatory musculoskeletal diseases, RA is the most common, purportedly accounting for 
up to 50% of the workload of most rheumatologists (Spector and MacGregor 2001).  
 
Epidemiological aspects of RA remain difficult to estimate as Symons & Silman (2003) 
suggested there is often a delay in presentation and problems concerning case definition of 
RA, due to the cumulative aspect of the ACR (American College of Rheumatology) 
classification criteria (Arnett, Edworthy et al 1988). Information generated by NOAR (The 
Norfolk Arthritis Register) suggests that in the United Kingdom the prevalence of RA is 
estimated at one percent and its incidence at 30.8/100 000 for women and 12.7/100 000 for 
men, if up to 12 months elapsed from symptom onset to notification (Wiles, Symmons et al 
1999). When the ACR criteria is applied cumulatively over five years, annual incidence   9
estimates are higher, at 54.0/100 000 for women and 24.5/100 000 for men (Wiles, Symmons 
et al 1999).  
 
Overall, the prevalence of RA is clearly higher in females (Kvien et al 2006) although the 
prevalence of RA in women may have fallen since the 1950s (Symmons, Turner et al 2002; 
Uhlig & Kvien 2005). RA affects all races and is evident throughout the world, with a lower 
prevalence in rural Sub-Saharan Africa and Caribbean blacks and a higher prevalence in the 
Prima Indians of the USA (MacGregor, Riste et al 1994; Sangha 2000). Trend analyses 
appear to be observing consistently improved health status for patients with RA through the 
new millennium (Uhlig, Heiberg et al 2008). The reported drop in the prevalence and 
incidence of RA has been attributed to better access to more aggressive treatments such as 
tumour necrosis factor alpha (TNF-α) agents (Uhlig, Heiberg et al 2008) and key trends in 
RA over a 40-year period, supporting the concept that the epidemiology of RA is a dynamic 
process (Doran, Crowson et al 2002). 
 
The implications of RA to the patient and to society however remain staggering. The overall 
medical costs for this disease alone are high with mean annual direct and indirect costs, per 
person with RA, at the turn of the century being £3575 and £3638 respectively (Cooper 
2000). In England, the total economic impact of RA was estimated to be £1.256 billion in 
1992-3, over half of which was accounted for by loss of earnings caused by RA disability 
(McIntosh 1996). With the rising costs of inflation and medication these estimates would now 
be much higher.  
 
Morbidity for people who have RA is substantial as, 6.4 years from disease onset, 
approximately 25% of patients are work disabled, rising to 50% at 20.9 years (Pincus, Wolfe 
et al 1994; Wolfe & Hawley 1998). Most studies agree that people with RA have a lower life 
expectancy compared with members of the general population of the same age and sex 
(Pincus, Wolfe et al 1994; Gabriel, Crowson et al 2003; Navarro-Cano, Del Rincon et al 
2003). For the people with RA unable to work due to disability, family income is reduced by 
35% with more abnormal scores for almost every demographic and clinical variable (joint 
counts, grip strength, sedimentation rate, pain, global severity, health assessment 
questionnaire, disability and anxiety and depression) (Pincus, Wolfe et al 1994; Wolfe & 
Hawley 1998).   10
2.1.2. Classification criteria 
For classification purposes to allow comparisons between different populations and to serve 
as entry criteria for clinical trials, there is consensus that the diagnosis of RA is usually made 
according to specific criteria (van Gestel, Anderson et al 1999; Singh, Solomon et al 2006). 
Most studies report participants as being diagnosed with rheumatoid arthritis according to the 
1987 revised criteria of The American College of Rheumatology (ACR - formerly the 
American Rheumatism Association, see Table 1, Arnett, Edworthy et al 1988).  The criteria, 
whilst providing a guide for classification of RA and an element of standardisation within 
clinical trials, have been criticised for exclusion of certain factors, especially lower limb 
detail such as foot erosions (Hulsmans, Jacobs et al 2000). Furthermore, the classification 
criteria are not designed to diagnose the individual patient in the clinic, where clinical 
judgment is deemed important (Harrison, Symmons et al 1998; Bukhari, Harrison et al 2001).  
 
Classification of pathology in individuals with RA is further complicated due to the 
fluctuating nature of the disease. Investigators have attempted to set core endpoints in RA 
trials (Boers, van Riel et al 1995) and called for an update in response criteria (Singh, 
Solomon et al 2006) and reassessment of individuals’disease status on a regular basis 
(Hulsmans, Jacobs et al 2000). Fortin, Stucki and Katz (1995) challenged investigators to 
address the threats of relevance of change within their study designs, as most people with RA 
may not be in a steady state and disease variations may vary greatly from one individual to 
another.  
 
Biochemical markers that have pathological relevance to RA may make classification and 
diagnosis more straightforward than reliance on specific criteria (Young-Min, Cawston et al 
2008). Rheumatoid factor is the only serological parameter in the ACR criteria but has a low - 
moderate sensitivity of 60-80% and poor specificity, although has been prognostically useful 
as it has good correlation with functional and radiographic outcome (Quinn, Gough et al 
2005).  
 
The recent identification of citrullinated proteins and production of anti-CCP (anti-cyclic 
citrullinated peptide) antibodies in the immune response has led to the development of a test 
that has facilitated clinicians’ ability to predict the development of RA in undifferentiated 
arthritis and even in healthy individuals many years prior to clinical onset (Zendman, van 
Venroij et al 2006; Avouac, Gossec and Dougados 2006). The anti CCP test has the potential   11
to revolutionise patient management as it can predict an aggressive disease course at 
diagnosis in undifferentiated arthritis and may be detected in healthy individuals many years 
prior to clinical onset of RA (Avouac, Gossec and Dougados 2006). 
 
Table 1. The revised criteria for classification of Rheumatoid Arthritis  
(Arnett, Edworthy et al 1988). 
 
Criterion  Definition 
Morning stiffness  Morning stiffness in and around the joints lasting at least one hour 
before maximal improvement. 
Arthritis of 3 or 
more joints 
 
At least 3 joints areas have simultaneously had soft tissue swelling 
or fluid (not bony overgrowth alone) observed by a physician. The 
fourteen possible joint areas are right or left PIP, MCP, wrist, elbow, 
knee, ankle and MTP joints. 
Arthritis of the hand 
joints 
At least one area swollen as above in the wrist, MCP or PIP. 
Symmetric Arthritis 
 
Simultaneous involvement of the same joint areas (as in 2) on both 
sides of the body (bilateral involvement of PIPs MCPs or MTPs is 
acceptable without absolute symmetry). 
Rheumatoid 
nodules 
Subcutaneous nodules over bony prominence, extensor surfaces, or 
in juxta-articular regions observed by the physician. 
Serum Rheumatoid 
Factor 
Demonstration of abnormal amounts of serum ‘rheumatoid factor’ 
by any method that has been positive in less than 5% of normal 
control subjects. 
Radiological 
changes 
 
Radiological changes typical of Rheumatoid Arthritis on PA hand 
and wrist roenterograms, which must include erosions or 
unequivocal bony decalcification localised to or most marked 
adjacent to the involved joints (osteoarthritis changes alone do not 
qualify) 
For classification purposes, a patient shall be said to have Rheumatoid Arthritis if he/she 
has satisfied at least four of the above seven criteria. Criteria 1 – 4 must have been present 
for at least six weeks. Patients with two clinical diagnoses are not excluded. Designations 
as ‘classic’, ‘definite’ or ‘probable’ rheumatoid arthritis are not to be made. 
Key: PIPs = Proximal interphalangeal joints, MCPs = Metacarpophalangeal joints, MTP = 
Metatarsophalangeal joints, PA = Posterioanterior.   12
In considering early markers, such as rheumatoid factor and citrullinated proteins for better 
diagnosis, other ways of observing the ongoing process of RA include modern imaging 
methods such as MRI and MSUS imaging. Both technologies are sensitive to detecting 
inflammation and structural damage and it is possible that exploring the use of these 
technologies further may lead to changes in the way RA is classified and monitored 
(McGonagle and Conaghan 1999; Skudlarek, Narvestad 2004).   
 
2.1.3. Aetiology and pathology 
In order to develop an understanding of the foot manifestations of RA, it is first important to 
discuss current concepts in the aetiology and pathology of the disease process. Over the past 
twenty five years there has been tremendous change in the understanding of rheumatoid 
arthritis and although, as Brooks (1998) confirms, the aetiology of RA has remained elusive, 
its pathogenesis is becoming increasingly well characterized. It is this insight that has led to 
the development of new therapies and interventions that can alter the pathological course of 
RA and thus affect how foot manifestations may be managed. 
 
Choy and Panayi (2001) present a paradigm shift in the approach to a patient with RA over 
the late 1980s and early 1990s that involved the transition of agreement from the traditional 
hypothesis that the pathogenesis of RA could be defined by a single cause external to the 
host. The paradigm shift brought new thinking that the pathogenesis of RA is multifactorial, 
including host genetic predispositions and internal dysregulations and may not require any 
external antigen or pathogen (Pincus and Wolfe 1994). It is suggested that the presentation of 
a relevant antigen to an immunogenetically susceptible host is believed to trigger RA (Harris 
1990; Bukhari, Harrison et al 2001). 
 
Emerging data indicates that several genetic risk determinants, each of which is non-
pathologic if occurring alone, can add up to confer disease risk. One of these genetic elements 
in RA has been mapped to the human leucocyte antigen (HLA) region (Weyand and Goronzy 
1997). RA has been found to be associated with several genes, mainly in the region encoding 
the major histocompatability complex (MHC) genes (MacGregor, Riste et al 1994). The 
presence of HLA-DR4 was significantly commoner among patients with RA who were 
caucasian (Sangha 2000). In populations of northern European descent, HLA-DR4 was 
associated with both an increased incidence of RA and more severe disease (O’Dell 2003).    13
However, only certain subtypes of HLA-DR4 (HLA-Dw4 and HLA-Dw14) have been 
associated with RA, with susceptibility being related to a shared epitope on the HLA 
molecule (Akil and Amos 1999). First degree relatives of those with RA are at an increased 
risk of developing RA, with siblings of severely affected patients at highest risk (MacGregor, 
Riste et al 1994). Monozygotic twins have a concordance rate of 12% to 15% whereas 
dizygotic twins have a rate one quarter of this (MacGregor, Riste et al 1994). 
 
The realisation that RA is a genetic disease has been significant in the understanding of it’s 
pathology with more detailed reviews now available (Wordsworth 1995; Lin, Cash et al 
1998; Choy & Panayi 2001; Jawaheer and Gregersen 2002; Firestein 2003). The last two 
decades in RA research have also seen a major shift from premolecular to molecular 
techniques. A major effort has been to determine which cytokines and inflammatory 
mediators are produced at the site of disease (Weyand and Goronzy 1997). This in turn has 
led to the development of new medicines and more targeted therapeutic management 
approaches (Hau, Kneitz et al 2002; Taylor, Steuer et al 2006; Brown, Quinn et al 2006).  
 
In brief, the major contributor to the pathogenesis of the synovitis and joint destruction in RA 
is thought to be cellular mechanisms initiated by the activation of T lymphocytes (Panayi 
1994). The viewpoint that RA represents the sequelae of systemic proliferation is supported 
by the finding of autoreactive T cells with atypical growth and differentiation behaviour 
(Weyand and Goronzy 1997; Scutellari and Orzincolo 1998). 
 
Panayi (1994) proposed a mechanism for RA as a pyramid that starts with the initiating event, 
the activation of the pathogenic T cells by the trimolecular complex consisting of the HLA-
DR4/1 molecule, the unknown rheumatoid antigenic peptide and the α-β T-cell receptor. 
 
Four stages have been classified (Panayi 1994) to aid in the thinking of possible targets for 
the development of new therapies.  These are: 
Stage 1: Initiation  
Stage 2: Recruitment 
Stage 3: Amplification and joint destruction 
Stage 4: Repair  
 
Patients are unlikely to have symptoms during the early events of immune recognition of   14
stage 1 of RA (Panayi 1994) and many patients do not develop erosions evident on 
radiograph until after two years from disease onset (Bukhari, Harrison et al 2001). The 
symptoms of RA are known to begin only when the production and release of cytokines by 
macrophages and activated T lymphocytes occur, angiogenesis begins in the synovial 
membrane, and neutrophils are attracted to the joint cavity in the recruitment phase (Panayi 
1994; Weyand and Goronzy 1997). 
 
These steps are mediated by the cytokines gamma-interferon (IFN-צ), interleukin-2 (IL-2), 
TNF-α (tumour necrosis factor) and IL-1 (interleukin-1) (Choy and Panayi 2001). Cytokines 
can amplify and perpetuate the inflammatory response and it is evident that the cytokines and 
their activities are complex (Choy and Panayi 2001). There is also little doubt that rheumatoid 
factor amplifies the inflammation in RA (Kalsi and Isenberg 1993; Panayi 1994).  
 
As evidence builds, it is clear that knowledge of the sequence of pathological events will 
allow instigation of the most effective treatment for RA as soon as possible after diagnosis 
has been made. The effects of early therapeutic intervention and adjustment of 
pharmacological therapies at various stages of the pathological disease process of RA, will 
affect how the disease manifests itself within the foot (Helliwell, Woodburn et al 2007). The 
mechanical destruction of the foot joints and progression of structural foot joint deformity 
once the disease is established is evidently understood (Helliwell, Woodburn et al 2007). 
What is less clear is how the soft tissues within the feet react to the changing course of the 
pathological fluctuations of the disease and whether those changes can affect mobility or 
predict poor function. 
 
2.1.4. Synovitis 
Inflammation of synovial cellular lining is thus established as an important manifestation of 
the disease mechanism of RA. There are many areas within the foot that have synovium and 
therefore are susceptible to the pathological processes described above. It is therefore 
essential to outline the appearance of normal synovium and then synovitis associated with 
joint destruction in order to discuss how foot structures may become destroyed as RA disease 
progresses.   15
2.1.4.1. Normal synovium 
Tarner, Harle et al (2005) give a detailed histological account of normal synovium and 
analysis of the different stages of synovitis. The following is a summary of the authors’ 
explanation of normal synovium: 
 
Normal synovial membrane can be identified macroscopically as a connective tissue layer of 
approximately 0.5 – 5mm thickness and covers the inner surface of joints, tendon sheaths and 
bursae. Synovial lining does not consist of a single specialized cell type with intercellular 
junctions and there is no continuous basement membrane. It is composed of two major types 
of synoviocytes; macrophage like (type A) and fibroblast-like (type-B). In normal synovium, 
the surface of the lining layer is formed by interdigitating synovial fibroblasts and synovial 
macrophages that are less abundant than the synovial fibroblasts (Tarner, Harle et al 2005). 
 
The synovium has a two-layer architecture, synovial lining and sub-lining, equivalent to the 
architecture of epithelium and endothelium. The synovial fluid is a plasma dialysate formed 
by diffusion through the synovial sub-lining and lining. The synovial sub-lining consists of 
soft, loose connective tissue based on a network of elastic fibres and different collagens. 
Within joints it has a soft, folded architecture that fills space between the articular surfaces 
facilitating smooth movement of the joints. The synovial sub-lining contains blood and lymph 
vessels, nerve fibres and numerous interspersed cells including macrophages, fibroblasts and 
adipocytes. An important physiological function of normal synovium is the nutrition of 
articular cartilage by production of synovial fluid (Tarner, Harle et al 2005).   
 
Tarner, Harle et al (2005) suggest that the innervation of the synovium has recently become a 
particular focus of rheumatology research because of its potential role in modulating synovial 
inflammation.  
 
2.1.4.2. Inflamed synovium of joints in rheumatoid arthritis 
According to Panayi (1994), once activated, the immune response becomes organised in the 
perivascular areas of the synovial membrane, as the increase in the number of T cells leads to 
the proliferation and differentiation of B cells and to the production of antibodies within an 
expanding scaffold of new blood vessels and synovial-cell proliferation.  
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The leukocytes, new blood vessels and synoviocytes form an inflammation activated 
synovium, often termed pannus (Figure 1), which is the pathological hallmark of the disease 
(Edwards 1988; Scott, Shipley et al 1998; Tarner, Harle et al 2005).  
 
Figure 1. Typical synovial joint affected by rheumatoid arthritis  
(from Brill, Eckes et al 2004). 
 
 
 
 
Panayi (1994) reports, on considerable evidence, that active attempts at healing are taking 
place within the rheumatoid synovium as new blood vessels are formed, leukocytes are 
recruited from the blood and there is proliferation of synoviocytes.  
 
Tarner, Harle et al (2005) discuss the phenotype of synovium as being altered and developing 
into a thickened and invasively growing tissue that destroys the adjacent cartilage and bone. 
The resultant synovial thickening can be measured and may result in a depth of more than 
eight cells, although this may vary depending on the sampling method used (Youssef, Kraan 
et al 1998). 
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Although the pathogenesis of RA synovitis is described in stages (Panayi 1994), 
distinguishing the specific features of the different stages of RA has proven to be difficult 
(Tarner, Harle et al 2005). Examination of synovial tissue biopsies obtained by needle 
arthroscopy from patients with early (less than 1 year) and late (longer than 1 year) RA found 
significant histological differences (mean lining thickness of p= 0.040) between ‘clinically 
active’ (ie: swelling with joint effusion) and ‘clinically inactive (ie: no joint effusion) 
synovitis, independent of disease duration (Baeten, Demetter et al 2000). These observations 
are consistent with other studies (Zvaifler, Boyle et al 1994; Tak et al 1997; Palosaari, 
Vuotila et al 2006).  
 
Tarner, Harle et al (2005) conclude two reasons for this difficulty, the first being that 
inflammatory arthritis is a continuous process that develops at an individual pace, in 
individual structures, in individual patients. Secondly, that acute and early arthritis are terms 
defined by clinical observation of arthritis onset, while synovial cell activation and 
histologically defined synovitis may develop prior to clinical manifestation of disease and 
persist, despite remission of the clinical signs of inflammation. The question of when to 
classify this disease as being ‘in remission’ is interesting. In recent years, as technology has 
advanced, sub-clinical synovitis is consistently reported within imaging studies (Klarlund, 
Ostergaard et al 2000; Tan, Tanner et al 2003; Brown, Quinn et al 2006). 
 
The differences observed, therefore, do not appear to depend primarily on disease duration 
but on disease activity at a given point in time during the course of the disease (Tarner, Harle 
et al 2005; Tak et al 1997; Palosaari, Vuotila et al 2006). RA synovium exhibits varying 
histology and, as Kirwan (2004) suggests, the different histological abnormalities may relate 
to the subsequent progression or non-progression of disease activity in different ways.  
 
The relationship between synovitis and joint damage (conventionally described by 
radiographic erosions) remains controversial (Panayi 1994; Pullar 1997; Gordon, Jones et al 
1997). Current opinion is split between authors who claim a direct link between synovitis and 
joint damage (Conaghan, O’Connor et al 2003; Tan, Tanner et al 2003) and those who 
suggest these are uncoupled processes (Kirwan 2004).  The concept of two or more 
pathologies involved in RA stems from radiographic observations that erosions progress 
despite suppression of synovitis (Mulherin, Fitzgerald et al 1996; Kirwan 1997; Kirwan 
2004) whilst studies utilising MRI suggest that bony changes in RA are secondary to   18
synovitis (McGonagle and Conaghan 1999; Conaghan, O’Connor et al 2003; Tan, Tanner et 
al 2003). Further evidence using MSUS supports the theory of joint synovitis remaining 
active as sub-clinical disease even after patients have been confirmed as being in ‘clinical 
remission’ (Brown, Quinn et al 2006; Tan, Tanner et al 2003). 
 
Therefore, synovitis within the foot joints is potentially a dynamic and progressive process 
that may not be clinically measurable. In addition, usually, within the foot in longitudinal 
studies, it is MTP joint synovitis or tenosynovitis that has been linked to metatarsalgia in 
patients with RA (Welsing, van Gestel et al 2001; Ødegard, Landewe et al 2006; van der 
Heijde, Landewe et al 20087; van der Leeden, Steultjens et al 2008). However, anatomical 
bursae have synovium and synovial lining (Warwick, Williams et al 1973) that may also be 
susceptible to the pathological processes of RA described above. This becomes important 
in considering the clinical implications of forefoot bursae, as well as MTP joint synovitis 
and tenosynovitis in causing metatarsalgia and consequent foot disability in patients with 
RA. 
 
2.2. The role of bursae within the RA foot  
Bursae are documented within traditional anatomy texts as closed pouches of fluid that 
facilitate movement between adjacent structures that are under conditions of pressure 
(Warwick, Williams et al (1973). The synovial lining of some bursae types resembles that of 
joints and tendon sheaths and therefore may be susceptible to synovial inflammation as 
associated with RA (Palmer 1995; O'Brien, Hart et al 1997; Narvaez, Narvaez et al 2002). 
Bursae within the forefoot appear particularly apparent in RA (Koski 1998) however there is 
a lack of specific anatomical definition of these bursae. This section describes the anatomy 
and histology of bursae that occur within the forefoot and discusses this differing presentation 
within the literature. The potential role of bursae in the progression of forefoot deformity in 
RA is highlighted and the application to clinical management of metatarsalgia is discussed. 
 
2.2.1. Classification of bursae 
Bursae are often not sub-classified, however the terminology of all bursae as ‘sacs’ of fluid 
may be misleading as specification of the anatomy and histology of bursae appears to differ 
between texts. For example, Saladin (2004) describes all bursae as fibrous sacs filled with   19
synovial fluid. Warwick, Williams et al (1973) conversely describe the existence of two main 
types of bursa, anatomical bursae and adventitious bursae. In a review of the anatomy of 
bursae of the foot, Hernandez, Hernandez and Hernandez (1991) convey bursae as being 
classified according to type (anatomical or adventitious), location, or nature (pathological or 
non pathological). They suggest that differentiating bursae in this way allows more specific 
diagnosis of foot symptoms, thus facilitating better targeted treatment aiming to relieve 
pressure mechanically and / or managing inflammation locally or systemically (Hernandez, 
Hernandez and Hernandez 1991). Interestingly, the latter authors only report on surgical or 
cadaveric investigations and do not suggest how differentiation of forefoot bursae may be 
achieved clinically to facilitate better treatment outcomes (Hernandez, Hernandez and 
Hernandez 1991). 
 
2.2.1.1. Anatomical bursae 
According to Warwick, Williams et al (1973), anatomical bursae are also known as synovial 
bursae. Not all bursae are however filled with synovial fluid which appears to present 
opportunities for confusion of their classification within the forefoot which is discussed in 
more depth in the later section on adventitious bursae.  
 
Warwick, Williams et al (1973), define anatomical bursae as naturally occurring bursae that 
develop during intrauterine life and contain a capillary film of synovial fluid that acts as a 
lubricant providing the cells of their synovial membrane with a wet environment on their free 
surfaces. This is described as a metabolic process that allows anatomical bursae to act as an 
intermediary between other anatomical structures and their surroundings (Warwick, Williams 
et al 1973). Arguably, the synovium of anatomical bursae therefore may be susceptible to the 
pathological processes of RA (Palmer 1995; O'Brien, Hart et al 1997; Narvaez, Narvaez et al 
2002). 
 
To compound the confusion over specifically diagnosing bursae pathology, anatomical bursae 
may occur in many sites throughout the human body and appear to vary widely in their 
presentation (McCance and Huether 2002). Anatomists have therefore attempted to address 
this by defining anatomical bursae via their location.  
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Warwick, Williams et al (1973) classify anatomical bursae as: 
•  Subtendinous: occuring between tendons and bone, tendons and ligaments, or 
between one tendon and another;  
•  Submuscular: occuring between muscle and bone, tendon or ligament; 
•  Subfascial: separating aponeurotic areas from bone; 
•  Interligamentous 
 
However, Hernandez, Hernandez and Hernandez (1991) use slightly differing terminology 
and classify anatomical bursae via location as being subfascial, subcutaneous, intertendinous 
or interligamentous. They also classify subfascial anatomical bursae into two groups. Group I 
are said to be located between the origin or insertion of a tendon and bone. Group II are said 
to be located deep to tendon or muscle that crosses a bony prominence, between tendons and 
ligaments, or between tendons and muscles that glide over each other or run in close 
proximity to each other (Hernandez, Hernandez and Hernandez 1991). 
 
Bursae located around the knee joint are a typical illustration of the variation in anatomical 
bursae presentation (Meenagh et al 2006). For example, the prepatellar bursa lies superficial 
to the patella and appears as a flattened sac of synovial membrane supported by dense 
irregular connective tissue and interposed between skin and bone in the superficial fascia. 
Whereas the suprapatellar bursa is located deep to the quadriceps tendon and is in direct 
communication with the knee joint (Warwick, Williams et al 1973; Meenagh et al 2006). 
Similarly, the largest para-articular anatomical bursa of the hip region, the iliopsoas bursa, 
exhibits a flattened collapsed appearance in its non-pathological state (Bianchi et al 2002).  
 
Within the foot, the anatomical retro-calcaneal bursa, situated over the posterior-superior 
prominence of the calcaneus under the tendo-achilles contains a small amount of fluid rich in 
hyaluronate (Canoso et al 1988). Interestingly, Canoso et al (1988) also found that in healthy 
individuals the retrocaclcaneal bursa allows an extension of the fat pad to enter it during 
plantarflexion of the foot. In a cadaveric study, Theumann, Pfirrmann et al (2001) described 
the specifics of the anatomical intermetatarsal bursae in greater detail. Histopathologic 
analysis of the anatomical bursae between the metatarsal heads showed their appearance to be 
a space with an extremely attenuated cell lining on both sides and elongated, flattened nuclei 
that were subtended by a vascular connective tissue layer (see Figure 2) (Theumann, 
Pfirrmann et al (2001).    21
Figure 2. Histopathologic image of an anatomical bursa obtained between the metatarsal heads at 
the level of the phalangeal bases beyond the deep transverse metatarsal ligament.  
(From Theumann, Pfirrmann et al 2001). 
 
 
 
The anatomical bursa is depicted by the 
straight black arrow and the attenuated cell 
lining is shown on both sides, with elongated 
flattened nuclei by the white arrow heads. 
 
On magnetic resonance imaging, the anatomical intermetatarsal bursae appear oval or 
ellipsoid (see Figure 3) (Theumann, Pfirrmann et al 2001), although it appears that the sites 
and sizes of the intermetatarsal bursa may vary depending on the degree of metatarsal 
separation (Bossley and Cairney 1980; Claustre, Bonnel et al 1983; Chauveaux, Le Huec and 
Midy 1987; Theumann, Pfirrmann et al 2001). 
 
Figure 3. Coronal fat-saturated T1-weighted spin-echo (500/12) magnetic resonance image of the 
anatomical intermetatarsal bursa obtained at the level of the phalangeal bases beyond the deep 
transverse metatarsal ligament (from Theumann, Pfirrmann et al 2001). 
 
 
The anatomical intermetatarsal bursa (straight 
black arrow) lies between both interosseous 
tendons (white arrows) and the proximal phalanges 
of the third (PP3) and fourth (PP4) rays close to the 
neurovascular bundle (curved black arrow). 
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2.2.1.2. Adventitious bursae 
Adventitious bursae receive less attention in the literature than anatomical bursae and are 
therefore less well understood. They are said to occur within the subcutaneous tissues and 
have no synovial lining (Hernandez, Hernandez and Hernandez 1991) suggesting that Saladin 
(2004) is therefore incorrect in his definition of bursae. Adventitious bursae are reported to be 
acquired as a result of friction related to abnormal movement, which leads to separation of 
collagen fibres resulting in a localized collection of fluid between them (Hernandez, 
Hernandez and Hernandez 1991).  
 
The development of adventitious bursae is thus a consequence of mechanical trauma to 
provide the skin with more freedom of movement and they are not considered present before 
birth, being more common in adulthood (Warwick, Williams et al 1973). Warwick, Williams 
et al (1973) suggest that adventitious bursae are generally located in areas where the skin is 
subjected to repetitive shearing such as the forearm or elbow in writing or the buttock in 
certain sedentary occupations. Within the foot, the plantar forefoot fat pad area seems 
particularly susceptible to the development of adventitious bursae (Studler, Mengiardi, et al 
2008). 
 
Adventitious bursae have been described as multilocular, whilst anatomical bursae are 
unilocular (Hernandez, Hernandez and Hernandez 1991). However, the major differentiating 
factor between anatomical and adventitious bursae is in the histological appearance. Studler, 
Mengiardi et al (2008) compared magnetic resonance images of adventitious bursae within 
the forefoot in healthy subjects to histological appearance of cadaveric feet and symptomatic 
patients. They described the histological analysis of the adventitious bursae as always lacking 
an epithelial lining, but being ‘slit-like’ cavities within collagen sheets that contained areas of 
fibrosis tissue (see Figure 4) (Studler, Mengiardi et al 2008). On magnetic resonance imaging 
these bursae could be seen as alterations in the signal intensity of the plantar fat pad (Figure 
5) (Studler, Mengiardi et al 2008). 
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Figure 4. Histopathologic image of an adventitious bursa in a cadaveric foot (from Studler, 
Mengiardi et al 2008). 
 
 
The specimen reveals fibrosis 
(arrowheads) and a slitlike cavity 
within collagen sheets (arrow).  
 
 
Figure 5. Coronal T1-weighted magnetic resonance image (470/20) of plantar fat pad signal 
intensity alterations in right cadaveric forefoot (from Studler, Mengiardi et al 2008). 
 
 
 
 
The image shows fat pad signal 
intensity alterations (arrows) with 
blurred margins under first metatarsal
head. 
 
2.2.1.3. Pathological and non-pathological bursae 
Rarely reported in anatomical texts, Hernandez, Hernandez and Hernandez (1991) cite a 
description of pathological bursae by Jahss (1982) as bursae that may be either anatomical or 
adventitious, which have become thick-walled and distended from chronic pressure,   24
inflammation or infection. They do not explain how to distinguish pathological anatomical or 
adventitious bursae but do state that all pathological bursae are smooth to palpate clinically, 
uniloculular, benign, distended, deeply fixed, and not usually tender (Hernandez, Hernandez 
and Hernandez 1991). 
 
In their review of bursae within the foot, Hernandez, Hernandez and Hernandez (1991) also 
attempt to distinguish the variance in presentation of bursae within the foot by further 
classifying pathologic bursae as inflammatory, non inflammatory, suppurative and calcified 
or ossified. They then go on to further subdivide non-inflammatory bursae into pressure-
induced, traumatic or spontaneous (Hernandez, Hernandez and Hernandez 1991).  
 
The classification of bursae as pathological and non-pathological seems predominantly 
relevant to the forefoot however it also appears contradictary to the seminal ‘Grays Anatomy’ 
text definition presented by Warwick, Williams et al (1973) earlier in this section. This may 
explain why there appears to be confusion and a lack of detail in the literature over the 
description of the clinical appearance and clinical management of bursae within the forefoot. 
Discussion of the occurrence and presentation of bursae within the forefoot therefore 
warrants further attention.  
 
 
2.2.3. Forefoot Bursae  
The foot is a complex structure and there are many anatomical texts that describe the anatomy 
well (Warwick, Williams et al 1973; Sarrafian 1983; Romanes 1986). As discussed above, 
Hernandez, Hernandez and Hernandez (1991) report on cadaveric studies that have identified 
numerous small bursae throughout the foot that have differing presentation and histology. 
Within the forefoot, in healthy subjects, pathological pressure-induced bursae are reported to 
be the most common form (Hernandez, Hernandez and Hernandez 1991). These typically 
overlay bunion deformities, tailor’s bunions, hammer toes, underlie plantarflexed metatarsals 
and overlay dorsal exostoses (Hernandez, Hernandez and Hernandez 1991). However, 
adventitious bursae within the plantar fat pad are commonly seen (Studler, Mengiardi et al 
2008) particularly in RA (Helliwell et al 2007). 
 
Hernandez, Hernandez and Hernandez (1991) describe the pathogenesis of adventitious 
bursae as an initial protective mechanism that causes increases in fibrosis and thickening of   25
the bursa walls via altered mechanical stress and friction forces within the tissues.  A cycle of 
intermittent pain and inflammation that may lead to eventual chronic inflammation and 
constant pain can thus be created with further sequelae including localised necrosis with 
ulceration and possible sinus tract and fistula formation (Hernandez, Hernandez and 
Hernandez 1991). Helliwell et al (2007) similarly relate the development of adventitious 
bursae within the forefoot in RA to compressive and shearing forces acting on the skin sites 
of high pressure, for example, the MTP joints, although, in contrast to the study by Studler, 
Mengiardi et al (2008), they describe the bursae as forming in areas where the plantar fat pad 
has been displaced. 
 
Whilst the focus has been towards the treatment and management of adventitious bursae 
within the forefoot, little has been directed towards the anatomical intermetatarsal bursae. It is 
possible that in patients with RA reported metatarsalgia could be related to enlarged bursae 
that are either adventitious or anatomical. Due to the similarities in the histology between 
anatomical intermetatarsal bursae and synovial tissue these may be a more probable cause of 
clinical symptoms of metatarsalgia in RA (Awerbuch, Shephard et al 1982; Koski 1998) than 
adventitious bursae. 
 
Anatomical intermetatarsal bursae may also be more relevant in the cause of metatarsalgia 
due to their close anatomical association with the intermetatarsal neurovascular bundles. The 
intermetatarsal spaces are complex, being divided into inferior and superior levels that are 
separated by the deep transverse metatarsal ligament (Chauveaux, Le Huec and Midy 1987).  
 
In the superior space, tendinous and ligamentous structures lay close together and in the 
inferior space, the lumbrical muscles lay adjacent to the neurovascular bundle (Theumann, 
Pfirrmann et al 2001). Anatomical intermetatarsal bursae are described as being located 
between two metatarsal heads, above the deep transverse metatarsal ligament (Bossley and 
Cairney 1980; Claustre, Bonnel et al 1983) and between the interosseous tendons in the 
superior level (Awerbuch, Shephard et al 1982). They are clearly depicted in cadaveric 
specimens as being intimately related with the neurovascular bundles (Theumann, Pfirrmann 
et al 2001, see Figure 6) and present in each of the four intermetatarsal spaces (Chauveaux, 
Le Huec and Midy 1987). 
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Figure 6. Line drawing of a coronal view of the forefoot at the level of the metatarsal heads 
(from Theumann, Pfirrmann et al 2001). 
 
 
        Key: 1 = dorsal interosseous tendons, 2 = plantar interosseous tendons, 3 = lumbrical   
        muscles, 4 = adductor hallucis tendon, 5 = deep transverse metatarsal ligament, 6 =  
        superficial transverse metatarsal ligament, 7 = perforating fibres, 8 = lateral sesamoid  
        bone, 9 = neurovascular bundles, 10 = flexor digitorum longus tendons. Metatarsal  
        heads 1-5 (M1-M5) are depicted. 
 
 
 
In 25 cadaver dissections of healthy feet, Chauveaux, Le Huec and Midy (1987) 
demonstrated the presence of a bursa in the second and third spaces in every case, in the 
fourth space in 21 cases and 15 in the first space. They reported averages of the 
measurements of the bursae in the intermetatarsal spaces to be 2.3 to 3cm in anterior-
posterior length for the second and third spaces and 2cm for the first and fourth spaces 
(Chauveaux, Le Huec and Midy 1987). In a later cadaveric study, the first intermetatarsal 
bursa is also described as having a unique anatomical shape as it was orientated along the 
adductor hallucis tendon like a tendon sheath (Theumann, Pfirrmann et al. 2001). In the 
second and third spaces, the bursa overlapped in front of the anterior aspect of the deep 
transverse metatarsal ligament, extending distally by about one centimetre to reach the lateral 
margin of the base of the proximal phalanx (see Figure 7) (Chauveaux, Le Huec and Midy 
1987). The opposite was true in the fourth space where the bursa was clearly behind the 
posterior margin of the transverse ligament (Chauveaux, Le Huec and Midy 1987).  
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Figure 7. Anatomic section of the plantar forefoot depicting the intermetatarsal bursa of the 
2
nd and 3
rd space. A schematic line drawing and B cadaveric plantar dissected approach  
(from Chaveaux et al 1987). 
 
 
Key: 1=plantar interdigital ligament; 2 = supra-transverse intermetatarsacapital bursa; 3 = 
plantar digital nerve; 4 = tendon of flexor digitorum brevis; 5 = cellulo-adipose tissue; 
6=tendon of flexor digitorum longus;  
 
 
A 
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2.2.4. Forefoot bursitis  
Bursitis, like synovitis, is particularly relevant in RA and often clinically dominant in early 
disease and with RA disease progression (O’Brien, Hart et al 1997; Grassi and Cervini 1998, 
Narvaez, Narvaez et al 2002; Scheel, Schmidt et al 2005). Patients with RA frequently 
present with a throbbing pain under the metatarsal head that usually persists at rest and is 
exacerbated when the area is first loaded (Woodburn and West 1999).  Inferred links are 
made between the formation of adventitious bursae under the metatarsal head region in 
consequent areas of assumed torsional tissue stress and altered mechanical forces of foot 
function during gait in patients with RA (Woodburn and West 1999; Boutry, Larde et al 
2003; Helliwell et al 2007).  
 
Anatomical, intermetatarsal bursae, however, are less well discussed relative to the abnormal 
mechanical processes of RA.  Mechanically, the anatomical intermetatarsal bursae have been 
suggested to be important in their role as shock absorbers as they facilitate the metatarsal 
heads to glide in a dorso-plantarly direction enabling the forefoot to adapt to irregularities of 
the ground surfaces, particularly during gait (Bossley and Cairney 1980; Awerbuch, Shephard 
et al 1982; Claustre, Bonnel et al 1983; Chauveaux, Le Huec and Midy 1987; Theumann, 
Pfirrmann et al 2001). Bursitis in the forefoot therefore may involve the anatomical 
intermetatarsal bursae or adventitious bursae within the fat pad beneath the metatarsal heads 
(Hernandez, Hernandez et al 1991; Ashman, Klecker et al 2001; Studlker et al 2008).  
 
In healthy subjects, normal movement and stability of the forefoot at the level of the 
metatarsal heads are dependent upon stable metatarsals and good mobility of the MTP and 
interphalangeal (IP) joints (Donatelli and Wolf 1990). During gait the forefoot, via the 
metatarsal heads, tolerates up to 28% of the vertical forces of weightbearing (Bus, Maas et al 
2004). Abnormal mechanical foot function related to pronation and supination within the 
joints of the foot and ankle, however, can cause hypermobility and hypomobility of the 
forefoot (Donatelli and Wolf 1990). Abnormal hindfoot pronation in particular may cause the 
metatarsals to rotate in a valgus direction, disrupting the architecture of the intermetatarsal 
spaces and triggering torsional stresses within the plantar fat pad of the forefoot (Donatelli 
and Wolf 1990). It is hypothesised that the torsional stresses within the fat pad may result in 
adventitious bursae formation (Studler, Mengiardi et al 2008). As the spaces become crushed 
between the metatarsal heads, the classic ‘burning pain’ of the forefoot may be linked linked 
to irritation and inflammation of the intermetatarsal bursae (Bossley and Cairney 1980;   29
Zanetti, Strehle et al 1997; Iagnocco, Coari et al 2001).  
 
In contrast to adventitious bursitis (Studler, Mengiardi et al 2008), anatomical intermetatarsal 
bursitis reportedly has a low prevalence within healthy populations (Chauveaux, Le Huec and 
Midy 1987; Zanetti, Strehle et al 1997; Iagnocco, Coari et al 2001). The pathogenesis of 
anatomical intermetatarsal bursitis without underlying systemic disease remains unclear. 
Within RA, the process of intermetatarsal bursitis is complicated by the pathological invasion 
and destruction of synovial structures and the mechanical influences of forefoot loading 
during gait. The synovium of intermetatarsal bursae are susceptible to the pathological 
processes of RA in the same way as the synovium of joints and tendon sheaths (detailed in 
section 2.1.3, page 12). As RA disease progresses, the synovium of bursae become distended 
and thickened (O’Connor & Grainger 2002). Confirmed surgically, the intermetatarsal bursae 
reportedly hypertrophy in RA and gradually extend beyond their normal site towards the 
dorsal or plantar region of the foot (Claustre, Bonnel et al 1983). Consequently, when 
intermetatarsal bursae become hypertrophied and increased in size, they may compress the 
plantar digital nerves, resulting in the sensation of ‘burning pain’ similar to that of a Morton’s 
neuroma (Bossley and Cairney 1980; Chauveaux, Le Huec and Midy 1987; Theumann, 
Pfirrmann et al 2001).  
 
Loss of function of the anatomical intermetatarsal bursae within RA has received little 
attention in the conceptual thoughts of mechanical dysfunction of the foot. Explanations for 
the mechanical influences of synovitis in the foot joints and tenosynovitis in the forefoot 
tendons in RA are usually the focus of foot investigations. Foot deformities and anomalous 
concentrated foot pressures due to abnormal pronation are reported as being related to the 
combined effects of repeated episodes of synovitis, weakening of the joints and eventual 
destruction of the integrity of the feet in RA (Woodburn, Helliwell et al 2002; Turner, 
Helliwell et al 2006).  It is possible that early inflammatory changes due to RA in the 
anatomical intermetatarsal bursae may contribute significantly to the mechanical disruption 
of the forefoot. Changes in soft tissue volume distribution through the forefoot during loading 
have been described (Weijers, Walenkamp et al 2003) and surgical studies have highlighted 
that as the anatomical intermetatarsal bursae become hypertrophic in RA they gradually 
extend beyond their normal site towards the dorsal or plantar region of the foot (Claustre, 
Bonnel et al 1983).  
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Most of the literature to date on forefoot bursae and bursitis has been presented via cadaveric 
and / or surgical investigation. What remains unclear is how the different presentations of 
bursitis within the forefoot may be clinically diagnosed, especially if the findings by Koski 
(1998) that intermetatarsal bursitis may be one of the first features of RA but is often missed 
by clinical examination are to be accepted. Furthermore, in cadaver or surgical studies, unless 
chronically inflamed (see Figure 8), both adventitious and anatomical intermetatarsal bursae 
are said to be easily ruptured, the latter due to a transparent membrane that is difficult to 
isolate from the adipose tissue (Chauveaux, Le Huec and Midy 1987). This may explain why 
forefoot bursitis in RA is under-reported in clinical studies. 
 
Figure 8. Large chronic forefoot bursal swellings (white arrows) in a patient with severe 
rheumatoid arthritis undergoing extensive forefoot surgery  
(reproduced with kind permission from Michael Backhouse 2006). 
 
 
 
 
As technology has advanced, MSUS has been used to identify a high prevalence of 
intermetatarsal bursitis within patients with early RA that were not clinically apparent (Koski 
et al 1998). If non-invasive clinical palpation of the plantar metatarsal area is relatively 
insensitive for bursitis in early RA disease it is likely that diagnosis of foot symptoms may be 
delayed (Koski 1998). In late stage foot RA disease bursitis is usually described as a fluctuant 
palpable swelling (Helliwell, Woodburn et al 2007), (see Figure 9).  
 
   31
Figure 9. Photographs representing the foot in early stages of RA (A), established stages of 
RA (B) and advanced stages of RA (C) according to the classification by  
Helliwell, Woodburn et al (2007).  
 
 A 
 
B
C
 
Palpable swelling indicative of bursitis can be 
seen in the region of the second and third 
MTP joints (C, white arrow heads). 
 
Investigators have therefore proposed that intermetatarsal bursitis is often an undiagnosed 
cause of foot symptoms in these patients (Koski et al 1998; Olivieri, Scarano et al 2004). The 
evidence for this, however, remains limited. Both studies used small samples and the 
methodologies for specifying the identified structures as anatomical intermetatarsal bursitis, 
as opposed to adventitious bursitis, were not apparent.  
 
It is possible that chronic adventitious bursae may appear the same on MSUS as anatomical 
bursae and that location becomes the only defining feature that characterises bursa in the 
clinical environment. MRI studies give better detail regarding the anatomical region of the   32
formation of chronically inflamed bursae within the forefoot, although without histological 
analysis confirmation of the bursal type remains speculative (Ashman, Klecker and Yu 2001; 
Helliwell et al 2007; Studler, Mengiardi et al 2008). Compare Figure 10 and Figure 11. 
 
 
Figure 10. Coronal T1-weighted magnetic resonance image of an adventitious bursa under 
the first metatarsal head in a symptomatic patient (from Studler, Mengiardi et al 2008). 
 
 
The image shows a signal intensity 
alteration (white arrows) with indistinct 
margins in plantar fat pad beneath first 
metatarsal head of right forefoot. 
 
 
Figure 11. Transverse forefoot T1 weighted fat suppressed post iv gadolinium enhanced 
MR image of intermetatarsal bursitis in the third intermetatarsal space                    
(from Helliwell et al 2007). 
 
The image shows a pathological 
proven rheumatoid nodule formation 
within the intermetatarsal bursa 
(white arrow).  
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2.2.5. Relevance and differential diagnosis of forefoot bursitis 
Specific diagnosis of forefoot symptoms due to bursitis may thus be important in RA. 
Differentiating pain in the forefoot due to synovitis or tenosynovitis, from pain due to bursitis 
(either anatomical or adventitious), however, poses a problem clinically if the aim of 
treatment is more targeted, anatomically site-specific, therapeutic intervention.  
Diagnosing forefoot bursitis clinically is difficult, as many disorders may give rise to 
discomfort in the metatarsal region of the forefoot (Ashman, Klecker et al 2001; Bancroft, 
Peterson and Kransdorf 2008). Using MRI in a heterogenous population, Bancroft, Peterson 
and Kransdorf (2008) identify the following soft tissue pathologies that may occur:  
•  Cystic Tumor–Like Lesions  
•  Ganglia  
•  Synovial cysts  
•  Adventitious bursa 
•  Noncystic Tumor–Like Lesions  
•  Morton's neuroma  
•  Rheumatoid nodules  
•  Callus 
•  Synovial-Based Processes  
•  Synovial chondromatosis  
•  Pigmented villonodular synovitis  
•  Gout 
•  Plantar Fibromatosis  
•  Giant Cell Tumor of Tendon Sheath  
•  Lipoma  
•  Soft Tissue Chondroma  
•  Synovial Sarcoma  
•  Undifferentiated Pleomorphic Sarcoma  
•  Leiomyosarcoma 
 
Notably within their list adventitious bursa is mentioned but not anatomical, intermetatarsal 
bursa (Bancroft, Peterson and Kransdorf 2008). In particular, reviews of foot pathology in 
RA often omit bursae and describe soft tissue complications such as MTP joint synovitis, 
synovial cysts (or herniation of the synovial membrane through the joint capsule), 
tenosynovitis or rheumatoid nodules as affecting the forefoot (Kerry, Holt et al 1994; 
Michelson, Easley et al 1994; Weiner-Ogilvie 1999).  
 
Investigations of Morton’s neuromas are often linked to anatomical intermetatarsal bursitis 
and both pathologies are considered to be related to abnormal mechanics or tight footwear in   34
otherwise healthy individuals (Awerbuch, Shephard et al 1982; Chauveaux, Le Huec and 
Midy 1987; Zanetti, Strehle et al 1997; Iagnocco, Coari et al 2001; Theumann, Pfirrmann et 
al 2001; Luukkainen 2009) as well as in patients with RA (Awerbuch, Shephard and Vernon-
Roberts 1982). Interestingly, histopathological analysis of intermetatarsal spaces in ten 
patients from a sample of twenty who had been investigated surgically for Morton’s neuroma 
revealed hypertrophy of synovium of the intermetatarsal bursae consistent with RA changes 
(Awerbuch, Shephard and Vernon-Roberts 1982). Of those ten patients, two already were 
known to have RA; three had no evidence at the time of surgery, but developed seropositive 
RA within four years following the surgery; one patient was seropositive but with no other 
evidence of RA and four patients had no serological or clinical features of RA at the time of 
the study (Awerbuch, Shephard and Vernon-Roberts 1982). 
 
Table 2. The stages of foot disease in RA (Helliwell, Woodburn et al 2007). 
Disease stage  Clinical picture 
  
Early Foot Disease  •  Joint pain and stiffness in the foot and ankle 
•  Pain under the MTPJs 
•  Patients describe a sensation of ‘walking on pebbles’ 
•  Positive metatarsal squeeze test 
Established Foot Disease  •  Plastic changes 
•  Tibialis posterior tendon dysfunction 
•  Secondary features develop such as areas of raised plantar 
pressure or digital deformity 
•  Formation of secondary lesions such as corns or callus 
•  Complications may manifest: vasculitis, ulceration and 
neuropathy. 
Advanced Foot Disease  •  Mechanical instability exacerbates inflammatory processes 
•  Subtalar and midtarsal joint subluxation 
•  Planovalgus foot posture 
•  Marked forefoot deformity 
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In their account of the epidemiology of foot disease, Helliwell, Woodburn et al (2007) 
specify a positive metatarsal squeeze test in early stage RA (refer to Table 2) although 
highlight that it is often difficult to distinguish between swelling due to joint effusion, 
synovitis or inflammation of periarticular structures. Forefoot bursitis, depending on the stage 
of the disease however, is a significant omission from the classification, further highlighting 
the lack of evidence on this feature.  
 
In summary, the terminology of forefoot bursitis within the literature is confusing although 
bursae appear to be an important feature of the forefoot in RA. MRI appears to give good 
detail on the differential diagnosis of bursitis from other soft tissue pathologies that may 
occur within the forefoot. MRI may also give good detail on the location of bursitis. MSUS 
is promising in detecting location of bursae and appears to show a higher prevalence of 
forefoot bursitis in patients with RA than in healthy populations. Differentiating 
adventitious bursae formation from anatomical bursae formation however is difficult unless 
confirmed by histology. For these reasons it is possible that without appropriate 
investigative techniques, forefoot bursitis in RA is under-reported or mis-represented in 
clinical studies and therefore treatment may be delayed or be inappropriate. For example, if 
forefoot bursitis is related to the disease process of RA then treatment may be aimed at 
managing the disease, in contrast, if forefoot bursitis forms as a response to instability of 
the forefoot, treatment should be directed towards stabilising the forefoot.  
 
In addition, in the absence of longitudinal data, the relationship between forefoot bursitis, 
poor clinical symptoms and foot disability remains speculative. This becomes important in 
considering the clinical implications of forefoot bursitis in causing metatarsalgia and 
consequent foot disability. Usually, in longitudinal studies, it is MTP joint synovitis or 
tenosynovitis that has been linked to metatarsalgia in patients with RA (Welsing, van Gestel 
et al 2001; Ødegard, Landewe et al 2006; van der Heijde, Landewe et al 20087; van der 
Leeden, Steultjens et al 2008). If, however, forefoot bursitis may be a manifestation of RA 
disease, it seems essential to clearly define the prevalence of this in a large population of 
patients with RA and to determine if it does change over time. 
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2.3. Evaluation of the effects of rheumatoid arthritis on the foot 
To be effective in improving clinical outcomes, investigation and treatment of patients should 
be evidence based. Implicit in this is the need for an awareness of the presence, nature and 
extent of disease. Within this section, the literature is reviewed according to how the effects 
of disease in the foot and subsequent podiatric interventions are currently evaluated.  
 
2.3.1. Assessment of rheumatoid arthritis disease within the foot 
Study of the effects of disease in individuals with RA is complicated due to its fluctuating 
nature. Most people with RA may not be in a steady state and disease progress may vary 
greatly from one individual to another. The challenge for investigators is, therefore, in the 
measurement of predictive disease factors and interventional changes (Fortin, Stucki & Katz 
1995) and many measures to assess disease process and effects of care in RA have been 
developed.   
 
Benchmarks for longitudinal and observational studies in rheumatology include measures of 
impairment, disability and handicap (Helliwell, Woodburn et al 2007) (see Table 3). In order 
to facilitate the use of these in both clinical and research practices a core set of domains, that 
include measures of health status, disease process, damage, toxicity or adverse reactions, 
mortality, work disability and costs, has been suggested through the OMERACT (Outcome 
Measures in RA Clinical Trials) conferences (Molenaar, van der Heijde and Boers 2000). 
Unfortunately, within the field of podiatry no specific standard exists and the measurement of 
disease state of the foot due to RA remains limited (van der Leeden, Steultjens et al 2008). 
 
When measuring RA disease activity in clinical studies, self-administered arthritis specific 
functional instruments such as the Health Assessment Questionnaire (Fries, Spitz et al 1980) 
and the Arthritis Impact Measurement Scale (Meenan, Mason et al 1984) are valid, reliable 
and have excellent correlation with long term outcomes. Unfortunately, these standard 
instruments have been criticised as they do not specifically or comprehensively measure 
symptoms directly attributable to RA foot disease (Saag, Saltzman et al 1996).  
 
A review, detailing the instruments that have been used to specifically measure foot function, 
foot pain and foot-related disability in patients with RA, has recently been published (van der 
Leeden, Steultjens et al 2008). This review identified measurement instruments that have   37
been used within the published literature and investigated them for reliability, consistency 
and validity, however the authors concluded with concerns on the quality of many of these 
measures (van der Leeden, Steultjens et al 2008). Mostly the focus of outcome measures is on 
assessment of foot structure and gait mechanics and only recently has the assessment of foot 
related pain, disability and function been included in some studies (van der Leeden, Steultjens 
et al 2008). 
 
 
Table 3. Examples of outcome measures for the foot 
(adapted from Helliwell, Woodburn et al 2007). 
 
Outcome Measure  Instrument 
Performance measure  Walking distances & times; grip strength 
Measures of physical signs  DAS28; No of swollen joints; No of tender joints; Ritchie 
articular index, duration of morning stiffness, fatigue 
Measures of symptoms  Pain – VAS, 5 point Likert scale; Mc Gill Questionaire 
Functional status  The Stanford Health Assessment Questionnaire (HAQ); 
The Steinbrocker scale  
Health status and Quality of Life 
(QoL) 
SF-36; EuroQol; EQ-5D; Sickness Impact Profile 
Disease Specific measures of health 
status and quality of life (QoL) 
The Arthritis Impact Measurement Scale (AIMS); the 
Rheumatoid Arthrtitis-specific Quality of Life Instrument 
(RAQoL) 
Laboratory measures  ESR, CRP, Rh Factor 
Radiological assessments  Sharp index, Larsen index, Steinbroker,  
 
2.3.2. Assessment of foot structure and mechanics 
Traditional podiatric assessment methods tend to focus on skeletal structure and 
biomechanical stresses on foot function.  These have been the cornerstone of practice for the 
past twenty years but have more recently been challenged as lacking in reliability (Weiner-
Ogilvie & Rome 1998; Evans, Copper et al 2003) or not sufficiently validated (Wrobel 2000, 
Parker, Nester et al 2002). For assessment of the foot in RA, Helliwell, Woodburn et al   38
(2007) recommend the ‘look, feel and move’ principles based on the GALS (gait, arms, legs 
and spine) screening tool, although this has yet to be adopted within routine podiatry practice 
and remains a subjective exercise for research trials. 
 
Weiner-Ogilvie (1999) concluded, in a review of foot involvement in RA, that no unified 
method was used to measure foot involvement in RA. Later, in a systematic review of 
podiatric interventions for the RA foot, the same conclusions were made (Bowen, Burridge 
and Arden 2005) although some main themes of outcome measures were collated as gait 
assessment, measurement of plantar foot pressures, pain measurement, assessment of physical 
function, and treatment tolerance (see Table 4).  
 
Foot pressure measurement appeared to be the most common mode of outcome measure in 
determining the effectiveness of clinical interventions such as foot orthoses and callus 
debridement for patients with RA (Bowen, Burridge and Arden 2005). This may be because 
the equipment required for plantar foot pressure measurement is readily available, relatively 
easy to use and potentially clinically informative regarding foot orthotic interventions 
(Woodburn and Helliwell 1996; Otter, Bowen et al 2004; Tuna, Birtane et al 2005;  van der 
Leeden, Steultjens et al 2006; Turner, Helliwell et al 2006; Semple, Turner et al 2007). 
 
More recently, evidence linking radiological erosion scores and joint damage on radiographs 
to increased plantar forefoot pressures has been found (Davys, Turner et al 2005; Tuna, 
Birtane et al 2005; van der Leeden, Steultjens et al 2006). However, joint damage is late stage 
disease and it would be useful to know if inflammation in early disease or during flares 
influences the biomechanics during gait. No interventional study has yet reported on 
assessment of soft tissue problems in RA, such as bursitis, relative to mechanical 
compensation and none have utilised MSUS imaging as a technique to assess and inform foot 
status in RA patients. 
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Table 4. Collated information under main theme headings of all outcome measures utilised
within the review papers (adapted from Bowen, Burridge and Arden 2005). 
 
Gait  
 
•  8m footswitch walkway 
•  Footswitch stride analyser 
•  Temporal distance values (Mean velocity, cadence, mean stride length, step 
width,  step length, foot angle, walking distance/time, single limb stance) 
Pain 
 
•  Visual analogue scales: 100mm / 0 -10 / 10cm 
•  Verbal report 
•  Foot pain & disability (Foot Function Index) 
•  Global arthritis pain 
Physical 
function 
 
•  Functional capacity: Functional status: Steinbrocker classification & global 
scale of 0 – 10 (10 indicating total disability), Disease activity score (DAS), 
Health assessment questionnaire (HAQ), Larsen Index joint erosion scores in 
hands and feet, Disability (adapted Arthritic Impact Measurement Scales), 
Physiologic Cost Index (PCI), Patients’ self assessment of performance of 
ADLs, Patient problems: National Centre for Medical Rehabilitation Research 
(NCMRR) template 
•  Grip strength (Vigormeter) 
•  Physical assessment of painful joints of feet, ankles, hands & wrists 
•  Lower extremity synovitis: joint count method of ACR   
•  Lower extremity function: ambulation section of the Robinson-Bashall 
functional assessment (standing, walking & stair climbing), & the walking & 
stair climbing components of the Toronto Activities of Daily Living Measure 
Foot pressure 
 
•  Emed pedar in-shoe system (plantar pressures, stance phase duration, 
calculation of cadence) 
•  Emed Pedar (forefoot plantar pressures peak pressure, peak force, contact time)
•  Emed Pedar (in-shoe peak pressures) 
•  Podoscope (weightbearing plantar pressure distribution) 
•  Prototype contact sensitive walkmat system 
•  Optical pedobarograph (highest pressure area under each foot) 
Treatment 
tolerance 
 
•  Daily and weekly use patterns (semi-structured telephone interviews) 
•  Self reported adverse reactions, wearing time  
•  Subjects impression of treatment effectiveness: 10cm VAS 
•  Comfort assessment during walking – likert scale/ 5 options 
•  Patients asked their overall opinion regarding the hosiery. 
•  Perceived advantages and disadvantages of orthopaedic footwear 
•  Attitude to prescribing orthopaedic footwear 
•  Satisfaction with co-operation with pedorthists 
•  Satisfaction / Dissatisfaction (fit and comfort, style, colour, weight, other) 
Structural 
assessment 
•  HAV angle measured with weightbearing radiographs 
•  Foot length and height measurement 
•  Range of motion (tibiotalar, subtalar, midtarsal, hip, knee joints) 
Physical 
examination 
•  Strength of selected lower extremity muscles 
•  Range of motion & motor strength of the ankle and foot 
Visual 
observation 
•  Complete lower extremity evaluation, stance and gait 
•  Unassisted gait and ability to perform heel rise test 
Material 
compression  
•  Teclock® dial gauge (under 3
rd met head) 
Sensation  
 
•  Semmes-Weinstein monfilaments (1, 10 & 75g)   40
2.3.3. Assessment of foot-related pain, disability and function 
There are a growing number of examples of multi-domain questionnaires that seek to assess 
function, pain and disability relevant to the RA foot.  These include the Foot Function Index 
(FFI) (Budiman-Mak, Conrad and Roach 1991); the Foot Health Status Questionnaire 
(FHSQ) (Bennett and Patterson 1998); the Manchester Foot Pain Disability Questionnaire 
(MFPDQ) (Garrow, Papageorgiou et al 2000), the Leeds Foot Impact Scale (LFIS) 
(Helliwell, Reay et al 2005) and the Bristol Foot Score (BFS) (Barnett, Campbell and Harvey 
2005). 
 
Interestingly the FHSQ, MFPDQ and BFS were developed for general populations (Bennett 
and Patterson 1998; Garrow, Papageorgiou et al 2000; Barnett, Campbell and Harvey 2005) 
yet the FFI and LFIS appear to be the most ultilised instruments with positive ratings (van der 
Leeden, Steultjens et al 2008). The FFI was developed to measure the impact of foot 
pathology on function, in terms of pain, disability and activity restriction, for assessment of 
surgical interventions (Budiman-Mak, Conrad and Roach 1991).  The investigators did not 
intend it to be used specifically to RA as the source of the pathology although the test 
subjects all had a definitive diagnosis of RA (Budiman-Mak, Conrad and Roach 1991). The 
LFIS was developed specifically for RA patients to measure foot pain and disability at all 
stages, including early and late stage RA (Helliwell, Reay et al 2005).  
 
Both the FHSQ and FFI are criticised as being developed by expert professionals (Barnett, 
Campbell and Harvey 2005) whereas MFPDQ, BFS and LFIS all were developed with 
qualitative methodological approaches that involved a series of patient questioning so that the 
more recently validated instruments are patient facing (Garrow, Papageorgiou et al 2000; 
Barnett, Campbell and Harvey 2005; Helliwell, Reay et al 2005).  
 
It is clear that the emphasis is shifting from measurement of the biomechanical aspects of gait 
and foot function alone, towards developing patient-orientated measures based on the 
patient’s own experience of their foot disease. Medical definitions of disease within the RA 
foot do, however, still tend to be omitted. Whether it is because access to diagnostic 
information (such as biopsy, serology and imaging results) has been difficult for podiatrists 
and foot health clinicians, or whether these facilities (in particular MSUS imaging) are seen 
as emerging practices, remains debatable.   41
2.4. The role of imaging modalities in the assessment of rheumatoid arthritis 
The past three decades have seen extraordinary advances in medical imaging and innovations 
such as computed tomography, ultrasound and magnetic resonance imaging for evaluation of 
synovitis in RA (Tan, Tanner et al 2003). With the advent of improved imaging technology in 
the form of MRI and MSUS, specific diagnosis of symptoms within the forefoot is enhanced 
over clinical examination without the requirement for invasive surgical intervention 
(Weishaupt, Treiber et al 2003; Olivieri, Scarano et al 2004). This section discusses the main 
modalities utilised in musculoskeletal imaging and, in particular, discusses the recent 
developments of MSUS imaging as a clinical modality for assessment of foot status 
performed by podiatrists. 
 
2.4.1. Radiography 
Radiography was the first medical imaging modality used, when Wilhelm Conrad Roentgen 
discovered x-rays and their medical use, in 1895, whilst famously experimenting on his 
wife’s hand (Bushberg, Seibert et al 2002).  The radiation was unknown at the time and so 
Roentgen named the rays ‘x’ conceiving the term ‘x-rays’ (Bushberg, Seibert et al 2002).  
 
The following is a summary of the physical properties of x-rays adapted from Bushberg, 
Seibert et al (2002):- 
 
•  x-rays are produced when highly energetic electrons interact with matter and convert 
their kinetic energy into electromagnetic radiation 
•  A large voltage is applied between two electrodes (cathode and anode) in an x-ray tube 
and, as electrons pass through, they attain the kinetic energy 
•  When x-rays have passed through body structures they are ‘collected’ onto specially-
treated plates (similar to camera film) or digital media and a "negative" type picture is 
made (the radiograph) 
•  The more solid a structure is, the whiter it will appear on the film (bones therefore leave 
the film only slightly exposed and appear light or white on the x-ray film) 
 
In RA, radiographic findings are classically described as periarticular osteopenia, marginal 
erosions, diffuse joint space narrowing, effusions and subluxations (Canoso 1997). 
Radiological damage is considered to be an outcome measure in clinical trials as well as   42
routine clinical examination that reflects the severity and progression of RA (Boers, Tugwell 
et al 1994) and is integral to the 1987 revised ACR classification of RA (Arnett, Edworthy et 
al 1988). Furthermore, within the feet in RA, evidence suggests that radiographic findings 
may be as frequent as, or more frequent than, those observed in the hands (Isomaki, Kaarela 
et al 1988). 
 
Until recently, radiography has been the mainstay imaging technique for detection of RA 
disease. Latterly, however, the limitations of x-ray imaging have been highlighted due to it’s 
insensitivity in the detection of early disease changes in RA (Conaghan, O’Connor et al 
2003). Radiological diagnosis is insensitive to soft tissue changes, with poor association with 
pain and thus may take months or years for the plain film to detect cortical bone erosions 
which results in significant delay between presentation and treatment (Farrant, O'Connor and 
Grainger 2007). 
 
A further limitation to x-rays is that they may be harmful due to the exposure of cells to 
ionising radiation. Exposure to radiation causes microscopic damage to living tissue, resulting 
in skin burns and radiation sickness at high doses and cancer, tumours and genetic damage at 
low doses. The biological effects of radiation may cause cell death and affect the function of 
an organ or genetically damaged cells that pass on the genetic transformations to their 
descendants, increasing the risk of cancer (Bushberg, Seibert et al 2002). 
In addition x-rays are now criticised in that they produce a two-dimensional representation of 
a three-dimensional object and this limits the ability to measure structures and track 
progression of disease. In clinical trials the Sharp - van der Heijde and Larsen - Scott are the 
most widely used methods of scoring radiographs that provide objective measures and allow 
assessment of progression of disease (van der Heijde 1996; Ejbjerg, Vestergaard et al 2005). 
Both scoring systems are restricted by the ability of x-ray imaging to detect actual disease 
activity and magnetic resonance imaging (MRI) is emerging as more superior in the detection 
of temporal changes in structural joint damage in RA (Ejbjerg, Vestergaard et al 2005). 
2.4.2. Magnetic resonance imaging 
Magnetic Resonance Imaging is now established as a useful method for assessment of 
musculoskeletal status (Gaffney, Cookson et al 1995; Klarlund, Ostergaard et al 2000; 
Narvaez, Narvaez et al 2002; Tan, Tanner et al 2003). The principles of MRI are explained by   43
McGonagle and Conaghan (1999) relative to its use in rheumatology. MRI most frequently 
relies on the relaxation properties of excited hydrogen nuclei in water and lipids. Protons in 
human tissues are randomly oriented but when placed in a powerful, uniform magnetic field 
the protons with a resulting non-zero spin have to arrange either parallel (longitudinal 
magnetism) or antiparallel (transverse magenetism) to the applied magnetic field, according 
to quantum mechanics. The time taken for longitudinal magnetism to return to its original 
state is termed T1 and the time taken for transverse magnetism to disappear is termed T2. A 
magnetic resonance image is therefore formed by measurement of the resultant signal 
generated by movement of the protons in a magnetic field that has different strengths across a 
given area. Depending on which MRI sequences are used, the appearance of tissues will vary. 
The most commonly utilised MRI sequences are T1-weighted and T2-weighted spin echo 
(McGonagle and Conaghan 1999). 
 
In clinical practice, one advantage of an MRI scan is that it is harmless to the patient (unless 
using gadolinium enhancement), as it uses strong magnetic fields and non-ionizing radiation. 
Compare this to Computed Tomography (CT) scans and traditional radiographs (x-rays) 
which involve doses of ionising radiation that may increase the risk of malignancy 
(McGonagle and Conaghan 1999; Bushberg, Seibert et al 2002). Furthermore, radiography is 
the most widely used imaging modality for rheumatoid arthritis, yet it is insensitive for 
showing bone damage in early RA disease and is insensitive to synovial inflammation, in 
contrast to MRI that is sensitive to synovitis (McGonagle and Conaghan 1999; McGonagle, 
Conaghan et al 2001; Evangelisto, Wakefield et al 2004). 
 
MRI has an advantage over other imaging modalities in that it allows an effective assessment 
of both articular and soft tissue structures such as bursae (Narvaez, Narvaez et al 2002). 
Because of the synovial fluid that distends the bursa, bursitis typically appears with low 
signal intensity on T1-weighted images and high signal intensity on T2-weighted images 
(Narvaez, Narvaez et al 2002). A summary of the advantages and disadvantages of MRI 
formulated by Wakefield, Kong et al (2003) can be seen in Table 5. 
 
There is no doubt that MRI contributes an additional tool, aimed at earlier and more accurate 
diagnosis, leading investigators to propose that MRI might allow an earlier decision to start 
appropriate medication in patients with early RA (McGonagle and Conaghan 1999; 
McGonagle, Conaghan et al 2001; Tan, Tanner et al 2003; Evangelisto, Wakefield et al 
2004). MRI of the foot and ankle has formerly been considered to be advantageous in the 
assessment of musculoskeletal abnormalities as it enables clear depiction of tendons   44
ligaments, muscles, cartilage and bone (Heron 1993; Ostendorf, Scherer et al 2004). Analysis 
of MRI scans of the forefeet detected synovitis and bone oedema in patients with early RA in 
whom MRI of the finger joints was normal (Ostendorf, Scherer et al 2004). Heron (1993) 
believed that access to MRI would become more generally available to foot health providers 
and that it would replace many of the techniques employed in foot and ankle imaging. 
However, more than a decade later, the use of and referral for MRI remains relatively rare for 
musculoskeletal foot and ankle pathology. 
 
 
Table 5. The Advantages and Disadvantages of MRI                               
(Adapted from Wakefield, Kong et al 2003). 
Advantages of MRI  Disadvantages of MRI 
Multiplanar 
No ionising radiation 
Considered a good imaging measure 
More sensitive than clinical, x-Ray and 
MSUS for the detection of synovitis and 
erosions 
Standardised inaging protocols and 
sequences 
Expensive (equipment, running and 
personnel costs) 
Time consuming (eg. Hand and wrist takes 
approximately 50 mins.) 
Not well tolerated by some patients who are 
anxious and claustrophobic (some may 
require sedation); problematic for elderly 
who find it difficult to lie flat or still;  
High level of expertise required 
Motion artefacts 
Too sensitive (ie. uncertainty about the 
clinical significance of findings) 
Unsuitable for patients with ferromagnetic 
devices/implants such as heart valve  
Possible harmful effects if gadolinium 
injections are required   45
The reasons for this probably lay within the economics of MR imaging as a clinical tool. 
Costs of MRI have been questioned as a limitation (Wakefield, Balint et al 2005). High levels 
of expertise are required to operate the equipment and interpret the images and it can be time 
consuming, for example a hand and wrist may take approximately 50 minutes (Wakefield, 
Kong et al 2003). Further inconvenience may be experienced by the patient as, to undergo an 
MRI scan of their feet, they are required to attend the radiology department where the MRI 
scanner is housed for which there may be a delay of up-to six weeks from the time of their 
referral (Wakefield, Kong et al 2003). Wakefield, Kong et al (2003) further explain that the 
static image taken using high field MRI may be uncomfortable as patients have to maintain 
their foot in an exact position for lengths of time.  
 
The development of dedicated extremity MR scanners for the peripheral joints has potential 
to be useful for diagnosis of musculoskeletal foot pathology (Naraghi, White et al 2009).  
Naraghi, White et al (2009) compared a 1.0-T extremity MR with a 1.5-T conventional high-
field-strength MR. In that study the former machine was preferred by the majority RA 
participants in terms of system noise, and comfort (Naraghi, White et al 2009). Both 
machines were low resolution, which may affect accuracy of measurement, although the 
authors also reported good agreement for erosions and synovitis (Naraghi, White et al 2009). 
Whilst, extremity MR scanners may now be more feasible, further evidence is required that 
specifically addresses issues of low resolution and accuracy of measurement of foot 
pathology. The issue of extremity MR being a fixed, non-portable device also remains a 
limiting factor in its timely clinical use. 
 
2.4.3. Musculoskeletal ultrasound imaging 
Favourable comparisons of MRI to MSUS in the detection of inflammatory soft tissue lesions 
in rheumatological disease continue to be reported by authors (Gibbon and Wakefield 1999; 
Cantini, Salvarani et al 2001; Melchiorre, Calderazzi et al 2003; Terslev, Torp-Pedersen et al 
2003; Szkudlarek, Narvestad et al 2004). In their review of the role of MRI and MSUS in 
early RA, Wakefield, Kong et al (2003) support the opinions that MSUS is painless, harmless 
(no ionising radiation), is readily accessible for use within the clinical environment and 
relatively inexpensive. 
 
There are also important advantages for the patient with foot symptoms as the MSUS 
equipment can be made available within the clinical environment, any area of the foot can be   46
scanned rapidly at one time-point and treatment decisions, such as MSUS guided steroid 
injections can be made and implemented immediately. A summary of the advantages and 
disadvantages of MSUS formulated by Wakefield, Kong et al (2003) can be seen in Table 6. 
 
Table 6. The Advantages and Disadvantages of MSUS                                 
(Adapted from Wakefield, Kong et al 2003). 
Advantages of MSUS  Disadvantages of MSUS 
Relatively inexpensive 
Available in most radiology departments 
and increasingly available in many 
rheumatology departments 
Potential immediate availability in 
outpatient departments enabling rapid 
decision making 
Ability to scan several joints on one time 
point 
Well tolerated 
No ionising radiation, allowing multiple 
assessments in time and place 
Relative short scanning time (all joints < 
40 minutes, hands and feet 5 minutes) 
Allows real time, dynamic joint 
assessments 
Portable 
Operator dependant and steep learning curve 
Limited transducer access, for example, for deep 
joints such as the hip or more superficial joints 
where adjacent joints are in close proximity such 
as carpal bones 
Limited data on sensitivity to change with 
treatment 
Additional time required in clinical setting 
Lack of standardized methodology 
  
Review of the medical literature reveals that MSUS imaging is becoming accepted in 
rheumatological clinical practice as an aid to musculoskeletal assessment and diagnosis 
(Wakefield, Gibbon et al 1999; Backhaus, Burmester et al 2001; Balint, Kane et al 2001).   47
However, MSUS is extremely operator dependant and the use of this technology involves not 
only the underpinning detailed anatomical knowledge and the ability to recognise structures 
on screen, but also the understanding of the physics of MSUS and the recognition of 
principles of safety and recognition of artefacts.  
2.4.3.1. Basic principles of musculoskeletal ultrasound 
A sound wave consists of a mechanical disturbance of a medium (gas, liquid or solid) caused 
by acoustic energy which passes through the medium at a fixed speed (Fish 1990). The 
vibrations are measured as cycles per second, or hertz (Hz). Audible sound is in the range of 
60Hz to 20,000Hz and anything above 20,000Hz is considered ultrasound. In MSUS the 
vibrations are measured in 1 million hertz, or megahertz (MHz) so that frequencies used are 
high (1 - 20 MHz region) (Fish 1990).  
 
Ultrasound scanners rely on the same principles as SONAR (Sound, Navigation, And 
Ranging) with pulse – echo (or pitch and catch) (Fish 1990). Sound waves are emitted from a 
probe housing an electro-mechanical transducer that contains piezo-electric crystals, which 
vibrate when an electrical voltage is applied (Fish 1990). Fish (1990) gives a useful text 
reference that gives a detailed account of the physics of ultrasound waves as the pass through 
the body tissues. A summary of this process is charted in Figure 12.  
2.4.3.2. Musculoskeletal ultrasound artefacts 
Understanding of the basic principles of sound and various artefacts is essential to optimise 
the diagnostic value of ultrasound images (Table 7). Anisotropy (Figure 13), acoustic 
shadowing, mirror images, comet tail effects, reverberation artefacts and slice thickness can 
lead to misdiagnoses (Fish 1990).  
2.4.3.3. Musculoskeletal ultrasound safety 
Techniques for medical imaging all utilize some form of energy that must be capable of 
penetrating tissues to produce an image (Bushberg, Seibert et al 2002). In diagnostic imaging, 
mechanical energy (in the form of high frequency sound waves) is used in ultrasound 
imaging and the electromagnetic spectrum outside the visible light region is used for x-ray 
imaging, MR imaging and nuclear medicine (Bushberg, Seibert et al 2002). The diagnostic 
advantage of a medical image relates to both the technical quality of the image and the 
conditions of its acquisition (Bushberg, Seibert et al 2002). Therefore, the higher the power 
levels of the ultrasound, the better the image.   48
Figure 12. Flow diagram of the passage of ultrasound waves through the body tissues 
(adapted from Fish 1990). 
 
 
                                                                                                    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sound waves pass through the tissues.  
Speeds of propagation 
through different soft tissues 
varies slightly, but are 
approximately 1540m/s 
(transit time of 6.5μs/cm). 
At a boundary between two tissues, some 
ultrasound waves pass on and some are reflected, 
refracted, scattered, attenuated or absorbed as 
they pass through the body. 
The strength of the reflection 
depends on the angle that the 
beam is directed and the 
acoustic impedance of the 
tissue that the beam travels 
through. 
A large difference in 
acoustic impedance leads to 
a high degree of reflection 
eg. soft tissue-bone or soft 
tissue-air interfaces. 
At the boundary between 
two different types of soft 
tissue (eg: muscle-fat) the 
degree of reflection is small.  
Acoustic impedance is 
determined by the density 
and the stiffness of the tissue 
that the sound passes 
through. 
Ultrasound is reflected at tissue interfaces where 
the beams angle of incidence is perpendicular to 
the interface. 
This is highly angle dependant and refraction can 
occur when the beam is bent by passing through 
an area of different acoustic impedance from the 
surrounding tissue. 
Attenuation occurs throughout the image and 
occurs due to reflection, refraction, absorption 
and scatter. 
If the tissue boundary is small relative to the 
wavelength of ultrasound or the surface is rough, 
the ultrasound beam is diffused/scattered.
Reflected sound waves pass back to the probe 
where mechanical vibrations are changed to 
electrical signals by the same transducer working 
in reverse.  
MSUS probe is placed on the skin surface.    49
Table 7. Common artefacts encountered with MSUS (adapted from Fish 1990). 
Artefact Definition 
Anisotropy or beam 
obliquity artefact 
The most common and the result of the sound wave striking the anatomical 
structure at an angle of less than 90
o so that the tissue does not appear to 
exhibit the same acoustic physical properties in all directions. Acoustic 
shadowing occurs after heavy attenuation of the signal compared to the 
surrounding tissue. Acoustic enhancement is the opposite.  
Mirror images  Occasionally a very strong reflection can give rise to a mirror image of what 
is already seen.  
Comet tail effects  When a long tail of bright echoes can sometimes be seen trailing from very 
strong reflectors. These can be caused by foreign bodies such as shot, metal-
ware or gas bubbles.  
Reverberation 
artefacts 
Usually seen in the near field due to multiple reflection between the probe 
face and a deeper structure.  
Slice thickness  The cross section of the slice thickness is greater than the structure being 
examined and instead of seeing a clear boundary it can sometimes fill in with 
echoes or appear a dark grey  
 
 
Figure 13. A posterior longitudinal MSUS scan to demonstrate anisotropy at the 
attachment of the Achilles tendon at the posterior aspect of the calcaneus in a healthy 
subject lying prone. 
 
Key: ** = Anisotropy; PC = Posterior calcaneus; TA = Achilles tendon 
Equipment: Diasus MSUS system (Dynamic Imaging Ltd. UK)   50
 
The American Institute of Ultrasound in Medicine Report on Medical Ultrasound Safety 
(AIUM 1994) reported on laboratory trials where some risk of ultrasound exposure damage to 
tissues has been documented at much higher intensities than is used in diagnostic ultrasound. 
As sound waves gradually travel through the body, they can be absorbed by the visco-elastic 
nature of the tissues they pass through, which can be likened to friction or damping and 
usually the energy is dispersed as heat (Fish 1990). This is supported by the ‘Statement on the 
Safe Use, and Potential Hazards of Diagnostic Ultrasound’ that was prepared by the Safety 
Group of the British Medical Ultrasound Society (BMUS) in June 2000 and reconfirmed by 
the BMUS Council in October 2007 (BMUS 2000). 
 
All documented adverse biological effects induced by ultrasound have occurred at these 
higher intensities and include rise in tissue temperature and mechanical bioeffects such as 
cavitation (AIUM 1994). The risk associated with ultrasound is thus attributed to levels of 
exposure that are never used within clinical practice.  An excellent safety record exists in that, 
after decades of clinical use, there is no known instance of human injury as a result of 
exposure to diagnostic ultrasound (AIUM 1994). The power levels used are thus a 
compromise and a balance between patient safety and image quality (Bushberg, Seibert et al 
2002).  
 
2.4.3.4. Musculoskeletal ultrasound equipment 
According to the American Institute of Ultrasound in Medicine’s official statement on 
clinical safety (AIUM 1994), current data indicate that the benefits to the patient of the 
prudent use of diagnostic ultrasound outweigh the risks, if any, that may be present. All 
modern MSUS systems should comply with the AIUM 1994 recommendations on the 
inclusion of thermal and mechanical indices within the output display. During clinical 
assessments with ultrasound equipment, the total ultrasound exposure is kept as low as 
reasonably achievable, known as the ALARA principle (As Low As Reasonably Achievable) 
(AIUM 1994; BMUS 2000). 
 
The choice of equipment, in particular, the transducer is thus important yet may be confusing 
to the trainee user. The transducer is periodically driven by an electrical pulse and a pulse is 
then received back at the transducer after reflection or scatter of tissue interfaces (Kremkau   51
1998). The time of arrival of the echo from a given interface depends on the depth of that 
interface.  The instrument can use the time of arrival of an echo after transmission as an 
indication of the depth of the interface.  
 
Since the transducer is used to both transmit and receive the ultrasound beam, reviewers 
indicate that there is always a trade-off between depth of penetration and resolution 
(Wakefield, Gibbon et al 1999). That is, the higher the frequency, the greater the resolution, 
but the less depth of tissue penetrated (see Figure 14).  
 
 
Figure 14.  Longitudinal skin section demonstrating MSUS frequency (MHz) compared to 
depth of tissue penetrated in a large joint  
(schematic by RH09 graphic design, Southampton, 2009). 
 
 
For MSUS, high frequency transducers of approximately 7.5 - 10MHz or higher are 
appropriate (O’Connor and Grainger 2002, see Table 8). 
 
The size of the active length of the MSUS transducer (probe) is another important factor to 
consider (Backhaus, Burmester et al. 2001; Schmidt and Backhaus 2008).  The active length 
of the MSUS transducer may vary from 6cm to 2cm depending on the machine into which 
they are built (Schmidt and Backhaus 2008). For example, longer probes are said to provide 
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good overviews for larger joints and tendons whereas small ‘footprint’ transducers, known as 
‘hockey sticks’, allow better coupling to small joints and around bony surfaces (Schmidt and 
Backhaus 2008). In particular, these transducers are said to be excellent for visualization of 
small superficial structures such as hammer toes (Schmidt and Backhaus 2008). Most 
transducers used in MSUS practice are linear, however curved array probes are also available 
and are useful for visualize deeper anatomical structures and are mainly used for abdominal 
ultrasound (Schmidt and Backhaus 2008). 
 
Table 8. Transducer frequency compared to depth of tissue penetrated (adapted from Rockett
1999; Backhaus, Burmester et al 2001). 
Transducer frequency  Structures readily identified 
3.5 – 7.5MHz  Large joints (eg: hip, shoulder) 
7.5 – 16MHz  Small joints, tendons, ligaments, neuroma, bursae, nodules 
10 – 20MHz  Very superficial structures (eg: extensor tendons of toes) 
16 – 28MHz  Discrete layers within the skin 
 
The use of ‘stand off’ pads and techniques for using a water bath to facilitate the ultrasound 
wave conduction over gross structural deformities are also available. These techniques 
reportedly increase the field of view in anatomical areas where the contour of the part is 
such that it only allows a small area of contact (Stokes, Hides and Nassiri 1997). 
 
Cost of the equipment also requires consideration according to its proposed use. The cost of a 
high quality, high resolution system can range from £30,000 to over £130,000 and lower 
resolution units from £12,000 to £20,000. Wakefield, Gibbon et al (1999) argue that a 
misconception is often made that a low cost unit is ideal for use in the clinical setting but, 
unfortunately, this is often where the operator is the least experienced. In this situation, it is 
recommended that the highest possible imaging quality is essential and that a more 
experienced sonographer could probably manage with a lower resolution system.  
 
2.4.3.5. Musculoskeletal ultrasound applications 
Most MSUS investigations are performed using ‘grey scale’, which means images are 
produced in a black and white format; each white dot in the image represents a reflected 
sound wave (Kremkau 1998). Sound waves that return to the transducer (probe) are   53
interpreted as a signal on screen (white). When the sensor picks up no echoes, there will be 
no signal (black). When sound waves change speed, even minutely, the interface that exists 
between the tissues will appear as contrast (Fish 1990). For example, sound beams do not 
penetrate the bone cortex so it shows up as a bright echo and fluid is anechoic, with fluid in 
bursae depicted as being dark (Fish 1990; Kremkau 1998). Tendons are characteristically 
hyperechoic (bright) on ultrasound demonstrating a bright fibrous pattern. Muscle is 
relatively hypoechoic (dark) to tendon fibres and ligaments that are hyperechoic (bright) 
(Figure 15). 
 
Figure 15. A longitudinal MSUS scan at the posterior aspect of the calcaneus in a 
healthy subject lying prone. 
 
Key:.TA = Achilles tendon; PC = posterior aspect of calcaneal bone; 
f = retrocalcaneal fat pad 
Equipment: Diasus MSUS system (Dynamic Imaging LTd, UK) 
 
Traditional grey scale MSUS imaging allows visualisation of synovitis, joint capsule rupture, 
bursitis, tenosynovitis, tendonitis and tendon rupture, joint surface irregularities and erosions, 
osteophytes, loose joint bodies and foreign bodies (Coakley, Samanta et al 1994; Koski 1998; 
Backhaus, Kamradt et al 1999; Schmidt, Volker et al 2000; Wakefield, Gibbon et al 2000; 
Grassi, Filippucci et al 2001).  
 
Steroid injections, joint aspiration and synovial biopsy have also proven to be readily   54
performed under MSUS guidance (Kane, Greaney et al 1998; van Vugt, van Dalen et al 1998; 
Crawford et al 1999; Koski 2000; Wen-Chung 2000; Kane et al 2001; Qvistgaard et al 2001; 
Koski & Hermunen 2001; Balint, Kane et al 2002; Fredberg, Bolvig et al 2004; Grassi, 
Filipucci et al 2004; Genc, Saracoglu et al 2005). 
 
Pathological changes of soft tissue structures within the foot are, reportedly, readily identified 
by MSUS which can be a useful aid in the diagnosis of foot symptoms (Riente, Sedie et al 
2006) (Table 9).   
 
Table 9. Reported applications for diagnostic ultrasound within the foot & ankle. 
Effusions and impingements of the ankle 
joints 
Bell and McNally (2002)  
 
Tenosynovitis of tibialis anterior, posterior 
and peroneus longus, brevis  tendons 
Koski (1995)  
 
Achilles tendon imaged in its full length and 
calcification, ruptures and bursitis can be 
differentiated 
Ridola and Palma (2001)  
 
Lesions of plantar fascia and calcaneal spurs   Bygrave, Betts et al (1998); Kane, Greaney et 
al (2001); Balint, Kane et al (2002)  
Diagnosis of morton’s neuroma  Jones, Bygrave et al (1999); Irwin, 
Konstantoulakis et al (2000)  
Diagnosis of persistent post operative pain  Brown, Betts et al (1994)  
Screening of diabetic and rheumatoid patients 
for high metatarsal pressures 
Young, Coffey et al (1995)  
 
 
More recently, the advances in colour Doppler and power Doppler MSUS have shifted the 
focus to assessing changes in joints and soft tissues as a result of inflammation such as 
effusions, proliferating synovium and active synovitis (Wakefield, Brown et al 2003). Balint, 
Mandl and Kane (2008) suggest that detection of changes in synovial perfusion by power 
Doppler could be advantageous in determining whether an erosion is active or burned out or   55
which parts of pannus are inflamed and which parts are fibrotic. Whilst this may provide 
more convincing evidence for targeted treatment, the authors also warn that interpretation of 
power Doppler MSUS is complicated by the frequent presence of artefacts (Balint, Mandl 
and Kane 2008). 
 
2.4.3.6. The role of musculoskeletal ultrasound imaging in rheumatoid arthritis 
Grey scale and power Doppler MSUS have become an established imaging technique for RA 
synovitis (Backhaus, Kamradt et al 1999; Wakefield, Gibbon et al 2000; Backhaus, Sandrock 
et al 2002; Hau, Kneitz et al 2002; Szkudlarek, Court-Payen et al 2003; Scheel, Schmidt et al 
2005). Previously, criteria for diagnosis of early RA involved the assessment of bone erosion 
detected radiologically by x-ray (Arnett, Edworthy et al 1988). However, conventional 
radiography is insensitive in the detection of synovitis (Backhaus, Kamradt et al 1999; 
Wakefield, Gibbon et al 2000; Backhaus, Sandrock et al 2002). It is now also accepted that 
clinical examination may be relatively insensitive (Wakefield, Brown et al 2004; Brown, 
Quinn et al 2006; Brown, Conaghan et al 2008) and that imaging studies have confirmed a 
discrepancy between clinical examination and MRI-detected synovitis (Klarlund, Ostergaard 
et al 2000; Goupille, Roulot et al 2001; Brown, Quinn et al 2006). O’Connor and Grainger 
(2002) predicted that the demonstration of synovitis by MSUS would be most important in 
the measure of therapeutic response and outcome in patients with RA.  
 
There appears to be agreement within the literature that MSUS is a sensitive measure for 
detection of synovitis and that MSUS is capable of detecting significantly more synovitis than 
clinical assessment alone (Bresnihan and Kane 2004; Wakefield, Green et al 2004). MSUS 
has been shown to detect extensive sub-clinical synovitis and that this led to altered 
management in 12% of cases (Karim, Wakefield et al 2001). Giving credence to this, patients 
with RA and apparent clinical remission have been demonstrated to have measurable 
synovitis by grey scale and power Doppler MSUS (Brown, Quinn et al 2006). 
 
Despite this increasing evidence for the potential application of MSUS in the evaluation of 
RA synovitis and tenosynovitis, there remains a lack of standardisation between studies 
(Joshua, Lassere et al 2007). For example, synovitis may be detected by ultrasound when it is 
thickened, because it appears as hypoechoic intra-articular tissue (O’Connor and Grainger 
2002) (Figure 16). The skill in interpretation of MSUS images is essential, as detection of   56
synovial hypertrophy by greyscale MSUS without power Doppler can be found in healthy 
subjects. Synovial hypertrophy has been observed by MSUS within healthy subjects with 
normal limits for MTP joint synovitis recorded as 2.9mm or less (Luukkainen, Ekman et al 
2009).  
 
Attempts have been made to produce semi-quantitative scoring methods for quantification of 
ultrasound detected synovitis (Szkudlarek, Court-Payen et al 2003; Scheel, Schmidt et al 
2005) although in both studies mean disease duration of participants was indicative of late 
RA, suggesting that results may not be comparable for patients with early RA. The 
OMERACT Ultrasound Special Interest Group has gone some way to addressing these 
concerns, in continuing to focus its work on defining and standardizing approaches for MSUS 
assessment (Wakefield, Balint et al 2005; Wakefield, D’Agostino et al 2007; Joshua, Lassere 
et al 2007). 
 
 
Figure 16. MSUS image of synovitis of the fifth metatarsal joint in a patient with 
rheumatoid arthritis (from: the EULAR Guidelines for Musculoskeletal Ultrasound in 
Rheumatology, Filippucci E and Farina A 
http://www.doctor33.it/eular/ultrasound/Foot.htm Accessed February 2009). 
 
 
                               Key: Marked hypoanechoic joint cavity widening (*).  
 mt = metatarsal head; pp = proximal phalanx. AU4-Idea 
                               Equipment: Esaote Biomedica  
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2.4.3.7. Musculoskeletal ultrasound imaging of bursae in rheumatoid arthritis 
On MRI and MSUS the synovium of swollen bursae within the knee, hip and shoulder in 
patients with RA are reported as similar in appearance to the characteristics of joint synovitis 
(O’Connor and Grainger 2002; Hermann, Backhaus et al 2003; Meenagh, Iagnocco et al 
2006; Finlay and Friedman 2006). 
 
Swollen bursae are stated as more readily identifiable by MSUS than synovitis with thickened 
synovium of a bursa appearing as hypoechoic tissue and the fluid within appearing anechoic 
(O’Connor and Grainger 2002). Other authors however have reported poor reliability in the 
use of MSUS to detect swollen bursae within shoulders (Hermann, Backhaus et al 2003). 
Among 30 patients without demonstration of swollen bursae on ultrasound, MRI identified 
swollen bursae in 9 (30%). Of the 13 shoulders with swollen bursae demonstrated by 
ultrasound, 4 (31%) escaped detection by MR Imaging (P=0.2668) (Hermann, Backhaus et al 
2003). 
 
Identification of swollen forefoot bursae also appears challenging due to potential close 
associations with Morton’s neuromas. Morton’s neuromas are commonly mistaken for 
swollen intermetatarsal bursae (Bossley and Cairney 1980; Awerbuch, Shephard et al 1982; 
Zanetti, Strehle et al 1997; Iagnocco, Coari et al 2001) and therefore it is important to 
distinguish the appearance of these on MSUS.   
 
Confusion may also exist in the use of MSUS to detect bursae in the plantar area of the 
forefoot as the appearance of other inflamed soft tissues may be similar. Other causes of soft 
tissue inflammation such as MTP joint synovitis, tenosynovitis, stress fracture, tendon sheath 
ganglion are readily distinguishable by MRI (Bancroft, Peterson and Kransdorf 2008). 
However, there appears to be very little evidence of studies using MSUS to distinguish 
pathology in the plantar forefoot area. Consequently, there is currently no standardized 
method for MSUS imaging of bursae in the plantar forefoot area. 
 
In cadaver dissections, Chauveaux, Le Huec and Midy (1987) determined that the 
intermetatarsal bursae usually bulge spontaneously anteriorly beyond the transverse 
metatarsal ligament. Similarly, Claustre, Bonnel et al (1983) had previously described 
hypertrophied intermetatarsal bursae that had gradually extended beyond their normal site 
towards the dorsal or plantar region of the foot. In his investigation of intermetatarsal bursae   58
in patients with early RA, Koski (1998) used the latter information from cadaver studies to 
determine his MSUS protocol. On MSUS, he described intermetatarsal bursae as 
‘anechogenic’ and bulging more than 1mm under the metatarsal head level (Koski 1998) 
(Figure 17). Morton’s neuroma, on the other hand, are usually well defined by MSUS as an 
hypo-echoic mass, ovoid in shape, with its long axis aligning to the shaft of the metatarsals 
(Ellis, Teh et al 2002).  van Holsbeeck (1999) suggested that compression with the transducer 
can aid diagnosis in this instance as bursae were compressible, whilst neuroma were not.  
 
To complicate the picture further, adventitious bursae that may occur due to mechanical 
stress underneath the metatarsal heads within the plantar fat pad area are also readily 
identifiable by MSUS (Gregg, Schneider and Marks 2008). A major limitation of the study by 
Koski (1998) was that his technique for identifying the bursae on MSUS as anatomical 
intermetatarsal bursae was not validated against any other method, such as MRI or 
histological analysis through biopsy. His approach was justified through a detailed 
knowledge of the anatomical structures being imaged and the interpretation of the MSUS 
grey scale image of the bursae.  
 
 
Figure 17. A) MSUS scan of bursitis (single white arrow) between the 2
nd and 3
rd 
metatarsal heads demonstrating an anechoic area whilst the area between the 3
rd and 4
th 
metatarsal heads is normal and echogenic. B) Photograph demonstrating the ultrasound 
scan taken in the transverse view of the right foot (from Koski 1998). 
A  B  
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2.4.3.8. Documentation of musculoskeletal ultrasound images 
For those clinicians trained in diagnostic MSUS techniques, further recommendations 
propose that all scans should be performed according to a standardised approach (Backhaus, 
Burmester et al 2001).  
 
•  All pathological findings should be documented in two perpendicular planes, longitudinal 
and transverse  
•  All scans should be performed moving from proximal to distal 
•  When examining the ankle and heel the patient should be in the supine position for 
ventral and lateral scans and the prone position for dorsal scans with the hip and knee 
joints in their neutral positions 
•  For the foot, the patient should be in the supine position for dorsal scans and the prone 
position for plantar scans. 
•  For the foot scans should be performed moving from proximal to distal 
 
The OMERACT Ultrasound Special Interest Group have gone some way in defining and 
standardizing approaches for MSUS assessment (Wakefield, Balint et al 2005; Wakefield, 
D’Agostino et al 2007; Joshua, Lassere et al 2007) although there remains a reported lack of 
standardisation between published studies (Joshua, Lassere et al 2007). In particular, there 
appears to be little evidence for standardized MSUS imaging approaches for assessment of 
the foot and at the time of the studies that form this doctoral thesis there was no definition for 
MSUS assessment of plantar forefoot bursitis. It was anticipated that the development of 
tailored learning to areas directly relevant to the discrete field of foot and ankle pathology 
may be the answer to this (Brown, Roberts et al 2007). 
 
2.4.3.9. Training issues and legislation for use of musculoskeletal ultrasound 
Diagnostic ultrasound is stated as being the most operator dependent imaging technique 
(Grassi and Cervini 1998).  Although the procedure itself has no specific side effects, harm 
may result from incorrect acquisition and interpretation of images (O’Connor and Grainger 
2002). The reported lengthy learning curve for this skill is related primarily to the quality and 
interpretation of the ultrasound images that are greatly dependent on the expertise and 
experience of the operator (Balint and Sturrock 1997). Secondary to this is the use of older 
instrumentation where image quality may have been poorer and instruments were not so user   60
friendly (Balint and Sturrock 1997). 
 
A critical issue is one of overall image resolution, which has to be analysed carefully. MSUS 
requires high frequency probes in order to achieve the necessary resolution for accurate 
diagnosis and artefacts are common with potential for variation in interpretation of image, 
particularly with respect to the positioning of the transducer array (O’Connor and Grainger 
2002). For example, if structures that contain multiple parallel linear sound interfaces, such as 
tendons or muscles, are not visualised with the transducer array perpendicular to the long axis 
of the linear interfaces, there is reflection of the beam away from the transducer causing a 
reduction in echogenicity of the tissue (O’Connor and Grainger 2002). This mimics disease 
of these structures and represents a liability in the assessment of tendons and muscles 
(O’Connor and Grainger 2002). Knowledge about the basic principles relevant to sound 
waves and a detailed anatomical knowledge of the structures under investigation are therefore 
mandatory (Backhaus, Burmester et al 2001).  
 
Recommendations by the professional body of the sonologists regarding the training for 
MSUS advise two supervised ultrasound lists per week over a six-month period (O’Connor 
and Grainger 2002). In an attempt to standardise the quality of MSUS education, national and 
international societies for example, BMUS (British Musculoskeletal Ultrasound Society), 
EULAR (European League Against Rheumatism) and EFSUMB (European Federation of 
Societies for Ultrasound in Medicine and Biology) have begun to establish training guidelines 
for MSUS (Backhaus, Burmester et al 2001; Valentin and Jager 2003). EULAR experts in 
MSUS have provided recommendations for the conduct and content of MSUS courses with 
hands on experience organized at different levels of basic, intermediate and advanced, 
specifically for non-radiologists (Naredo, Bijlsma et al 2008). Others have been developing 
specific competencies for MSUS (Brown, O’Connor et al 2005; Brown, O’Connor et al 2006) 
and e-learning packages that complement these training programmes are also available for the 
continued support in learning the techniques of MSUS (Filippucci,Meenagh et al 2007).  
 
Repetition to the point of over-learning is needed to become really proficient (French, Neville 
et al 1994) and support from medical colleagues in the acquisition of these skills is a major 
factor. A good relationship with radiology colleagues is thus essential for the practice and 
development of the skills through the initial stages of the ‘learning curve’.  
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2.4.3.10. The use of musculoskeletal ultrasound performed by a Podiatrist 
As technology has improved, clinical expertise in performing musculoskeletal ultrasound has 
also advanced dramatically and some have made it clear that these techniques should be 
accessible to non-radiologists (Gibbon 1996; O’Connor and Grainger 2002). Podiatrists are 
required in their training to have a detailed thorough anatomical knowledge of the foot and 
ankle (QAA 2001) and could potentially be the most appropriate practitioners to include this 
skill as part of their role within foot and ankle assessment (Bowen 2003; Bowen, Dewbury et 
al 2008).  
 
Models for the use of MSUS for health professionals other than radiologists have been 
demonstrated (Filipucci, Unlu et al 2003; Taggart, Filipucci et al 2006). There have been 
some attempts at defining the learning curve of rheumatologists. D’Agostino, Maillefert et al 
(2004) reported good achievement of agreement for two novices (kappa scores 0.63 and 0.62) 
but reduced accuracy for the third novice on diagnosis of 70 patients using MSUS. 
Agreement within this study was recorded as diagnosis with no attempt to blind each 
investigator to clinical signs (D’Agostino, Maillefert et al 2004). Other authors have 
investigated quality of image acquisition concluding that a novice could obtain acceptable 
images in 24 non-consecutive hours of active scanning after an intensive self teaching 
programme (Filipucci, Unlu et al 2003; Taggart, Filipucci et al 2006). Taggart, Filipucci et al 
(2006) suggest agreement of 80% of scans in interpretation of images during their 
competency assessment. 
 
As explained earlier within this chapter (section 2.3, page 29) instrumentation for gait 
mechanics, foot pressure analysis and patient facing questionnaires have proven to be 
invaluable in aiding and augmenting investigations of the foot and ankle (Woodburn and 
Helliwell 1996; Hodge, Bach et al 1999; Garrow, Papageorgiou et al 2000; Barnett, Campbell 
and Harvey 2005; Helliwell, Reay et al 2005).  The extensions to the scope of practice of 
diagnostic skills for the podiatric practitioner have enabled clinical access to information on 
body structures and systems with the outcome of more effective management of foot and 
ankle pain (Wall 1997; Puttemans and Nemery 1998; Hodge, Bach et al 1999). Similarities 
exist between these skills and the potential of diagnostic MSUS imaging for use by informed 
clinicians in aiding assessment and evaluation of the management of foot problems.  
 
Real time MSUS imaging of foot and ankle structures could emerge as an adjunct to current   62
podiatric and rheumatologic practices or as an interim means of guiding clinical decisions 
towards other investigative routes. In achieving this, regulation of extended scope practices is 
essential for the safety of patients. The validation of education and skills training and 
subsequent professional indemnity insurance of Podiatrists are the responsibility of the Health 
Professions Council and The Society of Chiropodists and Podiatrists (London, UK) (DOH 
2000).  Effective communication with the OMERACT Ultrasound Special Interest Group and 
the professional bodies of rheumatologists and radiologists regarding the skills acquisition 
courses for diagnostic musculoskeletal ultrasound is therefore required to take the 
developments in training of podiatrists and other allied health professionals further.  
 
2.5. Justification for the study 
The justification brings together thoughts from the subject material presented in the literature 
review and the important issues regarding the relevance of bursae in the forefoot in patients 
with RA. In summary, the key issues identified are: 
1.  The effects on the foot are important in RA but under-investigated 
2.  Clinical examination alone is relatively insensitive to the detection of synovitis 
and bursitis within the foot in RA 
3.  Bursae appear to be important contributors to forefoot pathology in RA and may 
be readily identified with MSUS 
4.  MSUS imaging performed by a Podiatrist could enhance current clinical 
treatment decisions for pathology within the forefoot in RA 
 
Many authors agree that RA commonly affects the feet causing swelling and pain within the 
foot joints that reduces a person’s ability to walk (Platto, O'Connell et al 1991; Wiener-
Ogilvie 1999; Costa, Rizack et al 2004; Redmond, Waxman et al 2006). However, most 
attention in the assessment of RA disease status is directed towards hands; for example the 
recommended standard for quantifying disease activity in RA, the Disease Activity Score 
(DAS28), does not include feet (Prevoo, van't Hof et al 1995) and classification criteria for 
RA have been criticised for exclusion of certain factors such as foot erosions (Hulsmans, 
Jacobs et al 2000). 
 
The prevalence of foot pathology in RA is usually related to the duration of systemic illness 
(Spiegel and Spiegel 1982; Michelson, Easley et al. 1994; Shi, Tomita et al. 2000) yet little is   63
known about the appearance and progression of the patho-physiological effects of RA within 
the foot. Most studies that have reported on foot pathology and interventions for foot 
pathology in RA, utilize cross sectional designs but there is clearly a need for better quality 
information about progression and risk factors for progression of foot disease in RA to enable 
more fitting targeted therapies. 
 
It is now accepted that clinical examination of RA synovitis within the foot is relatively 
insensitive (Woodburn, Udupa et al. 2002) and that imaging studies have confirmed a 
discrepancy between clinical examination and imaging detected synovitis (Klarlund, 
Ostergaard et al 2000; Goupille, Roulot et al 2001; Tan, Tanner et al 2003; Brown, Quinn et 
al 2006). As conventional radiography has also been confirmed as insensitive in the detection 
of synovitis (Backhaus, Kamradt et al 1999; Wakefield, Gibbon et al 2000; Backhaus, 
Sandrock et al 2002) assessment of the feet in patients with RA by MSUS could provide 
clinicians with further information regarding the patterns of soft tissue changes and 
progression of RA through the course of the disease. Notably, the presence of swollen 
anatomical bursae may be associated with the same disease process as synovitis of joints and 
tendons and is an important, but often may be an undiagnosed, cause of pain in the forefoot in 
RA (Koski 1998; Olivieri, Scarano et al 2004). Although the presence of swollen anatomical 
bursae have been linked with RA disease progression (O’Brien, Hart et al 1997; Narvaez, 
Narvaez et al 2002) and MSUS is more sensitive than clinical examination at detecting 
swollen anatomical intermetatarsal bursae (Koski 1998), the presence of anatomical bursae 
and adventitious bursae within the foot in patients with RA has largely received very little 
attention within the literature. 
 
Following review of the literature (see Appendix 1 for search strategy), no work has been 
identified that has sought to use MSUS to determine the prevalence and natural history of 
swollen bursae within the forefoot in patients with RA. It may be possible that the imaging of 
bursae within the forefoot by MSUS would add new information to the clinical assessment of 
the condition in RA. If this proves true, the information would provide immediate 
information to support more timely and effective targeted clinical management to address 
pain, disability and loss of mobility within the foot.  
 
As training courses and competencies are designed for the use of MSUS by non-radiologists 
(Brown, O’Connor et al 2005; Brown, O’Connor et al 2006; Naredo, Bijlsma et al 2008) and   64
tailored learning to discrete areas of clinical practice are advocated (Brown, Roberts et al 
2007) then the use of MSUS imaging performed by a podiatrist to identify swollen bursae 
within the forefoot could also be an important benefit to patient care.  
 
2.6. Research questions 
Using MSUS performed by a podiatrist, this doctoral study provided an opportunity to assess 
the prevalence and natural history of bursae occurring within the forefeet of patients in 
secondary care who were being managed for RA. A second aim was to determine if the 
presence of bursae occurring within the forefeet was associated with patient reported foot 
impact outcome measures in this patient population. 
 
The outline research questions addressed within the thesis were therefore as follows: 
Chapter 4: Reliability of the MSUS technique 
a)  Is diagnostic ultrasound, performed by a podiatrist, a reliable technique to identify the 
prevalence of bursae in the RA plantar forefoot? 
b)  Does the presence of MSUS detectable bursae in the plantar forefoot area of patients 
with RA change following a period of intervention (anti-TNF-α therapy)? 
c)  Is MSUS responsive to change in prevalence of bursae in the plantar forefoot area of 
patients with RA following a period of intervention (anti-TNF-α therapy)? 
Chapter 5: Prevalence of MSUS detectable forefoot bursae in RA patients. 
a)  What is the prevalence of bursae within the forefeet of healthy subjects and patients with 
RA detectable by MSUS and detectable clinically? 
b)  Which are the most common sites in the RA plantar forefoot for MSUS detectable 
bursae?  
c)  Is there a difference between the prevalence of MSUS detectable bursae within the 
forefeet of healthy subjects and RA participants? 
d)  Is the prevalence of MSUS detectable bursae within the forefeet of RA participants 
associated with patient reported outcome measures such as LFIS? 
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Chapter 6: Changes in prevalence of MSUS detectable forefoot bursae in RA after one 
year. 
a)  Does the prevalence of MSUS detectable bursae in the plantar forefoot area of patients 
with RA change over time? 
b)  If the prevalence of MSUS detectable bursae does change after one year what predicts 
that change? 
 
2.7. Summary of chapter two 
This chapter has laid the foundations for the thesis. It has introduced the research problem, 
background literature, justification and research questions. On these foundations, the report 
can proceed with a detailed description of the research. 
 
The methodology and results are therefore discussed within the chapters three, four, five, six 
and seven of this doctoral thesis. Conclusions are also given, followed by implications for 
future research. 
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3.0 Chapter Three: Methodology  
Following review of the literature, it is apparent that bursae appear to be an important 
contributor to forefoot pathology in RA and that MSUS performed by a podiatrist may be an 
effective method in evaluating this. However, there is currently no evidence to support this 
supposition.  
 
3.1. Aim 
The aim of this doctoral study was therefore to develop a reliable MSUS imaging technique 
to be performed by a podiatrist to assess the prevalence and natural history of bursae 
occurring within the forefeet of patients in secondary care who were being managed for RA. 
A second aim was to determine if the presence of bursae occurring within the forefeet was 
associated with patient reported foot impact outcome measures in this patient population. 
 
3.2. Hypotheses 
3.2.1. Null hypotheses (Ho)  
1. A podiatrist performing MSUS is not reliable in the detection of forefoot bursae in patients 
with RA. 
2. MSUS detectable bursae within the forefoot are not a prevalent factor in patients with RA. 
3. MSUS detectable bursae within the forefoot are not associated with patient reported foot 
impact outcome measures in patients with RA. 
3.2.2. Alternative hypotheses (H1) 
1. A podiatrist performing MSUS is reliable in the detection of forefoot bursae in patients 
with RA. 
2. MSUS detectable bursae within the forefoot are a prevalent factor in patients with RA. 
3. MSUS detectable bursae within the forefoot are associated with patient reported foot 
impact outcome measures in patients with RA. 
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3.3. Scope of the doctoral study 
The three studies that form the scope of this thesis were conducted over a three and a half 
year period, from February 2005 to September 2008. All participants who had RA attended 
the Wellcome Trust Clinical Research Facility, Southampton Universities Hospital NHS 
Trust.  All healthy control participants attended the Biomechanics Laboratory, School of 
Health Professions and Rehabilitation Sciences, University of Southampton.  
 
3.4. Ethical approval 
The Local Research Ethics Committee approved the protocol for the first phase of the study 
(assessment of the forefoot by MSUS in patients with rheumatoid arthritis on anti-TNFα 
therapy) in March 2004. Sponsorship and Professional Indemnity Insurance was received 
from the Southampton University Hospitals Trust (SUHT) in April 2004. This was followed 
by the period of recruitment (N=32), data collection and report for the first phase (reliability 
of the technique) of the study between February 2005 and June 2007.  
 
The Local Research Ethics Committee approved the protocol for the second phase of the 
study (MSUS assessment of the forefeet of patients with rheumatoid arthritis, N=200, at 
baseline and twelve months) in June 2006 (see Appendix 2). Sponsorship and Professional 
Indemnity Insurance was also received from SUHT in June 2006. Recruitment and data 
collection of the second phase commenced in July 2006 and was completed in September 
2007. 
 
The School of Health Sciences Research Ethics Committee approved the protocol for the 
healthy control participants in the second phase of the study (MSUS assessment of the 
forefeet of participants who do not have systemic musculoskeletal pathology; N=20) in 
November 2006, subsequently approved for amendment to N=50 in November 2007 (see 
Appendix 3). Sponsorship and Professional Indemnity Insurance was received from the 
University of Southampton in December 2006 and for the amendment in November 2007. 
Recruitment and data collection of healthy control participants took place between February 
2008 and April 2008.  
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3.6. Study design 
The overarching philosophy of the doctoral study is rooted in positivistic, epidemiological, 
observational (non-experimental) research. Bowling (2002) explains positivism as an 
approach that aims to discover laws using quantitative methods that emphasize positive facts, 
and epidemiology as being concerned with the distribution of, specific causes of, and risk 
factors for diseases in populations. 
 
Most studies reporting on prevalence of foot manifestations in RA tend to use cross sectional 
methodological designs. For example, Shi, Tomita et al (2000) used a cross sectional design 
to investigate two groups of patient; those who had RA less than ten years and those who had 
RA for more than ten years. Michelson, Easley et al (1994) systematically examined the feet 
of an unselected group of ninety nine patients with RA, with average disease duration of 
thirteen years. The prevalence of the manifestations of RA within the foot in both studies was 
related to the duration of systemic illness (Michelson, Easley et al 1994; Shi, Tomita et al 
2000). 
 
However, cross sectional studies are limited to one time point and one population; so that 
exposure and outcome are measured at the same time (Byrne 1998) and little would therefore 
be known about the appearance and progression of pathology within the foot. Fortin, Stucki 
and Katz (1995) challenged researchers to address the “threats to relevance of change” in RA 
disease, within their study designs. In a cohort study, exposure is measured in the present and 
outcome is recorded at some point in the future (Byrne 1998). Therefore to confirm 
relationships and predictors of disease, longitudinal cohort studies with prospective 
measurements would be ideal (Byrne 1998) (Table 10). 
 
To answer the research questions (Chapter two, section 2.6, page 64) and be able to accept or 
reject the null hypotheses, the optimal research design for studies two and three was selected   69
to be a longitudinal cohort study. Embedded within the design of study two was a case 
reference study, to enable comparisons of baseline demographic and clinical characteristics of 
the RA study sample. 
 
Table 10. Summary of the ideal study design (from Byrne 1998). 
A measure of outcome should be: 
  Well defined 
  Specific 
  Objective 
  Widely accepted as a measure of success 
  Directly observed by an independent observer 
  Based on long-term, quality-of-life variables (ideally from 
questionnaires answered by patients) 
  Measured prospectively 
  Recorded as part of a comprehensive database, along with all 
potentially confounding factors, and quantified or coded properly 
 
The aim of the comparison was to identify factors that reduced or increased the presence 
MSUS detectable bursae related to RA patients that were not present in healthy individuals. 
For the preliminary phase of the research, the reliability of the MSUS technique (chapter 
four, page 96), a short, interventional, prospective study was deemed an appropriate method 
of provisionally exploring the research hypotheses for studies two and three and at the same 
time enabling reliability of MSUS technique to be determined.  
 
3.7. Sample  
For medical clinical research Byrne (1998) describes an ideal sample as one which is: 
•  Large enough to answer the research question 
•  Homogenous for the topic or research question 
•  Representative of a broad population and 
•  Drawn from several different hospitals (multicentre) 
This was used to guide this research sample. 
 
3.7.1. Sample size and power calculations: RA participants 
No data exists that compares forefoot bursae with patient-related foot disability and function,   70
therefore power calculations were performed from correlation sample size tables (Machin, 
Campbell et al 1997) using initial data analyses from 20 participants in the preliminary 
validation study (Chapter 4, page 96). A small sample of twenty from the preliminary study 
gives an idea of what correlation coefficient could be anticipated for significance in results, 
although the power calculations may still be interpretable as the data would be highly 
variable (Machin, Campbell et al 1997).  Since the main outcome variable for this study was 
to be patient-related foot disability and function, with MSUS detectable bursae as the 
predictor variable, data for the association between foot pain and disability (measured by the 
MFPDQ) and presence of MSUS detectable bursae from the preliminary study (chapter four, 
page 96) formed the primary power calculation.  
 
Associations between foot pain and disability (measured by the MFPDQ) and presence of 
MSUS detectable bursae resulted in a Pearson’s Correlation coefficient of 0.211 (p=0.371). 
From the preliminary study data, power calculations indicated that to establish levels of 
association between ‘foot pain and disability’ and ‘presence of bursae’ at the 5% two sided 
significance level with 80% power, 179 cases would be appropriate and with 90% power, 239 
would be appropriate using Pearson’s Correlation Coefficient. Furthermore, it was agreed 
that: 
•  this figure should be raised to allow for 20% drop out and in case the data was found 
to be non-normally distributed and 
•  Spearman’s Correlation Coefficient should be used instead.  
 
Secondly, within the pilot study, associations between patients’ global impression of their 
well being and presence of MSUS detectable bursae were of borderline significance and 
therefore formed the next power calculation. From the study one data, associations between 
patients’ global impression of their well being and presence of MSUS detectable bursae 
resulted in Pearson’s Correlation coefficient of 0.444 (p=0.057). Power calculations indicated 
that to establish levels of association between ‘well being’ and presence of MSUS detectable 
bursae at the 5% two sided significance level with 80% power, 36 cases would be appropriate 
and with 90% power, 47 would be appropriate using Pearson’s Correlation Coefficient.  
Again, it was agreed that: 
•  this figure should be raised to allow for 20% drop out and in case the data was found 
to be non-normally distributed and 
•  Spearman’s Correlation Coefficient should be used instead.    71
 
Finally, initial data analysis for associations between DAS-28 scores and presence of MSUS 
detectable bursae resulted in Pearson’s Correlation coefficient of 0.076 (p=0.749) indicating 
little or no association. Therefore, this data was the focus of the final power calculations and 
suggested that to establish levels of no association between DAS-28 and presence of bursae at 
the 5% two sided significance level with 80% or 90% power, the number of cases should be 
as high as feasible using Pearson’s Correlation Coefficient (or Spearman’s Correlation 
Coefficient if the data was found to be non-normally distributed).  
 
There are currently 1400 RA patients registered with Southampton General Hospital 
Rheumatology department and on average 70 are seen each week. Within the time and 
resource limits of this pragmatic clinical study, the proposed recruitment target was a sample 
of 200 patients with RA. 
 
3.7.2. Sample Size: Control Participants 
As the study was not a case matched controlled interventional study, the control sample size 
was selected as one third of the RA participant sample to act as a comparator sample for 
descriptive purposes that was analogous with other studies in this field (Szkudlarek, Court-
Payen et al 2001; Ejbjerg, Vestergaard et al 2005; Brown, Conaghan et al 2008). 
 
3.7.3. Sample selection: RA participants 
During the preliminary determination of the reliability of the MSUS technique study (Chapter 
four, page 96) a consecutive sample of participants with RA who were starting anti-TNF-α 
therapy and who were attending the Rheumatology Department, Southampton General 
Hospital were recruited. For studies two and three (Chapter five, section 5.4, page 127 and 
Chapter six, section 6.4,  page 165) a consecutive sample of participants with RA, who were 
attending the Rheumatology Department, Southampton General Hospital as part of their 
normal care, were investigated.  
 
In all studies the population investigated was homogenous for RA which was required to be 
diagnosed according to the ACR criteria (Arnett, Edworthy et al 1988) and the clear 
eligibility criteria (section 4.4.2. page 97, section 5.4.2.1, page128, section 6.4.2.1 page 166) 
ensured that members of both samples were representative of the wide spectrum of adults   72
who have RA.  
 
Byrne (1998) describes a homogenous sample as being part of the criteria for an ideal sample. 
The participants in all three studies were homogenous for RA, although within the samples 
for studies two and three there was a wide variation in disease state and manifestations of 
disease on the foot. According to Byrne (1998), including different disease states in the same 
study may reduce validity of results and careful consideration of conclusions that can 
subsequently be drawn is deemed essential.  
 
Using MSUS, one small study had previously suggested that MSUS detectable forefoot 
bursae were highly prevalent and of clinical importance in a sample of patients with early RA 
(Koski 1998). To our knowledge, there was no other existing longitudinal data that had 
investigated the prevalence of forefoot bursae in RA and it had received little attention in the 
literature (see Section 2.2, Chapter 2, page 18). The participant sample for the preliminary 
study was homogenous in that all participants were starting anti-TNF-α therapy. However, for 
studies two and three, to determine the true prevalence of MSUS detectable forefoot bursae in 
secondary care, it was important to include a wide variety of disease states. Interpretation of 
results, therefore, have to be noted with caution as, it is possible that, splitting the participants 
into groups for the analyses of associations of MSUS detectable forefoot bursae may have 
reduced the statistical power. Further investigation in other groups, for example early RA, 
would be interesting follow up studies. 
     
The approach of the overall study was a pragmatic, clinical one; thus the samples were both 
drawn from one population of those who were registered under the care of the Rheumatology 
Department, Southampton University Hospitals’ Trust. Therefore, although this ensured good 
internal validity, findings from this study can only apply to the population of RA patients 
registered under the care of the Rheumatology Department, Southampton University 
Hospitals’ Trust. Multi-centre collaborative studies are recommended to reduce threats to 
reliability and validity of an investigation (Bowling 2002) although this was not a feasible 
option within the scope of this research. 
 
For ease of recruitment within each study a consecutive sampling method was utilised. 
Advantages of consecutive samples are that they enable easier monitoring and follow-up with 
good response rates and retention of sample members (Bowling 2002). Random sampling is   73
considered the ‘gold standard’ method for recruitment of participants as it allows each 
member of the target population group a ‘non-zero’ chance of inclusion within the sample, 
but is more difficult to achieve (Bowling 2002). To minimize selection bias within the 
studies, the recruitment of participants was targeted at the whole population attending within 
a clearly defined time frame of six months. The response bias, or extent to which the RA 
population within the main study deviated from the whole population of patients who 
attended within that time frame, could then be determined via non-responder analyses 
conducted at both baseline (section 5.8.1, page 135) and twelve month assessments (section 
6.7.1.1, page 170) . 
 
3.7.4. Sample selection: control participants 
A convenience sample of staff and students within the School of Health Sciences, University 
of Southampton, were recruited onto the study to act as comparator healthy controls to the 
RA participants. Like consecutive sampling, convenience sampling has advantages in 
analytic research in that subjects are easy to recruit, near at hand and likely to respond 
(Bowling 2002) making it the most appropriate method to recruit the control participants. 
 
3.8. Observational outcomes 
3.8.1 Preliminary study (reliability of technique)  
In order for a technique to be accurate in detecting alterations in observed disease state, it 
must first be proven reliable (Bowling 2002). Usually a new technique is tested against a 
‘reference test’ or ‘gold standard’ (Bowling 2002). To determine the ability of MSUS 
performed by a podiatrist (CB) to detect forefoot bursae within RA, inter-rater reliability was 
assessed against two consultant radiologists (KD or MS). Both consultant radiologists (KD 
and MS) were expert in musculoskeletal ultrasound and one (KD) had acted as mentor to the 
podiatrist (CB) in learning the techniques of MSUS assessment of the forefoot.  
 
3.8.1.1. Musculoskeletal ultrasound imaging equipment 
A Diasus diagnostic ultrasound scanner (Dynamic Imaging, Livingston, Scotland UK) was 
used by the podiatrist (CB) (see Appendix 4 for technical specifications). The Diasus scanner 
is a musculoskeletal application specific ultrasound system dedicated to detailed high 
resolution imaging including: mains-lead, footswitch, operator manual (Figure 18). It   74
operates as a system with dual probe, but for the study, a 5-10MHz 26mm ultra wideband 
linear array probe was used.  
 
A Philips HDI 5000 System (Royal Philips Electronics, Netherlands) was used by the 
radiologist (KD or MS).  The Philips system includes MicroFine™ Imaging, Broadband 
Flow® Imaging, Power Contrast Harmonic Imaging, Tissue Harmonic Imaging, Tissue 
Doppler Imaging, Pulse Inversion Harmonics, Power Motion Imaging, Advanced 3D 
imaging, Panoramic imaging, adaptive system intelligence and leading-edge connectivity 
(http://www.heartstream.com/main/products/ultrasound/general/philips_5000/index.html). 
This system operates with broadband linear probes and in order for direct comparisons to be 
made within the study a 5 - 12 MHz probe was also used. 
 
Figure 18. Photographs of the Diasus MSUS machine used by the Podiatrist within all three 
studies.                                                   
 
 
 
 
3.8.1.2. Musculoskeletal ultrasound scanning protocol 
On the same day, both MSUS foot scans were performed (see Table 11 for overview of 
scanning protocol) in real time. Scanning was in B-Mode using the 5 – 10 MHz probe. 
Images were recorded in two perpendicular planes, longitudinal and transverse and 
performed moving from proximal to distal as suggested by the EULAR (European League   75
against Rheumatism) “working group for musculoskeletal ultrasound in rheumatology” 
guidelines (Backhaus, Burmester et al 2001). The EULAR guidelines recommend a dorsal 
approach to detect MTP joint synovitis with the patient in a supine position however at the 
time of this study there was no definition for detecting clinically apparent plantar forefoot 
bursae. Lack of standardization and variation in scanning technique amongst sonographers 
has been deliberated as contributing to disagreement between experts (Scheel, Schmidt et al 
2005).We therefore decided to use a plantar approach to determine the prevalence of MSUS 
detectable bursae within the forefoot.  
 
Table 11. Overview of MSUS technique scanning protocol. 
1.  The nature of the test was explained 
2.  The participant was asked to sit in a supine position on the bed 
3.  The participant’s hosiery was removed and the ultrasound probe placed on the plantar 
aspect of each foot 
4.  The forefeet of all participants were scanned by the investigators using 5 – 10 MHz 
probes. 
5.  Scans for bursitis were taken both longitudinally and transversely from a plantar 
approach of the forefoot 
6.  The second and fifth MTP joints and inter-metatarsal spaces for both feet were scanned 
longitudinally and transversely from the plantar view 
7.  Images of the plantar aspects of the forefoot in both feet were recorded in transverse and 
longitudinal aspects and saved on the Diasus ultrasound machine hard drive 
8.  Observations of synovial thickening / synovitis (grey scale and power Doppler) and 
erosions of the second and fifth metatarsophalangeal joints were noted  
 
 
Koski (1998) also utilised a plantar approach to detect intermetatarsal bursae 
sonographically and clinically by palpation, however the reason for this and the limitations 
were not discussed in his paper. Our justification for using a plantar approach was based on 
the work by Koski (1998) and on previous clinical observations of pain and palpable bursae 
occurring within the plantar forefoot area. In addition, from review of the literature (see 
section 2.2, page 18) the classification of forefoot bursae was confusing and it was apparent 
that the plantar swellings that had been observed clinically by palpation could be attributed   76
to either anatomical intermetatarsal bursae or adventitious bursae within the plantar fat pad. 
Our technique for scanning the plantar forefoot area was also later described by the AIUM 
(2007) for investigation of the presence of neuroma or intermetatarsal bursitis. A further 
justification for the plantar MSUS scan approach was that previous cadaver studies 
investigating forefoot bursae had been conducted via a plantar approach (Chauveaux, Le 
Huec and Midy 1987; Studler et al 2008) as had MSUS and surgical studies of Morton’s 
neuroma (Irwin, Konstantoulakis et al 2000; Jones, Bygrave et al 1999). 
 
For each scan in our preliminary study the participant was therefore seated, with legs 
extended on a flatbed plinth so that the soles of the feet were facing the operator, with 
ankles dorsiflexed. The transducer was placed longitudinally on the plantar aspect of the 
first intermetatarsal space, and digital pressure was applied by the examiner on the dorsal 
surface of the foot. The transducer was moved laterally with its centre at the level of the 
metatarsal heads. The process was repeated for the remaining inter metatarsal spaces and 
then repeated transversely (see Figure 19). 
 
Figure 19. Photographs demonstrating the transverse (A) and longitudinal (B) positions of 
the MSUS transducer to assess the plantar forefoot area. 
A   B  
 
To judge the extent of forefoot bursae against the extent of effect of RA on the forefoot 
joints, the second and fifth MTP joints were also scanned longitudinally and transversely 
from the plantar view. Due to timing and availability of the radiologists within the 
preliminary study only thirty minutes was allowed for each foot assessment. Therefore 
observations of synovitis and erosions by MSUS were conducted within just two joints in   77
each foot (second and fifth MTP joints) also from the plantar approach rather than the more 
conventional dorsal approach.  
 
The second MTPJ was selected for investigation because it is in line with the centre of load 
through the forefoot during gait (Jacob 2001), it is easily accessible for the MSUS 
transducers, and was considered representative of the MTPJs. The fifth MTPJ was also 
selected for its ease of accessibility with the MSUS probes (Szkudlarek , Narvestad et al 
2004) and as it has been reported as being the most common site of radiographic and 
sonographic erosion (Grassi et al 2001). The first MTPJ was excluded due to the sesamoid 
bones underlying its plantar aspect. 
 
The presence and location of any bursal swelling across the plantar forefoot region and any 
synovial thickening/synovitis and erosion within the second and fifth MTPJs identified by 
MSUS was recorded on a data sheet (see MSUS data sheet in Appendix 5). Transverse and 
longitudinal ultrasound images of each plantar forefoot and longitudinal images of each 
fifth and second MTP joint were saved by the podiatrist on the Diasus ultrasound machine. 
 
To reduce recall bias, all investigators (CB, KD and MS) were blinded to each other’s results. 
Participants were primarily assessed by the podiatrist (CB) within the Wellcome Trust 
Clinical Research Facility, Southampton General Hospital. Participants were then escorted by 
a research nurse to the Radiology department where the second MSUS scan was performed 
by the radiologist (KD or MS). 
 
During the data collection for this preliminary study, it became clear that the plantar approach 
to detect MTP joint synovial thickening / synovitis was a major limitation. The ability to 
assess synovitis in some participants, using the linear MSUS 5 – 10 MHz transducer (active 
length 40mm; see Figure 20) to achieve 7.5 MHz frequency with the Diasus machine, was 
hampered by structural lesser toe deformities and MTP joint subluxation, even with use of 
liberal amounts of coupling gel.  
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Figure 20. Photograph of the Diasus MSUS system 8 – 16MHz (active length 26mm) and 
5 – 10 MHz (active length 40mm) transducers. 
 
 
Therefore a dorsal approach to assess MTP joint synovial thickening / synovitis, as 
recommended by the EULAR “working group for musculoskeletal ultrasound in 
rheumatology” guidelines was considered for the main study (Backhaus, Burmester et al 
2001). However some expected difficulty in assessing MTP joint synovial thickening / 
synovitis from the dorsal approach still existed, as severe retraction of the lesser toes and 
subluxation of the MTP joints did not allow good transducer contact from this direction 
either. 
 
In retrospect, the use of ‘stand off’ pads and techniques for using a water bath to facilitate 
the ultrasound wave conduction over gross structural deformities of the foot may have 
produced better results. These techniques reportedly increase the field of view in 
anatomical areas where the contour of the part is such that it only allows a small area of 
contact (Stokes, Hides and Nassiri 1997). At the time of this study these techniques were 
not readily available within either the podiatric or radiology clinical department. Similarly, 
small transducer footprints such as ‘hockey stick’ probes, may have also been easier to use 
over the deranged MTP joints (Backhaus, Burmester et al 2001), but this was not an 
available feature of the Diasus machine used within the study either.  
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Additionally, in the preliminary study, due to forefoot structural deformity in some 
participants, it was clear from the conceptual stage that tenosynovitis was too difficult to 
assess using the proposed Diasus ultrasound machine. As well as MTP joint synovitis, the 
appearance of flexor tenosynovitis on MSUS is a key differential diagnosis for plantar 
forefoot tenderness (Koski 1995). This inability to measure tenosynovitis using the Diasus 
MSUS machine also has to be acknowledged as a significant omission and therefore a major 
limitation in the second and third studies regarding the assessment of the associations of 
MSUS detectable forefoot bursae with patient reported foot impact outcome measures. 
 
3.8.1.3. Reliability of MSUS technique performed by a podiatrist 
An important issue within the preliminary study one was measurement error between 
clinicians and between machines. For the preliminary study, the podiatrist’s (CB) technique 
was tested for reliability against expert radiologists (KD and MS). Although this is a 
common way of determining reliability, validity can be questioned, especially with the use 
of two different machines and two different radiologists. In the design of the reliability 
study, two assumptions were made, firstly that the radiologists were experts in the field of 
MSUS imaging and secondly that their inter-tester reliability in technique in detecting 
forefoot bursae was of an acceptable standard. 
 
The OMERACT (Outcome Measures in Rheumatology) framework incorporates a filter to 
aid decisions as to the applicability of measures (Boers, Brooks et al 1998). The filter 
incorporates truth, discrimination and feasibility as words that represent questions to be 
answered of the measure (Boers, Brooks et al 1998). Truth represents issues of face, 
content and construct and criterion validity; discrimination represents issues of reliability 
and sensitivity to change; feasibility represents selection of measures (Boers, Brooks et al 
1998). 
 
From Table 12 it can be seen that using the OMERACT filter, that, although the 
podiatrist’s technique was confirmed as being reliable, there are limitations that affect the 
overall validity of the technique in the detection of forefoot bursae. In terms of ‘truth’ the 
result is relevant against an expert in imaging techniques but the podiatrist’s (CB) 
technique may be biased towards over detection of forefoot bursae.    80
Table 12. Evaluation of the podiatrist’s MSUS technique reliability against the  
OMERACT filter (Boers, Brooks et al 1998). 
Truth 
Is the measure 
truthful? 
Does it measure what 
is intended? 
Is the result unbiased 
and relevant? 
The Podiatrist’s technique in detecting forefoot bursae with 
MSUS was reliable with very good agreement with radiologists. 
 
The Podiatrist’s ability to acquire and interpret images from the 
Diasus MSUS machine was comparable to the radiologists using 
the higher definition and more costly Philips HDI 5000 system. 
 
Detection of bursae by any investigator or either MSUS machine 
was not validated by any other imaging method such as MRI. 
 
Detection of bursae by any investigator or either MSUS machine 
was not validated by histological biopsy analysis. 
 
Detection of bursae by the podiatrist was not validated by 
cadaveric investigations. 
Discrimination 
Does the measure 
discriminate between 
situations of interest? 
States at one time (for 
classification or 
prognosis) 
States at different 
times (to measure 
change) 
Using an intervention that enabled observation of a quick change 
in RA disease state, changes in the presence of forefoot bursae 
were detected by the radiologists over a twelve week period. 
 
The technique was not sensitive enough to measure actual change 
of individual bursae that may have altered in size. 
 
The technique for the ability of MSUS to detect change in 
forefoot bursae only refers to the radiologists and the Philips HDI 
5000 system. 
Feasibility 
Can the measure be 
applied easily, given 
the constraints of time, 
money, and 
interpretability? 
The MSUS machine was relatively low cost, readily available and 
portable for use in the clinical setting. The consensus meeting 
indicated low error in the podiatrist’s (CB) technique for 
interpretation and acquisition of images of the machine indicated 
good reliability within against a high specification machine 
utilised in radiology.    81
The presence of MSUS detectable bursae within the forefoot was not validated by any other 
‘gold standard’ imaging technique, such as MRI or by histological analysis through biopsy. 
As well as intermetatarsal bursae and adventitious bursae, soft tissue swelling at the level of 
the MTP joints can be related to MTP joint synovitis or tenosynovitis that could be better 
differentiated using MRI (Ashman, Klacker and Yu 2001; Helliwell, Woodburn et al 2007; 
Studler et al 2008). At the time of the preliminary reliability study, the OMERACT MSUS 
special interest group had highlighted limited data in terms of comparisons of MRI with 
MSUS (Wakefield, Balint et al 2005). Due to its restricted availability MRI was not 
feasible for our study.  
 
Whilst MRI may give better detail regarding anatomical location of a bursa within the 
forefoot than MSUS, without histological analysis, confirmation of the tissue type remains 
speculative (Ashman, Klacker and Yu 2001; Studler et al 2008). Similarly, reliability of 
technique may have been better confirmed by cross referencing MSUS assessment of fresh 
cadaver forefeet from patients with RA with findings following immediate dissection. 
Access to fresh cadaver feet was not feasible within the remit of this study. 
 
In terms of discrimination, MSUS was able to detect change in presence of forefoot bursae, 
although was not sensitive enough to measure actual change of individual bursae that may 
have altered in size. Of note is that the technique for the ability of MSUS to detect change 
in forefoot bursae only refers to the radiologists and the Philips HDI 5000 system. 
Assumptions were made that these results could be conferred to the podiatrist and the 
Diasus MSUS machine, following good agreements from the baseline data. This could, 
however, have reduced the reliability of the findings from the longitudinal data in study 
three and further analysis of agreements for the change data in the preliminary, reliability 
study would have been beneficial. 
 
In terms of feasibility, the implications for this part of the study did include the 
potential for utilizing the more affordable, MSUS machine in the clinical 
environment for more timely. We confirmed that the technique could be applied easily, 
within the constraints of time, money, and interpretability and demonstrated that MSUS 
has the potential to be employed to further investigate and undertake assessment of 
forefoot bursae. However, further work is necessary to validate the technique and gain 
accurate results.    82
 
Given unlimited resources, to validate the MSUS technique for detection of forefoot bursae 
would ideally involve:- 
•  A study that allowed MSUS imaging of fresh cadaver feet from individuals who had 
RA with confirmation of detected bursae by immediate dissection 
•  The use of MRI as an external validator for location of forefoot bursae in patients with 
RA 
•  The use of MSUS guided biopsy of forefoot bursae in patients with RA to confirm 
tissue type through histological analysis.  
 
 
3.8.2. Prevalence and natural history of musculoskeletal ultrasound detectable 
forefoot bursae 
Once reliability of technique had been established, the main variables of interest investigated 
within studies two and three were the prevalence of MSUS detectable forefoot bursae 
(explanatory variable) and patient reported foot disability and impairment (dependent 
variable).  
 
3.8.2.1. Musculoskeletal ultrasound scanning protocol  
For the second and third studies (Chapter five, page 125 and chapter six, page 164) the 
podiatrist (CB) used the Diasus diagnostic ultrasound scanner (Dynamic Imaging, Livingston, 
Scotland UK) in the same mode as for the first phase reliability study (Chapter four, page 96). 
Following analysis of the reliability study data, whilst agreements for techniques in 
identifying forefoot bursae and MTP joint erosions were very good, agreements between the 
investigators for MTP joint synovitis were poor. The scanning protocol from study one 
(Table 11) was modified for studies two and three to include the observation of all MTP 
joints via a dorsal approach, although for identification of plantar forefoot bursae a plantar 
scan approach was maintained, as discussed above. The reliability of the data for MTP joint 
synovitis and erosion from the second and third studies was, however, not retested and 
therefore not known, so had to be excluded from the final analyses. 
 
Within the analyses for studies two and three there is thus a possibility that MSUS detectable 
bursae and MTP joint synovitis may be correlated and collinear but with the lack of data on   83
MTP joint synovitis we cannot be sure. We did adjust for disease activity which does suggest 
that MSUS detectable bursae may be independent of MTP joint synovitis, however 
clarification of this is recommended for future investigations. 
 
Failure to use the measures of MTP joint synovitis and erosion and failure to measure 
tenosynovitis within the second and third studies using the Diasus MSUS machine has to be 
acknowledged as a significant limitation regarding the assessment of the associations of 
MSUS detectable bursae with patient reported foot impact outcome measures. This is, 
however, a feature that is endemic in all studies on MTP joint synovitis in the foot in RA that 
haven’t taken account of forefoot bursae. Furthermore, it does not invalidate MSUS as a tool 
for predicting foot symptoms in RA. 
 
Scans were completed after the foot assessments but during the same visit within the 
Wellcome Trust Clinical Research Facility, Southampton General Hospital. Within the 
reliability study, clinical foot status was determined by the podiatrist (CB) so that the 
radiologists (KD and MS) were blinded to the results of the foot assessment. However, this 
meant that the MSUS measurements performed by the podiatrist (CB) were not performed 
independently to the clinical foot assessments. The same approach was used within the 
second and third studies (Chapter five, page 125 and Chapter six, page 164), that is the 
clinical activity and clinical foot assessments were performed by the same individual (CB) 
and not determined by an independent assessor. Thus there was no attempt at blinding of the 
results of the clinical foot assessments from results of the MSUS assessments.  
 
For the second and third studies it was not feasible to have numerous independent 
investigators and as such investigator bias and recall bias therefore need to be taken account 
when interpreting the data. Investigator bias is common in social research on human beings 
(Bowling 2002) and we attempted to reduce the effect of this bias by maintaining a 
systematic order to the data collection (see study protocol flow charts, Chapter five, page 
134, Chapter six, page 169) and using experienced independent data handlers to double 
enter and clean all the information onto the SPSS data sheet. 
 
3.8.2.2. Assessment of patient reported foot impact in RA 
For foot and ankle investigations it is recommended that as a minimum for data collection,   84
researchers capture the variables of local pain, global pain, foot function and general function 
(activities of daily living) (Bowen, Burridge and Arden 2005). 
 
Within the preliminary reliability study (Chapter four, page 96), foot pain and disability were 
determined by the use of a validated patient administered questionnaire, the Manchester Foot 
Pain and Disability Questionnaire (MFPDQ) (Garrow, Papageorgiou et al 2000) (see 
Appendix 6). A second instrument, the foot function index (Budiman-Mak, Conrad and 
Roach 1991) was also trialled within the preliminary reliability study with a view to 
undertaking a cross-reference study to determine which instrument would be most beneficial 
for use within the second and third studies. 
 
The MFPDQ asked participants to rate a series of questions that took approximately five 
minutes to complete at the same visit as the MSUS scans. The MFPDQ index consists of 19 
items divided into four sub scales; functional problems, pain intensity, personal appearance 
and difficulties in performing work or leisure related tasks (Garrow, Papageorgiou et al 
2000). Responders are asked to grade the severity of their disability by marking whether the 
disability is present ‘none of the time’ (scored 0), ‘on some days’ (scored 1) or ‘on most or 
every day’ (scored 2). Total scores for each of the subscales are then calculated and expressed 
as a percentage (Garrow, Papageorgiou et al 2000). However, validation of the instrument did 
not apply to the separate domains, creating concerns for internal validity if the different 
domains are analysed separately. The MFPDQ was therefore analysed as a total score within 
the preliminary reliability study, however the results were limited as this tool had not been 
validated for sensitivity to change in RA related foot status. 
 
The FFI asked patients to score, on a series of 100mm visual analog scales, their foot 
pathology in terms of three sub scales for foot pain, foot disability and activity restriction. It 
also took approximately five minutes to complete at the same visit as the MSUS scans. A 
criticism of the FFI is that it was designed by groups of professionals and then validated 
using RA patients to sensitively measure foot pathology in terms of the three sub scales 
(Barnett, Campbell and Harvey 2005). Further issues arose within the preliminary reliability 
study in the complex way that the final score is derived. For each item a score is derived, by 
dividing the attached 100mm horizontal line into ten equal segments and assigning a number 
ranging from 0 to 9 to each segment. To obtain a sub scale score, the item scores for a sub-
scale are totaled and then divided by the maximum total possible for all the sub-scale items   85
which the patient indicated were applicable. The score is multiplied by 100 and a total FFI 
score is derived by calculating the average of the three sub-scales (Budiman-Mak, Conrad 
and Roach 1991).  
 
The most common problem encountered by the investigator within the preliminary reliability 
study with this instrument was in the calculation of a score from a point that was exactly on a 
whole number; for example, where a patient had annotated exactly over 8mm, a decision had 
to be made as to whether the score should be 7, or 8. Patients also encountered difficulty in 
completing the FFI scales and many did not complete all sections. Furthermore, some patients 
may have had ankle joint pain but did not report it as the questions within the FFI are focused 
on the foot. Therefore, in light of the experienced limitations, the FFI was discounted from 
the study and the MFPDQ was considered for use as the measure for foot pain and disability 
within studies two and three without undertaking a cross-reference study of the two outcome 
measures. 
 
During the preliminary reliability study it was evident that MFPDQ was a more suitable 
instrument than FFI, however, limitations of concern for the MFPDQ also existed. The 
MFPDQ had been developed and validated for use with general populations and therefore 
was not specific to RA (Garrow, Papageorgiou et al 2000). The questions within the MFPDQ 
had the rider “because of pain in my feet” and therefore some aspects of the impact of RA on 
the feet may have been under-reported. This may be why the MFPDQ reportedly has a 
demonstrated floor and ceiling effect for patients with severe RA foot deformity (Helliwell 
2003). Furthermore, some participants within the preliminary reliability study had hindfoot 
symptoms (when assessed by the podiatrist) but did not report them as they stated that “the 
questions were focused on pain in their feet and not their ankles”.  
 
The decision to use the MFPDQ in studies two and three was ultimately changed and a 
different, new measure, the Leeds Foot Impact Scale (LFIS) was used instead within the 
second and third studies (see Appendix 7). The rationale for the change in approach was that 
during the course of the preliminary reliability study, results from the validation of the LFIS 
were published, with high reliability for measurement of patient related foot symptoms in RA 
and sensitive to change in foot status (Helliwell, Reay et al 2005).  
 
The advantage of LFIS over MFPDQ was that it was developed specifically for RA patients   86
to measure foot symptoms related to impairment, footwear and activity participation 
limitation and restriction at all stages of their disease (to include early and late stage RA) 
(Helliwell, Reay et al 2005).  
 
In the development of LFIS, 131 items were selected, from patient interviews and a series of 
statements broken into three subgroups classified according to the WHO ICD (The World 
Health Organization International Classification of Diseases) classification of ‘activity’ (37 
items), ‘impairments’ (56 items) and ‘participation’ (24 items), with ‘impairment’ and a 
further subgroup classified as ‘footwear related’ (14 items) (Helliwell, Reay et al 2005). 
Following further analysis, the final version of LFIS now has: 
•  two dimensions with fifty one items 
•  good test, retest reliability 
•  no systematic differences  
•  been tested for responsiveness to change (Helliwell, Reay et al 2005).  
 
LFIS is presented as a self-completed questionnaire that takes about five minutes for patients 
to complete, with the two subscales for impairment and footwear (LFISIF), and activity 
limitation and participation restriction (LFISAP) that are used for analyses. LFISIF contains 
twenty one items related to foot pain and joint stiffness, as well as footwear related 
impairments. LFISAP contains thirty items related to activity limitation and participation 
restriction (Helliwell, Reay et al 2005). Responses to each question are dichotomized as yes 
or no and scoring is a simple tally and therefore advocated as clinically simple to use 
(Helliwell, Reay et al 2005). 
 
Having decided to use LFIS instead of MFPDQ in studies two and three, at that stage, a cross 
reference study between MFPDQ and LFIS would have been interesting; however in the 
development of LFIS the authors had reported that it did demonstrate good concurrent 
validity to the MFPDQ (Helliwell, Reay et al 2005). In addition, in 2008, van der Leeden, 
Steultjens et al rated LFIS as one of the most utilized instruments for measurement of the 
impact of RA disease on the foot. As studies two and three were not directly compared to 
study one, this would not introduce any bias. 
 
Therefore, LFIS was justified as being selected over MFPDQ, as the better measure of 
assessment of the impact of RA disease on the foot over time for use within studies two and   87
three. Permission was granted from the authors for LFIS to be used within this doctoral study. 
 
3.8.2.3. Assessment of confounding factors 
The confidence that a change in MSUS detectable bursae is followed by changes in LFIS 
subscale scores is subject to interpretation bias due to extraneous variables that could 
confound the results. Bowling (2002) describes a confounding variable as an extraneous 
factor (a factor other than the variables under study), not controlled for, which distorts the 
results. Confounding thus arises when an association between an explanatory variable and 
dependent variable is being investigated, but the outcome and exposure are both strongly 
associated with a third variable (Petrie and Sabin 2005).   
 
Age and gender are common confounding variables (Bowling 2002) and so these variables 
were controlled for separately by observation of the comparator healthy subjects at the 
baseline assessments. A second key method for addressing confounding variables is to fit a 
regression model (Bowling 2002) so that the relationship between the variable of interest 
(MSUS detectable bursae) and the outcome (LFISIF and LFISAP) can be examined while 
holding the other variables constant. 
 
Confounding variables should be considered on the basis of biological or clinical view and be 
related to the outcome. Confounding variables therefore identified from the preliminary study 
(Chapter four, page 96) were: 
•  Age 
•  Gender 
•  Disease duration (years) 
•  Presence of rheumatoid factor (sero-positive or sero-negative) 
•  Weight  (kg) 
•  Height (cm) 
•  Limb dominance (left or right) 
•  Current medication and previous use of Disease Modifying Anti-Rheumatic Drugs 
(DMARDs)  
•  C-reactive protein (CRP) (mg/litre) 
•  Erythrocyte Sedimentation Rate (ESR) (mm/hour) 
•  Participants’ global impression of well being measured via a visual analog scale   88
(VAS 100mm where 0 was ‘Best Imaginable Health State’ and 100 equal to ‘Worst 
Imaginable Health State’) 
•  DAS-28 (ie. assessment of the patient’s global impression of health and disease 
activity and the number of painful, tender and swollen joints calculated as part of the 
28 joint Disease Activity Score; DAS-28 remission scores < 2.6; low disease activity 
scores ≥ 2.6 but < 3.2; moderate disease activity scores ≥ 3.2 but < 5.1; high disease 
activity scores ≥ 5.1; van der Heijde, van't Hof, et al  1993) 
•  Foot joint mobility (observation of the range of movement within the ankle joints, 
sub-talar joints, mid-tarsal joints and first MTP joints were recorded by CB and 
documented as full range, limited range or absent range) 
•  Foot structure (observation of MTP joint subluxation and pes-planus) 
Copies of the demographic and clinical data collection forms are attached in Appendix 8, 
Appendix 9 and Appendix 10. 
 
Of note is that within the preliminary (reliability) study clinical activity was measured via the 
DAS-28 score that was performed independently by a trained joint assessor. For the second 
study, DAS-28 scores were obtained from clinical medical notes and the rheumatology 
department database. During the second study, DAS-28 scores were however not available 
for all participants. Therefore for the final study, the investigator (CB) was trained in DAS-28 
technique and also performed these assessments.  
 
In study three, the fact that there was a change in personnel performing the DAS-28 
obviously had no impact between studies one and two as the data between those studies 
was not used interchangeably. During study three, the DAS-28 assessment was always 
performed before the MSUS foot assessments and it is possible that at a purely 
subconscious level that this may have affected the interpretation of the MSUS images 
leading to a greater reporting of MSUS detectable forefoot bursae. Whilst we cannot fully 
rule this out, the prevalence of MSUS detectable forefoot bursae and the association 
between MSUS detectable forefoot bursae and DAS-28 did not differ significantly between 
studies two and three. This would argue against a major bias. 
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3.9. Data storage  
The chief investigator has overall control of and acts as custodian for the data generated by 
studies.  
 
3.9.1. Preliminary study (reliability of technique)   
This study was embedded within a larger study that was investigating RA participants’ 
responses to anti-TNF-α therapy.  The custodian of the data was therefore the chief 
investigator for that study and all data was held at the Rheumatology Research Department, 
Southampton Hospital NHS Trust, in a locked filing cabinet. Access to the data was restricted 
to the researcher and the research team as identified at ethical approval.   
 
All information recorded was stored on a password locked computer database and coded such 
that all participants’ names were replaced with two letters to ensure anonymity and that at no 
time any personal details were revealed. Data stored on the Diasus ultrasound system, also at 
that stage was coded and not directly identifiable to any participants. The Diasus ultrasound 
system is owned by the School of Health Sciences, University of Southampton and housed 
within a gait laboratory that is managed by a laboratory technician and locked when not in 
use.  
 
Participants were also encouraged to review their individual records, however no requests 
were forthcoming. 
 
3.9.2. Prevalence and natural history of musculoskeletal ultrasound detectable 
forefoot bursae 
The chief investigator for this study was the main investigator and custodian of the data. All 
personal information therefore is held within a locked filing cabinet within the secure office 
of the Chief Investigator in the School of Health Sciences and will be stored for 15 years in 
line with the University of Southampton data protection policy and ethical approval.   
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All information recorded was stored on a password locked computer database and coded such 
that all participants’ names were replaced with a number to ensure anonymity and that at no 
time any personal details were revealed. As above in the preliminary study data stored on the 
Diasus ultrasound system was also at that stage coded and not directly identifiable to any 
participants.  
 
3.10. Statistical analysis 
All statistical analyses were performed by the investigator (CB) and checked for accuracy by 
an expert medical statistician. 
 
Throughout the statistical analyses, statistical significance is stated as p<0.05 as well as 
whether one or two tailed tests were used to avoid Type 1 and Type II errors. The error of 
rejecting a true null hypothesis is a type 1 error (or alpha error) and the failure to reject a null 
hypothesis when it is actually false is a type II error (beta error) (Byrne 1998) (Table 13). 
This section outlines the statistical methods and data analysis techniques used to minimize 
risk of type I and type II errors. 
 
 
Table 13. Features of Type I and Type II errors (Adapted from Byrne 1998). 
Features of a Type I Error  Features of a Type II Error 
  Rejection of a true null hypothesis    An acceptance of a false null hypothesis 
    The chance of missing a real effect 
  False claim of a difference    False claim of no difference when a 
difference actually exists, but the sample 
size is too small to prove it 
  Common when a researcher is too ready 
to reject the null hypothesis (alpha error)
  Common when a researcher is too ready 
to accept the null hypothesis (beta error) 
  Occurs approximately 5% of the time with
a P value threshold of <0.05 
  Occurs approximately 20% of the time 
with a power of 80% (power = 1 – ß) 
  Analogous to convicting an innocent 
person 
  Analogous to acquitting a guilty person 
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3.10.1. Data evaluation software 
Data evaluation and statistical analysis were performed using the Statistical Package for 
Social Sciences (SPSS) version 14.0 software (SPSS, Chicago IL). 
3.10.2. Data entry 
Bias can occur within studies due to incorrect data entry (Byrne 1998). To minimize data 
entry error, all data was entered onto the SPSS data sheet by the investigator (CB) for the 
preliminary, validation study (Chapter four, page 96) and checked by a second investigator 
(SS) for errors. Prior to analysis of data in the main study (Chapters five, page 125 and six, 
page 164), all data was double entered and cleaned by independent MRC (Medical Research 
Council) data managers for both baseline and twelve month assessments.  
 
3.10.3. Checking assumptions 
Each data set was initially examined by the investigator (CB) using histograms and scatter 
plots to determine normalcy and any ‘outliers’ that may have occurred due to data entry bias 
or normal biological outliers.  
 
For investigation of associations, before the relationship between MSUS detectable forefoot 
bursae and foot impact scores could be entered into a multivariate regression model with the 
predictor, confounding variables, diagnostic tests for assumptions were performed. 
Diagnostic tests for colinearity, constant variance and normal probability of standardized 
residuals were executed to determine suitability for multiple linear regression modeling. 
 
3.10.4. Descriptive statistics 
The demographic and clinical characteristics of the study participants are presented as the 
mean, standard deviations (SD) and range and presented graphically as histograms and bar 
charts. 
 
3.10.5. Study one: inter-observer agreements 
Levels of agreement may be calculated using Bland and Altman plots, intra class correlation 
coefficients or by Cohen’s kappa statistic (Petrie and Sabin 2005).  The former are used to 
measure continuous data and the latter measure categorical data (Petrie and Sabin 2005).   92
Sensitivity and specificity diagnostic tests provide further information about the levels of 
agreement (Petrie and Sabin 2005). 
 
Inter-observer agreements between the podiatrist (CB) and radiologists (KD or MS) produced 
categorical data and therefore were calculated by overall agreement (percentage of observed 
exact agreement), sensitivity and specificity values and kappa statistics.   
 
3.10.5.1. Study one: sensitivity and specificity 
Sensitivity is the proportion of individuals with the disease who are correctly identified by the 
test (true positives). Specificity is the proportion of individuals without the disease who are 
correctly identified by the test (true negatives) (Petrie and Sabin 2005). Both should, ideally, 
be close to 1 (or 100%), however in clinical practice this is not always achievable and it may 
be that sensitivity may be excellent at the expense of specificity and vice versa (Petrie and 
Sabin 2005).  Generally, in clinical studies, it appears that if both values are over 80% the 
results are very good and if both are over 70% the test results could be reasonably accepted 
(Bowling 2002).  
 
3.10.5.2. Study one: kappa agreement 
The kappa statistic allows assessment of the extent of the reproducibility of a measurement 
(reliability) and is useful to measure agreement between different observers (inter-rater 
agreement) using the same measurement techniques and agreement between replicate 
measurements taken at different points in time. Therefore kappa is useful as it informs how 
much of the possible agreement between two observers has occurred over and above 
chance (McGinn, Wyer et al 2004). The use of kappa to test agreement can sometimes be 
difficult to interpret, as it may reflect actual change rather than poor reliability of the 
measure (Bowling 2005).  
 
Kappa can be thought of as the chance-corrected proportional agreement, and possible values 
range from +1 (perfect agreement) via 0 (no agreement above that expected by chance) to -1 
(complete disagreement) (Table 14). The unweighted kappa statistic (unweighted for 
dichotomous scoring, that is, presence or absence of MSUS detectable bursae) was the most 
appropriate test for this reliability study.   93
Table 14. Qualitative classification of kappa values as degree of agreement beyond chance  
(McGinn, Wyer et al 2004). 
Kappa Value  Degree of agreement 
beyond chance 
0 None 
0-0.2 Slight 
0.2-0.4 Fair 
0.4-0.6 Moderate 
0.6-0.8 Substantial 
0.8-1.0 Almost  perfect 
 
 
3.10.6. Studies two and three: Prevalence and natural history of musculoskeletal 
ultrasound detectable forefoot bursae 
The prevalence of bursae per foot and per anatomical site within the forefoot is described via 
the mean, standard deviations and frequencies and presented graphically as histograms, bar 
charts and box plots. Differences in the prevalence of MSUS detectable bursae and clinically 
detectable bursae were determined by non parametric Chi squared analyses for independent 
samples. Chi squared analysis allows the numbers with, and without, the characteristic in 
each of the response groups to be tested for discrepancies. A large discrepancy between 
observed and corresponding expected frequencies is an indication that the two groups differ 
(Petrie and Sabin 2005). 
 
To explore whether there were differences between those individuals with MSUS detectable 
bursae only and those with MSUS detectable bursae that were also clinically palpable, the 
data was split into groups that were analysed for differences using analysis of variance. This 
test allows a single global statistical assessment to determine whether the means differ in any 
group and is more appropriate than performing tests to compare means in each of the pairs of 
groups that is linked to high Type I errors (Petrie and Sabin 2005). 
 
Due to the small number of patients in the preliminary reliability study, normal distribution of 
the data was not assumed and Spearman’s Correlation Coefficient was used to determine 
interrelationships between the MSUS imaging data and the clinical observations and   94
demographical variables. Within the studies two and three, Gaussian distribution was 
observed for each of the variables and so Pearson’s correlation coefficient was used to 
determine interrelationships between the MSUS detectable bursae, LFISIF and LFISAP and 
other explanatory variables. 
 
Correlation analysis is concerned with measuring the degree of association between two 
variables. The measurement demonstrates how close the observations are to a straight line 
drawn through the midst of the points between two variables (Petrie and Sabin 2005). The 
range is from -1 to +1, where perfect correlation is either +1 or -1 and no correlation is 0 
(Petrie and Sabin 2005). To investigate the extent to which two variables are associated linear 
regression techniques are used, whilst multiple linear regression techniques are used to 
investigate the extent of relationships that include more than one explanatory variable (Petrie 
and Sabin 2005). 
 
3.10.7. Studies two and three: Regression models 
Once assumptions had been checked and suitability established, linear and logistic regression 
analyses were used to determine associations between the individual data for total numbers of 
MSUS detectable bursae, disease impact on the foot (LFISIF and LFISAP) and other 
explanatory variables. Multiple linear regression techniques were also used to assess the 
impact of disease impact on the foot (LFISIF and LFISAP) and other explanatory variables that 
were significantly associated with both disease impact on the foot (LFISIF and LFISAP) and 
the total numbers of MSUS detectable bursae.  
 
3.10.8. Study three: Natural history of MSUS detectable bursae  
Differences between baseline and one year measures for returnees were analysed using paired 
t-tests for parametric related numerical data for explanatory and outcome variables of weight, 
height, global well-being VAS, ESR, CRP, DAS-28, MSUS detectable bursae, LFISIF and 
LFISAP. Chi squared tests were used to analyse differences for non-parametric data related to 
clinical foot care, use of DMARDs and anti-TNF-α therapy and foot structure. 
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3.10.9. Studies two and three: Non responder analyses  
To ensure that the responder populations for studies two and three were representative of the 
RA population after checking assumptions of normality, an unpaired t-test for numerical 
parametric data was performed to compare the means in the responders and non responders 
for age. Simple chi squared analyses were performed on the categorical data of gender, 
seropositivity, and number of DMARDs and anti TNFα therapy between responders and non-
responders. 
 
The same approach was used to determine if there were any differences between the returnees 
and non returnees at the twelve month assessments. 
 
3.11. Timescale for completion of the studies 
The time frame for the main data collection was dependent on the recruitment of suitable 
participants and, as such, the end of the study data collection occurred when the last patient 
had attended.  
 
All pilot work and validation of the technique within the preliminary study took place 
between July 2004 and June 2007. Ethical approval was granted from the Local Research 
Ethics Committee in March 2004. Data collection for the RA participants recruited to the 
studies two and three (Chapter five, page 125 and Chapter six, page 164) were performed 
between July 2006 and September 2008. Ethical approval for the latter study was granted 
from the Local Research Ethics Committee in June 2006.  
 
Data collection for the healthy participants recruited to the main study took place during a 
two week period in February 2008. Ethical approval was granted from the School of Health 
Sciences Research Ethics Committee in November 2006 and subsequent amendments to the 
study protocol were approved in December 2007 (See Gantt Chart Appendix 11). 
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4.0 Chapter Four: Reliability of musculoskeletal ultrasound technique 
and pilot study to test the methodology for subsequent study 
4.1. Introduction 
Due to the wide use of MSUS and the depth and breadth of training required, new proposals 
advocate tailored learning of the technique to discrete fields of practice (Brown, Roberts et al 
2007). This doctoral work was novel, in that it was the first study to evaluate tailored learning 
by consensus of image interpretation and also by reproducibility of technique of MSUS to the 
discrete field of foot and ankle practice.  In other words, evaluation of the inter-observer 
agreement in the use of MSUS, between an allied health professional (podiatrist) and a 
radiologist, expert on MSUS imaging of the foot.  
 
4.2. Aims 
This study provided an opportunity to evaluate the inter-observer agreement between a 
radiologist and podiatrist, in the MSUS assessment of the forefoot of patients with RA. The 
study also allowed investigators to determine whether MSUS is a key modality for assessing 
the prevalence of plantar forefoot bursae in RA and the responsiveness of MSUS to 
demonstrate change in bursae. 
 
Data from this study was therefore used to answer the following research questions: 
d)  Is diagnostic ultrasound, performed by a podiatrist, a reliable technique to identify the 
prevalence of bursae in the RA plantar forefoot? 
e)  Does the prevalence of MSUS detectable bursae in the plantar forefoot area of patients 
with RA change following a period of intervention (anti-TNF-α therapy)? 
f)  Is MSUS responsive to change in prevalence of bursae in the plantar forefoot area of 
patients with RA following a period of intervention (anti-TNF-α therapy)? 
 
4.3. Study design 
A blinded inter rater reliability study design was utilized, in which the forefeet of a 
consecutive cohort of patients with RA were examined with MSUS, by two investigators.  
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4.4. Subjects 
A consecutive cohort of patients with RA diagnosed according to the ACR criteria (Arnett, 
Edworthy et al 1988) starting anti-TNF-α therapy (infliximab, etanercept or adalimumab) 
was examined at baseline and twelve weeks following therapy. 
 
4.4.1. Participant recruitment 
The initial approach for recruitment was based upon potential participants with RA 
attending the Rheumatology Department, Southampton General Hospital NHS Trust who 
were starting anti-TNF-α therapy.  Those responding to the request for assistance were 
entered onto the test programme following a detailed patient interview and explanation of 
the study.  During this initial phase of contact, the individual was actively given the 
opportunity to ask any questions.  Finally, informed consent was successfully obtained and 
documented for each recruit.  An example of the patient information sheet is included in 
Appendix 12. 
 
4.4.2. Selection criteria   
All individuals with RA who were undergoing active treatment and starting anti-TNF-α 
therapy were considered appropriate for this study.  However, those with learning 
difficulties or unable to comprehend the patient information sheet were not selected, as the 
nature of consent would have been inappropriate. 
Inclusion criteria 
-  Individuals with RA diagnosed according to the ACR criteria (Arnett, Edworthy et al 
1988; table 1, page 11). 
-  Individuals with RA who were undergoing active treatment at the Rheumatology 
Department, Southampton General Hospital. 
Exclusion criteria 
-  Individuals who had previous surgery to the forefoot. 
-  Individuals who had received a corticosteroid injection to the forefoot within the 3 
months prior to commencement of the study. 
-  Individuals who had concomitant musculoskeletal disease, such as primary   98
osteoarthritis, gout, Pagets, systemic lupus erythematosus (sle). 
-  Individuals who had a serious medical (other than RA) or psychological disorder that 
may affect the study protocol. 
-  Individuals who were unable to give informed consent. 
4.4.3. Rheumatology screening      
Prior to data collection, the diagnosis of RA was confirmed by the supervising consultant.  
Moreover, the same consultant was available throughout the study to avoid any potential 
investigator bias.  Following acceptance into the study all participants were assessed by a 
trained specialist rheumatology nurse and Disease Activity Scores (DAS-28) were 
calculated (Prevoo, van't Hof et al 1995). 
 
4.5. Data collected 
All investigators were blinded to the other’s results in order to minimise the risk of 
selection bias (Bowling 2005).   
4.5.1. Location 
All data collection during this phase that was undertaken by the Podiatrist (CB), took place 
in the ‘Wellcome Trust’ Clinical Research Facility. All data collection during this phase 
that was undertaken by the Radiologist (KD or MS), took place in the Department of 
Radiology, Southampton General Hospital.  On each occasion, the same treatment bays and 
ultrasound facilities were utilised in an attempt to standardise environmental factors, such 
as room temperature and scanning positions.  Furthermore, whilst the preliminary 
examination was conducted, at each site, curtains surrounding the beds were drawn.  This 
action was undertaken to preserve the patient’s dignity at all times, in line with ethical 
guidelines.   
4.5.2. Assessment of demographic and clinical characteristics 
General demographic data of age, sex, disease duration, presence of rheumatoid factor, 
weight, limb dominance, current medication, current and previous use of Disease 
Modifying Anti-Rheumatic Drugs (DMARDs) were obtained from the Rheumatology 
Department database and clinical notes.  
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Clinical characteristics included visual analog scale (VAS 100mm) assessment for the 
patient’s global impression of health and assessment of disease activity by the number of 
painful, tender and swollen joints calculated as Disease Activity Scores (DAS-28). Foot 
symptoms were determined by the use of a validated patient administered questionnaire, the 
Manchester Foot Pain and Disability Questionnaire (MFPDQ) (Garrow, Papageorgiou et al 
2000). The MFPDQ asked participants to rate a series of questions and took approximately 
five minutes for participants to complete at the same time as the MSUS scans. A copy of 
the MFPDQ form can be seen in Appendix 6. 
4.5.3. Other clinical data 
Laboratory assessments included blood tests for C-reactive protein (CRP) and Erythrocyte 
Sedimentation Rate (ESR) on the same day as the MSUS scans. 
 
The patients’ hospital notes were examined for any reference to forefoot bursitis, synovitis 
or erosion. The forefeet of all patients were assessed by an experienced podiatrist (CB) and 
the presence of swelling and tenderness of the MTP joints and the location and numbers of 
clinically apparent plantar bursae were recorded.  
4.5.4. Imaging data 
On the same day, the MSUS foot scans were performed by both the podiatrist (CB) and a 
radiologist (KD or MS) in real time but both investigators were blinded to each other’s 
results. A research assistant ensured that participants were escorted between the two MSUS 
assessment areas and also ensured that neither investigators could view the others findings. A 
Diasus MSUS scanner (Dynamic Imaging, Livingston, Scotland UK) was used by the 
podiatrist (CB) and a Philips HDI 5000 System (Royal Philips Electronics, Netherlands) was 
used by the radiologist (KD or MS) (see Chapter three, section 3.8.1.1, page 73). 
 
To judge the extent of forefoot bursae against the extent of effect of RA on the forefoot 
joints, the second and fifth MTP joints were also scanned longitudinally and transversely 
from the plantar view (for rationale see Chapter three, section 3.8.1.1, page 73). See 
Appendix 5 for MSUS data collection sheet). 
4.5.5. Musculoskeletal ultrasound imaging protocol 
See Chapter 3, section 3.8.1.2, page 74.    100
4.6. Consensus of image interpretation protocol 
At the end of the data collection period, a consensus meeting took place between the 
radiologist (KD) and the podiatrist (CB). During this meeting, all images as recorded by the 
Diasus (Dynamic Imaging Ltd, Livingston, Scotland, UK) MSUS unit where there was no 
agreement of presence of forefoot bursae, MTP joint synovitis and erosion from the results 
of the study were discussed. The radiologist (KD) explained to the podiatrist (CB) how to 
improve on MSUS image interpretation. 
 
Following the consensus meeting, 36 ultrasound real time images were randomly selected 
from the data collected using the Diasus (Dynamic Imaging Ltd, Livingston, Scotland, UK) 
MSUS unit, by an independent research assistant (OS). All images from which the 36 were 
selected had previously been confirmed by the radiologist as being MSUS detectable 
forefoot bursae, MTP joint synovitis, erosion or normal. All 36 images were numbered and 
logged by the research assistant (OS). All 36 images were randomised in an unrestricted 
random method of allocation by the research assistant (OS) and the sequence for image 
viewing was selected by the research assistant (OS) drawing the numbers from a hat. Both 
the primary investigator (CB) and consultant radiologist (KD) were blinded to the image 
selection procedure. 
 
The two investigators independently scored all 36 images for the presence of forefoot 
bursae, MTP joint synovitis, MTP joint erosions or healthy. The Investigator (CB) 
identified images as forefoot bursae, MTP joint synovitis, MTP joint erosions or healthy 
and recorded as such against the image number. The radiologist (KD) also identified the 
images at the same time as forefoot bursae, MTP joint synovitis, MTP joint erosions or 
healthy and recorded as such against the image number. The investigator (CB) and 
radiologist (KD) were blinded to each others findings. 
 
4.7. Summary of study one protocol 
For a summary of study one protocol see Figure 21. 
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Figure 21. Flow diagram of a summary of the protocol for study one. 
 
1. All patients with RA about to begin 
treatment with anti-TNF-α therapies 
were rescreened by rheumatology 
nurse specialist 
1i. Interested and suitable participants 
invited to discuss the study further with 
rheumatology consultant. 
3. Willing participants complete 
commence anti-TNF-α therapy 
regimen in Wellcome Trust Clinical 
Research Facility 
1ii.  patient information sheet and consent 
form to be given to prospective participants 
by rheumatology consultant  2. Informed consent taken and copy 
given to patient. 
4ii. Participants completed the MFPDQ 
questionnaire 
4i. Podiatrist assessed both feet clinically  
5ii.MSUS scans of both feet performed by  
Radiologist in Department of Radiology
4. Assessment of demographic and 
clinical characteristics carried out in 
Wellcome Trust Clinical Research 
Facility on the same day as anti-
TNF-α therapy regimen commences. 
6. Medical notes consulted for 
background clinical demographic 
information 
1iii. GP information letters to be sent 
5i. MSUS scans of both feet performed by 
Podiatrist in Wellcome Trust Clinical 
Research Facility   
5. All MSUS scans performed on the 
same day as anti-TNF-α therapy 
regimen commences. 
7. Participants return for 
reassessment at twelve weeks 
following commencement of anti-
TNF-α therapy regimen 
7i. Results analysed at end of study period.  
7ii. Consensus meeting on agreement of 
image interpretation between radiologist and 
podiatrist 
3i Blood tests carried out for CRP and ESR   102
4.8. Results 
The analysis focuses on: 
1.  Clinical and demographical description of the participants 
2.  Inter-observer reliability of MSUS technique 
3.  Prevalence of plantar forefoot bursae detected by MSUS by the radiologist 
4.  Change in prevalence of plantar forefoot bursae following anti-TNFα therapy 
intervention 
 
4.8.1. Participant demographics at baseline visit 
A consecutive sample of thirty two patients with RA and starting anti-TNF-α therapy were 
recruited. All patients fulfilled the classification criteria of the American College of 
Rheumatology for RA (Arnett, Edworthy et al 1988, table 1, page 11). One patient 
withdrew due to time issues during the visit. Thirty one patients completed the study at 
baseline. There were 24 female and 7 male patients, 12 rheumatoid factor negative and 19 
rheumatoid factor positive. The mean age was 59.58 (SD 10.14) years, mean weight 70.66 
(SD 15.35) kg, mean reported well-being was 60.92 (SD 21.12) mm and all patients had 
active disease with mean DAS-28 scores of 5.8 (SD 0.9), mean ESR 37.86 (24.48) mm/hr 
and mean CRP of 31.92 (27.15) mg/l. The mean number of MSUS detectable forefoot 
bursae per individual was 3.8 (SD 2.5) and mean number of clinically detectable forefoot 
bursae was 1.5 (SD 1.9) (Table 15 and Table 16).  
 
Table 15. Demographic characteristics of the validation study participants at baseline. 
 Variable  No  Mean (SD)  Range 
Age (years)  31  58.97 (10.56)  37-76 
Time since RA diagnosis (years)  31  11.13 (10.52)  1-39 
Weight (kg)  31  70.8 (15.35)  47.7-107.5 
MFPDQ (max /38)  29  23.17 (9.23)  0-35 
Overall well being (100mm VAS)   28  60.29 (21.12)  20-100 
MSUS detectable forefoot bursae  30  3.8 (2.5)  0 - 9 
Clinically detectable forefoot bursae  30  1.5 (1.9)  0 - 6 
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Table 16. Clinical characteristics of the validation study participants at baseline. 
Variable  No  Mean (SD)  Range 
ESR (mm/hour)  29  37.86 (24.48)  4.0-106.0 
CRP (mg/litre)  29  31.92 (27.15)  2.0-117.0 
DAS-28  29  5.76 (0.93)  3.91-7.52 
 
4.8.2. Participant demographics at twelve week follow up visit 
All thirty one participants returned for reassessment at twelve weeks. There was a trend 
towards reduction in all outcome variables with mean ESR of 26.5 (16.4) mm/hr, mean 
CRP of 13.98 (15.38) mg/l, mean DAS-28 scores of 4.54 (1.5), mean reported well being of 
45.31 (23.25) mm, mean MFPDQ of 17.13 (9.73), mean number of MSUS detectable 
forefoot bursae 3.6 (2.8) and mean number of clinically detectable forefoot bursae 1.1 (2.0) 
(Table 17 and Table 18). 
 
 
Table 17. Demographic characteristics of the study participants at twelve weeks. 
 Variable  No  Mean (SD)  Range 
Age (years)  31  58.97 (10.56)  37-76 
Time since RA diagnosis (years)  31  11.13 (10.52)  1-39 
Weight (Kg)  27  73.25 (15.25)  50-108.18 
MFPDQ (max /38)  24  17.13 (9.73)  0-34 
Overall well being (100mm VAS)   26  45.31 (23.25)  0-100 
MSUS detectable forefoot bursae*  26  3.6 (2.8)  0 - 9 
Clinically detectable forefoot bursae**  26  1.1 (2.0)  0 - 7 
Key: *Total numbers of MSUS detectable bursae per individual; ** Total numbers of 
clinically palpable bursae per individual 
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Table 18. Clinical characteristics of the study participants at twelve weeks. 
Variable  No  Mean (SD)  Range 
ESR (mm/hour)  26  26.5 (16.4)  2-67 
CRP (mg/litre)  26  13.98 (15.38)  2-55.5 
DAS-28   26  4.54 (1.5)  2.04-7.03 
 
4.8.3. Inter-observer agreement in detection of forefoot bursae using ultrasound 
To determine the ability of the podiatrist (CB) to reliably detect bursae within the forefoot, 
the results of MSUS scan interpretations were compared against expert MSUS radiologists 
(KD or MS) who acted as the ‘gold standard’ assessors. 
 
4.8.3.1. Exact agreements 
Overall agreement was 83.3% for presence or absence of MSUS detectable forefoot bursae 
(Table 19), 81.8% for presence or absence of MTP joint erosion (Table 20) and 68.4% for 
presence or absence of MTP joint synovitis (Table 21).  
 
Table 19. Relation between the podiatrist’s and radiologist’s results of MSUS scans for 
the detection of the presence or absence of plantar forefoot bursae (N=60 feet, two feet 
data missing), in the RA study participants 
  Pod presence   Pod absence  Total  
Rad Bursae Presence,  N(%)  42 (70%)  9 (15%)  51 
Rad Bursae Absence,  N(%)  1 (1.7%)  8 (13.3%)  9 
Key: Pod = Podiatrist; Rad = Radiologist 
 
Table 20. Relation between the podiatrist’s and radiologist’s results of MSUS scans for 
the detection of the presence or absence of MTP joint erosion (N=110 joints, 14 joint 
data missing) in the RA study participants. 
  Pod presence   Pod absence   Total  
Rad Erosion Presence, N(%)  44 (40%)  9 (8.2%)  53 
Rad Erosion Absence, N(%)  11 (10%)  46 (41.8%)  57 
Key: Pod = Podiatrist; Rad = Radiologist   105
. 
Table 21. Relation between the podiatrist’s and radiologist’s results of MSUS scans for 
the detection of MTP joint synovitis (N=120 joints, 4 joint data missing) in the RA 
study participants. 
  Pod presence   Pod absence   Total  
Rad Synovitis Presence, N(%)  68 (56.7%)  13 (10.8%)  81 
Rad Synovitis Absence, N(%)  25 (20.8%)  14 (11.7%)  39 
Key: Pod = Podiatrist; Rad = Radiologist 
 
 
4.8.3.2. Sensitivity and specificity 
Results from analysis in this study of both feet for forefoot bursae as individual data, show 
that the sensitivity of clinical examination by palpation by the podiatrist was 50% and 
specificity was 75% for detection of bursae, when compared to MSUS detection by the 
radiologist (Table 22). Therefore there was low (50%) agreement between the proportion 
of individuals identified with forefoot bursae by clinical palpation when compared to 
detection of forefoot bursae by MSUS performed by the radiologist. Agreement was higher 
(75%) for the proportion of individuals without bursae identified by clinical palpation when 
compared to detection of forefoot bursae by MSUS performed by the radiologist. 
 
Table 22. A two by two table showing the raw data of agreement scores for 
clinical examination by a podiatrist compared to a radiologist performing MSUS 
imaging to detect bursae in the forefeet of patients with RA. 
Presence of MSUS  bursae  baseline 
visit, radiologist 
N=60 feet 
 
  presence  absence  
presence  
13 (a)  1 (b) 
Presence of clinically 
palpable bursae, 
baseline visit, 
podiatrist 
 
absence 
13 (c)  3 (d) 
 Sensitivity = a/(a+c) = 13/(13+13) = 50%;  Specificity = d/(b+d) = 3/(1+3) = 75% 
 
Results from analysis in this study of both feet (for bursae, MTP joint erosion and 
synovitis) and each MTP joint (for erosion and synovitis) as individual data show that the   106
sensitivity of the podiatrist using MSUS was 82.4% for detection of forefoot bursae, 83.0% 
for detection of MTP joint erosion and 83.4% for detection of MTP joint synovitis. 
Specificity of the podiatrist using MSUS was 88.9% for detection of forefoot bursae, 80.7% 
for detection of MTP joint erosion and 35.9% for detection of MTP joint synovitis (Table 
23, Table 24, and Table 25). 
 
In other words, there was high (82.4%) agreement between the proportions of individuals 
identified with forefoot bursae by MSUS performed by the podiatrist when compared to 
detection of forefoot bursae by MSUS performed by the radiologist. Agreement was higher 
(88.9%) for the proportion of individuals without bursae identified by MSUS performed by 
the podiatrist when compared to detection of forefoot bursae by MSUS performed by the 
radiologist. 
 
Table 23. A two by two table showing the raw data of agreement scores for a 
podiatrist compared to a radiologist performing MSUS imaging to detect bursae in 
the forefeet of patients with RA. 
Radiologist  N=60 feet  
Bursae Positive  Bursae Negative 
Bursae 
positive 
42 (a)  1 (b)   
Podiatrist 
Bursae  
negative 
9 (c)  8 (d) 
Sensitivity = a/(a+c) = 42/(42+9) = 82.4%;  Specificity = d/(b+d) = 8/(1+8) = 88.9% 
 
Table 24. A two by two table showing the raw data of agreement scores for a 
podiatrist compared to a radiologist performing MSUS imaging to detect erosion 
in the second and fifth MTPJs of the forefeet of patients with RA. 
Radiologist  N=110 joints  
Erosion Positive  Erosion Negative 
Erosion 
positive 
44 (a)  11 (b)   
Podiatrist 
Erosion  
negative 
9 (c)  46 (d) 
Sensitivity = a/(a+c) = 44/(44+9) = 83.0%;  Specificity = d/(b+d) = 46/(11+46)= 80.7%   107
Table 25. A two by two table showing the raw data of agreement scores for a 
podiatrist compared to a radiologist performing MSUS imaging to detect synovitis 
in the in the second and fifth MTPJs of the forefeet of patients with RA. 
Radiologist  N=120 joints 
Synovitis Positive  Synovitis Negative 
Synovitis 
positive 
68 (a)  25 (b)   
Podiatrist 
Synovitis 
negative 
13 (c)  14 (d) 
Sensitivity = a/(a+c) = 68/(68+13) = 83.4%;  Specificity = d/(b+d) = 14/(25+14) = 35.9% 
 
There was high (83.0%) agreement between the proportions of individuals identified with 
MTP joint erosion by MSUS performed by the podiatrist when compared to detection of 
MTP joint erosion by MSUS performed by the radiologist. Agreement was also high 
(80.7%) for the proportion of individuals without MTP joint erosion identified by MSUS 
performed by the podiatrist when compared to detection of MTP joint erosion by MSUS 
performed by the radiologist. 
 
There was high (83.4%) agreement between the proportions of individuals identified with 
MTP joint synovitis by MSUS performed by the podiatrist when compared to detection of 
MTP joint synovitis by MSUS performed by the radiologist. Agreement was however low 
(35.9%) for the proportion of individuals without MTP joint synovitis identified by MSUS 
performed by the podiatrist when compared to detection of MTP joint synovitis by MSUS 
performed by the radiologist. 
 
Results demonstrate that sensitivity and specificity values for the podiatrist in detecting 
bursae and MTP joint erosions within the forefeet of participants with RA are both over 80% 
and therefore very acceptable. However, results for the detection of MTP joint synovitis by 
the podiatrist were less acceptable. Whilst sensitivity for MTP joint synovitis was over 80% 
and thus very good, specificity was poor at 35.9% indicating that the podiatrist was over-
reporting false positives (Table 26).  
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Table 26. Summary of sensitivity and specificity values for inter-tester reliability of a 
podiatrist compared to a radiologist performing MSUS imaging to detect bursae, erosion 
and synovitis in the forefeet of patients with RA. 
  Sensitivity  Specificity  
Bursae  82.4% 88.9% 
Erosion  83.0% 80.7% 
Synovitis  84.0% 35.9% 
 
 
During the data collection for this preliminary study, it became clear that the plantar approach 
used to detect MTP joint synovial thickening / synovitis was a major limitation. The ability to 
assess synovitis in some participants, using the linear MSUS 5 – 10 MHz transducer (active 
length 26mm; see Figure 20, page 78) to achieve 7.5 MHz frequency with the Diasus 
machine, was hampered by structural lesser toe deformities and MTP joint subluxation, even 
with use of liberal amounts of coupling gel. This may account for the poor agreements in the 
MSUS detection of MTP joint synovitis between the investigators. 
 
Clinically, it is important to decide whether a test requires high sensitivity or high 
specificity and what the implications of false positives and false negative test results are 
(Petrie and Sabin 2005). 
 
Figure 22.  Schematic diagram depicting sensitivity and specificity relative to false 
positive and false negative results (adapted from Petrie and Sabin 2005). 
 
 
 
 
 
Test value 
False negatives  False positives 
Normal Bursitis 
Sensitivity / 
True positives 
Specificity / 
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In this study, synovitis, for example, is readily treatable and therefore the high sensitivity of 
84% in detecting it is preferred. If synovitis was a serious and untreatable pathology, high 
specificity would be preferred to avoid making a false positive diagnosis (Figure 22) and 
the low specificity of 35.9% would be unacceptable.   
4.8.3.3. Kappa 
Kappa scores for from the primary data revealed moderate agreement for MSUS detectable 
bursae (N=60, kappa 0.522; p<0.001) and MTP joint erosions (N=110, kappa 0.636; 
p<0.001) and fair agreement for MTP joint synovitis (N=120, kappa 0.216; p=0.015) (see 
Table 27). 
 
Table 27. Kappa values for inter-tester reliability of a podiatrist compared to a radiologist 
performing MSUS imaging to detect bursae, erosion and synovitis in the forefeet of 
patients with RA. 
  Kappa statistic  P value 
Bursitis  0.522 p<0.001 
Erosion  0.636 p<0.001 
Synovitis  0.216 p=0.015 
Consensus  0.702 p<0.001 
 
Data from this analysis therefore indicates that acceptable sonographic images were 
obtained from the primary investigation, particularly for bursae, by the podiatrist with 
significant and moderate agreement with the radiologist. 
 
4.8.4. Image interpretation consensus meeting 
During the consensus meeting, images recorded by the Diasus MSUS unit were discussed 
and agreed as MSUS detectable bursae (Figure 23), MTP joint synovitis (Figure 24) and 
MTP joint erosion (Figure 24).  
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Figure 23. MSUS image of the left foot plantar metatarsal area of a study participant 
with RA demonstrating a bursa as a demarcated complex mass protruding beyond the 
3rd and 4th metatarsal heads with hypertrophied synovium and anechoic spaces 
containing synovial fluid (arrow). The image is seen from the plantar aspect and in the 
transverse plane. 
 
 
Key: M4 = 4
th metatarsal head; M3 = 3
rd metatarsal head; P = plantar surface;  
D = dorsal surface 
Equipment: Diasus MSUS system (Dynamic Imaging LTd, UK) 
 
 
Figure 24. A MSUS image of synovial thickening (S), joint effusion (E) and bone 
changes (B) within the right fifth plantar MTPJ of a study participant with RA. The image 
is seen from the plantar aspect and in the longitudinal plane. 
 
Key: PP = proximal phalanx; MH = metatarsal head. 
Equipment: Diasus MSUS system (Dynamic Imaging LTd, UK)   111
Following the consensus meeting, and tests on a randomised selection of 36 images from 
the Diasus machine, substantial levels of agreement were achieved between the podiatrist 
and radiologist for 8/9 forefoot bursae, 4/10 MTP joint synovitis, 6/9 MTP joint erosions 
and 8/8 healthy images (Table 28) with  kappa 0.702; p<0.001 (Table 31).   
  
Table 28. Contingency table showing a comparison of results between the radiologist and 
podiatrist for image interpretation following the consensus meeting. 
 
Radiologist    
   synovitis erosion  bursae  healthy  poor image  Total 
Podiatrist  synovitis  4  0  0  4  0  8 
   erosion  1  5  0  1  0  7 
   bursae  0  1  8  0  0  9 
   healthy  1  0  0  10  0  11 
   poor image  0  0  0  0  1  1 
Total  6  6  8  15  1  36 
 
 
 
Table 29. Contingency table showing a comparison of results between the podiatrist and 
actual images for image interpretation following the consensus meeting. 
 
Original images    
   synovitis erosion  bursae  healthy  poor image  Total 
Podiatrist  synovitis  8  0  0  0  0  8 
   erosion  1  6  0  0  0  7 
   bursae  0  0  9  0  0  9 
   healthy  2  1  0  8  0  11 
   poor image  0  0  0  0  1  1 
Total  11  7  9  8  1  36 
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Table 30. Contingency table showing a comparison of results between the radiologist and 
actual images for image interpretation following the consensus meeting. 
 
Original images    
   synovitis erosion  bursae  healthy  poor image  Total 
Radiologist  synovitis  5  0  0  1  0  6 
   erosion  0  5  1  0  0  6 
   bursae  0  0  8  0  0  8 
   healthy  6  2  0  7  0  15 
   poor image 0  0  0  0  1  1 
Total  11  7  9  8  1  36 
 
Agreement between the podiatrist and original images was 9/9 forefoot bursae, 8/10 MTP 
joint synovitis, 6/9 MTP joint erosion and 8/8 healthy images (Table 29) with kappa 0.854 
(p<0.001) (Table 31). Agreement between the radiologist and original images was 8/9 
forefoot bursae, 5/10 MTP joint synovitis, 6/9 MTP joint erosions and 7/8 healthy images 
(Table 30) with kappa 0.638, p<0.001 (Table 31). 
 
Following further training, levels of agreement increased to a ‘very good standard’ that was 
also ‘statistically significant’ (p<0.001).  Interestingly, following further training, the levels 
of agreement between the podiatrist and the original images increased to the category of 
‘almost perfect’ (p<0.001) whilst agreement scores for the radiologist were lower, but still 
significant (p<0.001) (Table 30). 
 
  
Table 31. Summary of kappa values for inter-tester reliability of a podiatrist, radiologist 
and actual images for image interpretation following the consensus meeting. 
  Kappa statistic  P value 
Podiatrist v Radiologist  0.702 p<0.001 
Podiatrist v Original images  0.854 p<0.001 
Radiologist v Original images  0.638 p<0.001   113
 
4.8.5. Prevalence of forefoot bursae in patients with RA detected by MSUS 
performed by an experienced radiologist at baseline 
Bursae were detectable in 82.4% (51/62) of feet, synovitis in 65.3% (81/124) of MTP joints 
and erosions in 42.7% (53/124) of MTP joints detected by MSUS and scanned by the 
radiologist.  The mean number of bursae per patient detected by MSUS was 3.8 (SD 2.5) 
and by clinical examination was 1.5 (SD 1.9). On clinical examination by palpation of the 
plantar forefoot area 41.4% (N=24/58 feet, 4 missing data) of feet had clinically detectable 
bursae. On retrospective analysis of participants’ clinical notes, no documentation of foot 
related bursitis was found in the medical records of any of the participants (Figure 25).  
 
 
Figure 25. A stacked bar chart representing the comparison between the numbers of 
plantar forefoot bursae detected by clinical palpation, MSUS by radiologist and 
reported within medical records for individual data. 
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Of those with MSUS detectable bursae 96.6% had bursae in both feet. Of those with 
clinically detectable bursae, 64.3% had bursae in both feet. In comparison, on clinical 
examination 46.6% (N= 27/58 feet, 4 missing data) had detectable MTP joint synovitis 
(Figure 30). The mean number of synovitis affected MTP joints per patient was 2.39 (SD 
2.9) by clinical examination. Of those with clinically detectable MTP joint synovitis 
(N=17/31), 76.4% (N=13/17) demonstrated MTP joint synovitis in both feet.  
 
Figure 26. A bar chart representing the comparison between the percentage of forefoot 
bursae, MTP joint synovitis, and erosion detected by clinical palpation, MSUS by 
radiologist and reported within medical records for individual data. 
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On retrospective analysis of participants’ clinical notes documentation of synovitis within 
the MTP joints was found in the medical records of 6.5% (N=2) of the patients and in a 
further 19.4% (N=6) foot pain or foot problems were documented, although not attributed 
to any cause.  On MSUS for individual cases 90% (N=27/30 feet) displayed MTP joint 
synovitis and from those, 59.3% (N=16/27) displayed symmetry within the second MTPJs 
and 74.1% (N=20/27) displayed symmetry within the fifth MTP joints.  
 
On MSUS for individual cases in 93.1% (N=27/29 feet, 2 missing data) of patients erosion 
of at least one MTP joint was noted (Figure 26). From those 14.8% (N=4/27) displayed 
symmetry within the second MTP joints and 59.3% (N=16/27) displayed symmetry within   115
the fifth MTP joints. 
 
4.8.6. Prevalence of forefoot bursae detectable by MSUS in patients with RA performed 
by an experienced radiologist after twelve weeks of anti-TNF-  therapy 
Tumour Necrosis Factor (TNF) inhibition is known to be an effective way of reducing 
synovitis (Hau, Kneitz et al 2002; Taylor,Steuer et al 2006) and a high prevalence of 
forefoot bursae have been linked with RA disease progression. Therefore reassessment 
following twelve weeks of therapy was an ideal opportunity to determine whether MSUS 
could be responsive to change in prevalence of forefoot bursae within the foot in RA 
participants. 
 
All thirty one participants returned for reassessment at twelve weeks. There was a trend 
towards reduction in all outcome variables (Tables 15, 16, 17, 18, pages 102 and 103; 
Figure 27) and using paired samples t-tests all differences between baseline and twelve 
weeks for clinical disease measures were significant: DAS-28 (t = 3.712, p = 0.001), CRP (t 
= 3.889, p = 0.001), ESR (t = 4.014, p < 0.001), foot pain and disability (t = 3.712, p = 
0.001) and global wellbeing VAS (t = 2.7351, p =0.011). 
 
 
Figure 27. A simple bar chart representing changes in clinical and disease variables 
following twelve weeks of anti-TNF-α therapy. 
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Figure 28. A simple bar chart representing the percentages of cases of MSUS 
detectable forefoot bursae and MTP joint synovitis at baseline and following twelve 
weeks of anti-TNF-α therapy. 
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Observed presence of MSUS detectable forefoot bursae was noted in 83.3% (50/60) of feet 
at baseline and 75% (39/52) of feet at twelve weeks (Figure 20). At twelve weeks 19.2% 
(10/52) of feet had changed from MSUS detectable forefoot bursae being present to absent 
and 9.6% (5/52) changed from MSUS detectable forefoot bursae being absent to present. 
No change was observed in presence of MSUS detectable forefoot bursae in 63.5% (33/52) 
of feet and absence in 5.8% (3/52) of feet. 
 
Observed presence of MTP joint synovitis by MSUS from 60 feet (120 joints) indicates 
presence in 67.5% (81/120 joints) at baseline and 54.8% (57/104 joints) at twelve weeks 
(Figure 28). At twelve weeks 25.9% (27/104 joints) had changed from MTP joint synovitis 
being present to absent, and 13.5% (14/104 joints) changed from MTP joint synovitis being 
absent to present. No change was observed in presence of MTP joint synovitis in 41.3% 
(43/104 joints) and absence in 19.2% (20/104 joints). 
 
There was a trend towards reduction in presence of MSUS detectable forefoot bursae and 
MTP joint synovitis that was observed by MSUS performed by the radiologist (Figure 28) 
however using a McNemar test for categorical data of related groups, no significance was 
found.    117
4.9 Summary of findings  
1. Inter-observer reliability between the podiatrist and radiologist performing MSUS 
imaging of the forefoot 
The first part of the investigation set out to test the reliability of a podiatrist using a MSUS 
to assess forefoot pathology in patients with RA. Acceptable sonographic images were 
obtained from the primary investigation by the podiatrist with moderate agreements with 
the expert radiologist for MSUS detectable forefoot bursae and MTP joint erosion. 
Following further training, levels of agreement increased to a very good standard for 
MSUS detectable forefoot bursae, MTP joint erosion and MTP joint synovitis. 
 
2. MSUS detection of forefoot bursae 
The second part of this preliminary study attempted to investigate the presence of bursae 
within the forefeet of patients with RA using two different methods, clinical examination 
and MSUS. The data suggests that forefoot bursae are a common and under-reported cause 
of foot problems, that MSUS detected a higher prevalence of forefoot bursae than clinical 
examination and that this was an area in which MSUS could provide further important, 
clinically relevant, information.  These findings provided information regarding the 
prevalence of MSUS detectable bursae as observed by an experienced radiologist using a 
high resolution Philips HDI 5000 MSUS system. 
 
 
3. MSUS detection of change in prevalence of plantar forefoot bursae following a 
period of intervention 
Findings from this study indicate that there is a trend towards change in MSUS detectable 
bursae within the forefoot, towards a reduction in number after twelve weeks of anti-TNF-α 
therapy, although the reduction was not statistically significant. The same trend was also 
observed for reduction in synovitis within the second and fifth MTP joints, which also was 
not statistically significant. Findings also indicate that MSUS is an acceptable technique to 
detect changes in the prevalence of forefoot bursae. 
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4.10. Discussion 
4.10.1. Reliability of technique 
This was the first study to investigate tailored learning of MSUS to the discrete field of foot 
and ankle practice, in evaluating the inter-observer agreement in the use of MSUS between 
an allied health professional (podiatrist) and an expert radiologist on imaging of the foot. 
We demonstrated good agreement for MSUS detectable forefoot bursae and MTP joint 
erosions, but only fair agreement for the presence of MTP joint synovitis.  
 
Competency assessment in MSUS is an important issue (Brown, O’Connor et al 2005). 
Usually, reliability in technique is reported by rheumatologists who have trained, or are 
being trained, in MSUS that are tested against experienced MSUS sonographers or 
radiologists (Szkudlarek, Court-Payen et al 2003; D’Agostino, Maillefert et al 2004; 
Scheel, Schmidt et al 2005; Naredo, Moller et al 2006).  The podiatrist in this study had 
followed recommended BSR (British Society for Rheumatologists) training in MSUS 
techniques, followed by further training and mentorship from expert radiologists. 
Podiatrists are regularly involved in the assessment and management of musculoskeletal 
foot and ankle pathology. With extended scope practice in the use of MSUS by podiatrists, 
there are the potentially valuable benefits to patients, as well as lower costs in service 
provision.  
 
In our study overall exact agreement between the radiologist and podiatrist was recorded as 
83.3% for MSUS detectable forefoot bursae, 68.3% for MTP joint synovitis and 81.8% for 
MTP joint erosions. Acceptable sonographic images were obtained by the podiatrist with 
moderate agreements for MSUS detectable forefoot bursae (kappa 0.522, p <0.001) and 
MTP joint erosions (kappa 0.636, p <0.001). Low agreements for MTP joint synovitis 
(kappa 0.216, p =0.015) were obtained initially, however following further training, levels 
of agreement for all three variables increased to a good standard (kappa 0.702, p <0.001).  
 
Within the MSUS literature, the foot is under-investigated and those who have reported on 
assessments of the foot joints have observed similar low agreement scores for synovitis 
(Szkudlarek, Court-Payen et al 2003; D’Agostino, Maillefert et al 2004; Scheel, Schmidt et 
al 2005; Naredo, Moller et al 2006). Inter-observer reliability among 14 experts in MSUS 
produced overall good agreements for all examined joints (kappa 0.76) although low 
agreement for ankle and toe joints (kappa 0.28) was reported (Scheel, Schmidt et al 2005).   119
In evaluating scanning technique and diagnostic criteria, a group of 23 experts in MSUS 
who scanned shoulder, wrist and hand, ankle and foot, and knee joints, reported ‘exact’ 
overall agreement of 91% for synovitis, 87% for cortical abnormalities and 83.5% for 
bursitis but only ‘fair‘ agreements for the ankle and foot region (kappa 0.54) (Naredo, 
Moller et al 2006). In MSUS examination of synovitis of the metacarpophalangeal joints 
and MTP joints, the learning curve of three rheumatologists in MSUS techniques was 
investigated (D’Agostino, Maillefert et al 2004). The agreements at the final evaluations 
were good for two of the trainees, (kappa 0.63 and 0.62), consistent with our findings, 
however for the third trainees was poor (kappa 0.18). This highlights the variability of 
learning requirements for the technique (D’Agostino, Maillefert et al 2004). 
 
The use of MSUS by the podiatrist within this study did reveal good sensitivity and 
specificity for detecting forefoot bursae (82.4% and 88.9%) and MTP joint erosion (83.0% 
and 80.7%), although in detection of MTP synovitis sensitivity was good, specificity was 
low (83.4% and 35.9%) with over-reporting of false positives.  
 
Disagreement between experts in clinical MSUS imaging techniques is not uncommon, 
with sonographers differing (sometimes substantially) in their interpretation of images 
(Scheel, Schmidt et al 2005). A lack of standardisation and variation in scanning technique 
amongst sonographers has been deliberated as contributing to the disagreements (Scheel, 
Schmidt et al 2005). Results following the consensus meeting in this study, indicated that 
there was a small amount of disagreement observed between the podiatrist and the 
radiologist; it is unclear whether the disagreement was due to the podiatrist’s technique, 
image resolution or differing specifications of the MSUS machines. 
 
In common with other researchers (Scheel, Schmidt et al 2005) this research team did 
encounter difficulties in our technique for using MSUS to detect synovitis in the MTP joints 
from the plantar aspect of the foot, especially if deformities or subluxation of those joints 
were present. Difficulty in assessing MTP joint synovial thickening / synovitis existed where 
severe retraction of the lesser toes and subluxation of the MTP joints did not allow good 
transducer contact. Interestingly, others have scanned each joint in the dorsal aspect of the 
hands and feet, reporting that this technique was preferred to a palmer or plantar scan because 
of its reliability for detecting synovitis (D’Agostino, Maillefert et al 2004) although they did 
not mention technique where deformity and subluxation existed in the MTP joints. Therefore   120
a dorsal approach to assess MTP joint synovial thickening / synovitis, as recommended by the 
EULAR “working group for musculoskeletal ultrasound in rheumatology” guidelines was 
considered more appropriate for the next phase of the research (Backhaus, Burmester et al 
2001).  
 
In retrospect, the use of ‘stand off’ pads and techniques for using a water bath to facilitate 
the ultrasound wave conduction over gross structural deformities of the foot may have 
produced better results. These techniques reportedly increase the field of view in 
anatomical areas where the contour of the part is such that it only allows a small area of 
contact (Stokes, Hides and Nassiri 1997). At the time of this study these techniques were 
not readily available within either the podiatric or radiology clinical department. Similarly, 
small transducer footprints such as ‘hockey stick’ probes, may have also been easier to use 
over the deranged MTP joints (Backhaus, Burmester et al 2001), but this was not an 
available feature of the Diasus machine used within the study.  
 
From our experiences within this study, the technique for image acquisition and 
interpretation of forefoot bursae was acceptable, although we recommend that further work 
on establishing reliability of protocols for MSUS assessment of the foot and ankle joints be 
undertaken. 
 
Inter-machine and intra-operator reliability would have added credence to the validity of 
the technique we have developed within this study, for using MSUS imaging to detect 
forefoot bursae in patients with RA. However, the feasibility of testing intra-operator 
reliability to detect forefoot bursae for this study was questioned and debated. If the 
technique is tested too soon, the operator may remember, and recall bias will affect the 
results but if the test is undertaken too late, the prevalence of forefoot bursae may have 
changed. Therefore at this stage, a pragmatic clinical approach was adopted and no further 
reliability testing was undertaken. 
 
 
4.10.2. Prevalence of forefoot bursae 
Using MSUS we confirmed a high prevalence of plantar forefoot bursae in patients with 
RA within this study and have demonstrated that these bursae are usually bilateral and 
symmetrical. The use of MSUS within this study did reveal a higher sensitivity for   121
detecting forefoot bursae than clinical palpation. Based on the study participants, of those 
with MSUS detected bursae only 50% would be detected by clinical examination alone. 
Clinical examination of the plantar forefoot missed many cases of forefoot bursae, 
suggesting that bursae within the forefoot may be a common but under-reported cause of 
problems in RA.  
 
There are other reports of similar findings, of bursae in the forefoot being poorly 
documented, that have emphasised the importance of rheumatologists being aware of the 
existence of numerous small, synovial bursae in the forefoot (Olivieri, Scarano et al 2004). 
In a previous similar study investigating early RA (mean disease duration of 1.1 years), 
intermetatarsal bursae were reported as clinically palpable in 5 patients from a cohort of 25 
(20%); yet 14 of 25 (56%) patients were deemed to have MSUS detectable plantar forefoot 
bursae (Koski 1998). Our own study findings in patients with more established severe 
disease, reveal a higher prevalence of MSUS detectable plantar forefoot bursae with 26 of 
30 (83.9%) patients recorded as having presence MSUS detectable plantar forefoot bursae 
and 14 of 30 (48.4%) detected by clinical palpation. Differences in the participant sample 
(mean disease duration 11.13 years in our study) and MSUS machine specifications, 
however, make true comparisons between the studies difficult.  
 
4.10.3. Changes in presence of MSUS detectable forefoot bursae following 
intervention therapy 
The second part of this study involved the investigation of plantar forefoot bursae 
detectable by MSUS, performed by a radiologist, following a period of intervention.  Using 
the small sample of subjects from the preliminary study, this question formed an important 
foundation in the development of the next phase of the study that aimed to investigate the 
prevalence and natural history of plantar forefoot bursae in a larger sample. 
 
Whilst no statistical significance, in changes in the presence of MSUS detectable plantar 
forefoot bursae or MTP joint synovitis, was found there was an observable trend towards 
their reduction after twelve weeks of anti-TNF-α therapy. The trend was also noted in the 
clinical and laboratory assessments of RA disease status (ESR, CRP, DAS-28 and 
MFPDQ) and these reductions were statistically significant demonstrating that TNF 
inhibition did dampen down the disease process in the RA participants within this study.  
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It may be that treatment switches off the disease process of RA, but twelve weeks was not 
enough time for synovial hypertrophy to regress, or that disease that is not clinically 
evident  remains longer than thought, as recently reported by Brown et al (2006). 
Therefore, acknowledging that the changes that occurred in MSUS detectable plantar 
forefoot bursae and MTP joint synovitis followed the same pattern as the trend to reduction 
in clinical and laboratory measures, pragmatically it was accepted that MSUS was 
responsive to those changes. 
 
Of further note, in the minority of patients where the prevalence of MSUS detectable 
plantar forefoot did increase, some patients’ MFPDQ scores (perceived foot pain) 
improved.  This anomalous increase could be attributable to adventitious bursae, due to 
increased mechanical stress as mobility improved for those patients, rather than an increase 
in anatomical bursae due to the disease process of RA.  
 
4.11. Potential limitations 
A number of potential limitations within this preliminary study should be acknowledged.  
The prevalence of MSUS detectable bursae within the forefoot was not validated by any 
other ‘gold standard’ imaging technique, such as MRI or by histological analysis through 
biopsy. As well as intermetatarsal bursae and adventitious bursae, soft tissue swelling at the 
level of the MTP joints can be related to MTP joint synovitis or tenosynovitis that could be 
better differentiated using MRI (Ashman, Klacker and Yu 2001; Helliwell, Woodburn et al 
2007; Studler et al 2008). At the time of the preliminary reliability study, the OMERACT 
MSUS special interest group had highlighted limited data in terms of comparisons of MRI 
with MSUS (Wakefield, Balint et al 2005). Due to its restricted availability MRI was not 
feasible for our study. Others have attempted to validate imaging findings using fresh 
cadavers (Theumann, Pfirmann et al 2001; Studler et al 2008) however this technique was 
also not a feasible option during the initial phases of our study. 
 
Furthermore, in the preliminary study, due to forefoot structural deformity in some 
participants, it was clear from the conceptual stage that tenosynovitis was too difficult to 
assess using the proposed Diasus ultrasound machine. As well as MTP joint synovitis, the 
appearance of flexor tenosynovitis on MSUS is a key differential diagnosis for plantar 
forefoot tenderness (Koski 1995). This inability to measure tenosynovitis using the Diasus   123
MSUS machine also has to be acknowledged as a significant omission and therefore a major 
limitation in the second and third studies regarding the assessment of the associations of 
MSUS detectable forefoot bursae with patient reported foot impact outcome measures. 
 
Previously in the literature, MSUS detectable bursae in the forefoot have been referred to as 
‘bursitis’ (Koski 1998) yet more recently power Doppler mode is advocated to determine 
whether synovium is actively inflamed, allowing a more precise definition of ‘active 
synovitis’ (Brown, Quinn et al 2006; Balint, Mandl and Kane 2008). The technique for the 
use of power Doppler in assessment of changes in synovial perfusion has been a 
development subsequent to the commencement of this doctoral thesis (Balint, Mandl and 
Kane 2008). Whilst the MSUS machine utilised by the radiologists had power Doppler 
mode, the MSUS machine utilised by the podiatrist (CB) did not. To avoid complication in 
the use of terminology, at this stage of the study a decision was made to refrain from using 
the term ‘bursitis’, preferring the term ‘MSUS detectable bursae’ instead. For future 
studies, a MSUS machine with Power Doppler will be a prerequisite. 
 
An important issue within this preliminary study one was measurement error between 
clinicians and between machines. For the preliminary study, the podiatrist’s (CB) technique 
was tested for reliability against expert radiologists (KD and MS). Although this is a 
common way of determining reliability, validity can be questioned, especially with the use 
of two different machines and two different radiologists. In the design of the reliability 
study, two assumptions were made, firstly that the radiologists were experts in the field of 
MSUS imaging and secondly that their inter-tester reliability in technique in detecting 
forefoot bursitis was of an acceptable standard. Using the OMERACT filter (Boers, Brooks 
et al 1998) (see Table 12, page 80) it can be seen that, although the podiatrist’s technique 
was confirmed as being reliable, there are limitations that affect the overall validity of the 
technique in the detection of forefoot bursae. 
 
Limitations relating to the sample are also highlighted. The sample was relatively small and 
comprised patients with severe disease; therefore generalizibility to the whole population of 
patients with RA needs to be confirmed.  Finally, whilst the consensus meeting did take 
place once data collection was complete, it is possible that there may have been an element 
of recall bias that should be acknowledged.  Image interpretation may have been enhanced 
during the post-consensus test as the images selected were taken from part of the cohort   124
that the podiatrist and radiologist used for the initial reliability analyses.  
 
4.12. Conclusion 
This study was the first to attempt to investigate inter-observer agreement in the use of 
MSUS, between an allied health professional (podiatrist) and an expert radiologist. 
Performance of MSUS in image acquisition and interpretation by the podiatrist was of an 
acceptable standard during the primary investigation and, following further training, levels 
of agreement increased to a very good standard. We observed a high prevalence of MSUS 
detectable plantar forefoot bursae in patients with RA. Furthermore, there was a trend for 
MSUS detectable bursae within the forefoot to decrease after twelve weeks of anti-TNFα 
therapy, although this was not significant. Clinical examination of the plantar forefoot 
missed many cases of MSUS detectable bursae indicating that MSUS may be a valuable 
tool for providing clinically relevant information as part of the ongoing clinical assessment 
of the foot in RA. 
 
This preliminary study therefore laid the foundations for the next phase of the research. The 
MSUS imaging technique for the proposed primary investigator (CB) within study two was 
proven to a very good standard. MSUS was accepted as a key modality for assessing the 
prevalence and natural history of plantar forefoot bursae in RA.  
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5.0 Chapter Five: Prevalence of MSUS Detectable Forefoot Bursae 
in RA Participants 
5.1. Introduction 
During the reliability study in chapter four we noticed that both investigators (Radiologist 
and Podiatrist) identified a high prevalence of MSUS detectable forefoot bursae. As the 
sample was small and there were no control subjects we were unable to determine if this 
was a relevant finding. Chapter five details the second study which forms the doctoral 
thesis and, in view of the findings, provides a frame of reference for the prevalence of 
MSUS detectable bursae in a larger cohort. 
 
From the literature review (Chapter 2, page 8) it was evident that the role of soft tissues 
such as bursae in the process of rheumatoid foot disability is less well explored than MTP 
joint synovitis (Costa, Rizack and Zimmermann 2004; van der Leeden,  Steultjens et al 
2008).  
 
The anatomy and physiology of bursae within the foot and the confusion over terminology 
of those detectable within the plantar forefoot area are outlined in detail in Chapter two 
(section 2.2, page 18). Specific features of bursae within the plantar forefoot area have 
previously been identified using MRI and histological analyses (Theumann, Pfirrmann et al 
2001; Studler, Mengiardi et al 2008). Whilst MRI has become the gold standard imaging 
modality in the detection of soft tissue lesions in RA, it remains a less economical clinical 
tool than musculoskeletal ultrasound (MSUS).  MSUS continues to be reported as 
comparable and more readily accessible in assessing soft tissues in RA (Melchiorre, 
Calderazzi et al 2003; Terslev, Torp-Pedersen et al 2003; Szkudlarek, Narvestad et al 
2004). In healthy subjects, bursae are reportedly not detectable by MSUS (Meenagh, 
Iagnocco et al 2006), but the presence of hypertrophied bursae within the anatomical areas 
of the hip, shoulder and knee have been readily identified by MSUS (Hermann, Backhaus 
et al 2003; Finlay and Friedman 2006; Meenagh, Iagnocco et al 2006).  Bursae detectable 
by MSUS are described as having similar echo characteristics to joint synovitis (O’Connor 
and Grainger 2002). 
 
In a small cross sectional study of patients with early RA, a higher prevalence of bursae 
within the forefoot detectable by MSUS imaging was reported than were detectable in   126
normal control participants (Koski 1998). Further findings within that study suggested that 
bursae could promote symptoms within the forefoot in RA patients and that their detection 
clinically appears to be less sensitive than by MSUS imaging (Koski 1998).   
 
Other authors have suggested that bursae within the foot in RA may cause clinical 
symptoms when they enlarge or become inflamed (Hernandez, Hernandez and Hernandez 
1991; Beggs 2002). In the absence of large cohort, prospective data, however, the 
prevalence of bursae detectable by MSUS that are not clinically apparent within the fore 
foot in RA patients remains speculative. 
 
5.2. Aims 
The aim of this study was to investigate bursae (both adventitious and anatomical), 
occurring within the forefoot using MSUS, in a large cross-sectional cohort of patients with 
RA and a comparator cohort of healthy participants.  A further aim was to test the 
hypothesis that the presence of MSUS detectable bursae is a clinically relevant factor in 
patient reported foot disability in RA. 
 
Data from this study was used to address the following research questions: 
 
e)  What is the prevalence of bursae within the forefeet of healthy subjects and patients with 
RA detectable by MSUS and detectable clinically? 
f)  Which are the most common sites in the RA plantar forefoot for MSUS detectable 
bursae?  
g)  Is there a difference between the prevalence of bursae within the forefeet of healthy 
subjects and RA participants detected by MSUS? 
h)  Is the prevalence of MSUS detectable bursae within the forefeet of RA participants 
associated with patient reported outcome measures such as LFIS? 
5.3. Study design 
A controlled cross sectional study design was used, in which a large sample of RA patients 
and a matched sample of healthy participants were investigated for presence of bursae 
within their forefeet. The study design was based upon the preliminary study data results 
(Chapter 4, section 4.8, page 102).   127
5.4. Subjects: RA Participants 
A cross section of patients with RA diagnosed according to the ACR criteria, (Arnett, 
Edworthy et al 1988) who were attending secondary care rheumatology clinics as part of 
their normal care was investigated.  
 
5.4.1. Sample size: RA participants 
For explanation of how the sample size was calculated to ensure adequate power for 
statistical analyses, see Chapter 3, section 3.7.1, page 69. 
 
5.4.2. Participant recruitment: RA participants 
Consecutive patients attending outpatient clinics over a period of six months with a 
diagnosis of RA fulfilling the ACR criteria (Arnett, Edworthy et al 1988, Table 1, page 11) 
were identified from the Rheumatology Outpatient database, Southampton General 
Hospital (Southampton University Hospitals NHS Trust).  Potential participants were sent a 
letter of invitation and a participant information sheet (Appendix 13) by post prior to their 
normal rheumatology appointment. These described the study protocol and their proposed 
involvement and were received at least two days prior to their clinical appointment.  
 
Posters (Appendix 14) were also available within the Rheumatology Outpatients 
department for any patients to view, prior to commencement of the study. Suitable patients 
who, after reading the posters, wished to be considered for the study were given the 
appropriate letter of invitation and information sheet to contemplate participation at their 
next clinical visit. 
 
Patients who were willing to be considered for the study at that stage were asked, within the 
letter of invitation, to complete a reply slip which they were to return to the Rheumatology 
Research Department. Potential participants at that stage were given the opportunity to 
discuss the details of the study with the Principal Investigator for the site, or the Chief 
Investigator. If required, potential participants could postpone their decision until their next 
clinical appointment, providing the clinical appointment fell within the study timeframe. 
 
Those patients who were willing to take part in the study met with the Chief Investigator at   128
the end of their regular clinical appointment and the study protocol was explained in detail. 
Participants were encouraged to ask further questions before deciding to sign the form of 
consent. All willing participants were given a copy of the participant information sheet to 
keep and a copy of their signed consent form (Appendix 15). 
 
Once informed consent was obtained, patients were screened for acceptance onto the study. 
 
5.4.2.1. Selection criteria: RA participants 
All patients with RA attending the Rheumatology Outpatients’ clinic at Southampton 
General Hospital as part of their normal care within a six month period (July 2006 –January 
2007) were considered appropriate for this study. 
 
Inclusion Criteria 
-  Individuals with a diagnosis of RA according to the ACR criteria (Arnett, Edworthy et 
al 1988; Table 1, page 11) 
-  Individuals aged 18 years or over 
-  Individuals with RA undergoing routine care at the Rheumatology Department, 
Southampton General Hospital 
Exclusion Criteria 
-  Individuals who had received a corticosteroid injection to the forefoot within the 
previous three months prior to the foot assessments within the study 
-  Individuals who could not walk five metres 
-  Individuals who had concomitant musculoskeletal disease (for example, primary 
osteoarthritis, gout, Paget’s disease, systemic lupus erythematosus) 
-  Individuals who had a serious medical (other than RA) or psychological disorder that 
could affect the study protocol 
-  Individuals who were unable to give informed consent 
 
5.5. Subjects: control participants 
Staff and students within the University of Southampton were invited to participate within 
the study. 
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5.5.1. Sample size: control participants 
For explanation of how the sample size was calculated to ensure adequate power for 
statistical analyses, see Chapter 3, section 3.7.2, page 71. 
 
5.5.2. Participant recruitment: control participants 
Posters (Appendix 16) were available within the School of Health Professions and 
Rehabilitation Sciences for any staff or students to view, prior to commencement of the 
study. Staff and students, who after reading the posters, wished to be considered for the 
study were given the appropriate letter of invitation and information sheet (Appendix 17). 
These described the study protocol and their proposed involvement, and were sent out at 
least two days prior to their participation in the study. 
 
Those staff and students who were willing to take part in the study met with the chief 
investigator prior to their participation and the study protocol was explained in detail. Staff 
and students were allowed to ask further questions before deciding to sign the form of 
consent. All willing participants were given a copy of the participant information sheet to 
keep and a copy of their signed consent form. 
 
Once informed consent had been obtained, participants were screened for acceptance onto 
the study. 
 
5.5.2.1. Selection criteria: control participants 
Staff and students from the University of Southampton were considered appropriate to 
participate within this study. 
 
Inclusion criteria 
-  Staff or student at the University of Southampton 
-  Individuals who were aged 18 years or over 
Exclusion criteria 
-  Individuals who had received a corticosteroid injection to the forefoot within the 3 
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-  Individuals who could not walk five metres 
-  Individuals who had a diagnosed musculoskeletal disease (for example, rheumatoid 
arthritis, primary osteoarthritis, gout, Paget’s, systemic lupus erythematosus) 
-  Individuals who had a serious medical or psychological disorder that could affect the 
study protocol 
-  Individuals who were unable to give informed consent. 
 
5.6. Data collected 
Data collection for the RA participants took place between August 2006 and September 
2007. Data collection for the control participants took place in February 2008 during a two 
week period. 
 
5.6.1. Location 
All data collection for the RA participants was undertaken in the Wellcome Trust Clinical 
Research Facility, Southampton General Hospital.  On each occasion, the same 
consultation rooms and ultrasound facilities were utilised in an attempt to standardize 
environmental factors, such as room temperature and scanning positions.  Furthermore, 
whilst the preliminary examination was conducted, at each site, action was taken to 
preserve the patient’s dignity at all times, in line with ethical guidelines.   
 
All data collection for the control participants was undertaken in the biomechanics 
laboratory, School of Health Professions and Rehabilitation Sciences (now School of 
Health Sciences), University of Southampton. 
 
5.6.2. Assessment of demographic and clinical characteristics 
For the RA participants, general demographic data including age, gender, disease duration, 
presence of rheumatoid factor, weight and limb dominance were noted. Current medication 
and previous use of Disease Modifying Anti-Rheumatic Drugs (DMARDs) were obtained 
from the clinical notes and Rheumatology Department database. Laboratory assessments 
included C-reactive protein (CRP) and Erythrocyte Sedimentation Rate (ESR) and were 
obtained from the clinical notes and Rheumatology Department database.  
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Clinical characteristics collected included the participants’ global impression of well-being 
measured via a visual analog scale (VAS 100mm, where 0 was ‘Best Imaginable Health 
State’ and 100 was equal to ‘Worst Imaginable Health State’). Assessment of the patient’s 
global impression of health and disease activity and the number of painful, tender and 
swollen joints was by the 28 joint Disease Activity Score (DAS-28) (van der Heijde, van't 
Hof, et al 1993). DAS-28 remission scores < 2.6; low disease activity scores ≥ 2.6 but < 
3.2; moderate disease activity scores ≥ 3.2 but < 5.1; high disease activity scores ≥ 5.1 (van 
der Heijde, van't Hof, et al  1993). DAS-28 scores were obtained from the clinical notes and 
Rheumatology Department database.  
 
For the control participants, general demographic data including age, gender, weight and 
limb dominance were noted. Clinical characteristics collected included participants’ global 
impression of wellbeing measured via a visual analog scale (VAS 100mm), the same as for 
the RA participants. 
 
5.6.3. Assessment of foot status 
All participants, both RA and controls, underwent the same foot assessments conducted 
prior to the MSUS assessments. The feet were examined clinically for the presence of 
bursae by an experienced podiatrist (CB) using palpation of the plantar forefoot areas for 
the presence of fluctuant swellings separate from synovitis and tenosynovitis. The range of 
movement at the ankle, subtalar and first MTP joints were noted as being ‘full’, ‘limited’ or 
‘rigid’ and the presence of MTP joint subluxation and pes-planus foot type (determined by 
observed flattening of the medial longitudinal arch on weightbearing) were also noted by 
the podiatrist (CB) (see Appendix 18).  
 
Assessment of the impact of RA disease on the feet was measured using a validated patient 
administered questionnaire, the Leeds Foot Impact Scale (LFIS) (Helliwell, Reay et al 
2005) (Appendix 7). Although presented as one self completed questionnaire there are two 
subscales for impairment/footwear (LFISIF) and activity limitation/participation restriction 
(LFISAP). LFISIF contains twenty one items related to foot pain and joint stiffness as well as 
footwear related impairments and LFISAP contains thirty items related to activity limitation 
and participation restriction (Helliwell, Reay et al 2005). 
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5.6.4. MSUS imaging data  
All participants, both RA and controls underwent the same MSUS foot scans by the same 
investigator (CB). The MSUS foot scans were performed, on the same day following the 
clinical foot examinations, using a Diasus ultrasound system with a broadband linear 5 – 12 
MHz probe (Dynamic Imaging Ltd. Scotland UK). The scanning protocol from the 
preliminary validation study (Chapter three, section 3.8.1.2, page 75) was modified slightly. 
Scanning was in B-Mode using the 5 – 10 MHz probe. Images were recorded in two 
perpendicular planes, longitudinal and transverse and performed moving from proximal to 
distal as suggested by the EULAR (European League against Rheumatism) “working group 
for musculoskeletal ultrasound in rheumatology” guidelines (Backhaus, Burmester et al 
2001). The EULAR guidelines recommend a dorsal approach to detect MTP joint synovitis 
with the patient in a supine position however at the time of this study there was no 
definition for detecting clinically apparent swollen plantar forefoot bursae. We therefore 
decided to use a plantar approach to determine the prevalence of bursitis within the forefoot 
which we tested for reliability during study one (Chapter four, page 96). 
 
The presence and location of bursae across the plantar forefoot region for each participant 
identified by MSUS, previously defined as anechoic demarcated complex masses (both 
anatomical intermetatarsal and adventitious) and bulging more than 1mm under the 
metatarsal heads (anatomical intermetatarsal bursae) (Koski 1998, Bowen, Dewbury et al 
2008), were annotated on a foot chart adapted from study one (see MSUS data collection 
sheet, Appendix 19 for an example of a completed data sheet). 
 
5.6.5. MSUS training 
Prior to starting this second phase of the research, the reliability of the investigator’s (CB) 
scanning technique for the detection of bursae had been proven to a good standard of 
agreement against an expert MSUS radiologist (KD) (kappa 0.702; p<0.01) (Chapter four, 
page 96). That study has recently been published (Bowen, Dewbury et al 2008).  
 
 
5.7. Summary of study protocols 
For a summary of study protocols see Figure 29 and Figure 30.   133
Figure 29. Summary of the protocol for RA participants for the baseline study of the clinical 
relevance of MSUS detectable bursae. 
 
1. Suitable patients to be identified 
from SGH rheumatology database.
1i. Letters of invitation to be sent.
2. Willing patients complete reply slip 
and return to rheumatology research 
department.
1ii. Patients to be sent the participant  
information sheet with letters of invitation.
2i. Research administrator to add to 
Investigator’s Folder (held in rheumatology 
research department).
2ii. Potential participants also to be offered 
the opportunity to discuss the study with Dr 
Nigel Arden or Mrs. Catherine Bowen. 4. Willing patients to meet the chief 
investigator, Mrs Catherine Bowen 
and discuss study after their clinical 
appointment time.
5. Informed consent taken and copy 
given to patient.
5i. Patients screened for inclusion into the 
study.
5ii. Patients accepted onto study and sticker 
with study details placed  in medical records. 
Patient details coded. 
7i. Participant to complete the LFIS 
questionnaire.
7ii. Investigator to assess both feet clinically.
7iii. Investigator to scan both forefoot areas 
and complete ultrasound data collection 
sheet.
8. Participants to be informed of 
results of foot assessments and 
details for 12 month return visit.
9. Make provisional arrangements for 
12 month return appointment.
7. Foot assessments carried out.
6. Medical notes consulted for 
background clinical demographic 
information.
10. GP information letters to be sent.
3. Appointments sent to willing 
patients to coincide with their clinical 
visit.
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Figure 30. Summary of the protocol for control participants for the baseline study of the 
clinical relevance of MSUS detectable bursae. 
1. Posters to be placed within the 
School of Health professions and 
Rehabilitation Sciences.
2. Potential staff/student participants 
to notify the chief investigator, Mrs
Catherine Bowen.
2i. Potential staff/student participants to be 
given the participant  information sheet with 
letters of invitation.
2ii. Potential participants also to be offered 
the opportunity to discuss the study with Mrs
Catherine Bowen or Dr Nigel Arden. 3. Willing staff/student participants 
to meet the chief investigator, Mrs
Catherine Bowen and discuss study.
4. Informed consent taken and copy 
given to staff/student.
4i. Staff/Students screened for inclusion into 
the study.
4ii. Staff/ Students accepted onto study and 
student details coded. 
5.iii. Investigator to scan both forefoot areas 
and complete ultrasound data collection 
sheet.
7. Participants to be informed of 
results of foot assessments.
5. Foot assessments carried out.
5i. Participant to complete the LFIS 
questionnaire.
5ii. Investigator to assess both feet clinically. 
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5.8. Results 
The analyses focused on:  
1.  Description of the prevalence of MSUS detectable forefoot bursae in RA. 
2.  Associations of clinical outcome variables with the presence of MSUS detectable 
bursae and patient reported foot disability. 
3.  Analysis of the relationship between MSUS detectable forefoot bursae and patient 
reported foot disability. 
 
5.8.1. Participant demographic 
Of the 275 patients approached, 166 patients with RA agreed to participate in the study. 
Seventeen were subsequently excluded, following the assessment for suitability, as they did 
not meet all the inclusion criteria (Figure 31). After checking assumptions of normality, an 
unpaired t-test for numerical parametric data was performed to compare the means in the 
responders and non responders for age. Levene’s test for equality of variances was 
significant (p=0.038), suggesting one group was more variable in age distribution than the 
other, therefore ‘equal variances not assumed t statistic’ was used and there were no 
significant differences in the mean ages between responders and non-responders (t=0.765, 
p=0.445).  
 
Using Chi squared analyses for non parametric categorical data, there were no significant 
differences in terms of gender, seropositivity or number of DMARDs between responders 
and non-responders (Table 32). 
Table 32. Demographic comparison of responders and non responders for the baseline 
study of the clinical relevance of MSUS detectable bursae. 
  Responders  
(N=149) 
Non Responders 
(N= 126) 
Statistical values 
Age  59.43 (12.3) 
(range: 25-87) 
58.18 (14.4) 
(range: 19-90) 
t = 0.765; p = 0.445 
Gender  119 (79.9%) female 
30 (20.1%) male 
96 (76.2%) female 
30 (23.8%) male 
χ
2 = 0.541; p = 0.462; 
df=1 
Seropositivity  114 (76.5%) sero +ve 
32 (21.5%) sero -ve 
3 (2.0%) missing 
96 (76.2%) sero +ve 
24 (19.0%) sero -ve 
6 (4.8%) missing 
χ
2 = 0.146; p = 0.703; 
df=1 
DMARDs  120 (80.5%) yes  
29 (19.5%) none  
107 (84.9%) yes 
19 (15.1%) none  
χ
2 = 2.980; p = 0.395; 
df=3 
Key: +ve= positive; -ve=negative; t = test statistic; χ
2 = Pearson Chi- Square; 
df=degrees of freedom   136
 
Figure 31. RA participant recruitment flow chart of responders and non responders for the 
baseline study of the clinical relevance of MSUS detectable bursae. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
275 letters sent  
July 2006 – March 2007 
154 participants 
recruited: FeeTURA 1 
8 replied with 
definite no, did 
not want to 
take part 
12 responded yes but then 
withdrew/ withdrawn 
before assessment for 
suitability
9 responded to participate but 
then did not respond to telephone 
messages to arrange study 
appointments 
2 responded, but subsequently 
deceased 
101 no 
response 
1 excluded due to 
being too ill to 
attend 
1 excluded due to 
being in another 
study 
1 excluded due to 
recent leg fracture 
1 withdrew due to being called in 
hospital to have surgery 
1 excluded due to 
open foot wounds 
1 excluded due to 
having Psoriatic 
Arthritis 
149 participants completed the 
study/baseline assessments 
166 responders to participate   137
One hundred and forty nine patients (119 female and 30 male, 25 seronegative and 114 
seropositive) completed the study. Clinical and demographic variables are seen in Table 
33. The participants’ regular treatment of RA included 63.1% (N=94) taking methotrexate 
and 43.6% (N=65) taking anti-TNFα (Humira, Infliximab, Etanercept) therapy. Although 
59.1% had recorded foot symptoms in their clinical notes, only 32.9% were currently 
receiving clinical foot care on a regular basis (Table 34). 
 
Table 33. Demographic and clinical characteristics of the RA study participants for the 
baseline study of the clinical relevance of MSUS detectable bursae. 
Variable  N  Mean (SD)  Range 
Age (years)  149  59.3 (12.5)  25 - 87 
Duration of Arthritis (years)  148  12.3 (10.3)  0.5 - 43 
Weight (Kg)  148  73.3 (14.9)  43.8 - 118.9 
Height (cm)  115  164.2 (7.9)  147.0 - 187.5 
Global wellbeing (100mmVAS)  148  40.2 (24.2)  0 - 98 
ESR (mm/hour)   145  23.3 (19.2)  2.0 - 108.0 
CRP (mg/litre)   149  12.5 (18.1)  1.0 - 129.0 
DAS-28  111  3.9 (1.3)  1.11 - 6.9 
Key: SD=standard deviation; RA = Rheumatoid arthritis; VAS = visual analog score; 
DAS-28 = 28 joint disease activity score. 
 
 
Foot characteristics of the participants are reported in Table 35. The majority of 
participants experienced moderate foot impairment and footwear impact (mean LFISIF 
score of 11.09, SD 4.9) and moderate levels of activity participation limitation   (mean 
LFISAP score of 17.58, SD 9.2). The majority of participants also had bursae that were 
detectable by MSUS (mean number per individual 3.54, SD 2.2) and intermetatarsal bursae 
were the dominant bursae type (mean number per individual 2.81, SD 1.8). Observations of 
foot structure noted a high presence of a pes-planus foot type amongst the participants that 
was the same in both feet (94.8%; N=128/135). MTP joint subluxation was present within 
75.7% (N=112/148) in the right foot and 76.4% (113/148) within the left foot (Table 36).   
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Table 34. Clinical foot care of the RA study participants for the baseline study. 
Variable  Yes  No 
Foot symptoms in clinical notes  88 (59.1%)  59 (39.6%) 
Had seen a Chiropodist/ Podiatrist in the past  91 (61.1%)  58 (38.9%) 
Seeing a Chiropodist/Podiatrist on a regular basis 49 (32.9%)  100 (67.1%) 
 
Table 35. Foot characteristics of the RA study participants for the baseline study.  
Variable  N  Mean (SD)  Range 
MSUS detectable bursae*  149  3.54 (2.2)  0 - 9 
Clinically detectable bursae**  149  0.48 (1.1)  0 - 6 
LFISTOT  (x/51)  149  28.8 (13.1)  0 - 50 
LFISIF  (x/21)  149  11.09 (4.9)  0-21 
LFISAP (x/30)  149  17.58 (9.2)  0-30 
Key: SD=standard deviation; *Total numbers of MSUS detectable bursae per 
individual; ** Total numbers of clinically palpable bursae per individual; LFISTOT= 
Leeds Foot Impact Score, Total; LFISIF = Leeds Foot Impact Score, 
Impairment/Footwear subscale; LFISAP = Leeds Foot Impact Score, Activity 
Participation Limitation subscale. 
 
 
Table 36. Prevalence of foot structure deformity of the RA study participants for the 
baseline study. 
Variable  Deformity present  Deformity absent 
R MTP joint subluxation (N=148)  112 (75.2%)  36 (24.2%) 
L MTP joint subluxation (N=148)  113 (75.8%)  35 (23.5%) 
R Pes planus (N = 135)  128 (85.9%)  7 (4.7%) 
L Pes planus (N = 135)  128 (85.9%)  7 (4.7%) 
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5.8.2. Prevalence of forefoot bursae in the RA study group 
Using MSUS, 92.6% (N= 138) of patients had detectable bursae (mean numbers of bursae 
per individual = 3.54, range 0-9) within the plantar forefoot and of these 89.9% 
(N=124/138) had bursae in both feet. On clinical examination by palpation 23.5% (N=35) 
of patients had detectable bursae within the plantar forefoot. Of those that could be detected 
by MSUS, only 24.6% (N=34) had been picked up by clinical examination. Using a related 
samples t-test, the difference between bursae detected clinically and bursae detected by 
MSUS was significant (t=18.671; p<0.001). 
 
To explore whether there were differences between those individuals with MSUS 
detectable bursae only and those with MSUS detectable bursae that were also clinically 
palpable, the data was split into groups (no detectable bursae: group 1; bursae detectable by 
both MSUS and clinical palpation: group 2; bursae detectable by MSUS only: group 3; 
bursae detectable by clinical palpation only: group 4). The characteristics of each group can 
be seen in Table 37 and Table 38. 
 
 
Table 37. A two by two table showing the number and percentage of RA participants 
within each of the groups according to whether bursae are detectable clinically, by MSUS, 
by both MSUS and clinically or are not detectable. 
 
Clinically palpable bursae   
No  Yes 
No 
 
Group 1 
10 (6.7%) 
Group 4 
1 (0.7%) 
MSUS 
detectable 
bursae  Yes 
 
Group 3 
104 (69.8%) 
Group 2 
34 (22.8%) 
 
 
 
The data was then tested for ‘between group effects’ in clinical and disease variables using 
analysis of variance. As variables are constant when bursae group is group 4 as there is 
only one participant it was omitted from the statistical analyses and graphs.   140
Table 38. Demographic and clinical characteristics of the RA study participants divided 
by whether bursae are not detected, detectable by MSUS, detectable by both MSUS and 
clinical palpation or detectable by clinical palpation alone. 
 
 
Group 1 
N=10 
Group 2 
N=34 
Group 3 
N=104 
Group 4 
N=1 
ANOVA 
p-values 
Age (years) 
 
53.7 (17.1) 
25-87 
59.0 (11.3) 
33-81 
60.0 (12.1) 
26-85 
76 
 
0.241 
Duration of 
Arthritis (years) 
6.5 (4.6) 
2-16 
18.5 (11.5) 
1-43 
10.83 (9.5) 
0-43 
16 
 
0.000 
Global wellbeing 
(VAS 100mm) 
52.3 (25.1) 
0-79 
38.9 (23.3) 
0-81 
39.1 (23.8) 
0-98 
88 
 
0.079 
ESR (mm/hour) 
 
19.1 (20.2) 
2-61 
23.0 (17.9) 
5-100 
24.0 (19.6) 
2-108 
6.0 
 
0.698 
CRP (mg/litre) 
 
14.7 (21.5) 
1-69 
11.8 (12.1) 
1-46.9 
12.6 (19.5) 
1-129 
2.0 
 
0.911 
DAS-28 
 
4.2 (1.2) 
2.6-5.4 
3.9 (1.2) 
1.8-6.2 
3.9 (1.4) 
1.1-7.0 
- 
 
0.934 
LFIS Total (n/51)  25.5 (16.7) 
2-47 
31.2 (12.7) 
4-48 
28.1 (12.8) 
0-50 
31 
 
0.549 
LFISIF (n/21) 
 
10.7 (7.0) 
0-18 
12.3 (4.3) 
3-19 
10.7 (4.9) 
0-21 
14 
 
0.404 
LFISAP (n/30) 
 
14.7 (10.9) 
0-29 
18.9 (9.3) 
1-30 
17.3 (9.0) 
0-30 
17 
 
0.615 
Key: no detectable bursae: group 1; bursae detectable by both MSUS and clinical 
palpation: group 2; bursae detectable by MSUS only: group 3; bursae detectable by clinical 
palpation only: group 4 
 
 
Although some trends could be observed between groups (Table 38 and Figure 32) for 
each of the predictor variables, no significant differences between groups were found for 
age, weight, wellbeing (VAS), ESR, CRP, DAS-28, LFISIF and LFISAP. There was however 
a significant difference for duration of RA (p<0.001) with group 2 (both clinical and MSUS 
detectable bursae) having the greatest disease duration (Figure 33).  
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Figure 32. A bar chart representing the mean values of predictor variables within each 
of the groups according to whether bursae are detectable clinically, by MSUS, by both 
MSUS and clinically or are not detectable. 
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Figure 33. Stem and Leaf plots for duration of RA within each of the groups according 
to whether bursae are detectable clinically, by MSUS, by both MSUS and clinically or 
are not detectable. 
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After adjusting the p values for the number of tests performed, using Bonferroni correction 
for duration of RA, the significant differences were indicated between group 1 and group 2 
(p=0.003) and between group 2 and group 3 (p<0.001).  These findings suggest that 
individuals with no detectable bursae by either MSUS or clinical palpation are more likely 
to have lower disease duration than those with both MSUS and clinically detectable bursae. 
Further, those individuals with MSUS detectable bursae only (no clinical detection) are also 
more likely to have lower disease duration than those with both MSUS and clinically 
detectable bursae. 
 
5.8.3. Further categorical analysis of RA participants between MSUS detectable 
bursae, disease duration and disease severity  
MSUS detectable bursae were recoded into two categories, those individuals with one or no 
bursa and those with the presence of two or more bursae. The rationale for the cut- off point 
was that, on analysis of the healthy participant control data, only one or no bursae were 
identified in any individual. Disease activity was categorized by DAS-28 into remission (0-
2.59), low activity (2.6-3.19), moderate disease activity (3.2-5.09), high disease activity 
(5.1 and above).  Disease severity was categorized as rheumatoid factor positive or 
rheumatoid factor negative.  
 
On cross tabulation of data the majority of participants that had two or more bursae also 
had sero-positive disease (82.5%) (Table 39) and moderate levels of disease activity 
(37.8%) (Table 40). 
 
Table 39. A two by two table showing the cross tabulation results for 
dichotomized MSUS detectable bursae and disease severity (defined by presence of 
rheumatoid factor) of the RA study participants for the baseline study. 
 
MSUS detectable bursae   
Little/no bursae  Presence of 2 or 
more bursae 
Sero-positive  20 (17.5%)  94 (82.5%) 
Sero-negative  10 (30%)  22 (69.7%) 
χ2= 2.875; p= 0.090   143
 
Table 40. A two by two table showing cross tabulation results for dichotomized MSUS 
detectable bursae and disease activity (defined by categorized DAS-28 scores) of the RA 
study participants for the baseline study.  
  
MSUS detectable bursae 
 
   Little/ no bursae 
Presence of 2 or 
more bursae 
Remission  0 (0%)  20 (18%) 
Low activity  3 (2.7%)  10 (9%) 
Moderate activity  13 (11.7%)  42 (37.8%) 
DAS-28 
category 
  
   High activity  4 (3.6%)  19 (17.1%) 
χ2= 5.802; p= 0.122 
 
 
The categorical data was explored further for significant associations using logistic 
regression analyses. No significant associations were found between dichotomized MSUS 
detectable bursae and either disease severity or disease activity. 
 
 
5.8.4. Location of forefoot bursae in the RA study group 
The most common location for MSUS detectable bursae was the intermetatarsal (IM) 4/5 
space for both feet followed in order by IM 3/4, IM 1/2, IM 2/3, sub-metatarsal head 
(submet) 5, submet 2, submet 1, submet 3, submet 4 (Figure 34). Of note is that MSUS 
detectable intermetatarsal bursae were observed in 90.6% (N=135) of the RA participants 
(mean 2.81, range 0–8). 
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Figure 34.  Line drawings of a cross section of the left and right forefeet, at the level of 
the metatarsal heads. The drawing represents the presence and location of MSUS 
detectable bursae within the forefeet of patients with rheumatoid arthritis detectable by 
MSUS. Presence and location of MSUS detectable bursae in healthy control 
participants are also included as italicised data. 
 
 
 
 
Key: M1=first metatarsal head, M2=second metatarsal head, M3=third metatarsal head, 
M4=fourth metatarsal head, M5=fifth metatarsal head, MS=medial sesamoid,  
LS=lateral sesamoid. 
C=2% (N=1) 
C=4% (N=2)  C=36% (N=18) 
C=26% (N=13)   145
5.8.5. Analysis of associations for MSUS detectable bursae with patient reported 
foot impact outcome measures in RA participants  
To investigate whether MSUS detectable bursae were associated with patient reported foot 
impact outcome measures, the data was primarily explored using scatter plots and 
correlation plots to determine which clinical variables, decided on the basis of biological 
and clinical relevance, were related to MSUS bursae.  
 
5.8.5.1. Correlations 
Findings showed that total numbers of MSUS detectable bursae were significantly 
correlated with duration of RA (r=0.283, p<0.001), anti-TNF-α therapy (R=0.174, 0.034) 
and ESR (r=0.166, p=0.045) but no associations were seen with age, weight, wellbeing, 
CRP, DAS-28, methotrexate or foot structure variables (MTP joint subluxation and pes-
planus foot type) (Table 41 and Table 42). There was a significant weak correlation 
between total numbers of MSUS detectable bursae and impact of RA disease on the foot for 
both subscales of LFIS (LFISIF r=0.182, p=0.026; LFISAP r=0.215, p=0.009). In contrast, a 
zero correlation between MSUS detectable bursae and global wellbeing was noted (Table 
41).  
Table 41. The continuous data correlations between MSUS detectable bursae and relevant 
clinical variables for RA participants for the baseline study  
  
Pearson Correlation 
Coefficient 
Significance 
(2-tailed) 
Age (N=149)  -0.023  0.780 
Duration of RA (N=148) **  0.283  0.000 
Weight(kgs) (N=148)  0.048  0.562 
Height(cms) (N=115)  0.027  0.778 
Global wellbeing VAS (N=148)  0.000  0.996 
ESR (N=145) *  0.166  0.045 
CRP (N=141)  0.082  0.333 
DAS-28 (N=111)  -0.076  0.426 
LFISIF (N=149) *  0.182  0.026 
LFISAP (N=149) **  0.215  0.009 
   Key: **Correlation is significant at the 0.01 level (2-tailed); *Correlation is significant at 
the 0.05 level (2-tailed). 
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Table 42. The categorical data correlations between MSUS detectable bursae and relevant 
clinical variables for RA participants for the baseline study. 
  Spearman's 
Correlation 
Coefficient 
Significance  
(2-tailed) 
Disease severity (N=146) **  0.243  0.003 
Current TNF (N=149) *  0.174  0.034 
Current MTX (N=149)  -0.034  0.684 
  Key: **Correlation is significant at the 0.01 level (2-tailed); *Correlation is significant at 
the 0.05 level (2-tailed); TNF=anti-TNFα therapy; MTX = methotrexate. 
 
 
From the significantly correlated variables, foot impact scores (LFISIF and LFISAP) are the 
most clinically important within this study. To determine other explanatory variables for 
the variance in foot impact scores, correlations were also analysed between LFISIF and 
LFISAP and age, duration of RA, weight, height, global well being (VAS), ESR, CRP and 
DAS-28 (Table 43 and Table 44).  
 
Table 43. Continuous data correlations between LFISIF and explanatory 
variables for RA participants for the baseline study.  
  Pearson 
Correlation 
Coefficient 
Significance 
(2-tailed) 
MSUS bursae (N=149)*  0.182 0.026 
Age (N=149)  0.005 0.956 
Duration of RA (N=148)  0.125 0.130 
Weight (N=148)  -0.030 0.717 
Global well being VAS (N= 148)**  0.370 <0.001 
ESR (N=145)  0.193 0.020 
CRP (N= 141)  0.074 0.383 
DAS-28 (N= 97)**  0.237 0.012 
  Key: ** Correlation is significant at the 0.01 level (2-tailed); *Correlation is significant at 
the 0.05 level (2-tailed) 
 
Table 43 shows the findings that LFISIF was also significantly correlated with wellbeing 
VAS and ESR and Table 44 shows the findings that LFISAP was also significantly 
correlated with age, duration of RA, wellbeing VAS, ESR and CRP.   147
Table 44. Continuous data correlations between LFISAP and explanatory 
variables for RA participants for the baseline study.  
  Pearson 
Correlation 
Coefficient 
Significance 
(2-tailed) 
MSUS bursae (N=149)**  0.215 0.009 
Age (N=149)**  0.295 <0.001 
Duration of RA (N=148)**  0.174 0.034 
Weight (N=148)  -0.065 0.436 
Global well being VAS (N=148)**  0.327 <0.001 
ESR (N=145)**  0.319 <0.001 
CRP (N=141)*  0.182 0.031 
DAS-28 (N=111)**  0.315 0.001 
 
In the determination of other explanatory variables for the variance in foot impact scores, 
correlations between LFISIF and LFISAP and non-parametric data of current medication 
(methotrexate and anti-TNF-α therapy) and disease severity were also analysed (Table 45 
and Table 46).  
 
Table 45. Categorical data correlations between LFISIF and explanatory 
variables for RA participants for the baseline study.  
  Spearman’s 
Correlation 
Coefficient 
Significance 
(2-tailed) 
Disease severity (N=146)  -0.057 0.491 
Currently on anti-TNF-α therapy 
(N=149) 
0.071 0.388 
Currently on methotrexate (N=149)  0.098 0.234 
 
Table 46. Categorical data correlations between LFISAP and explanatory 
variables for RA participants for the baseline study. 
  Spearman’s 
Correlation 
Coefficient 
Significance 
(2-tailed) 
Currently on methotrexate (N=149)  -0.081 0.328 
Currently on anti-TNFα therapy 
(N=149)* 
0.164 0.046 
Disease severity (N=146)  0.021 0.797 
Key: * Correlation is significant at the 0.05 level (2-tailed)   148
Table 46 shows that only a weak significant correlation was found between LFISAP and 
participants who were taking anti-TNF-α therapy. 
5.8.5.2. Univariate linear regression analyses 
The relationship between foot impact scores and MSUS detectable bursae was then 
investigated further using and univariate and multivariate regression modelling with the 
identified confounding variables from results of the correlation analyses (Table 47 and 
Table 48).  
 
Table 47. Univariate linear regression results for associations between LFISIF and 
predictor confounding variables for RA participants for the baseline study.  
Explanatory 
Variable 
Outcome 
variable 
Regression 
coefficient β 
Standard 
Error 
P Value  95% CI 
Total Bursae*  LFISIF  0.406  0.180  P=0.026  0.049-0.763 
Age  LFISIF  0.002  0.033  P=0.956  -0.063-0.067 
Duration of RA  LFISIF  0.060  0.039  P=0.130  -0.018-0.138 
Wellbeing VAS*  LFISIF  0.076  0.016  P<0.001  0.045-0.107 
Weight  LFISIF  -0.010  0.027  P=0.717  -0.064-0.044 
ESR*  LFISIF  0.050  0,021  P=0.020  0.008-0.092 
CRP  LFISIF  0.020  0.023  P=0.383  -0.025-0.065 
DAS-28*  LFISIF  0.853  0.334  P=0.012  0.190-1.515 
Key: *denotes significant values 
 
Within Table 47 and Table 48, results using univariate linear regression show the 
regression coefficients extent and statistical significance that each of the predictor variables 
change for unit changes in LFISIF and LFISAP. There were significant associations for 
MSUS detectable bursae (LFISIF β=0.406, p=0.026; LFISAP β=0.891, p=0.009). This 
indicates that LFISIF score increases by 0.406 and LFISAP score increases by 0.891 for a 
unit increase in MSUS detectable bursae. 
 
The r
2 (R square) was 0.033 for the linear model of MSUS detectable bursae with LFISIF 
which indicates that the significant associations explain 3.3% of the variance in LFISIF . 
The r
2 (R square) was 0.047 for the linear model of MSUS detectable bursae with LFISAP 
which indicates that the significant associations explain 4.7% of the variance in LFISAP .   149
Table 48. Univariate linear regression results for associations between LFISAP and 
predictor confounding variables for RA participants for the baseline study.  
Explanatory 
Variable 
Outcome 
variable 
Regression 
coefficient β 
Standard 
Error 
P Value  95% CI 
Total Bursae*  LFISAP  0.889  0.333  P=0.009  0.230-1.547 
Age*  LFISAP  0.217  0.059  p<0.001  0.104-0.336 
Duration of RA*  LFISAP  0.159  0.073  P=0.030  0.012-0.299 
Wellbeing VAS*  LFISAP  0.124  0.030  P<0.001  0.066-0.183 
Weight   LFISAP  -0.044  0.051  P=0.384  -0.145-0.056 
ESR*  LFISAP  0.154  0.038  P<0.001  0.079-0.230 
CRP*  LFISAP  0.092  0.042  P=0.031  0.009-0.174 
DAS28*  LFISAP  1.980  0.571  P=0.001  0.849-3.111 
Key: * denotes significant values 
 
There were also significant associations for wellbeing (β=0.076; p<0.001), ESR (β=0.05; 
p=0.020) and DAS-28 (β=0.853; p=0.012) with LFISIF.  For LFISAP there were significant 
associations for wellbeing (β=0.124; p<0.001), ESR (β=0.154; p<0.001), CRP (β=0.092; 
p=0.031) and DAS-28 (β=1.98; p=0.001) (Table 47 and Table 48). 
 
In addition, when the correlation coefficient values are compared, LFISAP associations 
appeared to be stronger than LFISIF associations with both the primary and secondary 
outcome variables. Caution applies in interpretation of this as the scales for LFISIF and 
LFISAP are not equal, with LFISIF being nine points less. However, in an additional 
analysis, global well-being scores (due to its clinical relevance with mobility and disability) 
were computed with LFISIF and LFISAP scores transformed into percentages. Scatter plots 
and the estimate of the effect of well-being on LFISIF was 0.363 (CIs 0.214 – 0.512) and on 
LFISAP was 0.434 (CIs 0.237 – 0.631). Therefore well being appears to be a better 
association with activity participation limitation. 
5.8.5.3. Multivariate regression model analyses 
Potential confounding factors, with the relationship between patient reported impact of RA 
disease on the foot and total numbers of MSUS detectable bursae from predictor variables, 
were therefore identified as wellbeing VAS, ESR, DAS-28 and left foot MTP joint 
subluxation for LFISIF and age, duration of RA, wellbeing VAS, ESR, CRP, DAS-28 and 
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Before the relationship between MSUS detectable bursae and foot impact scores could be 
entered into a multivariate regression model with the predictor confounding variables 
diagnostic tests for assumptions were performed. All histograms and normal probability 
plots of standardised residuals showed that the distribution of the residuals was normal. All 
constant variance scatter plots showed no particular tendency for residuals to increase or 
decrease systematically, with the fitted values indicating that the constant variance 
assumption is almost met. In all scatter plots of residuals versus explanatory variable 
(MSUS bursae) there was no particular pattern, indicating a linear relationship between 
LFISIF and MSUS detectable bursae and LFISAP and MSUS detectable bursae. There were 
no colinearity indications for any of the models. The diagnostic tests for assumptions 
showed that the use of multiple linear regressions was an appropriate method of 
investigating further the extent to which MSUS bursae was linearly related to the outcome 
variable (LFIS) after adjusting for the other predictor variables. 
 
Having satisfied the assumptions, firstly, the potential confounding variables of age and 
disease duration were entered into a multivariate linear regression analysis model with 
LFISAP as the outcome variable and tested for interaction with MSUS detectable bursae. A 
significant relationship between LFISAP and total MSUS detectable bursae (β= 0.803, 
p<0.02) remained even after controlling for age and disease duration (Table 49). Disease 
duration was no longer significant, probably due to its colinearity with age. 
 
Thus controlling for age and disease duration, there is a significant linear relationship 
between LFISAP and MSUS detectable bursae (ß=0.803, p=0.019). This indicates that 
LFISAP score increases by 0.803 for every unit increase in MSUS bursae while age and 
duration of RA remain constant. The r
2 (R square) was 0.136 for the model, which indicates 
that the significant associations explain 13.6% of the variance in LFISAP . 
 
Table 49. Multivariate linear regression models for LFIS activity participation subscale scores 
(LFISAP) and predictor confounding variables for RA participants for the baseline study. 
Explanatory 
Variable 
Outcome 
variable 
Regression 
coefficient β 
Standard
Error 
P Value  95% CI 
Total Bursae  LFISAP 0.803  0.338  0.019  0.135–1.471 
Age LFISAP 0.209  0.059  0.001  0.093-0.326 
Duration of RA  LFISAP 0.072  0.073  0.329  -0.073-0.217   151
Secondly, to assess the influence of disease activity on the association between the 
occurrences of MSUS detectable bursae and foot impact scores, confounding measures of 
disease activity, ESR and global wellbeing (VAS) were also tested for interaction with both 
LFIS sub scales. The variables of CRP and DAS-28 were omitted from the model with 
LFISIF as they were not significant in the linear regression relationship and were omitted 
from the model with LFISAP due to their colinearity with ESR and wellbeing VAS.  
 
After adjusting for confounding variables of disease activity (ESR and wellbeing VAS), a 
significant linear relationship remained between MSUS detectable bursae and LFISIF 
(ß=0.377, p=0.033). The r
2 (R square) for this model was 0.177 which indicates that the 
significant associations for MSUS detectable bursae, age, global wellbeing (VAS) and ESR 
explain 17.7% of the variance in LFISIF (Table 50). 
 
Similarly, after adjusting for confounding variables of disease activity (ESR and wellbeing 
VAS), a significant linear relationship remained between MSUS detectable bursae and 
LFISAP (ß = 0.762, p=0.013). The r
2 (R square) for this model was 0.285 which indicates 
that the significant associations for MSUS detectable bursae, age, global wellbeing (VAS) 
and ESR explain 28.5% of the variance in LFISIF (Table 51).  
 
These findings indicate that LFISIF score increases by 0.379 for every unit increase in 
MSUS bursae and that LFISAP score increases by 0.703 for every unit increase in MSUS 
bursae while wellbeing VAS and ESR remain constant.  
 
 
Table 50. Multiple linear regression models for LFIS impairment subscale scores, MSUS 
detectable bursae and disease activity for RA participants for the baseline study. 
Explanatory 
Variable 
Outcome 
variable 
Regression 
coefficient β 
Standard 
Error 
P Value  95% CI 
Total Bursae  LFIS IF  0.377  0.175  0.033  0.031 - 0.722 
Age LFIS  IF  -0.010  0.032  0.758  -0.073 - 0.053 
Global VAS  LFIS IF  0.072  0.016  <0.001  0.039 - 0.104 
ESR LFIS  IF  0.026  0.021  0.212  -0.015 - 0.068 
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Table 51. Multiple linear regression models for LFIS activity limitation subscale scores, 
MSUS detectable bursae and disease activity for RA participants for the baseline study. 
Explanatory 
Variable 
Outcome 
variable 
Regression 
coefficient β 
SE  P Value  95% CI 
Total Bursae  LFISAP  0.762 0.302 0.013  0.164  -  1.359 
Age LFISAP  0.212 0.055 <0.001  0.103  -  0.320 
Global VAS  LFISAP  0.106 0.028 <0.001  0.050  -  0.162 
ESR LFISAP  0.094 0.036 0.010  0.023  -  0.166 
 
 
5.8.6. Analysis of the relationship of MSUS detectable bursae in RA participants and foot 
structure deformity 
Having produced a stable multivariate model, measures of the presence of forefoot 
deformity (MTP joint subluxation) were further investigated, in order to assess whether the 
association between the numbers of MSUS detectable bursae and LFISIF and LFISAP was 
independent of these confounding variables too. 
  
Results from the categorical correlations had showed a significant association between both 
LFIS subscale scores for the presence of MTP joint subluxation in left feet but none with 
right foot MTP joint subluxation, right foot pes-planus or left foot pes-planus. Higher mean 
scores for patient related foot symptoms (LFISIF and LFISAP) are seen with foot structure 
deformity in Table 52.  
 
Using univariate linear regression there were significant associations for left foot MTP joint 
subluxation for both LFISIF.(β=1.898; p=0.046) and LFISAP (β=3.599; p=0.042) (Table 53). 
The r
2 (R square) was 0.026 for the LFISIF model and 0.028 for the LFISAP model, which 
indicates that the significant associations explain 2.7% of the variance in LFISIF and 2.8% 
of LFISAP. 
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Table 52. A table showing the mean, standard deviation (SD) and range for LFISIF and 
LFISAP scores according to presence or absence of foot deformity for RA participants 
for the baseline study.  
LFISIF (x/21)  LFISAP (x/30)   
Deformity 
present 
Deformity 
absent 
Deformity 
present 
Deformity 
absent 
Right MTP joint 
subluxation 
11.6 (4.7) 
0-20 
9.75 (5.2) 
0-21 
18.5 (8.9) 
0-30 
15.19 (9.5) 
0-29 
Left MTP joint 
subluxation 
11.6 (4.7) 
0-20 
9.7 (5.3) 
0-21 
18.51 (8.9) 
0-30 
14.9 (9.5) 
0-29 
Right Pes-planus 
 
11.27 (4.8) 
0-21 
10.14 (6.0) 
4-19 
18.33 (8.9) 
0-30 
14.14 (10.1) 
3-29 
Left Pes-planus 
 
11.27 (4.8) 
0-21 
10.14 (6.0) 
4-19 
18.33 (8.9) 
0-30 
14.14 (10.1) 
3-29 
 
 
Table 53. Univariate linear regression results for associations between LFISIF, LFISAP and 
predictor foot structure confounding variables for RA participants for the baseline study. 
Explanatory Variable Outcome 
variable 
Regression 
coefficient β 
Standard
Error 
P Value  95% CI 
Right MTP joint 
subluxation 
LFISIF  1.830  0.934  0.052  -0.015 – 3.676 
Left MTP joint 
subluxation* 
LFISIF  1.898  0.942  0.046  0.036 – 3.760 
Right pes-planus  LFISIF  1.123  1.903  0.556  -2.641 – 4.886 
Left pes-planus  LFISIF  1.123  1.903  0.556  -2.641 – 4.886 
Right MTP joint 
subluxation 
LFISAP  3.261  1.739  0.063  -0.176 – 6.698 
Left MTP joint 
subluxation* 
LFISAP  3.599  1.752  0.042  0.137 – 7.061 
Right pes-planus  LFISAP  4.185  3.479  0.231  -2.696 – 11.066 
Left pes-planus  LFISAP  4.185  3.479  0.231  -2.696 – 11.066 
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To assess the relevance of foot structure deformity on the association between the 
occurrences of MSUS detectable bursae and foot impact scores, the confounding variable 
of left foot MTP joint subluxation was tested for interaction with both LFIS sub scales. 
When the left foot MTP joint variable was entered into the multivariate model, the 
association between MSUS detectable bursae and LFIS remained statistically significant 
(LFISIF ß=0.380, p=0.035; LFISAP ß=0.890, p=0.006) (Table 54 and Table 55).  
 
 
Table 54. Multiple linear regression models for LFIS impairment subscale scores and foot 
structure of participants for RA participants for the baseline study. 
Explanatory 
Variable 
Outcome 
variable 
Regression 
coefficient β 
Standard 
Error 
P Value  95% CI 
Total Bursae  LFIS IF 0.380  0.179  0.035  0.026  –  0.734 
Age LFIS  IF  -0.020  0.033  0.561  -.0086 – 0.047 
Left MTP joint 
Subluxation 
LFIS IF  1.993 0.964  0.040  0.089  –  3.898 
  
 
 
Table 55. Multiple linear regression models for LFIS activity participation limitation 
subscale scores and foot structure of participants for RA participants for the baseline study. 
Explanatory 
Variable 
Outcome 
variable 
Regression 
coefficient β 
Standard 
Error 
P Value  95% CI 
Total Bursae  LFIS AP 0.890  0.319  0.006  0.259  –  1.520 
Age 
 
LFIS AP  0.199 0.060  0.001  0.082  –  0.317 
Left MTP joint 
Subluxation 
LFIS AP  2.064  1.716  0.231  -1.329 – 5.457 
  
 
The r
2 (R square) was 0.059 for the LFISIF model and 0.138 for the LFISAP model which 
indicates that the significant associations explain 5.9% of the variance in LFISIF and 13.8% 
of LFISAP. 
 
The result that one foot (left) MTP joint subluxation should have a significant correlation 
whilst the other (right) had none, was investigated further to determine if the results were   155
due to measurement error. Three further models were therefore analysed. The regression 
model was firstly recalculated using right foot MTP joint subluxation (model a). Secondly 
both left and right feet MTP joint subluxation were entered into the model (model b). 
Finally a new variable was calculated as presence of MTP joint subluxation for both feet 
and this too was then entered into the model (model c). 
 
In each model with both LFISIF and LFISAP, MSUS detectable bursae remained significant:  
•  Model a. LFISIF β = 0.384, p=0.033; LFISAP β = 0.895, p= 0.006 
•  Model b. LFISIF β = 0.381, p=0.036; LFISAP β = 0.878, p=0.007 
•  Model c. LFISIF β = 0.380, p=0.035; LFISAP β = 0.890, p=0.006 
 
 
5.8.7. Analysis of the relationship of MSUS detectable bursae in RA participants 
when grouped according to whether clinically detectable or MSUS detectable 
The group data for bursae (section 5.8.2, page 138) that is, those individuals who had 
MSUS detectable bursae and clinically detectable bursae (group 2) and those individuals 
who had MSUS only detectable bursae (group 3)  were investigated to see if there was a 
linear relationship between both LFISIF and LFISAP scores and MSUS detectable bursae 
within the groups. 
 
There were no significant linear associations between either LFISIF or LFISAP scores or 
MSUS detectable bursae (Table 56) and the confidence intervals for each of the groups do 
not appear much different from each other, indicating reduced association. A trend can 
however be seen in the reduction in β values from those individuals who had MSUS 
detectable bursae and clinically detectable bursae (group 2) and those individuals who had 
MSUS only detectable bursae (group 3) for both LFISIF and LFISAP. 
 
Comparing β values does give more information on whether the lack of significance is that 
the association is different or is due to lack of statistical power (Petrie and Sabin 2005). In 
Chapter three (section 3.7.1, page 69) power calculations indicated that the sample was just 
adequately powered for reasonable statistical analyses. However when the data was split 
into groups for trend analyses, the power for each sample was not recalculated and it is very 
likely that the groups are underpowered and therefore statistical analyses on the group data 
should be interpreted with caution. This is a common problem in studies where the study is   156
well powered but becomes underpowered for grouping of data analyses (Petrie and Sabin 
2005). 
 
Nevertheless, the β values have not decreased to zero, therefore there is possibly an effect 
or association but not enough statistical power to determine this. 
 
 
Table 56. Univariate linear regression results for associations between LFISIF, LFISAP and 
MSUS detectable bursae within bursae groups for RA participants for the baseline study. 
  Explanatory 
Variable 
Outcome 
variable 
Regression 
coefficient β 
SE  P Value  95% CI 
Group 2  Total bursae  LFIS IF 0.592  0.351 0.101 -0.123  –  1.307 
Group 2  Total bursae  LFIS AP  1.117  0.763 0.153 -0.436  –  2.67 
Group 3  Total bursae  LFIS IF 0.382  0.264 0.152 -0.142  –  0.906 
Group 3  Total bursae  LFIS AP 0.876  0.483 0.073 -0.082  –  1.834 
 
 
5.8.8. Characteristics and prevalence of forefoot bursae in the control group 
participants  
Demographic and clinical variables are presented in Table 57.  Of the 50 control 
participants, pes-planus foot type was present in 59.2% (N=29/49) within the right foot and 
67.3% (N=29/49) within the left foot. No control participants were reported as having MTP 
joint subluxation in either foot. No bursae was observed clinically in any of the control 
participants however on MSUS, 38% (N=19) of participants had detectable bursae, 
although the mean numbers per individual were small (µ 0.68, range 0-3).  
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Table 57. Demographic and clinical characteristics of the healthy control 
study participants for the baseline study. 
Variable  N  Mean (SD)  Range 
Age (years)  50  33.2 (10.7)  19-61 
Weight (Kg)  50  73.99 (13.4)  54.5-120 
Height (cm)  50  170.5 (8.5)  150-191 
MSUS detectable bursae*  50  0.68 (0.9)  0 - 3 
Clinically detectable bursae**  50  0.00 (0.0)  0  
LFISTOT   50  1.1 (2.5)  0-13 
LFISIF   50  1.02 (2.2)  0-10 
LFISAP  50  0.1 (0.5)  0-3 
Global wellbeing (100mm VAS)  50  11.6 (9.2)  0-58 
Key: SD=standard deviation; *Total numbers of MSUS detectable bursae per individual; 
** Total numbers of clinically palpable bursae per individual; LFISTOT=Leeds Foot Impact 
Score, Total; LFISIF=Leeds Foot Impact Score, Impairment/Footwear subscale; 
LFISAP=Leeds Foot Impact Score, Activity Participation Limitation subscale; VAS=visual 
analogue scale. 
 
 
 
The location of the MSUS detectable bursae were IM 4/5 (L 36%, N=18; R 26%, N=13) 
followed by IM 3/4 (L 4%, N=2; R 2%, N=1). No associations of these bursae were seen 
with age, weight, height, foot structure variables and LFISIF or LFISAP.  
 
Differences between MSUS detectable bursae of the control participants and study RA 
participants were statistically significant (p<0.001). To ensure that this was not due to 
differences in age between the RA patients and controls we performed two additional 
analyses. Firstly we restricted both patients and controls to those below the age of 55 and 
secondly we performed analysis of variance on the whole cohort with age as a confounding 
variable. In both cases the p value remained statistically significant (p<0.001). 
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5.9. Summary of results 
1. Description of the prevalence of bursae within the forefoot in RA. 
In a large cross section of patients with RA in a hospital setting, bursae within the plantar 
forefoot detectable by MSUS are highly prevalent but under detected clinically. The 
prevalence of bursae within the plantar forefoot detectable by MSUS is significantly higher 
than in normal control subjects. The most common locations for MSUS detectable bursae 
in both RA and healthy participants were between the 4
th and 5
th metatarsal heads.  
 
2. Associations of the presence of MSUS detectable forefoot bursae with patient 
reported foot impact and clinical outcome variables.  
In a large cross section of patients with RA the presence of MSUS detectable bursae was 
associated with the patient reported foot impact as assessed by the Leeds Foot Impact 
Score. The strength of the association was higher between MSUS detectable bursae and 
activity participation limitation which also had a stronger association with global well-
being, indicating that this may be important to patients. 
 
3. Analysis of the relationship between MSUS detectable bursae and patient reported 
foot impact. 
In a large cross section of patients with RA, the association of MSUS detectable bursae and 
patient reported foot impact remained significant even when confounding factors associated 
with age and disease activity are adjusted for. 
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5.10. Discussion 
This study further demonstrates the use of MSUS in the detection of bursae in plantar 
forefoot in RA participants and also provides additional evidence for the prevalence of 
bursae within the forefoot in a large cross sectional cohort of patients with RA. We found 
that, of the plantar forefoot bursae that were detectable by MSUS in patients with RA, only 
a quarter were detected clinically. MSUS detectable forefoot bursae in RA participants 
were also significantly higher than in healthy control participants. Furthermore, the MSUS 
detectable bursae in the study patients with RA were significantly associated with patient 
reported foot impact outcome measures, which was independent of overall disease activity 
and foot structure deformity.  
 
Prior to the use of MSUS and MR imaging techniques, studies of bursae in RA feet have 
been based on cadaveric or surgical investigations (Bossley and Cairney 1980;  Claustre, 
Bonnel et al 1983; Shi, Tomita et al 2000). They suggested that swelling of forefoot bursae 
was more common with longer disease duration, which we have confirmed in this large 
clinical study. When the data was split into groups however, longer disease duration was 
associated with clinically palpable bursae and those with MSUS detectable bursae only 
were more likely to have the shortest disease durations. It highlights that in this cohort of 
RA participants, clinical examination alone would have missed considerable bursae in 
those with early disease. 
 
The high prevalence of MSUS detectable bursae in our study is confirmed by previous MRI 
findings in which bursitis was observed in 63% of patients with early RA also located 
between or beneath the metatarsal heads (Boutry, Larde et al 2003). Manifestations of RA 
have also been observed within the forefeet when hands have shown no abnormalities 
(Ostendorf , Scherer et al 2004) or less pathological changes than the feet (Boutry, Larde et 
al 2003; Ostendorf , Scherer et al 2004). Others using MRI have clearly indicated that 
bursitis in RA should not be overlooked and that imaging of the foot provides more 
information about the effects of RA (Ashman, Klecker and Yu 2001; Narvaez, Narvaez et 
al 2002).  
 
The use of MSUS to detect pathology in RA that is not clinically apparent and to guide 
treatment decisions is gaining recognition (Wakefield, Green et al 2004, Brown, Quinn et al 
2006; Wakefield, Freeston et al 2008). Difficulty in diagnosing specific soft tissue   160
pathology, such as synovitis or pathological changes in bursae within the foot clinically, 
has previously been reported (Beggs 2002; Ashman, Klecker, and Yu 2001; Luukkainen, 
Saltyshev et al 2003; Davys, Turner et al 2005).  
 
We did observe a substantial discrepancy between MSUS detectable bursae and clinically 
detectable bursae in our RA population, however there was also a moderate prevalence 
(38%) of MSUS detectable bursae between the fourth and fifth metatarsal heads in 
asymptomatic healthy controls. The latter were not clinically palpable and had no 
associations to foot structure or LFIS subscales and were probably physiological as 
described by Zanetti, Strehle et al (1997). Bossley and Cairney (1980) suggested that 
forefoot bursae vary depending on the degree of metatarsal separation and it may be that in 
some individuals the fourth intermetatarsal space is the largest and thus the bursa in that 
space more obvious. Luukkainen, Ekman et al (2009) also found moderate MTP joint 
synovitis detectable by MSUS in healthy participants, questioning the ability for MSUS 
techniques to differentiate between physiological and pathological tissue states.  
Nonetheless this does not explain the discrepancy between MSUS detectable bursae and 
clinically detectable bursae, as the MSUS detectable bursae within the control group of this 
study accounted for only half the MSUS detectable only bursae in the RA participants and 
the difference was real and statistically significant. 
 
A key and unique finding was the clear association between MSUS detectable bursae 
within the foot and patient reported foot impact assessed by both the impairment (LFISIF) 
and activity limitation (LFISAP) subscales of LFIS. To ascertain whether the association of 
MSUS detectable bursae with LFIS was due to disease activity, we initially explored the 
association of MSUS detectable bursae with markers of disease activity. Secondly we 
explored the association of MSUS detectable bursae with foot structure variables. Potential 
confounding factors within this relationship were age, disease duration ESR, CRP, DAS-
28, wellbeing and MTP joint subluxation. When the association of MSUS detectable bursae 
and LFIS was adjusted for the confounding factors there was still a significant association, 
suggesting that bursae may lead to foot related disability and poor function independent of 
overall disease activity and foot structure deformity. Other investigators have also found 
foot related symptoms in RA participants that were independent of disease activity (Turner, 
Helliwell et al 2008). In that study foot status was measured by both LFIS subscales and 
mechanical function and no imaging techniques were used to identify pathology.   161
 
These findings are also concurrent with others who have reported radiographic damage and 
disease activity independently contributing to changes in physical function in RA, 
regardless of disease activity (Kuper, van Leeuwen et al 1997; Welsing, van Gestel et al 
2001; van der Heijde, Landewé et al 2008). 
 
Whilst our findings indicate that there is an association of MSUS detectable forefoot bursae 
with patient reported foot impact scores, this does not necessarily constitute proof.  
As well as forefoot bursae, MTP joint synovitis, and flexor tenosynovitis on MSUS is a key 
differential diagnosis for plantar forefoot tenderness (Koski 1995). This inability to measure 
MTP joint synovitis and tenosynovitis using the Diasus MSUS machine has to be 
acknowledged as a significant omission (see Chapter three, section 3.8.1.2. page 75). 
Within the analyses there is thus a possibility that MSUS detectable bursae and MTP joint 
synovitis may be correlated and collinear but with the lack of data on MTP joint synovitis or 
tenosynovitis we cannot be sure. We did adjust for disease activity which does suggest that 
MSUS detectable bursae may be independent of MTP joint synovitis, however clarification of 
this is recommended for future investigations. 
 
It is not surprising that in the cross sectional sample with varied levels of RA disease 
duration and activity that structural deformities within the forefoot were highly prevalent. 
However, the lack of association of MTP joint subluxation with MSUS detectable bursae 
was surprising because it was associated with patient reported foot impact and was present 
in three quarters of the RA participants, but absent within healthy control participants. MTP 
joint subluxation is an important finding in the RA forefoot in later stage disease as 
concomitant displacement of the fatty pad can produce symptoms of foot pain and 
callosities (Costa, Rizack and Zimmermann 2004; van der Leeden,  Steultjens et al 2008). 
As bursae, detectable by MSUS but not apparent clinically, were more likely to seen in 
early RA disease, it is probable that MSUS detectable bursae are present in the forefoot 
prior to the onset of clinical deformity. This argument however lacks strength, as the 
examination of foot structure in this study was based on expert clinical judgement of the 
non weight-bearing foot. Dynamic plantar pressure measurements and gait data (to define 
foot status and determine foot loading to explore whether plantar forefoot bursae in the RA 
participants was related to a progress of rheumatic deformity of the foot) was not feasible 
within the confines of this study and will form the subject of a future study.   162
 
Interestingly there was an association of increased numbers of MSUS detectable bursae 
with anti-TNF-α therapy (but not methotrexate).  The length of time that participants had 
been taking anti-TNF-α therapy was not recorded within this study; however those 
individuals taking anti-TNF-α therapy are also likely to have the most aggressive RA and 
therefore would be expected to have the worse joint and soft tissue involvement. 
 
Finally, we noticed that MSUS detectable bursae were more strongly associated with 
LFISAP than LFISIF and that LFISAP was also more strongly associated with global 
wellbeing than LFISIF. Patients with RA have reported greater physical functional 
deterioration in lower limbs compared to upper limbs (Ringen, Dagfinrud et al 2008). This 
implies that bursae within the forefoot may have a crucial contributing impact on activity 
participation limitation which also significantly affects the patient’s global wellbeing. Of 
note, this was true for all the MSUS detectable bursae, even those not clinically detectable, 
therefore further highlighting the potential importance of identifying pathological bursae.  
 
5.11. Strengths and potential limitations 
This study has several strengths and a number of potential limitations. Strengths include: 
•  the large sample size  
•  a pragmatic clinical study representative of secondary care in the UK  
•  the use of patient reported clinical outcomes including disease activity and foot 
specific measures  
 
Potential limitations include the fact the presence of MSUS detectable bursae within the 
forefoot was not validated by any other ‘gold standard’ imaging technique, such as MRI or 
by histological analysis through biopsy.  
 
As well as intermetatarsal bursae and adventitious bursae, soft tissue swelling between the 
MTP joints can be related to MTP joint synovitis or tenosynovitis that could be better 
differentiated using MR imaging (Ashman, Klacker and Yu 2001; Helliwell, Woodburn et 
al 2007; Studler et al 2008. Gadolinium enhanced MRI would also provide clearer 
information relating to both synovial thickness, increased blood flow and inflammatory 
activity (Gaffney, Cookson et al 1995). Most previous studies have not used MRI due to its 
limited availability (Szkudlarek, Court-Payen et al 2003; D'Agostino, Maillefert et al 2004;   163
Naredo, Moller et al 2006). At the time of the preliminary reliability study, the OMERACT 
MSUS special interest group highlighted limited data in terms of comparisons of MRI with 
MSUS (Wakefield, Balint et al 2005), however due to its restricted availability MRI was 
not feasible for our study.  
 
The lack of availability of Power Doppler within this study to determine bursitis over 
bursae has already been highlighted in Chapter four (section 4.11, Page 121). 
 
Failure to use the measures of MTP joint synovitis and erosion and failure to measure 
tenosynovitis has to be acknowledged as a significant limitation regarding the assessment of 
the associations of MSUS detectable bursae with patient reported foot impact outcome 
measures. This is, however, a feature that is endemic in all studies on MTP joint synovitis in 
the foot in RA that haven’t taken account of forefoot bursae. It also does not invalidate 
MSUS as a tool for predicting foot symptoms in RA. 
 
Finally, patients treated in primary care only who may have less severe RA disease are not 
included and controls were not age matched, although limited analysis showed that this did 
not appear to significantly alter the findings (see section 5.8.9, page 157). 
 
5.12. Conclusion 
In a cross sectional study of patients with RA in a hospital setting, bursae within the 
forefoot were a common finding on MSUS, but less common in healthy controls. These 
findings also indicate that MSUS detectable bursae, within the foot in RA patients, may be 
associated with measures of foot impairment and disability that is important to the patient, 
independent of forefoot structural deformity, independent of RA disease activity and under-
detected clinically. Further work, however, is required to confirm this. 
 
This study has provided the baseline data for RA participants, with respect to the 
prevalence of MSUS detectable bursae. The data from this study therefore formed the base 
on which the final phase of the study progressed to evaluate the natural history of bursae 
within the feet. 
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6.0 Chapter 6: The natural history of MSUS detectable forefoot 
bursae in RA participants after one year 
 
Within chapter five we confirmed that MSUS detectable bursae within the forefoot are 
highly prevalent and under-diagnosed clinically.  The study was conducted in accordance 
with routine clinical practice and also demonstrated that MSUS detectable bursae may be 
associated with patients’ foot symptoms, mobility and quality of life. In order to optimize 
the management of foot symptoms associated with RA it would seem essential to describe 
the natural history and progression of bursae, detectable by MSUS, over time. Chapter six 
forms the final phase of the doctoral study in which changes in the presence of MSUS 
detectable forefoot bursae and factors that may predict those changes over time are 
investigated. 
 
6.1. Introduction 
There is a growing body of evidence that modern imaging modalities such as MRI and 
MSUS appear to be more superior than radiography in detection of temporal changes in 
structural joint damage in RA (Backhaus, Burmester et al 2002; Hau, Kneitz et al 2002; 
Ejbjerg, Vestergaard et al 2005; Naredo, Collado et al 2007; Iagnocco, Naredo and Tripodo 
2008; Brown, Conaghan et al 2008). MSUS has demonstrated that synovitis can progress, 
despite the improvement in traditional laboratory and clinical findings (Brown, Quinn et al 
2006; Brown, Conaghan et al 2008).  
 
The ability of MSUS to detect changes in RA disease before the onset of structural damage 
has become important with the advent of biologic therapies that can switch off the disease 
processes and thus arrest disease progression (Iagnocco, Naredo and Tripodo 2008). 
Usually it is synovitis that is investigated and investigation of changes in disease state may 
include synovitis within the MTP joints, although do not form the main focus of study 
(Ejbjerg, Vestergaard et al 2005; Naredo, Bonilla et al 20065; Joshua, Lassere et al 2007; 
van der Heijde, Landewe et al 2008).  
 
Longitudinal studies of manifestations of RA disease within the foot and ankle are lacking 
and most evidence is attributable to cross-sectional analytical data. Very little regarding the 
effect of RA disease on bursae within the forefoot is known, although it is typically 
accepted that some adventitious bursae are acquired as a result of biomechanical stress   165
through shearing forces related to abnormal movement (Hernandez, Hernandez, and 
Hernandez 1991). 
 
In our baseline study (Chapter five, page 125) we demonstrated that 92.6% of the RA 
participants had MSUS detectable bursae within their forefeet and that there was an 
independent association between MSUS detectable bursae and patient reported foot impact. 
To our knowledge, no studies have addressed the question of whether investigation of the 
natural history of forefoot bursae by MSUS would provide further insight into the 
manifestations of RA disease within the foot and whether this might be associated with 
patient reported foot impact outcome measures over time. 
 
 
6.2. Aims 
The aim of the final part of the investigation of RA patients was to determine if there was 
any change in the presence of MSUS detectable bursae over time and if there was what 
predicted that change? 
 
Data from this study was used to answer the following research questions: 
a)  Does the presence of MSUS detectable bursae in the plantar forefoot area of patients 
with RA change over time? 
b)  If the presence of MSUS detectable bursae does change after one year what predicts 
that change? 
 
 
6.3. Study design 
A one year cohort study design was used in which a sample of RA patients who had already 
been assessed (Chapter five, page 125) were reassessed one year following their initial 
visit.  
 
 
6.4. Subjects 
From the initial 149 patients who participated in the baseline study (chapter five, page 125) 
120 agreed to return at one year for reassessment.   166
6.4.1. Sample size 
For explanation of how the sample size was calculated to ensure adequate power for 
statistical analyses see Chapter 3, section 3.7.1, page 69. 
6.4.2. Participant recruitment 
All participants who took part in the baseline assessments (Chapter five, page 104) were 
contacted, via a letter of invitation and a participant information sheet, to return for 
reassessment at twelve months. Patients who were willing to be considered for the follow 
up study at this stage were asked, within the letter of invitation, to complete an enclosed 
reply slip. Potential participants at this stage were given the opportunity to discuss the 
details of the follow up study with the Principal Investigator for the site, or the Chief 
Investigator if they wished.  
 
6.4.2.1. Selection criteria 
All individuals with RA who had taken part in the baseline assessments were considered 
appropriate for this study according to the following criteria:  
Inclusion criteria 
-  Individuals who had taken part in the baseline assessments 
-  Individuals who had a diagnosis of RA according to the ACR criteria (Arnett, 
Edworthy et al 1988; Table 1, page 11 
-  Individuals who were attending the rheumatology outpatients’ clinic at Southampton 
General Hospital 
-  Individuals who were aged 18 years and over 
Exclusion criteria 
-  Individuals who had not taken part in the baseline assessments 
-  Individuals who had corticosteroid injection to the forefoot within the previous 3 
months prior to commencement of the study 
-  Individuals who could not walk five metres 
-  Individuals who had concomitant musculoskeletal disease (for example, primary 
osteoarthritis, gout, Paget’s disease, systemic lupus erythematosus) 
-  Individuals who had a serious medical (other than RA) or psychological disorder that 
could affect the study protocol 
-  Individuals who were unable to give informed consent   167
6.5. Data Collected 
Data collection took place between August 2007 and September 2008.  
 
6.5.1. Location 
For standardization all data collection during this study was undertaken in the same 
environment as the baseline assessments for the RA participants (chapter five, page 125), 
the ‘Wellcome Trust Clinical Research Facility, Southampton General Hospital.  On each 
occasion, the same consultation rooms and ultrasound facilities were utilised. 
 
6.5.2. Assessment of demographic and clinical characteristics 
For standardization, exactly the same demographic and clinical information was collected 
and noted in the same way as the baseline assessments for the RA participants (Chapter 
five, page 125). General demographic data including age, gender, disease duration, 
presence of rheumatoid factor, weight and limb dominance were noted.  
 
Current medication and use of DMARDs during the previous year were obtained from the 
clinical notes and rheumatology department database. Laboratory assessments included 
CRP and ESR and were obtained from the clinical notes and Rheumatology Department 
database.  
 
Clinical characteristics collected included participants’ impression of global well being 
measured via a visual analog scale (VAS 100mm, where 0 was ‘Best Imaginable Health 
State’ and 100 equal to ‘Worst Imaginable Health State’), assessment of the participants’ 
global impression of health and disease activity and the number of painful, tender and 
swollen joints calculated as part of the 28 joint Disease Activity Score (DAS-28) (van der 
Heijde, van't Hof, et al 1993). For DAS-28 scores are, remission < 2.6; low disease activity 
≥ 2.6 but < 3.2; moderate disease activity ≥ 3.2 but < 5.1; high disease activity ≥ 5.1 (van 
der Heijde, van't Hof, et al 1993). 
 
For the baseline study, DAS-28 scores were obtained from clinical medical notes and the 
rheumatology department database. During that study, however, DAS-28 scores were not 
available for all participants. Therefore for this twelve month study, the investigator (CB) was 
trained in DAS-28 technique and also performed these assessments.    168
6.5.3. Assessment of foot status 
For standardization, all returning participants underwent the same foot assessments 
performed and noted in the same way as in the baseline assessments (Chapter five, page 
125). The feet were examined clinically for the presence of bursae by an experienced 
podiatrist (CB) using palpation of the plantar forefoot areas, for the presence of fluctuant 
swellings separate from synovitis and tenosynovitis. The range of movement at the ankle, 
subtalar and first MTP joints were noted as being full, limited or rigid and the presence of 
MTP joint subluxation and pes-planus foot type (determined by observed flattening of the 
medial longitudinal arch on weightbearing) were also noted by the podiatrist (CB). 
 
Assessment of the impact of foot disease was measured using the validated patient 
administered questionnaire, the Leeds Foot Impact Scale (LFIS) (Helliwell, Reay et al 
2005). Both subscales for impairment/footwear (LFISIF) and activity limitation or 
participation restriction (LFISAP) were used for analyses (Helliwell, Reay et al 2005). 
 
6.5.4. MSUS imaging data   
For standardization, exactly the same MSUS assessments were performed and noted by the 
same investigator (CB) in the same way as in the baseline assessments (Chapter five, page 
125). The MSUS foot scans were performed on the same day immediately after the clinical 
foot examinations using a Diasus ultrasound system with a broadband linear 5 – 12 MHz 
probe (Dynamic Imaging Ltd. Scotland UK). The same MSUS imaging scanning protocol 
that was developed during the validation study (chapter three, section 3.8.1.2, page 75) and 
used in the baseline study was performed. The presence and location of bursae across the 
plantar forefoot region for each participant identified by MSUS, previously defined as an 
anechoic demarcated complex mass (both intermetatarsal and adventitious) and bulging 
more than 1mm under the metatarsal heads (intermetatarsal bursae) (Koski 1998, Bowen, 
Dewbury et al 2008), were annotated on a foot chart adapted from the validation study 
(Chapter four, page 96; see MSUS data collection sheet, Appendix 19). 
 
6.6. Summary of study three protocol 
For a summary of study three (twelve month returns) protocol see Figure 35. 
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Figure 35. Summary of protocol for RA participants for the return assessments at twelve months. 
 
1. Participants from study two to be 
identified six weeks prior to their 
proposed one year follow up visit.
1i. Letters of invitation to return to be sent.
2. Willing participants complete reply 
slip and return to rheumatology 
research department.
1ii. Patients to be resent the participant  
information sheet with letters of invitation.
2i. Research administrator to add to 
Investigator’s Folder (held in rheumatology 
research department).
2ii. All returning potential participants also to 
be offered the opportunity to discuss the study 
with Dr Nigel Arden or Mrs. Catherine Bowen.
4. Willing returning particpants to 
meet the chief investigator, Mrs
Catherine Bowen and discuss study 
after their clinical appointment time. 4i. Patients screened for re-inclusion into the 
study.
6i. Participant to complete the LFIS 
questionnaire.
6ii. Investigator to assess both feet clinically. 
6iii. Investigator to scan both forefoot areas 
and complete ultrasound data collection 
sheet.
7. Participants to be informed of 
results of follow up foot assessments.
6. Foot assessments carried out.
5. Medical notes consulted for 
updates on background clinical 
demographic information.
3. Appointments sent to willing 
returning participants to coincide with 
their clinical visit.
8. Medical notes signed for 
completion of study. 
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6.7. Results 
The analyses focused on:  
1.  Descriptive changes in the prevalence and distribution of MSUS detectable forefoot 
bursae after a period of twelve months 
2.  Associations of MSUS detectable bursae with patient reported foot impact measures 
and clinical outcome variables after a period of twelve months 
3.  Predictors of change in presence of MSUS detectable bursae 
6.7.1. Participant demographic 
Of the 149 RA patients who were assessed at baseline 120 agreed to return at one year in 
the study giving a response rate of 80.5% (Figure 36). Of the 29 participants who did not 
wish to return to the study: 
•  nineteen participants chose to withdraw from the study for various reasons  
•  three agreed to return, but were withdrawn from the study due to issues with 
appointment times 
•  seven gave no response from the letters of invitation to return  
6.7.1.1. Non-returnee analyses 
After checking assumptions of normality, an unpaired t-test for numerical parametric data 
was performed to compare the means in the responders and non responders for age, 
duration of RA, global well being VAS, ESR, CRP, DAS-28, LFISTOT, LFISIF, LFISAP, 
MSUS detectable bursae and MSUS detectable intermetatarsal bursae. Levene’s test for 
equality of variances was significant for LFISTOT (p=0.010) and LFISIF (p=0.018), 
suggesting one group was more variable in LFISTOT and LFISIF distribution than the other, 
therefore ‘equal variances not assumed t statistic’ was used. 
 
There were no significant differences between returnees and non-returnees for any of the 
tested variables (Table 58 and Table 59).  
 
Using Chi squared analyses for non parametric categorical data, there were also no 
significant differences between responders and non-responders in terms of gender, 
seropositivity, number of DMARDs, foot structure or clinical foot care (Tables 60, 61 and 
62). For the number of DMARDs and number of DMARDs plus anti-TNFα therapy some 
cells had expected count data of less than 5. Some have proscribed the use of chi squared 
when expected frequency is <5 (Kinnear and Gray 2006) therefore the Fishers exact test 
was also performed and in both cases the p value remained not significant.   171
Figure 36. RA participant recruitment flow chart of returnees and non returnees for the 
twelve month follow up study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FeeTURA 
149 participants 
19 withdrawn  3 agreed to return 
but then did not 
attend the study 
appointment
1 cancelled 
appointment then 
no response at 
chase up phone 
calls
1 not thought 
relevant 
1 in wheelchair 
and too difficult to 
attend 
4 too ill 
2 did not attend 
appointment then 
no response at 
chase up phone 
calls 
1 deceased 
1 moved out of 
area 
120 participants 
completed 
FeeTURA phase 2 
29 non responders 
2 very sorry but 
were not able to 
take part at that 
moment in time
9 gave no reason 
7 No response 
from phone/letter 
still being chased 
up   172
 
Table 58. Demographic and clinical variable comparisons of returnees and non returnees for 
the twelve month follow up study showing the mean (standard deviation) and range for each. 
  Returnees: 
Baseline (N=120) 
Non returnees: 
Baseline (N=29) 
Statistical values 
Age (years)  59.7 (12.1) 
25 - 87 
58.3 (13.3) 
26 - 82 
t=-0.543, p=0.588 
Duration of RA 
(years) 
12.0 (10.4) 
0.6 - 43 
13.4 (10.0) 
1 – 33 
t=0.616, p=0.539 
Global well being 
(100mm VAS) 
39.9 (23.9) 
0 - 98 
41.9 (25.3) 
0 - 97 
t=0.379, p=0.705 
ESR (mm/hour)  22.9 (18.3) 
2 - 100 
25.1 (22.7) 
2 - 108 
t=0.555, p=0.580 
CRP (mg/litre)  12.5 (19.3) 
1 - 129 
12.1 (11.8) 
1 – 48.4 
t=-0.126, p=0.900 
DAS-28  3.9 (1.3) 
1.1 – 6.8 
4.4 (1.5) 
1.8 – 7.0 
t=1.565, p=0.121 
 
Table 59. Foot assessment variable comparisons of returnees and non returnees for the twelve 
month follow up study showing the mean (standard deviation) and range for each. 
  Returnees:  
Baseline (N=120) 
Non returnees: 
Baseline (N=29) 
Statistical values 
LFISTOT  27.9 (13.5) 
0 – 50 
31.8 (10.3) 
2 – 48 
t=1.717, p=0.092 
LFISIF  10.9 (4.9) 
0 - 21 
11.8 (4.9) 
2 - 19 
t=1.798, p=0.078 
LFISAP  16.9 (9.5) 
0 – 30 
19.9 (7.4) 
0 -29 
t=-0.269, p=0.789 
MSUS detectable 
bursae* 
3.6 (2.2) 
0 - 9 
3.28 (2.1) 
0 - 9 
t=-0.705, p=0.482 
Clinically detectable 
bursae** 
0.52 (1.1) 
0 - 6 
0.31 (0.9) 
0 - 3 
t=-0.944, p=0.347 
Key: * = Total numbers of MSUS detectable bursae; ** = Total numbers of clinically palpable 
bursae per individual; LFISTOT= Leeds Foot Impact Score, Total; LFISIF = Leeds Foot Impact Score, 
Impairment/Footwear subscale; LFISAP = Leeds Foot Impact Score, Activity limitation/Participation 
restriction subscale.   173
Table 60.  Categorical demographic comparisons of returnees and non returnees for the 
twelve month follow up study. 
  Returnees: Baseline 
(N=120) 
Non returnees: 
Baseline (N=29) 
Statistical values 
Gender  98 (81.7%) female 
22 (18.3%)  male 
21 (72.4%) female 
8 (27.6%) male 
χ
2= 1.244, p=0.265 
df=1 
Seropositivity  93 (77.5%) sero +ve 
24 (20.0%) sero -ve 
21 (72.4%) sero +ve 
8 (27.6%) sero -ve 
χ
2= 0.679, p=0.410 
df=1 
DMARDs   88 (73.3%) ≥1 
32 (26.7%) none 
20 (69.0%) ≥1 
9 (31.0%) none 
χ
2=4.659*,p=0.199 
f=3.928, p=0.304 
df=3 
DMARDs and 
TNFα therapy 
99 (82.5%) yes 
21 (17.5%) none 
 
21 (72.4%) yes 
8 (27.6%) none 
χ
2=2.849**,p=0.415 
f=2.866, p=0.401 
df=3 
Key: +ve= positive; -ve=negative; t = test statistic; χ
2 = Pearson Chi- Square; f=Fishers exact test; 
df=degrees of freedom; *3 cells (37.5%) have expected count less than 5. The minimum expected 
count is 19; ** 1 cell (12.5%) has expected count less than 5. The minimum expected count is 1.36. 
 
Table 61. Foot structure comparisons of returnees and non returnees for the twelve month 
follow up study. 
  Returnees: Baseline 
(N=120) 
Non returnees: 
Baseline(N=29) 
Statistical values 
Right MTP joint 
subluxation Missing 1 
(0.8%) 
Yes 91 (76.5%) 
No 28 (23.5%) 
 
Yes 21 (72.4%),  
no 8 (27.6%) 
χ
2=0.208, p=0.648 
df=1 
Left MTP joint 
subluxation 
B:Missing 1 (0.8%) 
Yes 92 (77.3%) 
No 27 (22.5%) 
 
Yes 21 (72.4%),  
no 8 (27.6%) 
χ
 2=0.310, p=0.578 
df=1 
Right Pes-planus 
B:Missing 10 (8.3%) 
R: missing 4 (13.8%) 
Yes 106 (96.4%) 
No 4 (3.6%) 
 
Yes 22 (75.9%), 
No 3 (10.3%)  
 
χ
 2=2.898, p=0.089 
df=1 
Left Pes-planus 
B:Missing 10 (8.3%) 
R: missing 4 (13.8%) 
Yes 106 (96.4%) 
No 4 (3.3%) 
 
Yes 22 (75.9%), 
No 3 (10.3%)  
χ
 2=2.898, p=0.089 
df=1 
Key: B=baseline visit; R=return visit; df=degrees of freedom   174
Table 62. Clinical foot care comparisons of returnees and non returnees for the twelve month 
follow up study. 
  Returnees  
Baseline (N=120) 
Non returnees 
Baseline (N=29) 
Statistical values 
Foot symptoms in 
notes 
Yes 68 (56.7%) 
No 52 (43.3%) 
Yes 17 (58.6%), 
No 12 (41.4%) 
χ
 2=0.036, p=0.849 
df=1 
Seen podiatrist in 
past 
Yes 74 (61.7%) 
No 46 (38.3%) 
Yes 17 (58.6%), 
No 12 (41.4%) 
χ
 2=0.091, p=0.763 
df=1 
Currently seeing a 
podiatrist 
Yes 38 (31.7%) 
No 82 (68.3%) 
Yes 11 (37.9%), 
No 18 (62.1%) 
χ
 2=0.415, p=0.519 
df=1 
6.7.1.2. Returnee demographic 
120 patients (98 female and 22 male) with RA (24 seronegative and 93 seropositive, 3 data 
missing) completed the study: mean age 60.7 (SD 12.1) years, disease duration 12.99 (10.4) 
years. Treatment at twelve months included 78 (65%) taking methotrexate and 55 (45.7%) 
taking anti-TNF-α therapy. Baseline and one year follow up data for weight, height, global 
wellbeing VAS, ESR, CRP, DAS-28, total numbers of MSUS detectable bursae, total 
numbers of MSUS detectable intermetatarsal bursae, LFISIF, LFISAP and foot structure are 
shown in Table 63 and Table 64.  
 
After twelve months, the mean change in the number of MSUS detectable forefoot bursae 
observed showed an average increase with a magnitude of 0.1 for both, whilst mean 
changes in LFIS total (LFISTOT) and subscale scores (LFISIF and LFISAP) showed an 
average decrease with a magnitude of -0.7, -0.5 and -0.1 respectively. The mean change in 
global well being (VAS) decreased (equivalent to improvement in well being) and weight 
and height decreased by magnitude of -4.1, -0.1 and -0.25, respectively, whilst mean 
change in ESR, CRP and DAS-28 scores showed an increase by a magnitude of 1.7, 2.5 
and 0.2 respectively.  
 
After checking assumptions of normality, a paired t-test for related numerical parametric 
data was performed to compare the means at baseline and at twelve months for weight, 
height, global wellbeing VAS, ESR, CRP, DAS-28, total numbers of MSUS detectable 
forefoot bursae LFISTOT, LFISIF and LFISAP. Missing values were omitted from the 
analyses so that actual paired values are represented and there were no statistical 
differences for any of the variables.   175
Table 63. Comparison of demographic and clinical characteristics of the RA study 
participants at baseline and after twelve months. 
 
 
Baseline (N=120) 
Mean (SD) 
12 months (N=120) 
Mean (SD) 
Raw Change 
Mean (SD) 
Weight (kgs)  72.7 (15.3)  72.6 (15.3)  -0.1 (4.3) 
Height (cm)  164.3 (7.5)  164.3 (7.9)  -0.3 (2.0) 
Wellbeing (VAS)  39.9 (23.9)  35.8 (22.6)  -4.1 (25.7) 
ESR (mm/hour)  22.9 (18.3)  24.4 (20.0)  1.7 (16.5) 
CRP (mg/litre)  12.6 (19.3)  14.6 (25.0)  2.5 (28.6) 
DAS-28  3.9 (1.3)  4.1 (1.5)  0.2 (1.7) 
 
 
Table 64. Comparison of foot characteristics of the returning RA study participants at 
baseline and after twelve months. 
 
 
Baseline (N=120) 
Mean (SD) 
12 months (N=120) 
Mean (SD) 
Raw change 
Mean (SD) 
MSUS detectable 
bursae*  3.6 (2.2)  3.7 (2.2)  p0.1 (2.8) 
Clinically detectable 
bursae** 
0.52 (1.1)  0.47 (1.0)  P-0.5 (1.2) 
LFISTOTAL (x/51)  27.9 (13.5)  27.2 (13.4)  -0.7 (7.8) 
LFISIF (x/21)  10.9 (4.9)  10.4 (4.8)  -0.5 (3.2) 
LFISAP (x/30)  16.9 (9.5)  16.8 (9.7)  -0.1 (5.7) 
Key: * = Total numbers of MSUS detectable bursae; ** = Total numbers of clinically palpable 
bursae per individual;; LFISTOT= Leeds Foot Impact Score, Total; LFISIF = Leeds Foot 
Impact Score, Impairment/Footwear subscale; LFISAP = Leeds Foot Impact Score, Activity 
Participation Limitation subscale. 
 
Using Chi squared analysis for categorical data of clinical foot care, use of DMARDs, use 
of anti-TNF-α therapy and foot structure, statistically significant differences were noted for 
“currently seeing a chiropodist/podiatrist” (χ
2=36.015, p<0.001), number of DMARDs 
including methotrexate (χ
2=58.155, p<0.001), number of DMARDs including methotrexate 
and anti-TNF-α therapy (χ
2=59.860, p<0.001), right MTPJ subluxation (χ
2=22.978, 
p<0.001) and left MTPJ subluxation (χ
2=22.327, p<0.001) (Table 65 and Table 66).   176
Table 65. Comparison of clinical foot care of the returning RA study participants at 
baseline and after twelve months. 
  Baseline 
(N=120) 
12 months 
(N=120) 
Raw Change 
Currently seeing a 
chiropodist/podiatrist 
38 (31.7%)  54 (45.0%)  16 (13.33%) 
 
Table 66. Comparison of prevalence of foot structure deformity of the returning RA 
study participants at baseline and after twelve months. 
  Baseline 
(N=120) 
12 months 
(N=120) 
Raw Change 
Right MTP joint subluxation   91 (75.8%)  65 (54.0%)  - 26 (21.8%) 
Left MTP joint subluxation   92 (76.7%)  66 (55.0%)  - 26 (21.7%) 
Right pes planus   106 (88.3%)  115 (95.8%)  9 (7.5%) 
Left pes planus   106 (88.3%)  116 (96.7%)  10 (8.4%) 
 
No significant differences were found for pes-planus foot types. Of note, however, in Table 
66 are the raw changes in MTP joint subluxation between baseline and twelve months, in 
which foot structure deformity appears to have significantly reduced in participants over 
time.  Caution should be heeded in interpreting these results as the measurements 
undertaken for MTP joint subluxation were by subjective observation and it is possible that 
the results are due to measurement bias rather than true differences. 
 
6.7.2. Presence of MSUS detectable bursae at twelve months 
At twelve months following baseline assessments, using MSUS 93.5 % (N = 112) of 
patients had detectable bursae (mean numbers of bursae per individual = 3.7, SD = 2.2, 
range 0 - 11) within the plantar forefoot and of these, 85.7 % (N = 96) had bursae in both 
feet.  
 
After twelve months, the most common location for MSUS detectable bursae remained the 
intermetatarsal (IM) 4/5 space for both feet followed, in order by IM 1/2, IM 3/4, IM 2/3, 
sub-metatarsal head (submet) 5, submet 2, submet 1, submet 3, submet 4 (Figure 37 and 
Figure 38). MSUS detectable intermetatarsal bursae were found in 90.8% (N=109) of the 
RA participants (mean number per individual = 2.93, SD = 1.8, range 0 to 7).   177
Figure 37.  Bar chart showing the locations and frequencies of MSUS detectable 
plantar forefoot bursae within the left feet of RA participants at both baseline and 
twelve month assessments. 
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Key: L= left; IM= intermetatarsal; s=sub-metatarsal 
 
Figure 38.  Bar chart showing the locations and frequencies of MSUS detectable 
plantar forefoot bursae within the right feet of RA participants at both baseline and 
twelve month assessments. 
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6.7.3. Associations of MSUS detectable bursae at twelve months 
To investigate whether MSUS detectable bursae remained independently associated with 
patient reported foot impact outcome measures after twelve months, the data was primarily 
explored, as for the baseline visit, using scatter plots and correlation plots. 
6.7.3.1. Cross sectional correlations at twelve months 
Cross sectional findings showed that total numbers of MSUS detectable forefoot bursae 
were significantly correlated with impact of RA disease on the foot for the primary 
outcome of foot impact scores (LFISIF r=0.236, p=0.009; LFISAP r=0.235, p=0.010) at 
twelve months, but there were no significant associations with any of the other clinical 
variables (Table 67 and Table 68). 
Table 67. Continuous data correlations between MSUS detectable bursae and 
relevant clinical variables for RA participants at twelve months. 
  
Pearson Correlation 
Coefficient 
Significance 
(2-tailed) 
Age (N=120)  0.106  0.248 
Duration of Arthritis (N=119)   0.063  0.496 
Weight (kgs) (N=120)  -0.069  0.451 
Height (cms) (N=119)  -0.030  0.748 
Global wellbeing 100mm VAS 
(N=120) 
0.114  0.217 
ESR mm/hr ( (N=115)   0.043  0.644 
CRP mg/l (N=113)  -0.120  0.204 
DAS-28 (N=97)  0.041  0.693 
LFISIF (N=120) **  0.236  0.009 
LFISAP (N=120) **  0.235  0.010 
   Key: **Correlation is significant at the 0.01 level (2-tailed)/ 
  
Interestingly, within the baseline study (N=149), significant correlations had also been 
noted between MSUS detectable bursae and duration of RA and ESR (Table 41, Chapter 
five, page 145). Non returnee analyses demonstrated no significant differences within the 
returnee group, suggesting that the associations of MSUS detectable bursae with duration 
of RA and ESR at baseline may have been anomalous. Associations of MSUS detectable 
bursae with foot impact scores, on the other hand, have been justified as significant at two 
different time points (Table 67).   179
Table 68. Categorical data correlations between MSUS detectable bursae and 
relevant clinical variables for RA participants at twelve months. 
 
  Spearman's 
Correlation 
Coefficient 
Significance  
(2-tailed) 
Right MTP joint subluxation (N=120)  -0.038  0.678 
Left MTP joint subluxation (N=120)  -0.160  0.863 
Right pes planus (N=117)  0.095  0.310 
Left pes planus (N=118)  0.095  0.304 
Disease severity (N=117)   -0.106  0.255 
Currently taking TNF (N=117)   -0.014  0.880 
Currently taking MTX (N=149)  -0.010  0.917 
Key: TNF=antiTNFα therapy; MTX=methotrexate. 
  
 
The same methodology was used as for the baseline visit to assess clinical correlations at 
twelve months with foot impact scores (LFISIF and LFISAP) (chapter five, section 5.8.5.1, 
page 145). Significant associations at twelve months were observed between LFISIF and 
MSUS detectable bursae, global well being and DAS-28 (Table 69).  Significant 
associations at twelve months were observed between LFISAP and MSUS detectable bursae, 
age, global well being, disease duration, ESR, CRP and DAS-28 were observed (Table 70). 
 
 
Table 69. Continuous data correlations between LFISIF and explanatory 
variables for RA participants at the twelve month return visit. 
  Pearson 
Correlation 
Coefficient 
Significance 
(2-tailed) 
MSUS bursae (N=120)**  0.236 0.009 
Age (N=120)  -0.009 0.923 
Duration of RA (N=119)  0.131 0.155 
Weight (N=120)  -0.015 0.870 
Global well being VAS (N= 120)**  0.449 <0.001 
ESR (N=115)  0.172 0.066 
CRP (N= 113)  0.170 0.073 
DAS-28 (N= 97)**  0.415 <0.001 
 Key: ** Correlation is significant at the 0.01 level (2-tailed).   180
Table 70. Continuous data correlations between LFISAP and explanatory 
variables for RA participants at the twelve month return visit. 
  Pearson 
Correlation 
Coefficient 
Significance 
(2-tailed) 
MSUS bursae (N=120)**  0.235 0.010 
Age (N=120)**  0.315 <0.001 
Duration of RA (N=119)**  0.251 0.006 
Weight (N=120)  0.015 0.874 
Global well being VAS (N=120)**  0.502 <0.001 
ESR (N=115)**  0.353 <0.001 
CRP (N=113)*  0.218 0.020 
DAS-28 (N=97)**  0.457 <0.001 
  Key: ** Correlation is significant at the 0.01 level (2-tailed); *Correlation is significant at 
the 0.05 level (2-tailed). 
As well as MSUS detectable bursae, within the baseline study (N=149) significant 
correlations had also been noted between LFISIF and global well being VAS, LFISIF and 
ESR but not LFISIF and DAS-28. Non returnee analyses demonstrated no significant 
differences within the returnee group for these variables therefore the association between 
LFISIF and global well being VAS is justified by being significant at two different time 
points (Chapter five, section 5.8.5.1, page 145). 
 
Similarly, as well as MSUS detectable bursae, within the baseline study (N=149), 
significant correlations had also been noted between LFISAP and age, duration of RA, 
global well being VAS, ESR and CRP but not DAS-28. Non returnee analyses 
demonstrated no significant differences within the returnee group for these variables 
therefore the associations between LFISAP and age, duration of RA, global well being VAS, 
ESR and CRP are justified by being significant at two different time points (Chapter five, 
section 5.8.5.1, page 145). 
 
In terms of foot structure, at baseline, only left foot MTP joint subluxation was 
significantly associated with LFISAP, in contrast to the twelve month data presented in 
Table 71 and Table 72 that shows significant associations between right and left feet MTP 
joint subluxation and LFISIF and LFISAP. As mentioned earlier within section 6.7.1.2 
(Table 66, page 176  ), caution should be heeded in interpreting these results as the 
measurements undertaken for MTP joint subluxation were by subjective observation and it 
is possible that the results are due to measurement bias rather than true differences.   181
Table 71. Categorical data correlations between LFISIF and explanatory 
variables for RA participants at the twelve month return visit. 
  Spearman’s 
Correlation 
Coefficient 
Significance 
(2-tailed) 
Right MTP joint subluxation (N=120)*  -0.217 0.017 
Left MTP joint subluxation (N=120)**  -0.243 0.008 
Right pes planus (N=117)  0.059 0.529 
Left pes planus (N=118)  0.060 0.519 
Currently on methotrexate (N=120)  0.015 0.867 
Currently on anti-TNF-α therapy (N=117)  0.116 0.213 
Disease severity (N=117)  0.002 0.981 
Key: ** Correlation is significant at the 0.01 level (2-tailed); *Correlation is 
significant at the 0.05 level (2-tailed) 
 
 
Table 72. Categorical data correlations between LFISAP and explanatory 
variables for RA participants at the twelve month return visit. 
  Spearman’s 
Correlation 
Coefficient 
Significance 
(2-tailed) 
Right MTP joint subluxation (N=120)**  -0.245 0.007 
Left MTP joint subluxation (N=120)**  -0.259 0.004 
Right pes planus (N=117)  -0.022 0.818 
Left pes planus (N=118)  -0.023 0.803 
Currently on methotrexate (N=120)  0.027 0.772 
Currently on anti-TNFα therapy (N=117)  0.098 0.294 
Disease severity (N=117)  -0.079 0.399 
Key: ** Correlation is significant at the 0.01 level (2-tailed) 
6.7.3.2. Cross sectional univariate linear regression analyses at twelve months 
Results using univariate linear regression show the extent of the associations for MSUS 
detectable bursae such that LFISIF increases by 0.512 and LFISAP by 1.04 for a unit increase 
in MSUS detectable bursae (LFISIF β=0.512, p=0.009; LFISAP β=1.040, p=0.010). The r
2 
(R square) for the LFISIF model was 0.056 indicating that approximately 5.6% of the 
variability in LFISIF can be explained by the model. The r
2 (R square) for the LFISAP model   182
was 0.055 indicating that approximately 5.5% of the variability in LFISAP can be explained 
by the model.  
 
The extent of the associations were also calculated for wellbeing (β=0.095, p<0.001), and 
DAS-28 (β=1.408, p<0.001) with LFISIF.  For LFISAP there were significant associations for 
age (β=0.252, p<0.001), duration of RA (β=0235, p=0.006), wellbeing (β=0.216, p<0.001), 
ESR (β=0.168, p<0.001), CRP (β=0.084, p=0.020) and DAS-28 (β=3.005, p<0.001). No 
other associations were significant. 
 
Of note, at baseline, LFISAP associations appeared to be stronger than LFISIF associations 
with both the primary and secondary outcome variables (Chapter five, section 5.8.5.1, page 
145). From the above paragraph, it can be seen that this was also the case again at twelve 
months, although the same caution applies in interpretation of this as the scales for LFISIF 
and LFISAP are not equal, with LFISIF being nine points less. 
6.7.3.3. Cross sectional multivariate linear regression analyses at twelve months 
Diagnostic tests for assumptions showed that the use of multiple linear regressions was an 
appropriate method of investigating further the extent to which MSUS detectable bursae 
was linearly related to the outcome variable (LFIS) after adjusting for the other explanatory 
variables. All histograms and normal probability plots of standardised residuals showed 
that the distribution of the residuals was normal. All constant variance scatter plots showed 
no particular tendency for residuals to increase or decrease systematically with the fitted 
values, indicating that the constant variance assumption is almost met. In all scatter plots of 
residuals versus MSUS detectable bursae there was no particular pattern, indicating a linear 
relationship between LFISIF and MSUS detectable bursae and LFISAP and MSUS detectable 
bursae. There were no colinearity indications for any of the models. 
 
Using the same multivariate regression modeling technique as for the baseline data analyses 
(Chapter five, section 5.8.5.3, page 149), after one year, MSUS detectable bursae were still 
an independent factor associated with LFISIF (β=0.507, p=0.011) and LFISAP (β=0.857, 
p=0.024) when modeled with the confounding explanatory variables of age and disease 
duration (Table 73 and Table 74). The r
2 (R square) for the LFISIF model was 0.072, 
indicating that approximately 7.2% of the variability in LFISIF can be explained by the 
model. The r
2 (R square) for the LFISAP model was 0.179, indicating that approximately 
17.9% of the variability in LFISAP can be explained by the model.    183
Table 73. Multivariate linear regression model for LFIS impairment subscale scores and 
confounding explanatory variables at twelve months. 
 
Explanatory 
Variable 
Outcome 
variable 
Regression 
coefficient β 
Standard 
Error 
P Value  95% CI 
Total Bursae  LFISIF  0.507  0.196  0.011  0.118 - 0.896 
Age  LFISIF  -0.020  0.036  0.575  -0.091 – 0.051 
Duration of RA  LFISIF  0.057  0.042  0.176  -0.026 - 0.140 
 
 
Table 74. Multivariate linear regression model for LFIS activity participation limitation 
subscale scores and confounding explanatory variables at twelve months. 
 
Explanatory 
Variable 
Outcome 
variable 
Regression 
coefficient β 
Standard 
Error 
P Value  95% CI 
Total Bursae  LFISAP  0.857  0.375  0.024  0.114 – 1.600 
Age  LFISAP  0.211  0.069  0.003  0.075 – 0.347 
Duration of RA  LFISAP  0.190  0.080  0.019  0.032 – 0.348 
 
Furthermore, after one year, after adjusting for disease activity confounding variables, a 
significant linear relationship remained between MSUS detectable bursae and LFISIF 
(ß=0.525, p=0.009) at the 0.01 level and LFISAP (ß=0.732, p=0.029) at the 0.05 level 
(Table 75 and Table 76). The r
2 (R square) for the LFISIF model was 0.232, indicating that 
approximately 23.2% of the variability in LFISIF can be explained by the model. The r
2 (R 
square) for the LFISAP model was 0.376, indicating that approximately 37.6% of the 
variability in LFISAP can be explained by the model.  
 
 
Table 75. Multivariate linear regression model for LFIS impairment subscale scores and 
confounding explanatory disease activity variables at twelve months. 
Explanatory 
Variable 
Outcome 
variable 
Regression 
coefficient β 
Standard 
Error 
P Value  95% CI 
MSUS Bursae  LFISIF 0.525  0.198  0.009  0.131  –  0.918 
Age LFISIF  -0.031  0.041  0.445  -0.113 – 0.050 
DAS-28 LFISIF 1.393  0.310  0.000  0.778  –  2.008   184
 
Table 76. Multivariate linear regression model for LFIS activity participation limitation 
subscale scores and confounding explanatory disease activity variables at twelve months. 
Explanatory 
Variable 
Outcome 
variable 
Regression 
coefficient β 
Standard 
Error 
P Value  95% CI 
MSUS Bursae  LFISAP 0.732  0.330  0.029  0.078-1.386 
Age LFISAP 0.172  0.062  0.006  0.050  -0.295 
Global VAS  LFISAP 0.173  0.032  0.000  0.108-0.237 
ESR LFISAP 0.102  0.037  0.007  0.028-0.176 
 
Within the model for LFISIF  presented in Table 75, CRP and ESR were omitted as they 
were not associated with LFISIF and global wellbeing VAS was omitted due its colinearity 
with DAS-28 at twelve months. Within the model for LFISAP, presented in Table 76, CRP 
and DAS-28 were omitted due to their colinearity with VAS and ESR at twelve months. 
However, when the same model as the baseline assessments was used that included MSUS 
detectable bursae, age, global well being VAS and ESR, MSUS detectable bursae were still 
a significant independent association with LFISIF (ß=0.451, p=0.015) at the 0.05 level. 
 
The results for the twelve month analyses, for associations of MSUS detectable bursae with 
foot impairment and activity participation limitation, were therefore consistent with the 
results at baseline. This indicates that if a new model was to be produced with no prior 
assumptions on the data the same result for the associations between MSUS detectable 
bursae and both LFIS subscales would have been achieved at two separate time points, 
confirming that the association is real and independent of disease activity.   
 
6.7.4. Associations of change in presence of MSUS detectable bursae 
To determine associations of change in the presence of MSUS detectable bursae, raw 
values for change were calculated for individual data for each of the explanatory variables. 
Although the means for number of bursae were not significantly different between the 
baseline data and twelve months data (section 6.7.1.2. page 175), when assumptions for 
raw change values were checked, most values were normally distributed demonstrating a 
wide range of change within each of the explanatory variables. Figure 39 and Figure 40 
show the normal distributions for raw change for MSUS detectable bursae and both LFIS 
subscale values.    185
Figure 39. Histogram showing the raw change in total numbers of MSUS detectable bursae 
for returning RA participants between baseline and twelve month assessments. 
9.00 6.00 3.00 0.00 -3.00 -6.00 -9.00
MSUSburch
25
20
15
10
5
0
F
r
e
q
u
e
n
c
y
 
Key: MSUSburch: MSUS detectable bursae 
 
 
Figure 40. Histograms showing the distribution of magnitude and direction of change for 
LFISIF and LFISAP subscales for returning RA participants between baseline and twelve 
month assessments. 
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Key: LFISIF: Leeds Foot Impact impairment/footwear subscale; LFISAP: Leeds Foot 
Impact activity limitation/participation subscale. 
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Within Figure 39, it can be seen that the majority of participants did not have much change 
in total MSUS detectable bursae. However normal distribution shows that a similar number 
of participants had a reduction in MSUS detectable bursae as those who had an increase. 
 
The normal distribution of foot impact scores, seen in Figure 40, shows the same trend for 
LFISIF and LFISAP. The majority of participants did not have much change in foot impact 
scores, but a similar number had a reduction in scores as those who had an increase. 
 
Bowling (2002) suggests that this is probably due to the longitudinal nature of the data as 
well as sample drop out and that raw individual change should be tested rather than 
averaging the individual time points. From the statistical tests on the mean changes 
between baseline and twelve months (presented in section 6.7.1.2, page 174) there was a 
wide variance of change for MSUS detectable bursae and LFIS subscale scores but these 
were not significantly different. However, what was not known was whether the raw 
changes for each of those variables were related. 
 
6.7.4.1. Longitudinal correlations 
Following the trend observations, the data was explored further using scatter plots and 
correlations to determine any significant associations between the raw changes of MSUS 
detectable bursae and raw changes in each of the explanatory variables. Findings showed 
that there was a weak significant positive correlation between the changes in MSUS 
detectable bursae with changes in both LFISIF (PCC = 0.216, p=0.018) and LFISAP (PCC = 
0.193, p=0.036) but none with changes in global wellbeing VAS, ESR, CRP and DAS-28 
(Table 77, Figure 41 and Figure 42).  
 
Duration of RA at the twelve month return visit was also tested for association with raw 
change in MSUS bursae and a significant negative weak correlation was noted (PCC = -
0.269, p=0.003). 
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Table 77. Correlations between the raw changes in explanatory variables from the baseline to the 
twelve month assessment. 
 
     
change 
in 
LFISIF 
change 
in 
LFISAP 
change 
in 
MSUS 
bursae  
change 
in VAS  
change 
in ESR  
change 
in CRP 
change 
in  
DAS-28 
Pearson 
Correlation  1             
Sig. (2-tailed)               
change in 
LFISIF  
               
Pearson 
Correlation  0.410** 1           
Sig. (2-tailed)  0.000             
change in 
LFISAP  
               
Pearson 
Correlation  0.216*  0.193*  1         
Sig. (2-tailed)  0.018  0.036           
change in 
MSUS 
bursae  
               
Pearson 
Correlation  0.124  0.071  -0.023  1       
Sig. (2-tailed)  0.178  0.442  0.802         
change in 
well 
being 
VAS                  
Pearson 
Correlation  0.163  0.002  -0.079  0.322** 1     
Sig. (2-tailed)  0.087  0.987  0.406  0.001       
change in 
ESR  
               
Pearson 
Correlation  -0.019  0.097  -0.103  0.236*  0.477**  1   
Sig. (2-tailed)  0.843  0.324  0.290  0.014  0.000     
change in 
CRP  
               
Pearson 
Correlation  0.126  0.059  -0.149  0.318** 0.557**  0.331** 1 
Sig. (2-tailed)  0.259  0.599  0.180  0.004  0.000  0.003   
change in 
DAS-28  
               
Key: ** Correlation is significant at the 0.01 level (2-tailed); *Correlation is significant at 
the 0.05 level (2-tailed). 
 
 
Table 77 shows the correlations of changes in all clinical outcomes, although the focus of 
the analysis is the primary outcome of foot impact scores (LFISIF and LFISAP) and MSUS 
detectable bursae. For continuity, the same method was used as in the baseline visit to 
assess correlations of change in clinical outcomes between baseline and twelve months. 
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Figure 41. Scatter plot showing the association between changes in foot impairment 
(LFISIF) and MSUS detectable bursae from baseline to twelve months. 
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Figure 42. Scatter plot showing the association between changes in activity 
participation limitation (LFISAP) and MSUS detectable bursae from baseline to twelve 
months. 
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6.7.4.2. Longitudinal multivariate linear regression analyses 
To determine if changes in MSUS detectable bursae were independently related to changes 
in foot impact scores, the values of change for each of the explanatory variables were 
checked for assumptions and entered into same multivariate model as for the twelve month 
analysis (section 6.7.3.3, page 182). Even though the raw changes in the explanatory 
variables of global wellbeing VAS, ESR, CRP and DAS-28 were not significantly 
associated with either LFIS subscale change scores, they were forced into the model for 
continuity reasons and comparison between studies. After adjusting for age and disease 
variables (global wellbeing VAS and ESR) the changes in MSUS detectable bursae 
remained a significant independent factor at the 0.05 level associated with LFISIF (β=0.276, 
p=0.012) and LFISAP (β=0.450, p=0.028) (Table 78 and Table 79). The r
2 (R square) for 
the LFISIF model was 0.118 indicating that approximately 11.8% of the variability in LFISIF  
can be explained by the model. The r
2 (R square) for the LFISAP model was 0.050 
indicating that approximately 5.0% of the variability in LFISAP can be explained by the 
model.  
 
Table 78. Multivariate linear regression model for changes in LFIS impairment subscale 
scores, changes in MSUS detectable bursae and changes in disease activity between baseline 
and twelve months. 
Explanatory 
Variable 
Outcome 
variable 
Regression 
coefficient β 
Standard 
Error 
P Value  95% CI 
MSUS Bursae  LFISIF 0.276  0.108  0.012  0.062  –  0.491 
Age at baseline  LFISIF  -0.062  0.026  0.022  -0.114 - -0.009 
Global VAS  LFISIF  0.012  0.012  0.333  -0.012 – 0.036 
ESR LFISIF 0.037  0.019  0.059  0.001  –  0.075 
 
Table 79. Multivariate linear regression model for changes in LFIS activity participation 
limitation subscale scores, changes in MSUS detectable bursae and changes in disease 
activity between baseline and twelve months. 
Explanatory 
Variable 
Outcome 
variable 
Regression 
coefficient β 
Standard 
Error 
P Value  95% CI 
MSUS Bursae  LFISAP 0.450  0.203  0.028  0.048  –  0.852 
Age at baseline  LFISAP  -0.033  0.050  0.510  -0.132 – 0.068 
Global VAS  LFISAP  0.018  0.023  0.436  -0.027 – 0.063 
ESR LFISAP  -0.001  0.036  0.969  -0.070 – 0.073   190
6.7.5. Predictors of change 
From the multivariate regression analyses changes in both LFISIF and LFISAP appear to be 
predicted fairly well by the changes in the number of MSUS detectable forefoot bursae, 
after adjusting for age, global wellbeing VAS and ESR. The p-values (0.013 and 0.021) are 
not outstanding, but can be deemed good, given the sample size and the fact that count data 
for MSUS detectable bursae are being used as continuous. 
6.7.5.1. Comparison of baseline associations of MSUS detectable bursae with 
associations at twelve months 
These findings are further confirmed when baseline values for each of the predictor 
variables are analysed against MSUS detectable bursae for the cohort data at both baseline 
and twelve months. Both subscales of LFIS are significantly positively correlated with 
MSUS detectable bursae at baseline and again at twelve months (Table 80).  
 
Table 80. Correlations between cohort MSUS detectable bursae and relevant clinical 
variables for RA participants at baseline and twelve months. 
Baseline   Twelve months 
  
Pearson 
Correlation 
Coefficient 
Significance 
(2-tailed) 
Pearson 
Correlation 
Coefficient 
Significance 
(2-tailed) 
Age years(N=120)  -0.030  0.744  0.106  0.248 
Duration of RA  years 
(N=119)  
0.404**  0.000  0.063  0.496 
Weight(kgs) (N=120)  0.072  0.433  -0.069  0.451 
Height(cms) (N=119)  0.062  0.552  -0.030  0.748 
Global wellbeing 
100mmVAS (N=120) 
-0.001  0.988  0.114  0.217 
ESR mm/hr (N=115)   0.140  0.133  0.043  0.644 
CRP mg/l (N=113)  0.050  0.595  -0.120  0.204 
DAS-28 (N=97)  -0.114  0.276  0.041  0.693 
LFISIF (N=120) **  0.226*  0.013  0.236**  0.009 
LFISAP (N=12) **  0.254**  0.005  0.235**  0.010 
 
However, when the data were analysed further to determine if LFISIF or LFISAP values at 
baseline were related with MSUS detectable bursae at twelve months no significant 
associations were found (Figure 43 and Figure 44).    191
Figure 43. Scatter plot showing the association between foot impairment at baseline 
and MSUS detectable bursae at twelve months. 
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Figure 44. Scatter plot showing the association between activity participation 
limitation at baseline and MSUS detectable bursae at twelve months. 
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The scatter plots show a random pattern between LFIS scores at baseline and MSUS 
detectable bursae at one year indicating a lack of association between these variables. 
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6.7.5.2. Regression to the mean 
Bowling (2002) highlights that detection of any change in variables could be due to the 
regression to the mean phenomenon. This is also known as a regression threat or 
"regression artefact" and may occur with a non-random sample from a population and two 
measures that are imperfectly correlated. It is an important phenomenon to take note of 
because it affects the internal validity of the study design (Bowling 2002; Petrie and Sabin 
1998).  
 
A regression artefact occurs when participants have extreme measurements on variables of 
interest or there are normal fluctuations in the variable of interest over time. The net effect 
of regression toward the mean is that the lower scores (or measurements) on the pre-test 
tend to be higher on the post-test, and the higher scores (or measurements) on the pre-test 
tend to be lower on the post-test (Bowling 2002; Petrie and Sabin 1998). To test this effect, 
the regression models were recalculated with the addition of the baseline values of both 
LFIS subscale scores (Table 81 and Table 82). 
 
After adjusting for age and disease variables (global wellbeing VAS and ESR) and baseline 
LFIS subscale scores, the changes in MSUS detectable bursae remained a significant 
independent factor at the 0.05 level associated with LFISIF (β=0.248, p=0.016) but not with 
LFISAP (β=0.3740, p=0.063). The r
2 (R square) for the LFISIF model was 0.238 indicating 
that approximately 23.8% of the variability in LFISIF can be explained by the model. The r
2 
(R square) for the LFISAP model was 0.110 indicating that approximately 11.0% of the 
variability in LFISAP can be explained by the model.  
 
Table 81. Multivariate linear regression model for changes in LFIS impairment subscale 
scores, changes in MSUS detectable bursae and changes in disease activity between baseline 
and twelve months including baseline LFISIF. 
Explanatory 
Variable 
Outcome 
variable 
Regression 
coefficient β 
Standard 
Error 
P Value  95% CI 
MSUS Bursae  LFISIF 0.248  0.101  0.016  0.047  –  0.448 
Age at baseline  LFISIF  -0.055  0.025  0.029  -0.047 – 0.448 
Global VAS  LFISIF  0.003  0.012  0.778  -0.020 – 0.026 
ESR LFISIF  -0.041  0.018  0.026  -0.005 – 0.077 
LFISIF baseline  LFISIF  -0.233  0.057  0.000  -0.346 – -0.120   193
 
Table 82. Multivariate linear regression model for changes in LFIS activity participation 
limitation subscale scores, changes in MSUS detectable bursae and changes in disease 
activity between baseline and twelve months including baseline LFISAP. 
Explanatory 
Variable 
Outcome 
variable 
Regression 
coefficient β 
Standard 
Error 
P Value  95% CI 
MSUS Bursae  LFISAP  0.374  0.178  0.063  -0.021 – 0.769 
Age at baseline  LFISAP  0.014  0.052  0.791  -0.089 – 0.116 
Global VAS  LFISAP 0.013  0.022  0.567  -0.031–  0.057 
ESR LFISAP  0.007  0.035  0.835  -0.063 – 0.077 
LFISAP baseline  LFISAP  -0.166  0.063  0.009  -0.290 – (-0.042)
 
This suggests that the association of change between MSUS detectable bursae and foot 
impairment (LFISIF) is real and not due to regression artefact. However the association 
between change in MSUS detectable bursae and activity participation limitation just 
dropped out of the model for significance when baseline LFISAP data was included. It is 
therefore possible that changes within LFISAP may be attributed to the natural variation or 
random fluctuation in the impact of RA disease on the foot over time rather than MSUS 
detectable bursae. Results therefore should be interpreted with caution. However, the 
confidence intervals for MSUS detectable bursae within the LFISAP model did only just 
cross zero and it might be that the sample size of returnee participants was too small to 
determine the association.  
 
6.7.5.3. Person specific analyses according to changes in MSUS detectable bursae over 
twelve months 
The variance of the data for changes in MSUS detectable bursae was further examined as 
person specific data to investigate what, if anything, predicted those changes. Figure 45 
shows the MSUS scan images of a participant whose bursae count decreased from the 
baseline to the twelve month visit. To determine predictors of changes this data was 
grouped according to occurrences of MSUS bursae per individual (group A: 0-2 MSUS 
detectable bursae; group B: 3-6 MSUS detectable bursae; group C: 7-11 MSUS detectable 
bursae) at both baseline and twelve months. An increase in the number of MSUS detectable 
bursae was observed in 31 (25.8%) participants, whilst in 28 (23.3%) participants MSUS 
detectable bursae decreased and in 61 (50.8%) participants the number of MSUS detectable 
bursae remained the same after twelve months (Table 83).    194
Figure 45. MSUS images of the left plantar forefoot area of the same study participant 
with RA demonstrating enlarged bursae as anechoic areas between the second and third 
metatarsal heads and the third and fourth metatarsal heads (white arrows) (A) at 
baseline. (B) the same foot demonstrating a homogenous signal between the second and 
third metatarsal heads and third and fourth metatarsal heads at the twelve month visit. 
 
A  
 
 
B 
Key: M2 = second metatarsal; M3 = third metatarsal; M4 = fourth metatarsal;  
M5 = fifth metatarsal; P = plantar surface; D = dorsal surface   195
Table 83. A contingency table showing results for the comparisons between MSUS 
detectable bursae at baseline and after twelve months. 
 
Categories of MSUS detectable bursae at twelve 
months 
  
  
GroupA 
0-2 
Group B 
3-6 
Group C 
7-11 
Total 
 
Categories of MSUS 
detectable bursae at 
baseline 
 
GroupA  20  21  3  44 
   GroupB  15  39  7  61 
    
GroupC  4  9  2  15 
   Total  39  69  12  120 
 
 
The data was then analysed for mean change of the predictor variables according to the 
direction and magnitude of change of MSUS detectable bursae for each of the groups A, B 
and C.  
 
Table 84 shows the descriptive results indicating that there was a trend towards those 
individuals who exhibited a decrease in the number of MSUS detectable bursae to have 
longer mean disease duration but to have an improvement in well being and foot impact 
scores observed by a reduction in those scores. However they showed a mean increase in 
disease variables ESR, CRP and DAS-28. Those who exhibited an increase in MSUS 
detectable bursae tended to have shorter disease duration and deterioration in foot impact 
scores (observed by an increase in those scores) but a reduction in mean disease variable 
scores for ESR, CRP and DAS-28  
 
The data was further tested for significance of between-group effects using analysis of 
variance. Significant differences at the 0.05 level between groups were observed for change 
in LFISTOT (p=0.036), ESR (p=0.016) and CRP (p=0.014). After adjusting the p values for 
the number of tests performed using Bonferroni correction the results were significant for 
ESR (p=0.012) and CRP (p=0.011) between those who had no change in MSUS detectable 
bursae state and those who exhibited an increase in MSUS detectable bursae. For LFISTOT 
the differences were also between those who had no change in MSUS detectable bursae 
state and those who exhibited an increase in MSUS detectable bursae, however this became 
marginally non significant (p=0.053). 
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Table 84. Analysis of variance for the mean change observed for individuals in each of 
the predictor variables according to the direction and magnitude of change of MSUS 
detectable bursae. 
 
  Increase in 
bursae 
N=31 
No change in 
bursae 
N=61 
Decrease in 
bursae 
N=28 
ANOVA 
Statistical 
values 
Age (baseline)  61.1 (12.5) 
33 - 85 
58.8 (12.1) 
25-87 
60.1 (11.9) 
32 - 82 
f=0.409 
p=0.666 
Duration of RA 
(baseline) 
8.6 (6.7) 
2 - 30 
12.7 (9.8) 
0.5 - 38 
14.3 (14.1) 
2 - 43 
f=2.539 
p=0.083 
Raw change in 
LFIS* 
2.4 (9.6) 
-24 – 19 
-1.6 (6.1) 
-19 - 10 
-2.1 (8.1) 
-23 – 18 
f=3.414 
p=0.036 
Raw change in 
LFISIF 
0.5 (3.9) 
-11 – 6 
-0.6 (2.8) 
-8.0 – 6.0 
-1.3 (3.2) 
-10 – 5 
f=2.245 
p=0.111 
Raw change in 
LFISAP 
1.8 (6.7) 
-13 – 17 
-1.0 (5.3) 
-14 - 12 
-0.4 (5.1) 
-8 – 13 
f=2.629 
p=0.076 
Raw change in 
VAS 
-3.5 (27.5) 
-57 – 60 
-1.9 (26.0) 
-80.0 – 57.0 
-9.7 (22.8) 
-55 – 29 
f=0.893 
p=0.412 
Raw change in 
ESR* 
-5.1 (17.5) 
-42 – 55 
5.6 (14.5) 
-20.0 – 71.0 
0.62 (17.7) 
-33 – 56 
f=4.297 
p=0.016 
Raw change in 
CRP* 
-9.1 (24.2) 
-115 – 16 
9.7 (33.4) 
-45 - 216 
1.1 (14.2) 
-31 – 42 
f=4.442 
p=0.014 
Raw change in 
DAS-28 
-0.4 (1.6) 
-3 – 3 
0.3 (1.9) 
-4.1 – 4.9 
0.5 (1.4) 
-2 – 4 
f=1.528 
p=0.223 
Key: *Significant at the 0.05 level 
 
 
Using chi squared analyses there were no significant differences between the groups for 
disease severity, use of medication at baseline and twelve months, previous podiatry 
treatment, podiatry treatment at baseline and foot structure at baseline. A significant 
difference was noted between the groups for current podiatry treatment at twelve months, 
with those who exhibited an increase in MSUS detectable bursae having the least podiatric 
treatment (Table 85, Table 86 and Table 87). 
   197
Table 85. The disease severity and use of disease modifying medication at baseline and 
twelve months for individuals in each of the predictor variables according to the 
direction and magnitude of change of MSUS detectable bursae. 
  Increase in bursae 
(N=31) 
No change in 
bursae (N=61) 
Decrease in 
bursae (N=28) 
Statistical 
values 
Disease 
severity 
+ve 23 (74.2%) 
-ve 7 (22.6%) 
Missing 1 (3.2%) 
+ve 46 (75.4%) 
-ve 13 (21.3%) 
Missing 2 (3.3%) 
+ve 24 (85.7%) 
-ve 4 (14.3%) 
χ
2=0.896 
p=0.639 
TNF 
baseline 
No 21 (67.7%) 
Yes 10 (32.3%) 
No 19 (31.1%) 
Yes 42 (68.9%) 
No 14 (50%) 
Yes 14 (50%) 
χ
2=3.108 
p=0.211 
TNF 1yr  No 17 (54.8%) 
Yes 13 (41.9%) 
Missing 1 (3.2%) 
No 32 (52.5%) 
Yes 28 (45.9) 
Missing 1 (1.6%) 
No 14 (50%) 
Yes 13 (46.4%) 
Missing 1 (3.6%) 
χ
2=0.146 
p=0.930 
 
MTX 
baseline 
No 14 (45.2%) 
Yes 17 (54.8%) 
No 19 (31.1%) 
Yes 42 (68.9%) 
No 9 (32.1%) 
Yes 19 (67.9%) 
χ
2=1.905 
p=0.386 
MTX 1yr  No 10 (32.3%) 
Yes 21 (67.7%) 
No 17 (27.9%) 
Yes 44 (72.1%) 
No 8 (28.6%) 
Yes 20 (71.4%) 
χ
2= 0.198 
p=0.906 
Key: χ
2=Chi square statistic; pres=presence; abs=absence; TNF=antiTNFα therapy; 
MTX=methotrexate. 
 
 
Table 86. Clinical foot care at baseline and twelve months for individuals in each of the 
predictor variables according to the direction and magnitude of change of MSUS 
detectable bursae. 
  Increase in bursae 
(N=31) 
No change in 
bursae (N=61) 
Decrease in 
bursae (N=28) 
Statistical 
values 
Past pod 
baseline 
No 12 (38.7%) 
Yes 19 (61.3%) 
No 28 (45.9%) 
Yes 33 (54.1%) 
No 6 (21.4% ) 
Yes 22 (78.6%) 
χ
2=4.865 
p=0.088 
Current Pod 
at baseline  
No 21 (67.7%) 
Yes 10 (32.3%) 
No 46 (75.4%) 
Yes 15 (24.6%) 
No 15 (53.6%) 
Yes 13 (46.4.6%) 
χ
2=4.236 
p=0.120 
Current Pod 
at twelve 
months* 
No 20 (64.5%) 
Yes 11 (35.5%) 
No 33 (57.4%) 
Yes 24 (39.3%) 
Missing 2 (3.3%) 
No 9 (32.1%) 
Yes 19 (67.9%) 
χ
2=7.441 
p=0.024 
Key: *Significant at the 0.05 level; χ
2=Chi square statistic; pres=presence; abs=absence   198
Table 87. Foot structure deformity at baseline for individuals in each of the predictor 
variables according to the direction and magnitude of change of MSUS detectable 
bursae. 
  Increase in bursae 
(N=31) 
No change in 
bursae (N=61) 
Decrease in 
bursae (N=28) 
Statistical 
values 
Right MTP 
joint 
subluxation  
Pres 25 (80.6%) 
Abs 6 (19.4%) 
Pres 45 (73.8%) 
Abs 15 (24.6%) 
Missing 1 (1.6%) 
Pres 21 (75%) 
Abs 7 (25%) 
χ
2=0.406 
p=0.816 
Left MTP 
joint 
subluxation  
Pres 25 (80.6%) 
Abs 6 (19.4%) 
Pres 46 (75.4%) 
Abs 14 (23.0%) 
Missing 1 (1.6%) 
Pres 21 (75%) 
Abs 7 (25%) 
χ
2=0.296 
p=0.862 
Right pes 
planus  
Pres 25 (80.6%) 
Abs 1 (3.2%) 
Missing 5 (16.1%) 
Pres 55 (90.2%) 
Abs 2 (3.3%) 
Missing 4 (6.6%) 
Pres 26 (92.9%) 
Abs 1 (3.6%) 
Missing 1 (3.6%) 
χ
2=0.006 
p=0.977 
Left 
pesplanus  
Pres 25 (80.6%) 
Abs 1 (3.2%) 
Missing 5 (16.1%) 
Pres 55 (90.2%) 
Abs 2 (3.3%) 
Missing 4 (6.6%) 
Pres 26 (92.9%) 
Abs 1 (3.6%) 
Missing 1 (3.6%) 
χ
2=0.006 
p=0.977 
Key: χ
2=Chi square statistic; pres=presence; abs=absence 
 
 
The findings that podiatry treatment may influence the presence of MSUS detectable bursae 
within the forefeet of patients with RA were analysed further. To determine if changes in 
podiatric treatment status of individuals influenced the relationship between changes in foot 
impact scores and changes in MSUS detectable bursae the regression model (section 
6.7.3.3, page 182) was repeated with these variables (Table 88, Table 89, Table 90, Table 
91, Table 92, Table 93). 
 
Table 88. Multivariate linear regression model for LFIS impairment subscale scores and 
confounding explanatory variables at baseline. 
Explanatory 
Variable 
Outcome 
variable 
Regression 
coefficient β 
Standard 
Error 
P Value  95% CI 
Total Bursae  LFISIF  0.441  0.199  0.028  0.047 - 0.834 
Age  LFISIF  0.006  0.039  0.885  -0.072 – 0.083 
Podiatry treatment  LFISIF  1.955  1.022  0.058  -0.070 - 3.980 
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Table 89. Multivariate linear regression model for LFIS activity participation limitation 
subscale scores and confounding explanatory variables at baseline. 
 
Explanatory 
Variable 
Outcome 
variable 
Regression 
coefficient β 
Standard 
Error 
P Value  95% CI 
Total Bursae  LFISAP  1.000  0.355  0.006  0.296 - 1.704 
Age  LFISAP  0.229  0.070  0.001  0.091 - 0.367 
Podiatry treatment  LFISAP  3.418  1.838  0.065  -0.222 - 7.058 
 
Table 90. Multivariate linear regression model for LFIS impairment subscale scores and 
confounding explanatory variables at twelve months. 
 
Explanatory 
Variable 
Outcome 
variable 
Regression 
coefficient β 
Standard 
Error 
P Value  95% CI 
Total Bursae  LFISIF  0.539  0.192  0.006  0.158 -0.920 
Age  LFISIF  -0.036  0.036  0.323  -0.107 - 0.036 
Podiatry treatment  LFISIF  2.334  0.874  0.009  0.603 - 4.065 
 
Table 91. Multivariate linear regression model for LFIS activity participation limitation 
subscale scores and confounding explanatory variables at twelve months. 
 
Explanatory 
Variable 
Outcome 
variable 
Regression 
coefficient β 
Standard 
Error 
P Value  95% CI 
Total Bursae  LFISAP  0.948  0.360  0.010  0.235 - 1.660 
Age  LFISAP  0.181  0.068  0.009  0.047 - 0.315 
Podiatry treatment  LFISAP  6.111  1.636  0.000  2.871 - 9.352 
 
Table 92. Multivariate linear regression model for changes in LFIS impairment subscale 
scores and changes in MSUS detectable bursae and changes in podiatry treatment between 
baseline and twelve months. 
Explanatory 
Variable 
Outcome 
variable 
Regression 
coefficient β 
Standard 
Error 
P Value  95% CI 
Total Bursae  LFISIF  0.261  0.101  0.012  0.060 - 0.462 
Age  LFISIF  -0.043  0.024  0.071  -0.090 - 0.004 
Podiatry treatment  LFISIF  -0.565  0.631  0.372  -1.815 - .685   200
 
Table 93. Multivariate linear regression model for changes in LFIS activity participation 
limitation subscale scores and changes in MSUS detectable bursae and changes in podiatry 
treatment between baseline and twelve months. 
Explanatory 
Variable 
Outcome 
variable 
Regression 
coefficient β 
Standard 
Error 
P Value  95% CI 
Total Bursae  LFISAP  0.382  0.183  0.039  0.019 -  0.744 
Age  LFISAP  -0.009  0.043  0.828  -0.095 - 0.076 
Podiatry treatment  LFISAP  -0.062  1.137  0.956  -2.315 - 2.191 
 
After adjusting for age and podiatric treatment at baseline, MSUS detectable bursae 
remained a significant independent factor at the 0.05 level associated with LFISIF (β=0.441, 
p=0.028) and LFISAP (β=1.000, p=0.006) (Table 88 and Table 89).  
 
After adjusting for age and podiatric treatment at twelve months, MSUS detectable bursae 
remained a significant independent factor at the 0.05 level associated with LFISIF (β=0.539, 
p=0.006) and LFISAP (β=0.948, p=0.010) (Table 90 and Table 91).  
 
After adjusting for age and podiatric treatment the changes in MSUS detectable bursae 
remained a significant independent factor at the 0.05 level associated with LFISIF (β=0.261, 
p=0.012) and LFISAP (β=0.382, p=0.039) (Table 92 and Table 93).  
 
This indicates that the association between the presence of MSUS detectable bursae and 
foot impact scores is probably also independent of podiatric treatment. 
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6.8. Summary of results 
 
1. Descriptive changes in prevalence of MSUS detectable bursae 
At twelve months, there were no statistically significant changes in mean numbers of 
MSUS detectable bursae per individual, mean LFISIF and mean LFISAP scores between 
baseline and twelve months. The intermetatarsal space 4/5 remained as the most common 
site for MSUS detectable bursae. There were no significant differences in the means of 
clinical characteristics or demographic variables between baseline and twelve months 
assessments but the changes exhibited a wide variance and were normally distributed. 
 
Statistically significant differences were noted for regular podiatry treatment (more 
receiving care at twelve months) and use of DMARDs and anti TNF-α therapy. 
 
2. Associations with MSUS detectable forefoot bursae at twelve months 
Results at twelve months were consistent with those at baseline. MSUS detectable bursae 
remained a significant and independent factor (of disease activity) in its association with 
patient reported foot impact outcome measures. 
 
3. Associations with changes in presence of MSUS detectable forefoot bursae 
Changes in MSUS detectable bursae were significantly positively associated with changes 
in LFISIF and LFISAP and significantly negatively associated with duration of RA although 
in both instances this was a weak correlation. The association of changes in MSUS 
detectable bursae with changes in LFISIF and LFISAP remained independent of disease 
activity. 
 
4. Predictors of change in presence of MSUS detectable bursae 
Those individuals who had an increase in MSUS detectable bursae over time displayed 
greater deterioration in foot impact scores and tended to have had a reduction in podiatric 
treatment. However, they also displayed decreases in ESR and CRP and were more likely 
to have shorter disease duration. 
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6.9. Discussion 
The results from this study provide new prospective evidence for the prevalence and natural 
history of bursae within the forefoot in a large cross sectional cohort of patients with RA. 
We have confirmed that MSUS detectable bursae in the study patients with RA were 
significantly associated with patient reported foot impact outcome measures, independent 
of overall disease activity as hypothesized in the previous cross sectional study (Chapter 5, 
page 125). The analyses within this study also provide evidence that foot impairment, 
activity limitation and participation restriction do change over time and that these changes 
may be associated with changes in the presence of MSUS detectable bursae.  
 
Most current evidence for the manifestations of RA disease within the foot and ankle is 
attributable to cross-sectional analytical data with small sample sizes. The lack of foot 
specific longitudinal data has consequently been criticised as limiting the understanding of 
the full pathophysiology of RA within the foot, which has led to an inadequate evidence 
base for currently used clinical interventions (Bowen, Burridge and Arden 2005; Farrow, 
Kingsley et al 2005; Clark, Rome et al 2006; van der Leeden, Steultjens et al 2008). A 
recently published study was the first to longitudinally evaluate foot symptoms in a cohort 
of newly diagnosed patients with RA over a period of eight years (van der Leeden, 
Steultjens et al 2008). From a large sample of patients (N=848) forefoot involvement in 
patients with RA was emphasized as being important, with an increase in prevalence of 
forefoot erosion associated with RA disease progression (van der Leeden, Steultjens et al 
2008). 
 
Within this study results at twelve months were consistent with those at baseline. MSUS 
detectable bursae remained a significant and independent factor (of disease activity) in the 
contribution to foot impairment, activity limitation and participation restriction. Cross 
sectional findings showed that total numbers of MSUS detectable bursae were significantly 
correlated with impact of RA disease on the foot for both the impairment and the activity 
limitation and participation restriction subscales of the LFIS. If the baseline data presented 
in Chapter five (page 125) is compared, then some differences between baseline and twelve 
months existed where duration of RA, ESR, disease severity and left MTP joint subluxation 
were correlated with MSUS detectable bursae at baseline but not twelve months. However, 
when the variables were compared as a cohort, the data was largely consistent, with LFISIF 
and LFISAP being correlated with MSUS detectable bursae at both time points.   203
 
The intermetatarsal space 4/5 remained the most common site for MSUS detectable bursae 
and there were no statistically significant differences in mean numbers of MSUS detectable 
bursae per individual and mean LFISIF and LFISAP scores between baseline and twelve 
months. There were no significant differences either in the means of clinical characteristics 
or demographic variables between baseline and twelve months assessments but the changes 
in all variables appeared to be parallel exhibiting a wide variance that were normally 
distributed. This suggests that analysing means at baseline and twelve months may have 
masked the raw person specific changes observed in the variables or may have been due to 
normal fluctuations that may occur in clinical variables over time, described by Bowling 
(2002).  
 
To our knowledge, this is the first study that has investigated forefoot bursae in RA 
detected by ultrasound over a period of time. When the data was grouped according to 
person specific numbers of MSUS detectable bursae, an increase in the number of MSUS 
detectable bursae was observed in 31 (25.8%) participants, whilst in 28 (23.3%) 
participants MSUS detectable bursae decreased and in 61 (50.8%) participants the number 
of MSUS detectable bursae remained the same after twelve months. These findings imply 
that MSUS detectable bursae in the forefeet do change over time. Interestingly, this was 
true of all the other predictor variables consistent with the well documented variability of 
RA disease over time (Boers, van Riel et al 1995; Fortin, Stucki and Katz 1995; Hulsmans, 
Jacobs et al 2000; Singh, Solomon et al 2006).  
 
This highlights the use of longitudinal cohort data providing better statistical power against 
cross sectional data studied at different time points. van der Hejde, Landewe et al (2008) 
highlight that longitudinal data utilizes all available data within a prospectively followed 
cohort that allows adjustment for misleading intra-patient correlation. This is confirmed in 
longitudinal studies that have demonstrated that radiographic damage and radiographic 
progression of the hands and feet independently contribute to changes in physical function 
(Welsing, van Gestel et al 2001; Ødegard, Landewe et al 2006; van der Heijde, Landewe et 
al 2008).  
 
Further evidence from this study, of the association between MSUS detectable bursae and 
patient reported foot impact, was provided when raw change values between baseline and   204
twelve months were analysed. There was a significant positive correlation between the 
changes in MSUS detectable bursae, with changes in both subscales of the LFIS but no 
significant associations with changes in disease activity variables (ESR, VAS and DAS-
28). After adjusting for age and changes in disease activity the changes in MSUS detectable 
bursae remained an independent factor associated with patient reported foot impact. 
Although no previous study has examined forefoot bursae in RA in a longitudinal cohort, 
other investigators have found that foot related impairment and disability assessed by the 
LFIS is common amongst RA patients and independent of disease duration and global 
disease activity (Turner, Helliwell et al 2008). In that study, foot status was measured by 
structural deformity and biomechanical foot function and no account was taken of 
identification of pathology by imaging techniques (Turner, Helliwell et al 2008). This 
emphasizes the importance of studying the forefoot separately to general measures of 
disease activity. 
 
The data from this study therefore provides reasonable longitudinal cohort evidence to 
support previous propositions from small sample cross sectional data of the relationship 
between MSUS detectable bursae and RA foot related symptoms (Koski 1998). Changes in 
patient reported foot impact appear to be predicted fairly well by the changes in the number 
of MSUS bursae over a twelve month period. However, analyses of regression to the mean 
showed that some of the variance in LFISAP scores may be due to natural fluctuation in 
activity participation limitation over time. It is also possible that the smaller sample size of 
the returnee participants may not have enough statistical power, a common problem in 
longitudinal studies (Bowling 2002) so these findings should be interpreted with caution to 
avoid the possibility of rejection of a true null hypothesis. 
 
In investigating predictors of change in the presence of MSUS detectable bursae over time, 
findings indicated that those who had an increase in MSUS detectable bursae tended to 
have shorter disease duration with deterioration in foot impact scores. Conversely, they 
were more likely to experience a significant improvement in ESR and CRP but had a 
significant reduction in podiatric treatment and were significantly less likely to be under the 
regular of care of a podiatrist. This implies that deterioration in foot status would not be 
detected by the usual clinical methods and that the forefoot requires additional attention in 
RA patients. 
 
The scenario of increases in MSUS detectable bursae in those with early disease implies   205
that bursae are not related to disease progression. From the close relationship between 
MSUS detectable bursae and patient reported foot impact, independent of disease activity, 
we can hypothesize that mechanical trauma to the forefoot region due to higher levels of 
activity or altered foot mechanics may be key to the increase in numbers of MSUS 
detectable bursae for those with early disease. Some investigators have demonstrated 
correlations of MTP joint deformity in patients with RA with peak pressure and pressure 
time integrals for the first and fourth MTP joints (van der Leeden, Steultjens et al 2006). 
Others have also found that foot pain, swollen foot joint count and walking speed were 
independent predictors of foot related impairment and disability assessed by the LFIS 
(Turner, Helliwell et al 2008). No investigators have, to date, incorporated the use of 
MSUS imaging techniques to identify foot pathology with the use of biomechanical and 
clinical structural assessment techniques in understanding the burden of foot disease in 
patients who have RA and this area of research warrants further investigation. 
 
In explaining synovitis within joints, Brown, Conaghan et al (2008) highlight that grey 
scale MSUS primarily detects hypertrophy of the synovium but does not differentiate 
between inflammatory and non inflammatory synovitis. They also report that synovium 
may become chronically thickened and less reversible in established disease (Brown, 
Conaghan et al 2008). The same pathophysiology also may apply to anatomical bursae in 
RA (refer back to Chapter two, section 2.2. page 18) although in this study due to 
limitations of the MSUS technique we were not able to distinguish between active 
hypertrophied synovium of bursae and non active synovium. Furthermore, no techniques 
have yet been developed to detect differences between mechanically related inflamed 
hypertrophied synovium and active inflammatory synovium related to disease activity in 
RA within the foot. For future studies the use of power Doppler MSUS, Gadolinium 
enhanced MRI and/or biopsy for histological analysis of forefoot bursae would be needed 
to achieve this. 
 
A final point of interest was that the longitudinal data from the preliminary study (Chapter 
four, section 4.8.6, page 114) indicated that there was a trend towards reduction in the 
presence of MSUS detectable MTP joint synovitis and MSUS detectable bursae within the 
forefoot after twelve weeks of anti-TNF-α therapy, although the sample was small and the 
perceived reduction was not statistically significant. Others have also demonstrated 
significant reduction in synovitis of MCP (metacarpo-phalangeal) joints in patients with   206
RA starting anti-TNF-α therapy using MSUS (Hau, Kneitz et al 2002; Taylor, Steuer et al 
2006; Iagnocco, Naredo and Tripodo 2008). Within this longitudinal study statistically 
significant differences were noted in the use of DMARDs and anti-TNF-α therapy by the 
RA participants between baseline and twelve months, however when the group data was 
analysed according to changes in MSUS detectable bursae, no significant differences 
between the groups were noted. This discrepancy can probably be explained by the lack of 
documentation over when participants started or stopped taking DMARDs and/or anti-
TNF-α therapy.  
 
 
6.10. Strengths and potential limitations 
This study has several strengths and a number of limitations.  Its strengths include: 
•  a longitudinal cohort follow up design  
•  the large sample size 
•  a pragmatic clinical study representative of secondary care in the UK  
•  the use of patient reported clinical outcomes including disease activity and foot 
specific measures 
 
This study has several potential limitations, firstly, the lack of availability of Power 
Doppler within this study to determine activity of synovium in bursae and therefore bursitis 
has already been highlighted in Chapter four (section 4.11, Page 121). As has also already 
been highlighted and discussed within Chapter five (section 5.11, page 162) the lack of MR 
imaging, biopsy and histology and / or fresh cadaver dissection to validate the presence of 
bursae within the forefoot limits the ability to accurately differentiate MSUS detectable 
bursae from MTP joint synovitis or tenosynovitis.  
 
Secondly, the use of two time points spanning a one year period, although providing useful 
information, may have missed much of the variance and change in variables associated with 
fluctuations in disease state of RA. More time points would have allowed variations to be 
monitored and sensitivity of MSUS imaging to change in forefoot bursae to be measured by 
calculating the intra-observer variation and the smallest detectable difference between 
repeated measures (Østergaard and Wiell 2004; Ejberjerg, Vestergaard et al 2005) 
 
Thirdly, a large cohort of patients (N=120 from a baseline of N=149) with RA was   207
investigated longitudinally over one year. The sample at the twelve month visit was 
representative of the original cohort as analyses showed that there were no significant 
differences between returnees and non returnees. However, although the response rate of 
80.5% is generally considered to be acceptable within clinical studies (Bowling 2002) the 
reduction in returnees within this study may have affected statistical power (refer to sample 
size power calculations in Chapter three, section 3.7.1, page 69).  Weak correlations may be 
due to sample size and lack of statistical power, particularly when the MSUS detectable 
bursae sub groups of the cohort were analysed. Bowling (2002) regards this as a common 
problem in longitudinal clinical cohort studies where the return sample is usually lower 
than the initial sample recruited according to power calculations.  The reduced power thus 
limits the inferences that can be made from the statistical analyses regarding the 
associations between MSUS detectable bursae and patient reported foot impact outcome 
measures. 
 
Fourthly, there was evidence of a significant decrease in the presence of MTP joint 
subluxation noted between baseline and twelve months that could not be biologically 
explained. Our study was conducted in accordance with daily clinical practice and the 
recognition of measurement error and recall bias cannot be discounted.  The assessment of 
MTP joint subluxation within the study was by subjective observation and, although 
conducted by an experienced podiatrist, there were no other reliability checks.  
 
To our knowledge there are no reliable clinical methods for assessing level of deformity at 
the MTP joints other than by radiographic scoring of MTP joint damage (van der Leeden, 
Steultjens et al 2006). The structural index score is a composite measure of seven items that 
includes the grading of MTP joint subluxation severity from 0 – 12 however there is still 
reliance on the clinician’s subjective assessment (Platto, O’Connell et al 1991).  
 
Clinical judgement of foot deformity is subjective and susceptible to poor reliability 
(Turner, Helliwell and Woodburn 2007; Turner, Helliwell et al 2008) and makes defining a 
complete foot status a limiting factor. Future investigations of the foot in RA are proposed 
with the use of established measurements to determine foot status. For example, the Foot 
Posture Index that has been well validated to determine foot type (Redmond, Crosibie, 
Ouvrier e et al 2006; Redmond, Crane and Menz 2008), plantar foot pressure measurement 
(van der Leeden, Steultjens et al 2006) and three dimensional kinematic analysis of gait 
(Turner, Helliwell et al 2008).    208
 
Finally, as also mentioned in Chapter five (section 5.11, page 162) patients treated in 
primary care only who may have less severe RA disease were not included. 
 
 
6.11. Conclusion 
The findings provide new evidence that MSUS detectable bursae within the forefeet of 
participants with RA do change over time, increasing more in those individuals with early 
disease and those who are also less likely to be under the routine care of a podiatrist. The 
findings at twelve months indicate that the results from the baseline study of the association 
between MSUS detectable bursae within the forefeet and patients’ perception of their foot 
impairment and disability that was independent of overall RA disease activity were real. 
However, further study is required to confirm whether the association is also independent 
of MTP joint synovitis and plantar forefoot tenosynovitis. 
 
The data therefore supports the baseline study recommendations that clinicians should 
consider giving additional attention to the forefoot in RA patients. The findings also 
support the baseline recommendations for the use of specific techniques, such as MSUS, to 
determine a more precise evaluation of the effects of RA disease within the foot and how 
these change over time. 
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7.0 Chapter Seven: Discussion  
The primary aim of this doctoral thesis was to develop a reliable MSUS imaging technique 
to be performed by a podiatrist to assess the prevalence and natural history of bursae 
occurring within the forefeet of patients in secondary care who were being managed for 
RA. In doing so, it was anticipated that the MSUS technique and new knowledge of the 
prevalence of forefoot bursae may inform a more precise diagnosis of metatarsalgia in this 
patient group. It follows that this could potentially facilitate more timely and targeted 
treatment approaches for metatarsalgia. 
 
Chapters four, five and six have therefore outlined and discussed the results of the 
reliability of the proposed MSUS technique and subsequent prospective investigation of 
forefoot bursae in patients with RA using MSUS performed by a podiatrist. Chapter seven 
draws together the overarching results and discusses the implications for clinical practice. 
Some time is given to debating the reliability issues surrounding this doctoral study and the 
challenges of conducting clinical research in the clinical setting.  
 
7.1. Musculoskeletal ultrasound technique performed by a podiatrist 
Within this doctoral thesis MSUS has been identified as a suitable tool to locate bursae 
within the forefoot in RA patients and, following appropriate training and mentorship from 
radiologists, the technique was shown to be reliable when performed by a podiatrist. The 
null hypothesis (H0) stated in Chapter three (section 3.2, page 66) that ‘a podiatrist 
performing MSUS is not reliable in the detection of forefoot bursae in patients with RA’ 
can be rejected and the alternative hypothesis (H1) that ‘a podiatrist performing MSUS is 
reliable in the detection of forefoot bursae in patients with RA’ can therefore be accepted.  
 
This may be controversial amongst radiologists, but in the current climate of health policy, 
Lord Darzi’s intention to “establish a health service that is responsive to patients and local 
communities whatever the circumstances” reasons that traditional distinctions between 
professional roles will change (DOH 2008). By 2020 there will be 20 million people living 
with long term conditions who at present account for 70% of acute and primary care 
spending, 58% of GP appointments and 77% of inpatient bed stays (DOH 2007). A 
flexible, multi-skilled health workforce will therefore be required. 
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A number of changes have occurred over the past decade in the provision of health care 
delivery. Most of the changes are the result of Government policy including ‘The NHS 
Plan’ (DOH 2000), ‘Agenda for Change’ (DOH 1999) and ‘Modernising Regulation’ 
(DOH 2000), others have been brought about by the changing role of the allied health 
professional within health care teams. The NHS Plan (DOH 2000) recognised that delivery 
of modern health care would require crossing of traditional professional boundaries and 
extending professional practice. 
 
The scope of practice for podiatrists has constantly been in flux (Potter 2007; Graham 
2007; Bowen 2008; Vernon 2008). Most significant of these changes was the development 
of local anaesthesia in the late 1960s leading to the development of nail surgery techniques 
and the evolution of podiatric surgery (Borthwick 2001). During the 1980s and early 1990s 
a graduate profession was established along with the transition from a technical skills 
approach to learning to one of problem based learning and critical thinking (Camp 1996). A 
new type of graduate who was challenged to question and analyse the traditional podiatric 
treatment methods thus emerged. Many of these graduates have continued to grow and 
create an evidence base for the profession as they have progressed further with Masters 
degrees, doctorates of philosophy and a growing number of consultant and professorial 
posts. 
 
The extended roles of podiatrist in orthopaedics and rheumatology may include the 
administration of local steroid injections. The ability of podiatrists with this acquired new 
skill to use MSUS in guiding needle placement for the management of conditions such as 
morton’s neuroma, achilles tendonitis and plantar fasciitis, would undoubtedly improve the 
effectiveness of this therapy (Koski 2000).  
 
Results from the reliability study indicate that there is evidence that MSUS performed by a 
podiatrist is effective in the diagnosis of musculoskeletal pathology occurring within the 
forefoot. We confirmed good inter-observer agreement between a podiatrist and radiologist 
on MSUS assessment of the forefoot, particularly for MTP joint erosions and plantar 
forefoot bursae in patients with RA (Bowen, Dewbury et al 2008).  
 
Although we reported good sensitivity for the podiatrist detecting MTP joint synovitis, 
specificity was low (Bowen, Dewbury et al 2008). Difficulties were encountered in using   211
MSUS to detect MTP joint synovitis from the plantar aspect of the foot where deformities 
such as MTP joint subluxation were present, which have also been reported by others 
(radiologists and rheumatologists) experienced in MSUS imaging (Szkudlarek, Court-
Payen et al 2003; D'Agostino, Maillefert et al 2004; Scheel, Schmidt et al 2005; Naredo, 
Moller et al 2006).  
 
It was also clear from the conceptual stage that, in the preliminary study, due to forefoot 
structural deformity in some participants, tenosynovitis was too difficult to assess using the 
proposed Diasus MSUS machine. As well as MTP joint synovitis, the appearance of flexor 
tenosynovitis on MSUS is a key differential diagnosis for metatarsalgia (Koski 1995). A 
dorsal approach to the MSUS scan protocol may have been preferable however those who 
advocate this technique did not state whether deformity and subluxation of the MTP joints 
was excluded (D'Agostino, Maillefert et al 2004).  
 
At the time of this study there was no definition for detecting clinically apparent plantar 
forefoot bursae. Lack of standardization and variation in scanning technique amongst 
sonographers has been deliberated as contributing to disagreement between experts (Scheel, 
Schmidt et al 2005).We therefore decided to use a plantar approach to determine the 
prevalence of bursae within the forefoot.  
 
Koski (1998) also utilised a plantar approach to detect intermetatarsal bursae 
sonographically and clinically by palpation, however the reason for this and the limitations 
were not discussed in his paper. Our justification for using a plantar approach was based on 
the work by Koski (1998) and on previous clinical observations of pain and palpable 
swollen bursae occurring within the plantar forefoot area. Cadaver studies investigating 
forefoot bursae had been conducted via a plantar approach (Chauveaux, Le Huec and Midy 
1987; Studler et al 2008) as had MSUS and surgical studies of Morton’s neuroma (Irwin, 
Konstantoulakis et al 2000; Jones, Bygrave et al 1999).  
 
The preliminary study within this doctoral thesis confirmed that one podiatrist can utilize 
MSUS techniques to reliably detect forefoot pathology that is clinically under detected but 
highly prevalent on MSUS in patients who have RA. It is evident that further work on 
establishing reliability of protocols for MSUS assessment of the forefoot is required and to 
determine if others can also reliably use these techniques.   212
 
Before this new skill may be encompassed within extended scope podiatric practice a 
number of issues must be considered. These include, but are not restricted to: 
  The essential of having expert anatomical knowledge of the foot and ankle.  
  The reported steep learning curve in the interpretation of the on-screen grey scale 
images  
  The selection of equipment. 
  The resolution of medico-legal issues and professional indemnity 
 
7.2. The prevalence and natural history of MSUS detectable bursae 
In 2008, the current health secretary for the UK, declared the intention to focus on 
preventative health shifting the focus for the health professions, including podiatry, to 
prevent health problems rather than just responding to crises (DOH 2008). The current 
evidence base for prevention of foot health problems associated with RA is inadequate due 
to a previous lack of longitudinal cohort data. Results from a recently published eight year 
cohort study (N=848) indicate that forefoot involvement, detected radiologically and 
clinically in patients with RA is important in early RA disease (van der Leeden, Steultjens 
et al 2008). In our own one year prospective longitudinal cohort study, we have specifically 
identified a high prevalence of bursae detectable by MSUS that are not detectable by 
clinical assessment or prevalent in normal control participants. 
 
The null hypothesis (H0) stated in Chapter three (section 3.2, page 66) that ‘MSUS detectable 
bursae within the forefoot are not a prevalent factor in patients with RA’ can be rejected and 
the alternative hypothesis (H1) that ‘MSUS detectable bursae within the forefoot are a 
prevalent factor in patients with RA’ can therefore be accepted.  
 
As techniques in MSUS have advanced, knowledge of the effect of RA on the hand and 
foot joints has improved and consequently approaches to treatment of synovitis have 
improved (Hau, Kneitz et al 2002; Brown, Quinn et al 2006; Taylor, Steuer et al 2006).  
Traditionally, radiography has been the method through which the progression of RA 
disease has been assessed by demonstrating cartilage loss or bony erosion (Bushberg, 
Seibert et al 2002). In clinical trials the Sharp/van der Heijde score (van der Heijde 1996) 
and Larsen/Scott index (Scott, Houssien 1995) remain the most widely used methods of   213
scoring systems of radiographs that provide objective measures for investigators to 
determine RA disease progression. Both scoring systems are limited by the ability of x-ray 
imaging to detect actual disease activity. Radiography is further limited by the inability of 
x-rays to detect soft tissue changes (Bushberg, Seibert et al 2002).  
 
Similarly, clinical assessment techniques are proven relatively insensitive in assessment of 
RA disease within the foot, as clinically under reported manifestations of RA within the 
foot appear to be common a common finding in imaging studies (Koski 1998; Brown, 
Quinn et al 2006; Wakefield, Freeston et al 2008). Using MSUS, changes in MTP joint 
synovitis have been detected in patients who have RA but had been diagnosed clinically as 
in remission (Brown, Conaghan et al 2008). Data from our studies concur with these 
findings, suggesting that the current measures used to assess forefoot bursae, which largely 
rely on clinical assessment, are not sufficiently sensitive to exclude ongoing changes in 
forefoot bursae, especially in those with earlier RA disease.  
 
Data from this doctoral thesis therefore contributes to the growing body of evidence that 
modern imaging modalities such as MSUS appear to be superior in detection of temporal 
changes in the manifestations of RA than radiography and clinical assessment (Backhaus, 
Burmester et al 2002; Hau, Kneitz et al 2002; Ejbjerg, Vestergaard et al 2005; Naredo, 
Collado et al 2007; Iagnocco, Naredo and Tripodo 2008; Brown, Conaghan et al 2008). 
Furthermore, our findings confirm suggestions from others that bursae in the forefoot are 
poorly documented, may be difficult to detect clinically and may be the cause of foot 
symptoms (Olivieri, Scarano et al 2004).  
 
Loss of function of the intermetatarsal spaces, due to symptomatic bursae within RA, has 
received little attention in the conceptual thoughts of mechanical dysfunction of the foot. 
The presence of adventitious bursae within the plantar forefoot area has been even less well 
considered. Foot deformities and abnormally concentrated forefoot pressures are usually 
reported as being related to the combined effects of repeated episodes of synovitis that 
weakens the joints and eventually destroys of the integrity of the feet (Woodburn, Helliwell 
et al. 2002; Turner, Helliwell et al 2006).  This is probably due to the lack of suitable 
clinical tools that have been available to identify bursae within the forefoot. Mechanically, 
the role of the intermetatarsal bursae is said to be as shock absorbers that facilitate the 
metatarsal heads to glide in a dorso-plantarly direction, enabling the forefoot to adapt to   214
irregularities of the ground surfaces, particularly during walking or running (Bossley and 
Cairney 1980; Awerbuch, Shephard et al 1982; Claustre, Bonnel et al 1983; Chauveaux, Le 
Huec et al 1987; Theumann, Pfirrmann et al 2001). The association of MSUS detectable 
bursae with patient reported foot impact outcome measures that we detected may therefore 
be related to the destruction of the normal shock absorbency mechanisms of the forefoot 
and subsequent malfunction of the forefoot during walking. 
 
Whilst we did demonstrate that the association between MSUS detectable bursae and 
patient reported foot impact outcome measures was independent of RA disease activity and 
was consistent at both time points there are a number of factors that need to be considered. 
The associations, although significant resulted in weak correlation coefficients as well as 
low r
2 values within the regression models indicating that only a small percentage of the 
model could be explained by MSUS detectable bursae. Analysis of regression to the mean 
also suggested that the association of change between MSUS detectable bursae and activity 
participation limitation could be attributed to the natural variation or random fluctuation in 
the impact of RA disease on the foot over time. However, the confidence intervals for 
MSUS detectable bursae within the LFISAP model did only just cross zero and it might be 
that the sample size of returnee participants was too small to determine the association.  
 
The null hypothesis (H0) stated in Chapter three (section 3.2, page 66) that ‘MSUS 
detectable bursae within the forefoot are not associated with patient reported foot impact 
outcome measures in patients with RA’ cannot therefore be completely rejected.  
It may be that the association between MSUS detectable bursae and patient reported foot 
impact outcome measures were independent of RA disease activity but not independent of 
MTP joint synovitis and / or flexor tenosynovitis. It may also be that the power of the 
sample was to low to confirm the associations. 
 
We recommend that future studies of foot related symptoms in RA should therefore include 
identification of forefoot bursae as well as MTP joint synovitis by MSUS when defining 
extraneous variables and developing strategies to control for confounding factors. 
Furthermore, refinement of the technique to differentiate forefoot bursae from MTP joint 
synovitis and tenosynovitis within the forefoot is also essential and MSUS with power 
Doppler and / or MRI would be appropriate tools for this.  
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With insights gained from assessment of the forefoot using MSUS there is therefore 
potential for better targeting of treatment and preventative foot health. This would allow 
more targeted therapeutic approaches such as corticosteroid injection. Bursae within other 
anatomical areas responds well to injection (Koski 2000, Grassi, Filipucci et al 2001) and 
our own clinical experiences to date have indicated that MSUS guided steroid injection for 
swollen forefoot bursae is beneficial (Figure 46).  
 
Within the remit of the study, identification of symptomatic forefoot bursae by MSUS has 
also informed treatment decisions. Other treatment methods that participants have been 
referred for have included intramuscular Depomedrone injection and/or dose adjustment of 
DMARDs for better control, where there has been a high prevalence of symptomatic bursae 
and other joint involvement. At the current time, treatment approaches to symptomatic 
MSUS detectable forefoot bursae remain anecdotal and have yet to be rigorously 
investigated. 
 
 
Figure 46. MSUS images of the right plantar forefoot area of a study participant with RA 
demonstrating an enlarged bursa between the third and fourth metatarsal heads (A) and the 
same bursa immediately after injection with hydrocortisone (B). 
 
A: The patient complained of a painful right 
forefoot that was limiting her activity. 
 
B: the right forefoot immediately after 
injection of hydrocortisone 
 
NB. At a one month check, symptoms had resolved and the patient was able to return to 
their regular activities. 
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A final point of interest was that the longitudinal data from the preliminary study (Chapter 
four, section 4.8.6, page 144) indicated that there was a trend towards reduction in the 
presence of MSUS detectable MTP joint synovitis and MSUS detectable bursae within the 
forefoot after twelve weeks of anti-TNF-α therapy, although the sample was small and the 
perceived reduction was not statistically significant. However, significant changes were 
observed in ESR, CRP, DAS-28 and MFPDQ. These findings suggested that although the 
treatment switches off the disease process, twelve weeks may not have been long enough 
for MSUS detectable synovitis and bursal hypertrophy within the foot to regress.  
 
Others have also demonstrated significant reduction in synovitis of MCP joints in patients 
with RA starting anti-TNF-α therapy using MSUS (Hau, Kneitz et al 2002; Taylor, Steuer 
et al 2006; Iagnocco, Naredo and Tripodo 2008). Within this doctoral thesis longitudinal 
study, statistically significant differences were noted in the use of DMARDs and anti-TNF-
α therapy by the RA participants between baseline and twelve months, however when the 
group data was analysed according to changes in MSUS detectable bursae no significant 
differences between the groups were noted. This discrepancy can probably be explained by 
the lack of documentation over when participants started or stopped taking DMARDs 
and/or anti-TNF-α therapy. A key consideration in imaging studies should be whether with 
more sensitive tools to detect synovitis ‘is more pathology observed?’ or ‘is pathology 
observed in more detail?’  
 
There is clearly evidence to support the use of MSUS imaging of the foot as an essential 
component in the refinement of diagnosis and the development and implementation of 
effective care pathways for the assessment and treatment of foot and ankle pain and 
disability associated with RA.  The further development and use of MSUS assessment of 
the foot and ankle as a discrete field in clinical practice could be beneficial to patients with 
RA as well as conferring lower costs in service provision. 
 
7.3. Critique of research methodologies 
The studies that form this doctoral thesis have several strengths and a number of potential 
limitations, most of which have been highlighted previously (Chapter four, section 4.11, 
page 121, Chapter five, section 5.11, page 162 and Chapter six, section 6.10, page 206). 
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Key strengths include: 
  Preliminary reliability testing of the MSUS technique against a radiologist 
  the large sample sizes at the baseline and twelve month studies with an 80% 
response rate and the investigation of a comparator control at baseline  
  the study sample was representative of secondary care in the UK and the study was 
conducted in accordance with general clinical practice to facilitate transference of 
results for patient benefit.  
  the use of patient reported outcomes including disease activity and a measure of 
foot impact that had been developed and classified according to the WHO ICF 
(World Health Organisation International Classification of Functioning, Disability 
and Health) classification of impairment. 
 
 
A number of potential limitations within the studies that form the doctoral thesis should be 
acknowledged and these are grouped according to the following themes:- 
 
  Participant samples 
  MSUS imaging technique 
  MSUS measurement of forefoot bursae  
  Measurement of clinical activity and foot structure 
  Measurement of patient related foot disability using LFIS  
  Assessment of foot mechanics 
 
7.3.1. Participant samples 
For the cross sectional data in the main study there was a 45.8% none response rate 
(Chapter five, section 5.8.1, page 135) from the initial recruitment such that only 54.2% of 
the population were investigated. If non-responders were people without foot pain or foot 
symptoms this could over inflate our estimates of foot symptoms, foot disability and MSUS 
detectable bursae. We did perform a non-response analysis and found no significant 
differences in parameters of age, gender, seropositivity and DMARDs between responders 
and none responders, suggesting this was not a major issue, although we cannot be certain 
of this. However, as participants may have been selected on the basis of foot symptoms and 
not MSUS detectable bursae, none differential bias effects are not likely to have affected   218
results.  
 
We recruited only patients who were treated in secondary care clinics in the UK. Patients 
who were treated in primary care only, who may have less severe RA disease, were not 
included within the studies and this may limit the generalizibility of the results. Other 
authors have commented on the lack of UK studies of foot disease impact in RA based in 
primary care, but at the same time acknowledged that within the UK, most patients with 
RA currently receive their foot treatment within secondary care setting (Turner, Helliwell 
and Woodburn 2007). Studies within the secondary care environment are currently 
therefore more likely to be representative of current foot care for patients who have RA in 
the UK.  
 
In all studies the population investigated was homogenous for RA which was required to be 
diagnosed according to the ACR criteria (Arnett, Edworthy et al 1988) and the clear 
eligibility criteria (section 4.4.2. page 97, section 5.4.2.1, page 128, section 6.4.2.1 page 166) 
ensured that members of both samples were representative of the wide spectrum of adults 
who have RA. However, within the samples for studies two and three there was a wide 
variation in disease state and manifestations of disease on the foot.  
 
To our knowledge, there was no other existing longitudinal data that had investigated the 
prevalence of forefoot bursae in RA and it had received little attention in the literature (see 
Section 2.2, Chapter 2, page 18). The inclusion of participants with different severities of RA 
disease was therefore necessary within studies two and three. Interpretation of results, 
however, have to be noted with caution as, it is possible that, splitting the participants into 
groups for the analyses of associations of MSUS detectable forefoot bursae may have reduced 
the statistical power.  
 
Furthermore, with a mean disease duration of 12.3 years, it is possible that foot problems 
within this group may have been high and thus the reported prevalence of forefoot bursae 
within this patient group may have been over inflated. Future work regarding other 
populations, such as early RA and non-inflammatory arthritis would therefore be interesting.  
 
Within the baseline study (study two), the healthy control participants were not age 
matched with the RA participants due to difficulties in recruitment of the control sample   219
from a population of convenience. This may have introduced bias in the comparative 
analyses of explanatory variables; however we did conduct extra analyses on the sample 
data that showed that this did not appear to significantly alter the findings. 
 
7.3.2. Musculoskeletal imaging technique 
The presence of bursae within the forefoot was not validated by any other ‘gold standard’ 
imaging technique, such as MRI. As well as intermetatarsal bursae, and adventitious 
bursae, soft tissue swelling at the level of the MTP joints can be related to MTP joint 
synovitis or tenosynovitis that could be better differentiated using MRI. Most previous 
studies have not used MRI either, due to its limited availability (Szkudlarek, Court-Payen et 
al 2003; D'Agostino, Maillefert et al 2004; Naredo, Moller et al 2006). The OMERACT 
MSUS special interest group highlighted limited data in terms of comparisons of MRI with 
MSUS (Wakefield, Balint et al 2005), however within the preliminary study (Chapter four, 
page 96) we attempted to address this issue by demonstrating reliability through testing of 
the podiatrist’s MSUS technique against an expert radiologist using a high level MSUS 
machine and the results of this work have since been published (Bowen, Dewbury et al 
2008). 
 
It could be that bursae detectable by MSUS in the studies presented within this doctoral 
thesis have hypertrophied synovium that may not be inflammatory active. Gadolinium 
enhanced MRI would provide clearer information relating to both synovial thickness and 
increased blood flow enabling better definition of bursitis (Gaffney, Cookson et al 1995). 
More recently power Doppler mode is advocated to determine whether synovium is 
actively inflamed, allowing a more precise definition of active synovitis (Brown, Quinn et 
al 2006; Balint, Mandl and Kane 2008).  
 
Previously MSUS detectable bursae in the forefoot have been referred to as bursitis (Koski 
1998) and the technique for the use of power Doppler in assessment of changes in synovial 
perfusion has been a development subsequent to the commencement of this doctoral thesis. 
Whilst the MSUS machine utilised by the radiologists (KD and MS) in the validation study 
did have power Doppler mode, the MSUS machine utilised by the podiatrist (CB) did not. 
To avoid complication in the use of terminology, following analysis of the results from the 
technique validation, we decided to refrain from using the term bursitis in the baseline and 
twelve month studies, preferring the term ‘MSUS detectable bursae’ instead. For future   220
studies, a MSUS machine with power Doppler is recommended as a prerequisite. 
 
A further potential limitation in the MSUS imaging technique is that we could not 
accurately measure MTP joint synovitis and erosion or tenosynovitis. However, this was 
not the research question which was focused on whether forefoot bursae were common and 
if so, whether they were associated with patient reported foot impact outcome measures. 
We have satisfactorily demonstrated that forefoot bursae are common in patients with RA 
and that this may be associated with patient reported foot impact outcome measures 
independent of generalized disease measures (DAS- 28, CRP and ESR). 
 
The lack of data on MTP joint synovitis and erosion or tenosynovitis limits our ability to 
determine whether the association between MSUS detectable forefoot bursae and patient 
reported foot impact outcome measures is independent of these potential collinear / 
confounding variables. To answer this question one would almost certainly have to perform 
MRI of the feet, probably with gadolinium enhancement, however this was out-with the 
scope of the thesis. We do hope to follow this up as part of a post-doctoral research plan. 
 
7.3.3. Musculoskeletal ultrasound measurement of forefoot bursae 
During the reliability and preliminary studies, it became evident that measurement of the 
size of MSUS detectable bursae was unachievable with the MSUS equipment utilised. 
Measurement was difficult due to the three dimensional nature of bursae and the two 
dimensional output of MSUS. Dichotomising the data into absence or presence of 
individual bursae may have limited the ability to detect true change between the baseline 
and twelve month visits. There may have been bursae that either reduced or increased in 
size and this effect will have been missed in our analyses. Actual measurement of forefoot 
structures detected by MSUS will require more attention within future work and new 
technology such as 3D and 4D MSUS or MRI would be more appropriate to accomplish 
this. In addition, determination of the smallest detectable difference that was clinically 
meaningful would be useful to enhance clinical management decisions. 
 
Limitations relating to the analysis of presence or absence of MSUS detectable bursae 
during the validation of the technique should also be noted.  Using MSUS as an outcome 
measure for research is different to using MSUS for clinical diagnosis. Kappa agreements   221
are based on dichotomous categorical variables (Petrie and Sabin 2005) and so analysis of 
agreements for bursae were reduced to either presence or absence of bursae in either foot. 
Matching actual locations of bursae would have provided more credibility for reliability of 
the technique, although this did prove difficult in the preliminary study (Chapter four, page 
96) due to the three dimensional nature of bursae and the two dimensional output of MSUS. 
However, by not classifying MSUS detectable bursae according to exact location this could 
have biased results towards higher levels of agreement between the podiatrist and 
radiologist. We attempted to attenuate this by conducting the consensus meeting where 
exact anatomical regions were tested for agreement. 
 
Furthermore, with a number of confounding variables that potentially could distort the 
effect of the association between MSUS detectable bursae and patient reported foot impact 
scores, regression modelling techniques were used to discern meaning. Analysis of 
correlations and regression models revealed statistically significant associations between 
MSUS detectable bursae and patient reported foot disability scores, however, the 
correlation coefficients were not very strong. These correlations were probably limited by 
the fact that count data for MSUS detectable bursae was used as continuous data. The range 
of MSUS detectable bursae was from 0 -11 which, on the one hand is a continuous scale, 
but due to the small size of the scale may have impacted on the statistical power of the test. 
 
7.3.4. Measurement of clinical activity and foot structure 
Within the preliminary (reliability) study clinical activity was measured via the DAS-28 
score that was performed independently by a trained joint assessor. Clinical foot status was 
determined by the podiatrist (CB) so that the radiologists (KD and MS) were blinded to the 
results of the foot assessment. However, this meant that the ultrasound measurements 
performed by the podiatrist (CB) were not performed independently to the clinical foot 
assessments. The same approach was used within the main studies (Chapter five, page 125 
and Chapter six, page 164), that is the clinical activity and clinical foot assessments were 
performed by the same individual (CB) and not determined by an independent assessor. For 
the second and third studies it was not feasible to have numerous independent investigators 
and as such investigator bias and recall bias therefore need to be taken account when 
interpreting the data. Investigator bias is common in social research on human beings 
(Bowling 2002) and we attempted to reduce the effect of this bias by maintaining a   222
systematic order to the data collection (see study protocol flow charts, Chapter five, page 
133, Chapter six, page 169) and using experienced independent data handlers to double 
enter and clean all the information onto the SPSS data sheet. 
 
In study three, the investigator (CB) was trained in DAS-28 technique and also performed 
these assessments. The fact that there was a change in personnel performing the DAS-28 
obviously had no impact between studies one and two as the data between those studies 
was not used interchangeably. During study three, the DAS-28 assessment was always 
performed before the MSUS foot assessments and it is possible that at a purely 
subconscious level that this may have affected the interpretation of the MSUS images 
leading to a greater reporting of MSUS detectable forefoot bursae. Whilst we cannot fully 
rule this out, the prevalence of MSUS detectable forefoot bursae and the association 
between MSUS detectable forefoot bursae and DAS-28 did not differ significantly between 
studies two and three. This would argue against a major bias. 
 
The effect of investigator bias is related to the results of the clinical foot assessments and 
not LFIS scores. LFIS scores remained blinded to the podiatrist (CB) and therefore it is 
unlikely that the results from the main studies for the associations between LFIS scores and 
MSUS detectable bursae would be affected. It could be that results of the clinical foot 
assessments may have inflated the presence of MSUS detectable bursae. However, this bias 
could be attenuated by the fact that during the validation study the podiatrist (CB) 
underestimated the presence of MSUS detectable bursae compared to the radiologists (KD 
and MS) who used a more sensitive machine. 
 
7.3.5. Measurement of patient reported foot impact using the LFIS  
Results from the regression modeling techniques within the baseline and twelve month 
studies confirmed that the associations between MSUS detectable bursae and patient 
reported foot impact may be independent of overall disease activity. Whilst MSUS 
detectable bursae do explain some of the biological variance in both LFISIF and LFISAP 
scores, these values are probably lower due to measurement error of the MSUS technique 
and of the LFIS. 
 
The LFIS was selected as the primary outcome measure for the prediction of the impact of   223
MSUS detectable bursae on patient related foot disability due to its validation for use in 
detecting change in foot status in patients with RA. At the time of the development of this 
doctoral study, the LFIS was published as a new instrument that had been validated to 
measure the effectiveness of interventions for foot disability in patients who have RA 
(Helliwell, Reay et al 2005). The instrument had, however, not been used in any other 
previous studies and therefore power calculations for the main studies were performed 
using results from the MFPDQ in the preliminary study (Chapter four, page 96).  
 
In considering the use of LFIS for use in a randomised controlled trial, Turner, Helliwell 
and Woodburn (2007) report that a minimally clinically important difference for LFISIF 
would be 3 points (Standard deviation=5), but did not report on LFISAP. They did suggest 
that for a two treatment parallel-design randomised controlled trial of podiatry led foot care 
versus no foot care, that 85 per group would be required to detect a difference between the 
groups of three points based on 90% and 1% significance level (Turner, Helliwell and 
Woodburn 2007). If we apply these calculations to the main studies within this thesis, then 
with a sample of 149 at baseline and 120 at follow up there should be adequate statistical 
power to make inferences about the associations of LFISIF with the predictor variables. 
 
Measurement error may have been introduced, as difficulties were experienced by some 
participants in their interpretation of some of the LFIS statements. Respondents were asked 
to tick the statements that applied best to them at the time of the data collection about their 
feet as either "true" if the statement applied to them or "not true" if it did not.  Some 
participants required clarification of questions and some asked whether they could have 
responses that were sometimes true. Many participants were unsure of how to interpret the 
statement “Please choose the response that applies best to you at the moment”. Therefore 
responses to the statements may have varied between thoughts and feelings during the past 
couple of weeks to that day only.  
 
With the current limited published data that has used LFIS there appears to be no other 
available data on which to compare these participant reported difficulties. The authors of 
the LFIS did use rigorous item response techniques, Rasch analysis, in the validation of the 
LFIS and did report good test-retest results (Helliwell, Reay et al 2005).  The data 
generated within the main studies of this doctoral thesis will therefore inform robust sample 
size calculations for future work.   224
7.3.6. Foot mechanics 
Throughout the development of the studies we chose to focus on assessment of foot 
pathology and foot disability and no account was taken of the mechanical forces of foot 
function during gait. In a systematic review of measurement of foot related measures, van 
der Leeden, Steultjens et al (2008) recommend considering both self report and 
performance based instruments when investigating foot problems associated with RA. In an 
earlier study, van der Leeden, Steultjens et al (2006) demonstrated correlations of 
radiographic MTP joint deformity with peak pressure and pressure time integrals for the 
first and fourth MTP joints and correlations of high forefoot pressures with pain. Others 
have investigated the association between foot disabilities, assessed by both subscales of 
the LFIS, mechanics of function and foot mechanics and recommended that future 
prediction models may be enhanced by imaging based identification of foot pathology 
(Turner, Helliwell et al 2007).  Following results from the studies that form this doctoral 
thesis, the development of a technique to investigate the effect of foot mechanics in the 
relationship between MSUS detectable forefoot bursae in RA and foot disability is 
proposed for future investigations.  
 
Data from both baseline and twelve month visits of our studies showed that there was a 
significant association between MTP joint subluxation and patient related foot disability but 
not MSUS detectable bursae. We also performed further regression models that showed 
MSUS detectable bursae remained independent of the association between MTP joint 
subluxation and patient related foot disability. However, a significant decrease in the 
presence of MTP joint subluxation was noted between baseline and twelve months that 
could not be biologically explained. Our study was conducted in accordance with daily 
clinical practice and the recognition of measurement error and recall bias cannot be 
discounted.  The assessment of MTP joint subluxation within the study was by subjective 
observation and although conducted by an experienced podiatrist there were no other 
reliability checks. To our knowledge there are no reliable clinical methods for assessing 
level of deformity at the MTP joints other than by radiographic scoring of MTP joint 
damage (van der Leeden, Steultjens et al 2006). The structural index score is a composite 
measure of seven items that includes the grading of MTP joint subluxation severity from 0 
– 12 however there is still reliance on the clinician’s subjective assessment (Platto, 
O’Connell et al 1991).  
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It is important to use established measurements to determine foot status and for future 
investigations of the foot in RA, the use of the Foot Posture Index that has been well 
validated to determine foot type (Redmond, Crosibie, Ouvrier et al 2006; Redmond, Crane 
and Menz 2008), plantar foot pressure measurement (van der Leeden, Steultjens et al 2006) 
and three dimensional kinematic analysis of gait (Turner, Helliwell et al 2008) should be 
considered.  
 
7.4. Plans for future work  
The foot remains an under investigated area in the rheumatology literature. The 
investigations presented within this doctoral thesis have not only confirmed this but have 
provided robust data that contributes to the body of knowledge and understanding of 
pathology within the foot in RA. Further investigation of the foot in RA by MSUS has been 
justified and reliability issues of this being performed by a podiatrist identified. This is 
unique longitudinal data highlighting the high prevalence of MSUS detectable forefoot 
bursae that are susceptible to change over time.  
 
In order to optimize the management of these patients, it is essential to conduct further 
work on validation of the MSUS technique, confirmation of the association between MSUS 
detectable bursae and patient reported foot impact outcome measures and to differentiate 
the aetiology in terms of mechanical trauma and/or RA systemic inflammatory response. 
 
Given unlimited resources, this would ideally involve:- 
•  A study that allowed MSUS imaging of fresh cadaver feet from individuals who had 
RA with confirmation of detected bursae by dissection 
•  The use of MRI as an external validator for location of forefoot bursae in patients with 
RA 
•  The use of MSUS guided biopsy of forefoot bursae in patients with RA to confirm 
tissue type through histological analysis.  
•  Or the use of microbubble contrast agents in MSUS imaging to quantify or show ‘hot 
spots’ of active inflammation within the RA forefoot  
•  A study that incorporated assessment of the lower limb biomechanics and the 
assessment of metatarsal movement through the gait cycle. 
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The objectives that we consider are feasible to pursue within our research department for 
further study are: 
1.  To further develop the technique of identifying bursae within the forefoot in patients 
with RA and differentiating those that are in an active flare from those that are 
chronically hypertrophied, using Power Doppler MSUS imaging and magnetic 
resonance imaging. 
2.  To investigate mechanical function of the foot and ankle in patients with RA using 
computerised foot pressure technology and three dimensional gait analysis technologies 
to determine relationships between mechanical function and forefoot bursae. 
3.  To investigate the systemic inflammatory impact of RA using laboratory serology 
indicators and histopathology analyses of inflamed forefoot bursae to determine 
relationships between inflammatory flare and forefoot bursae.  
4.  To improve current clinical decision making and treatment pathways for patients with 
painful forefeet who have RA and thus impact positively on patient mobility, and 
activity participation. 
 
A cohort of patients with RA is now established who have been assessed at two time points. 
Further prospective investigation of forefoot bursae as independent markers and 
associations of change in patient reported foot impact in patients with RA would not only 
strengthen the data but allow changes in forefoot bursae to be compared over several time 
points. 
 
Foot pressure measurements have been recorded by an FScan® system (Tekscan Inc. USA) 
at both the baseline and return visit. The FScan® automatically records the amount of 
pressure occurring on the soles of the feet during each footstep, storing data on the system 
for later analysis. It was not feasible to interpret this data within the remit of this doctoral 
thesis, however future analyses will focus on the associations of foot pressure variables 
with the presence of MSUS detectable forefoot bursae. The addition of three dimensional 
kinematic analysis of rearfoot and forefoot motion in future studies will also enhance the 
predictive model. 
 
To differentiate active inflammatory synovium from non active synovium in forefoot 
bursae in RA, future work will involve the assessment of the foot by a portable MSUS 
system that has both Colour and Doppler mode functions. A sub section of participants will 
also undergo MRI assessment of the foot to validate the MSUS power Doppler findings. It   227
is also proposed that in participants who, after undergoing MRI scans of their feet, are 
identified as having forefoot bursitis a biopsy is taken of the bursa for histo-pathological 
examination 
 
With further insights and enhanced predictive modeling it is anticipated that a clinical 
treatment algorithm for forefoot symptoms due to bursae in RA patients will be determined. 
It is hoped that this will assist foot health clinicians to improve clinical treatment decisions 
that ultimately benefits patients who have RA in terms of improvement in foot impairment, 
activity limitation and participation restriction. 
 
 
 
7.5 Conclusions 
This doctoral thesis has introduced the research problem of investigation of the prevalence 
of forefoot bursae in the forefeet in patients with RA, by MSUS performed by a podiatrist, 
and the research questions and hypotheses. The study of bursae in the feet of patients who 
have RA was justified, definitions were presented and the methodology and results for each 
of the studies that form the thesis were described and discussed. Limitations were given and 
proposals for future work presented.  
  
This study was the first to attempt to investigate inter-observer agreement in the use of 
MSUS between an allied health professional (podiatrist) and an expert radiologist. 
Performance of MSUS in image acquisition and interpretation by the podiatrist was of an 
acceptable standard during the primary investigation and, following further training, levels 
of agreement increased to a good standard. MSUS imaging was also confirmed as a key 
modality for assessing forefoot bursae at baseline and changes in the presence of forefoot 
bursae over time. 
 
Further longitudinal study of patients with RA in a hospital setting confirmed that bursae 
within the forefoot was a common finding on MSUS but under-detected clinically and rare 
in healthy comparator control subjects. The findings that MSUS detectable bursae within 
the forefeet of participants with RA were related to patients’ perception of their foot impact 
that was independent of overall disease activity were unique, although could not be 
completely confirmed by the methodology used. These findings were strengthened by the   228
results that changes in MSUS detectable bursae were significantly associated with changes 
in patient reported impact at twelve months. However, more work is required to 
differentiate foot symptoms that could be related to bursae, MTP joint synovitis and 
tenosynovitis before the associations between MSUS detectable bursae and patient reported 
foot symptoms can be accepted. 
 
The data suggests that clinicians need to consider regular foot assessments and supports the 
use of specific techniques such as MSUS to determine a more precise evaluation of the 
effects of RA disease within the foot and the prediction of patient reported foot impact. The 
results of the studies that form this doctoral thesis therefore contribute to clinical practice in 
providing further information that helps in understanding of the disease process of RA 
within the foot. The key benefit for patients and service delivery lies within the possibility 
of podiatrists being able to image bursae within the foot in patients with RA in the clinical 
environment, facilitating timely treatment decisions.  
 
Finally, further work has been recommended to be undertaken in establishing reliable 
protocols for MSUS assessment of the foot in patients who have RA. In addition, 
recommendations have been made regarding the further development of techniques that 
facilitate the prediction of foot impairment, activity limitation and participation restriction, 
especially in the identification of forefoot bursae in patients who have RA. 
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Appendix 1 
Literature review 
Electronic Search Strategy 
The following databases were electronically searched for all articles related to 
musculoskeletal imaging of bursitis in the RA forefoot (1984 up to present): 
¾  PubMed 
¾  Embase  
¾  Cinahl 
¾  The Cochrane Database of Systematic Reviews  
¾  The Cochrane Database of Abstracts of Reviews of effects  
¾  The Cochrane Central Register of Controlled Trials 
¾  The Cochrane Database of methodology reviews 
¾  The Cochrane Methodology Register, the Health Technology assessment 
database  
 
Hand Search Strategy 
The following Journals were hand searched:  
¾  The Foot (1992 – present)   
¾  The Journal of British Podiatric Medicine (1991- 1997) 
¾  The British Journal of Podiatry (1998 – 2008) 
 
Only English Language studies and studies that were less than twenty years old were 
considered. Date limitations from 1984 – June 2004 were applied in order to obtain 
currency from the evidence. Non-human studies were not considered as applicable for 
inclusion in this review.  
 
Unpublished work, such as conference presentations, both aural and poster and 
consultations with ‘expert’ colleagues in the field, were not included in this review. 
Although the consequence of this is that very recent and ongoing work is not reviewed, 
to include all relevant conference presentations (essential to avoid bias) would have 
resulted in a very large database. Furthermore, the peer review process is an effective 
gateway for screening research and selecting only high quality work.  
 
Citations within key papers that fit the remit of the review were identified and included. 
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Search Terms 
Keywords related to musculoskeletal imaging, bursitis, rheumatoid arthritis and the foot 
and ankle were combined using Boolean logic to make the search more effective. 
Keywords used to search the current literature for the review were as follows:- 
 
¾  Rheumatoid Arthritis AND bursitis 
¾  Rheumatoid Arthritis AND bursitis AND foot 
¾  Rheumatoid Arthritis AND bursae 
¾  Rheumatoid Arthritis AND bursae AND foot 
¾  Rheumatoid Arthritis AND diagnostic imaging 
¾  Rheumatoid Arthritis AND diagnostic imaging AND foot 
¾  Rheumatoid Arthritis AND diagnostic imaging AND foot AND ankle 
¾  Rheumatoid Arthritis AND musculoskeletal ultrasound 
¾  Rheumatoid Arthritis AND musculoskeletal ultrasound AND foot 
¾  Rheumatoid Arthritis AND musculoskeletal ultrasound AND foot AND ankle 
¾  Rheumatoid Arthritis AND musculoskeletal ultrasound AND forefoot 
¾  Musculoskeletal ultrasound AND foot 
¾  Musculoskeletal ultrasound AND foot AND ankle 
¾  Musculoskeletal ultrasound AND forefoot 
¾  Rheumatoid Arthritis AND Magnetic Resonance imaging  
¾  Rheumatoid Arthritis AND Magnetic Resonance imaging AND foot 
¾  Rheumatoid Arthritis AND Magnetic Resonance imaging AND foot AND 
ankle 
¾  Magnetic Resonance imaging AND foot 
¾  Magnetic Resonance imaging AND foot AND ankle 
¾  Magnetic Resonance imaging AND forefoot 
¾  Rheumatoid Arthritis AND X-ray AND foot 
¾  Rheumatoid Arthritis AND erosion AND foot 
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Dynamic Imaging 
  
Diasus Ultrasound Scanning System 
Technical Specification 
  
Probe types  Ultra Wideband Electronic Linear Array 
Probe frequencies 
5-10MHz, 40mm active length 
8-16MHz, 26mm active length 
10-22MHz, 26mm active length 
Scan modes  B-Mode 
Screen format  Single/Dual image 
Resolution  640 x 440 pixels, 8 bits 
External interface 
Seven slide potentiometer gain controls 
2 rotary potentiometers controlling Transmit Power and Overall 
Gain 
86 key QWERTY keyboard and 29 dedicated function keys 
trackerball for measurements and text positioning 
15" Digital Autoscan Colour Monitor, high resolution, flicker free, 
low emission MPR-II compliance, screen resolution 800x600 
Standard PC communications ports 
Depth of view  100mm max 
Frame rate  30fps max 
Magnification  6 step zoom 
B-Mode features 
Inversion black-white/white-black, left-right/right-left 
Signal processing 
4.0 - 26.0MHz bandwidth, swept frequency, 4 post processing 
curves (gamma correction), 2D filtering, frame averaging, 
selectable multiple transmit focus positions 
Display information 
Patient ID, Hospital ID, Clinicion ID, measurement mode, post 
processing status, current scale, frame averaging status, transpose 
status, frozen status, time & date, transmit focus indicators, body 
mark, text annotation 
Software package  Distance (4) traced or ellipse area (2) curved line length (2) 
Input  115V AC/60Hz, 230V AC/50Hz, rated power 
300VA max 
Power 
Output  230V AC, 50/60Hz 230VA max for additional 
accessories 
Temperature  +10°C to +40°C 
Operating conditions 
Relative  30% to 80% Appendix 4 
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humidity 
Temperature  -10°C to +60°C 
Storage/transport  Relative 
humidity  30% to 90% (non condensing) 
Weight 65Kg  approx 
Physical 
Dimensions  537 x 1285 x 765mm (WxHxD) 
Electrical 
safety  EN60601-1-1, UL2601-1, Class 1, Type BF  
 
EMC  EN60601-1-2 
Acoustic 
power 
EN61157, on screen indication in accordance with 
Acoustic Output Display Standard 
Quality 
Dynamic Imaging is committed to a Total Quality 
Culture and has been assessed and registered as 
meeting the requirements of BS EN46001, the 
application of BS EN ISo 9001 to the manufacture 
of medical devices, under Annex II of EC Council 
Directive 93/42/EEC, the Medical Device Directive
Standards 
CE0120 
Diasus is identified with this CE Mark in 
compliance with EC Directive 93/42/EEC (Medical 
Devices Directive) 
Dynamic Imaging is registered as complying with 
EN46001, the internationally recognised quality 
system standard for medical devices. 
Accessories  Video printers, needle guide attachments 
Consumables  Gel, video printer paper, needle guides 
 
Dynamic Imaging Ltd 
9 Cochrane Square, Brucefield Industrial Park, Livingston, EH54 9DR, UK 
Telephone : +44 (0)1506 415282 
Fax : +44 (0)1506 415282 
email : sales@dynamicimaging.co.uk 
www.dynamicimaging.co.uk Appendix 5 
 
Version 3  237
Ultrasound report / data sheet RIGHT  FOOT               Wk 
No:…… 
 
Pt ID No:…………………………. …                   Date ………………………… 
Footwear ……………………………   
 
Please tick the appropriate boxes:- 
Synovitis hyperaemia 
detectable with PD  
Synovitis thickness grading  Anatomical 
location 
Yes   no  Mild  Moderate  Severe 
MPJ 2 
 
       
MPJ 5 
 
       
 
 Bursitis  Bursitis  measurements  (mm) 
 anato
mical 
advent
itious 
uniden
tifiable
longitudinal transverse  Distance  of 
bulging 
under the 
met head 
Sub met 1 
 
         
Inter met 1 / 2 
 
         
Sub met 2 
 
         
Inter met 2 / 3 
 
         
Sub met 3 
 
         
Inter met 3 / 4 
 
         
Sub met 4 
 
         
Inter met 4 / 5 
 
         
Sub met 5 
 
         
Comments: 
 
 
 
  
 
 
 
Key: PD = power Dopplar; mmt = measurement; MPJ = metatarsophalangeal joint; sub met = 
plantar metatarsal area; inter met = intermetatarsal capita space. 
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Ultrasound report / data sheet LEFT  FOOT              Wk No:…… 
 
Pt ID No:…………………………. …                   Date …………………………
  
Please tick the appropriate boxes:- 
Synovitis hyperaemia 
detectable with PD  
Synovitis thickness grading  Anatomical 
location 
Yes   no  Mild  Moderate  Severe 
MPJ 2 
 
       
MPJ 5 
 
       
 
 Bursitis  Bursitis  measurements  (mm) 
 anato
mical 
advent
itious 
uniden
tifiable
longitudinal transverse  Distance  of 
bulging 
under the 
met head 
Sub met 1 
 
         
Inter met 1 / 2 
 
         
Sub met 2 
 
         
Inter met 2 / 3 
 
         
Sub met 3 
 
         
Inter met 3 / 4 
 
         
Sub met 4 
 
         
Inter met 4 / 5 
 
         
Sub met 5 
 
         
Comments: 
 
 
  
 
 
 
 
 
Key: PD = power Dopplar; mmt = measurement; MPJ = metatarsophalangeal joint; sub met = 
plantar metatarsal area; inter met = intermetatarsal capita space. 
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Self administered questionnaire on disability associated with foot pain. 
Below are some statements about problems people have because of pain in 
their feet. 
For each statement indicate if this has applied to you during the past month. 
If so, was this only on some days or on most or every day in the past month? 
 
PLEASE TICK A BOX FOR EACH STATEMENT 
 
                                                   During the past month   
                                                   this has applied to me: 
   
None 
of the 
time 
 
On 
some 
days 
 
On 
most / 
every 
day 
 
 
Because of pain in my feet: 
      
I avoid walking outside at all        
I avoid walking long 
distances
      
I don’t walk in a normal way        
I walk slowly        
I have to stop and rest my feet        
I avoid hard or rough surfaces 
where possible
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None of 
the time 
On some 
days 
On 
most / 
every 
day 
Because of pain in my feet:        
I avoid standing for a long 
time
      
I catch the bus or use the car 
more often
      
I need help with 
housework/shopping
      
I still do everything but with 
more pain or discomfort
      
I get irritable when my feet 
hurt
      
I feel self conscious about my 
feet
      
I get self conscious about the 
shoes I have to wear
      
I have constant pain in my 
feet
      
My feet are worse in the 
morning
      
My feet are more painful in 
the evening
      
I get shooting pains in my 
feet
      Appendix 6 
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  None of 
the time 
On some 
days 
On 
most / 
every 
day 
not 
applicable
 
Because of pain in my feet: 
      
I am unable to carry out my 
previous work
      
I no longer do all my previous 
activities (sport, dancing, hill-
walking etc)
      
 
 
 
TICK HERE WHEN YOU HAVE READ ALL THE 
STATEMENTS ON THIS PAGE 
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LEEDS FOOT IMPACT SCALE 
 
On the following pages you will find some statements which have been made 
by people who have arthritis in their feet.  We would like you to tick "true" if 
the statement applies to you, and tick "not true" if it does not.      
  
Please choose the response that applies best to you at the moment.  
 
        TRUE   NOT TRUE 
 
1.  My feet get painful when I'm standing……………… 
 
2.  My feet hurt me……………………………………… 
 
3.  I find the pain in my feet frustrating………………… 
 
4.  The pain is worse when I've been on my feet all          
 day…………………………………………………… 
 
5.  At the end of the day there is pain and tension         
 in  my  feet……………………………………………. 
 
6.  I never get rid of the stiffness in the background……. 
 
 
 
 
Please remember to read each statement thinking about your feet.  
  Please choose the response that applies best to you at the moment.  
 
        TRUE   NOT TRUE 
 
7.  My feet throb at night………………………………..   
 
8.  My feet wake me up at night…………………………   
 
9.  I feel as though I've got pebbles in my shoes…………   
 
10.  I get pain every time I put my foot down……………. 
 
11.  I get a burning sensation all the time…………………   
 
12.  I cry with pain………………………………………… 
 
 
Please check you have ticked a box for every statement on this page 
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Please remember to read each statement thinking about your feet.  
Please choose the response that applies best to you at the moment.  
       
        TRUE   NOT  TRUE 
          
13.  I can only walk in certain shoes……………………..       
          
14.  I need shoes with plenty of room in them…………….. 
 
15.  I am limited in my choice of shoes……………………       
   
16.  I need a wider fit of shoes…………………………….. 
 
17.  I feel I need a lot of padding under my feet…………... 
 
18.  My footwear always feels heavy……………………… 
 
19.  I have to keep swapping and changing my shoes……… 
 
20.  I can't get any shoes on………………………………...   
 
21.  I walk bare foot all the time……………………………   
 
 
 
 
Please remember to read each statement thinking about your feet.  
Please choose the response that applies best to you at the moment.  
 
        TRUE   NOT TRUE 
 
22.  I feel unsafe on my feet……………………………… 
 
23.  I have to walk for a bit and sit for a bit……………….. 
 
24.  I can’t run……………………………………………. 
 
25.  I find I shuffle around……………………………….. 
 
26.  I am limping about all the time……………………… 
 
27.  I have to use a walking stick or walking frame……… 
 
 
 
 
Please check you have ticked a box for every statement on this page 
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Please remember to read each statement thinking about your feet.  
Please choose the response that applies best to you at the moment.  
 
        TRUE   NOT TRUE 
 
28.  It takes me all my time to climb the stairs…………… 
 
29.  I need help to climb stairs……………………………   
 
30.  I can't walk on cobbles………………………………. 
 
31.  I am unsteady on uneven surfaces…………………… 
 
32.  I can't walk as far as I would like to…………………       
      
33.  It takes me longer to do things……………………….       
      
34.  My whole life has been adapted……………………… 
 
 
 
Please remember to read each statement thinking about your feet.  
Please choose the response that applies best to you at the moment.  
 
        TRUE   NOT TRUE 
 
35.  My feet restrict my movement………………………         
        
36.  I get annoyed because I'm slower…………………….         
        
37.  I get frustrated because I can't do things so quickly…. 
 
38.  My whole life has slowed down………………………       
       
39.  It's reduced the range of things I can do……………..         
        
40.  I have to plan everything out…………………………       
      
41.  I can't keep up like I used to………………………….       
        
42. Socially  its  affected me a lot………………………….       
       
43.  I am ashamed of how I walk………………………….   
 
44.   I'm nervous of missing a curb edge…………………..   
 
Please check you have ticked a box for every statement on this page 
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Please remember to read each statement thinking about your feet.  
  Please choose the response that applies best to you at the moment.  
     
        TRUE   NOT TRUE 
   
45.  I feel isolated because I can't go very far………………       
     
46.  I feel I slow other people down………………………..       
     
47.  I can't do some of the things I take for granted…………       
          
48.  I can't go for walks with the people close to me………..       
          
49.  I'm finding it difficult to be  independent……………….     
     
50.  I dread finishing up in a wheelchair…………………….       
      
51.  I get frustrated because I can't do things for myself……       
   
        
 
Please check you have ticked a box for every statement on this page 
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Demographic data collection 
 
1 .           
         
 
 
 
 
 
 
 
2.  Date of visit:  ........./............./.......... 
 
3.  Year of diagnosis........./............./.......... 
 
4.  Does Patient have ACR diagnosis of Rheumatoid arthritis?  
Y e s       N o     
 
4a. Are they Seropos.          Seroneg.            ? 
 
5. Weight:..................kgs   Height...................cms 
 
6.  Diabetic   Yes   No 
 
7. Limb  dominance:  Left    Right   
 
8.  Have you had any lower limb/foot surgery in the past year (either limb)? 
Yes     (please specify limb/date of surgery)    No 
 
.............................................................................................................................................. 
 
9.  Have you had any foot/ankle steroid injections within the four weeks (either 
limb)? 
Yes     (please specify limb/date of surgery)  No 
...................................................................................................................... 
 
 
10.  Have you had any steroid injections (intramuscular) in the past eight weeks? 
 
Yes      No   
 
11.  Are you currently on Anti TNF therapy? 
Yes      No   
 
If yes, which one? ……………………………. 
 
12.  Are you currently on Methotrexate (MTX)? 
Yes      No   
 
 
Patient Addressograph  Patient Code 
Participant 
number: 
Age ……… 
RA duration ……… Appendix 8  
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13.  Which other arthritis drugs are you currently using (do not include anti-TNF therapy)? 
Gold injections/tablets 
 Sulphasalazine 
 Azathioprine 
 Penacillamine 
 Cyclosporin 
 Other  (please specify) 
 
 
14.  Which other arthritis drugs have you used in the past? 
 Gold  injections/tablets 
 Sulphasalazine 
 Azathioprine 
 Penacillamine 
 Cyclosporin 
 Other  (please specify) 
 
15. Present  Medication  (please list) 
  
...................................................................................................................... 
 
...................................................................................................................... 
 
...................................................................................................................... 
 
 
16. Is there any documentation of foot symptoms in the patients medical 
records? 
Yes      No   
If yes specify details: 
 
...................................................................................................................... 
 
...................................................................................................................... 
 
 
17.  Has the patient ever seen a chiropodist/podiatrist in the past? 
Yes      No   
 
Are they using a chiropodist/podiatrist now? 
Yes      No   
 
 
Investigator Signature:................................................  
 
Print name:......................................... Version 2: 01.09.06 
      
 
       5         4      3       2        1   1      2       3        4      5          5         4      3       2        1           1      2       3        4      5 
 
L  R  L  R 
Global VAS: Overall wellbeing: please indicate on the scale below 
 
        0                               100 
          ----------------------------------------------------------------------- 
Best  Imaginable     Worst  Imaginable 
Health State     Health State
 
 
 
ESR………………Date:……….. 
CRP………………Date:……….. 
DAS………………Date:……….. 
       
  Which joints are tender? (Please tick) Which joints are swollen? (please tick) 
Patient ID   _______________________  Modified Swollen and Tender Joint Count 
          d d m m y y y y 
 
Date: …………………. 
Bursitis 
 
MCPs
MTPsAppendix 10 
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Demographic data collection 
 
1 .           
         
 
 
 
 
 
 
 
2.  Date of 2
nd visit: ........./............./.......... 
 
3. Weight:..................kgs   Height...................cms 
 
4.  Diabetic   Yes   No 
 
5.  Have you had any lower limb/foot surgery in the past year (either limb)? 
Yes     (please specify limb/date of surgery)    No 
 
............................................................................................................................................ 
 
 
6.  Have you had any foot/ankle steroid injections within the four weeks (either 
limb)? 
Yes     (please specify limb/date of surgery)  No 
 
.................................................................................................................... 
 
 
7.  Have you had any steroid injections (intramuscular) in the past eight weeks? 
 
Yes      No   
 
8.  Are you currently on Anti TNF therapy? 
Yes      No   
 
If yes, which one? ……………………………. 
 
9.  Are you currently on Methotrexate (MTX)? 
Yes      No   
 
 
 
 
 
 
 
 
 
 
 
Patient Addressograph  Patient Code 
Age ……… Appendix 10 
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10.  Which other arthritis drugs are you currently using (do not include anti-TNF therapy)? 
Gold injections/tablets 
 Sulphasalazine 
 Azathioprine 
 Penacillamine 
 Cyclosporin 
 Other  (please specify) 
 
 
 
11. Present  Medication  (please list) 
  
.................................................................................................................... 
 
.................................................................................................................... 
 
.................................................................................................................... 
 
 
 
12.    Is the patient using a chiropodist/podiatrist now? 
Yes      No   
 
 
 
Investigator Signature:................................................  
 
Print name:......................................... 
 
 
 
 
   Year 03/04  Year 04/05  Year 06/07  Year 08/09 
Preliminary study       
Attendance at msk ultrasound list         
Ethics submission (anti tnf trial)         
Participant recruitment (stage 1)         
Ultrasound    reliability/sensitivity       
Analysis  of  results       
Discussion & Write Up                  ⌂   
Baseline RA       
Ethics submission (stage 2)        
Participant recruitment (stage 2 )        
Data collection (stage 2)         
Analysis  of  results       
Discussion & Write Up       ⌂ 
Baseline Healthy       
Ethics submission (stage 3)         
Participant recruitment (stage 3 )         
Data collection (stage 3)         
Analysis  of  results       
Discussion & Write Up         
Twelve month RA       
Participant recruitment (stage 4 )         
Data collection (stage 4)         
Analysis of results                          
Discussion & Write Up                       ⌂  
 
 
 
 
Legend 
                        ……… theoretical writing 
 
          ………… activities / data collection etc. 
 
⌂ ………… milestones eg. Abstract/paper submissions for conference presentations / articles etc. 
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RHEUMATOLOGY RESEARCH UNIT 
Mailpoint 63 
Level G 
West Wing 
Southampton General Hospital 
 
Tel: 023 8079 6711/8532 
Fax: 023 8079 6711 
Email: pamela.freeman@suht.swest.nhs.uk 
 
 
Study Number: RHM MED 0691 
Ethics Submission No: 06/Q1702/57 
 
 
PATIENT INFORMATION SHEET:  
 
Part 1 
 
1. Study title 
The ‘FeeTURA’ study 
 
Full title: Investigation of swelling in the feet due to rheumatoid arthritis 
using 
ultrasound scanning. 
 
 
2. Invitation to participate in the study 
 
You are being invited to take part in a research study. Before you decide it 
is important for you to understand why the research is being done and what 
it will involve. Please take time to read the following information carefully 
and discuss it with others if you wish.  
 
•  Part 1 tells you the purpose of this study and what will happen to you if 
you take part.   
•  Part 2 gives you more detailed information about the conduct of the 
study.  
 
Ask us if there is anything that is not clear or if you would like more 
information. Take time to decide whether or not you wish to take part. 
 
Thank you for reading this. 
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3. What is the purpose of the study? 
 
The main purpose of this study is to investigate swelling (inflammation) in 
the forefoot of patients with Rheumatoid Arthritis using musculoskeletal 
ultrasound.   
 
Rheumatoid arthritis (RA) causes pain and damage to many joints. The 
joints most likely to be involved are in the feet and hands. Most studies have 
concentrated on problems in the hands, but the disease can also cause 
other problems. 
 
Imaging using ultrasound is increasing in popularity within rheumatology as 
it allows observation of anatomical structures at the time of the clinical visit. 
The technique used for ultrasound imaging of these structures is the same 
as that used when unborn babies are scanned within the womb. There are 
other advantages of ultrasound over X-Rays which are usually used to 
assess the status of your joints and these are that it is painless and 
harmless (no ionising radiation). 
 
Swelling in the forefoot due to RA may be caused by bursitis. Bursitis is the 
inflammation of a fluid filled sac that usually occurs between the long bones 
and the toes of the feet. Being able to see lesions using ultrasound such as 
bursitis occurring in the feet and understand how they change over time 
when you attend your rheumatology outpatients or podiatry appointments 
would help us to decide on the best course of treatment for you and for 
future patients. For example, this may involve deciding on what medicines 
and/or doses to use for you or providing you with or adjusting your existing 
orthotic device / joint splint, thus preventing further pain, disability or mobility 
loss for yourself or future patients. 
 
 
 
4. Why have I been chosen? 
You have been chosen because you have rheumatoid arthritis and are due 
to attend the Department of Rheumatology, Southampton General Hospital 
(Southampton University Hospitals NHS Trust) as part of your usual care. 
 
 
5. Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take 
part you will be given this information sheet to keep and be asked to sign a 
consent form. If you decide to take part you are still free to withdraw at any 
time and without giving a reason. A decision to withdraw at any time, or a 
decision not to take part, will not affect the standard of care you receive. Appendix 13 
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6. What will happen to me if I take part? 
If you agree to participate in this study your regular appointment will be 
extended by forty five minutes. You will be required to participate in the 
study on two separate occasions, once now and again in twelve months 
time. For both occasions when you participate in the study it will be as part 
of your normal clinical visit so that you do not have to make any extra trips 
into the hospital. During your appointment we will scan the sole of your foot 
using a diagnostic ultrasound scanner in the same way that unborn babies 
are scanned within the womb.  
 
During the scan you will be asked to sit on a couch with your feet facing the 
investigator. The investigator will scan the soles of both your feet. Following 
each scan recording the investigator will note all areas of inflammation 
within that part of your feet. 
 
A clinical examination of your feet will involve the examination of the soles 
of both your feet by the investigator and any observations will be recorded 
on a pictorial diagram. The position of any lesions will be recorded and 
photographs of the soles of your feet will be taken. Foot pressure 
measurements will be recorded by a computerised system, FScan® 
Pressure sensitive insoles will be placed within your footwear and these are 
attached via a long cable to a computer. You will be asked to walk ten steps 
forward away from the computer so that any cable trip hazard is avoided. 
The computer automatically records the amount of pressure occurring on 
the soles of your feet during each footstep. 
 
You will also be asked to complete a questionnaire that asks you about foot 
pain and walking ability. The questionnaire will take you approximately five 
minutes to complete. 
 
The rheumatology nurse will assess your RA in the usual way and the 
information will be used within this study. A small number of people (10%) 
will be asked to undergo traditional ultrasound foot scan performed by a 
radiologist using the normal ultrasound equipment (Philips HDI 5000 
System broadband linear 5 - 12 MHz probe) in the Department of 
Ultrasound and Radiology, Southampton General Hospital (Southampton 
University Hospitals NHS Trust). The same scanning protocol will be used 
as for the Diasus scanner. These scans allow us to compare the two 
different ultrasound machines.  
 
About twelve months from your first appointment we will repeat the study 
and examine your feet in exactly the same way. Appendix 13 
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7. What do I have to do? 
Taking part in the study does not alter any of your standards of care. You do 
not need to alter your lifestyle or diet in any way. 
 
 
8. What are the possible disadvantages and risks of taking part? 
In laboratory trials some risk of ultrasound exposure damage to tissues has 
been documented. The risk, however, is attributed to levels of exposure that 
are never used within clinical practice.  An excellent safety record exists in 
that, after many years of clinical use, there is no known instance of human 
injury as a result of exposure to diagnostic ultrasound. During clinical 
assessments with new ultrasound equipment such as that being used in this 
study, the total ultrasound exposure is kept as low as reasonably achievable 
and this is known as the ALARA principle. Implementing ALARA within the 
study has required the chief investigator, Catherine Bowen, to attend a 
recognised training course in the use of ultrasound imaging. Mrs Bowen has 
further support for scanning technique supervision from the Dr Keith 
Dewbury, Consultant Radiologist, Department of Ultrasound at 
Southampton General Hospital (Southampton University Hospitals NHS 
Trust). 
 
It is possible that the Foot pressure measurements recorded by the FScan® 
system may pose some risk of trip or fall as the pressure sensitive insoles 
are placed within the your footwear and these are attached via a long cable 
to a personal computer. There is also a minor risk of you walking too far and 
toppling over the FScan® system. To avoid these hazards, the exact 
distance of the walkway will be explained to you and you will be supervised 
by the investigator at all times during this activity. 
 
9. What are the benefits of taking part? 
The information that we get from this study may help us to treat patients 
with rheumatoid arthritis better in the future. There may not be any direct 
benefits to you associated with taking part in this study; however, taking part 
in this study may identify bursitis, swelling or pain within your feet which 
would lead us to initiate appropriate treatment for you.  
 
10. What if there is a problem? 
Any complaint about the way you have been dealt with during the study or 
any possible harm you might suffer will be addressed. The detailed 
information on this is given in Part 2.   
 
The contact number for any complaints is: Dr Martina Dorward, Research 
Support Office, University of Southampton, Building 27, Highfield Campus, 
Southampton, SO17 1BJ.  Telephone: 023 8059 8848 Appendix 13 
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11. Will my taking part in this study be kept confidential? 
Yes.  All the information about your participation in this study will be kept 
confidential.  The details are included in Part 2.  
 
 
12. Contact for further information 
Further information can be obtained from  
 
Mrs Catherine Bowen in the Rheumatology Research Unit, Southampton 
General Hospital. Tel. 023 8079 8532 / 6711   
OR the School of Health Professions and Rehabilitation Sciences. Tel. 023 
8059 7637. 
 
And / or 
Dr Nigel Arden in the Department of Rheumatology, Southampton General 
Hospital on: 023 8079 8723  / 8523 / 6711. 
 
Thank you for reading this. 
 
This completes Part 1 of the Information Sheet. 
If the information in Part 1 has interested you and you are considering 
participation, please continue to read the additional information in Part 
2 before making any decision. 
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PATIENT INFORMATION SHEET:  Part 2  
 
18.  What will happen if I don’t want to carry on with the study? 
You can withdraw from the study at any time but if you give your permission 
information and any ultrasound images collected may still be used. 
 
19. What if there is a problem or something goes wrong? 
It is extremely unlikely that taking part in this research project will harm you. 
If this did occur, however, there are no special compensation arrangements. 
If you are harmed due to someone’s negligence, then you may have 
grounds for a legal action for compensation against (The University of 
Southampton or Southampton University Hospitals NHS Trust) but you may 
have to pay your legal costs.  The normal National Health Service 
complaints mechanisms will still be available to you. 
 
Regardless of this, if you have a concern about any aspect of this study, you 
should ask to speak with the researchers who will do their best to answer 
your questions (Contact number; 023 8059 7637).  If you remain unhappy 
and wish to complain formally, you can do this through the NHS Complaints 
Procedure.  Details can be obtained from the Patient Advice and Liaison 
Service (PALS) information point within the hospital or you can telephone 
them on 023 8079 8498 or email PALS@suht.swest.nhs.uk 
 
Alternatively, the consumers for ethics in research (CERES) 
http://www.ceres.org.uk/ is a recommended third independent participant 
support body. 
 
20. Will my taking part in this study be kept confidential? 
All information that is collected about you during the course of the research 
will be kept strictly confidential. Any information about you that leaves the 
hospital/surgery will be coded so that at no time will any of your personal 
details be revealed. The procedures for handling, processing, storage and 
destruction of any data collected during the study are compliant with the 
Data Protection Act 1998 and in line with the Southampton University 
Hospitals NHS Trust policy. 
 
21. What will happen to the results of the research study? 
We hope the results are useful and we intend to publish them in a 
rheumatological journal and to present them at scientific conferences. The 
results will also be utilised by the chief investigator for part completion of a 
PhD thesis to be submitted to the University of Southampton. You will not 
be identified in any reports or publications. 
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22. Who is organizing and funding the research? 
The study is cosponsored by the University of Southampton and 
Southampton University Hospitals NHS Trust and is organised by 
investigators from the School of Health Professions and Rehabilitation 
Sciences, University of Southampton and the Rheumatology and Radiology 
departments at Southampton General Hospital (Southampton University 
Hospitals NHS Trust) . 
 
23. Who has reviewed the study? 
The study has been peer reviewed by the Research division of School of 
Health Professions and Rehabilitation Sciences, University of Southampton 
and the Southampton University Hospitals NHS Trust research and 
development department. The Southampton and South West Hampshire 
Local Research Ethics Committee have also reviewed the study. 
 
If you agree to take part you will be given a copy of the information sheet 
and a signed consent form to keep. If you have read this information sheet 
and are happy to participate in the proposed study please sign the attached 
reply slip and return it in the stamped addressed envelope.  
 
 
Thank you for considering taking part and taking time to read this 
sheet. 
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We are looking for volunteers to take part in a 
study which is investigating foot problems in 
patients who have Rheumatoid Arthritis.  
 
We know that Rheumatoid Arthritis commonly 
affects the feet causing swelling and pain within 
the foot joints reducing a person’s ability to walk. 
Not much is known, however, about the 
appearance and progression of these swellings 
within the feet.  
 
This study has therefore been designed to 
investigate the presence of swelling within the 
feet using diagnostic ultrasound imaging and to 
see if there are any links with the disease process 
of rheumatoid arthritis and/or symptoms of foot 
pain and function. 
 
If you are interested in taking part in the study 
please ask at the rheumatology outpatient 
reception desk. 
 
Alternatively, please contact either: 
Dr Nigel Arden, Reader & Consultant Rheumatologist, 
telephone 023 8079 8532/6711. 
Or 
Mrs Catherine Bowen, Lecturer Podiatry,  
telephone 02380 597637. Appendix 15 
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RHEUMATOLOGY RESEARCH UNIT 
Mailpoint 63 
Level G 
West Wing 
Southampton General Hospital 
Tel: 023 8079 6711/8532 
Fax: 023 8079 6711 
Email: pamela.freeman@suht.swest.nhs.uk 
Study Number: RHM MED 0691 
Ethics Submission No: 06/Q1702/57 
Patient identification Number for this study: 
 
CONSENT FORM 
 
Title of Project: Investigation of swelling in the feet due to rheumatoid arthritis  
      using ultrasound scanning / The ‘FeeTURA’ Study. 
                               
Name of Researcher: Mrs Catherine Bowen      
   Please initial box 
1.  I confirm that I have read and understand the information sheet dated 
05.06.06 (version6) for the above study and have had the opportunity 
to ask questions and have had these answered satisfactorily. 
 
2.  I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical 
care or legal rights being affected. 
 
3.  I understand that sections of my medical notes may be looked at by 
responsible individuals from the University of Southampton and 
Southampton University Hospitals NHS Trust or from regulatory 
authorities where it is relevant to my taking part in research. I give 
permission for these individuals to have access to my records. 
 
4.  I agree to take part in the above study 
 
 
  
                             
 
Name of Patient          Date      Signature 
 
                             
 
Name of Person taking consent    Date      Signature 
(if different from researcher) 
 
 
 
Researcher      Date    Signature 
 
1 for patient; 1 for researcher; 1 (original) to be kept with hospital notes Appendix 16.     The ‘FeeTUH’ study 
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We are looking for volunteers to take part in a 
study which is investigating bursitis in the forefeet 
of healthy persons. 
 
Bursitis is inflammation (swelling) of a bursa and 
can occur in the forefoot causing pain and /or 
discomfort during walking. Numerous disorders 
may give rise to discomfort in the metatarsal 
region of the forefoot, however not much is 
known, about the appearance of bursitis within the 
feet. 
 
This study has therefore been designed to 
investigate the presence of bursitis within the 
forefeet of healthy persons using diagnostic 
ultrasound imaging and to see if there are any 
links with symptoms of forefoot pressures, foot 
swelling and foot pain. 
 
If you are interested in taking part in the study 
please contact: 
 
Mrs Catherine Bowen, Lecturer Podiatry,  
 
Telephone 02380 597637. Appendix 17 
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Study Number: 
Patient identification Number for this study: 
 
 
PARTICIPANT INFORMATION SHEET:   
 
Part 1 
 
1. Study title 
The ‘FeeTUH’ study 
 
Full title: Investigation of bursitis within the forefoot of healthy subjects as 
determined by non-invasive diagnostic ultrasound. 
 
 
2. Invitation to participate in the study 
 
You are being invited to take part in a research study. Before you decide it is 
important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss it 
with others if you wish.  
 
•  Part 1 tells you the purpose of this study and what will happen to you if you take 
part.   
•  Part 2 gives you more detailed information about the conduct of the study.  
 
Ask us if there is anything that is not clear or if you would like more information. 
Take time to decide whether or not you wish to take part. 
 
Thank you for reading this. 
 
 
3. What is the purpose of the study? 
 
Bursitis is inflammation (swelling) of a bursa and can occur in the forefoot causing 
pain and /or discomfort during walking. We know that bursae are pouches of fluid 
that facilitate movement between adjacent structures by reducing friction and that 
four anatomical connective tissue bursae have been identified between the 
metatarsal heads in the forefoot. Numerous disorders may give rise to discomfort in 
the metatarsal region of the forefoot, however not much is known, about the 
appearance of bursitis within the forefeet. 
 
Our previous study results have demonstrated that diagnostic ultrasound is capable 
of detecting changes within the forefoot tissues and joints due to Rheumatoid Appendix 17 
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Arthritis and that these are clinically underreported.  We do not yet know whether 
bursitis of the forefoot is also present in healthy persons.  
 
Imaging using ultrasound is increasing in popularity within clinical practice as it 
allows observation of anatomical structures at the time of the clinical visit. The 
technique used for ultrasound imaging of these structures is the same as that used 
when unborn babies are scanned within the womb. There are other advantages of 
ultrasound over X-Rays which are usually used to assess the status of bones and 
joints and these are that it is painless and harmless. 
 
The main purpose of this study is therefore to investigate the presence of bursitis 
within the forefeet of healthy people using diagnostic ultrasound imaging and to see 
if there are any associated links with symptoms of forefoot pressure, foot pain and 
foot swelling. 
 
 
4. Why have I been chosen? 
You have been chosen because you are healthy and are a student currently 
enrolled on the BSc Hons Podiatry programme and about to take part in a workshop 
on ultrasound imaging. 
 
 
5. Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take part you 
will be given this information sheet to keep and be asked to sign a consent form. If 
you decide to take part you are still free to withdraw at any time and without giving a 
reason. A decision to withdraw at any time, or a decision not to take part, will not 
affect the standard of teaching/ teaching support you receive. 
 
 
6. What will happen to me if I take part? 
If you agree to participate in this study it will be as part of your normal Podiatry 
teaching schedule so that you do not have to make any extra trips into the 
University. During the workshop we will scan the sole of your foot using a diagnostic 
ultrasound scanner in the same way that unborn babies are scanned within the 
womb.  
 
During the scan you will be asked to sit on a couch with your feet facing the 
investigator. The investigator will scan the soles of both your forefeet. Following 
each scan recording the investigator will note all areas of swelling within that part of 
your feet. 
 
A clinical examination of your feet will involve the examination of the soles of both 
your feet by the investigator and any observations will be recorded on a pictorial 
diagram. The position of any lesions will be recorded and photographs of the soles 
of your feet will be taken. Foot pressure measurements will be recorded by a Appendix 17 
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computerised system, FScan® Pressure sensitive insoles will be placed within your 
footwear and these are attached via a long cable to a computer. You will be asked 
to walk ten steps forward away from the computer so that any cable trip hazard is 
avoided. The computer automatically records the amount of pressure occurring on 
the soles of your feet during each footstep. 
 
You will also be asked to complete a questionnaire that asks you about foot pain 
and walking ability. The questionnaire will take you approximately five minutes to 
complete. 
 
 
7. What do I have to do? 
Taking part in the study does not alter any of your regular studies. In order to take 
foot pressures using the FScan® system we will require you to ensure that you 
attend wearing / bring with you suitable closed in footwear and socks (ie. Not 
sandals) for the ultrasound workshop. 
 
 
8. What are the possible disadvantages and risks of taking part? 
In laboratory trials some risk of ultrasound exposure damage to tissues has been 
documented. The risk, however, is attributed to levels of exposure that are never 
used within clinical practice.  An excellent safety record exists in that, after many 
years of clinical use, there is no known instance of human injury as a result of 
exposure to diagnostic ultrasound. During clinical assessments with new ultrasound 
equipment such as that being used in this study, the total ultrasound exposure is 
kept as low as reasonably achievable and this is known as the ALARA principle. 
Implementing ALARA within the study has required the chief investigator, Catherine 
Bowen, to attend a recognised training course in the use of ultrasound imaging. Mrs 
Bowen has further support for scanning technique supervision from the Dr Keith 
Dewbury, Consultant Radiologist, Department of Ultrasound at Southampton 
General Hospital (Southampton University Hospitals NHS Trust). 
 
It is possible that the Foot pressure measurements recorded by the FScan® system 
may pose some risk of trip or fall as the pressure sensitive insoles are placed within 
the your footwear and these are attached via a long cable to a personal computer. 
There is also a minor risk of you walking too far and toppling over the FScan® 
system. To avoid these hazards, the exact distance of the walkway will be explained 
to you and you will be supervised by the investigator at all times during this activity. 
 
9. What are the benefits of taking part? 
The information that we get from this study may help us to treat patients with 
rheumatoid arthritis better in the future. There may not be any direct benefits to you 
associated with taking part in this study; however, taking part in this study may 
identify bursitis, swelling or pain within your feet which would lead us to initiate 
appropriate treatment for you.  
 Appendix 17 
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10. What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any 
possible harm you might suffer will be addressed. The detailed information on this is 
given in Part 2.   
 
The contact number for any complaints is: Dr Martina Dorward, Research Support 
Office, University of Southampton, Building 27, Highfield Campus, Southampton, 
SO17 1BJ.  Telephone: 023 8059 8848 
  
 
11. Will my taking part in this study be kept confidential? 
Yes.  All the information about your participation in this study will be kept 
confidential.  The details are included in Part 2.  
 
12. Contact for further information 
Further information can be obtained from  
 
Mrs Catherine Bowen in the School of Health Professions and Rehabilitation 
Sciences on 023 8059 7637. 
 
Thank you for reading this. 
 
This completes Part 1 of the Information Sheet. 
If the information in Part 1 has interested you and you are considering 
participation, please continue to read the additional information in Part 2 
before making any decision. 
 
 
PATIENT INFORMATION SHEET:  Part 2  
 
18.  What will happen if I don’t want to carry on with the study? 
You can withdraw from the study at any time but if you give your permission 
information on any ultrasound images collected may still be used. 
 
19. What if there is a problem or something goes wrong? 
It is extremely unlikely that taking part in this research project will harm you. If this 
did occur, however, there are no special compensation arrangements. If you are 
harmed due to someone’s negligence, then you may have grounds for a legal action 
for compensation against The University of Southampton but you may have to pay 
your legal costs.   
 
Regardless of this, if you have a concern about any aspect of this study, you should 
ask to speak with the researchers who will do their best to answer your questions 
(Contact number; 023 8059 7637).  If you remain unhappy and wish to complain Appendix 17 
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formally, please contact Mr. Mike Potter, Head of Podiatry, School of Health 
Professions and Rehabilitation Sciences on 02380 595268. 
 
Alternatively, the consumers for ethics in research (CERES) 
http://www.ceres.org.uk/ is a recommended third independent participant support 
body. 
 
20. Will my taking part in this study be kept confidential? 
All information that is collected about you during the course of the research will be 
kept strictly confidential. Any information about you that leaves the University 
building will be coded so that at no time will any of your personal details be 
revealed. The procedures for handling, processing, storage and destruction of any 
data collected during the study are compliant with the Data Protection Act 1998 and 
in line with the Southampton University policy. 
 
21. What will happen to the results of the research study? 
We hope the results are useful and we intend to publish them in a clinically relevant 
journal and to present them at scientific conferences. The results will also be utilised 
by the chief investigator for part completion of a PhD thesis to be submitted to the 
University of Southampton. You will not be identified in any reports or publications. 
 
 
22. Who is organizing and funding the research? 
The study is sponsored by the University of Southampton and is organised by 
investigators from the School of Health Professions and Rehabilitation Sciences, 
University of Southampton and the Rheumatology and Radiology departments at 
Southampton General Hospital (Southampton University Hospitals NHS Trust) . 
 
23. Who has reviewed the study? 
The study has been peer reviewed by the Research division of School of Health 
Professions and Rehabilitation Sciences, University of Southampton and the 
Southampton University Hospitals NHS Trust rheumatology research department. 
The School of Health Professions and Rehabilitation Sciences Undergraduate 
Research Committee have reviewed this study. 
 
If you agree to take part you will be given a copy of the information sheet and a 
signed consent form to keep. If you have read this information sheet and are happy 
to participate in the proposed study please sign the attached reply slip and return it 
in the stamped addressed envelope.  
 
 
Thank you for considering taking part and taking time to read this sheet. Appendix 18 
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Participant code___________________________________   Date    _____________________ 
  
Foot Structure Assessment  mark as appropriate
Joint Assessment    mark as appropriate
 LEFT  RIGHT 
Location of peak pressure 
(A,B,C,D,E,F) 
  
Value of peak pressure (KPa)    
Time of peak pressure     
Total footstep time    
Force time-integral    
Mean force    
 
Sensor size: …………… 
Outcome/ any actions   delete as appropriate
Researcher’s Signature:         Date 
Foot Pressure Assessment    mark as appropriate
 
 
 
 
Hallux Abducto Valgus    present  /  absent      present  /  absent 
5
th MPJ Exostosis      present  /  absent      present  /  absent 
Lesser Toe Deformity    present  /  absent      present  /  absent 
MPJ Subluxation      present  /  absent      present  /  absent 
Pes Cavus       present  /  absent      present  /  absent 
Pes Planus     present  /  absent      present  /  absent 
RIGHT LEFT 
 
R.O.M 
Ankle Joint        Full / Limited / Rigid        Full / Limited / Rigid   
Sub Talar Joint      Full / Limited / Rigid        Full / Limited / Rigid   
Mid Tarsal Joint      Full / Limited / Rigid        Full / Limited / Rigid   
1
st MPJ          Full / Limited / Rigid        Full / Limited / Rigid 
 
RIGHT LEFT 
Comments (inc tissue viability, skin and nail condition) 
Footwear   Patients  Own   Bespoke  Stock 
   Suitable  /  Not  Suitable 
 
Orthoses   Simple  Insole   Moulded  Device TCI   None 
 
Ulceration   present / absent / past history 
If present state site, duration, appearance 
 
Other comments: 
Ref for Biomech Assess.    Yes  /  No    Ref to Orthotist  Yes / No 
Ref to Consultant / GP     Y e s   /   N o  
Ref for Vascular / Neurological Assess.  Yes / No 
Podiatric Treatment        Regular Appointment /  SR / SOS / Annual Recall / No Appendix 19     Version 6 / 05.12.05                 
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Ultrasound report / data sheet RIGHT  FOOT               Wk No:…… 
 
Pt ID No:…………………………. …                   Date …………………………   
Please tick the appropriate boxes:- 
Synovitis presence  Erosion present  Anatomical 
location  Yes No  Yes    No 
MPJ 1    √   √ 
MPJ2   √   √ 
MPJ3   √   √ 
MPJ4   √   √ 
MPJ 5    √  √  
 
Bursitis  Please tick if 
present 
Bursitis presence 
Please mark on the diagram where the bursae are 
Sub met 1   
Inter met 1 / 2   
Sub met 2   
Inter met 2 / 3   
Sub met 3   
Inter met 3 / 4  √ 
Sub met 4   
                
 
Inter met 4 / 5   
Sub met 5   
Other (please specify) 
                        
Comments: 
 
 
 
  
 
 
 
 
 
 
 
 
 
Key: MPJ = metatarsophalangeal joint; sub met = plantar metatarsal area; inter met = intermetatarsal capita 
space, M1 = 1
st metatarsal head. 
 
Plantar View
Plantar aspect
Dorsal aspectAppendix 19     Version 6 / 05.12.05                 
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Ultrasound report / data sheet LEFT  FOOT              Wk No:…… 
 
Pt ID No:…………………………. …                   Date …………………………   
Please tick the appropriate boxes:- 
Synovitis presence  Erosion present  Anatomical 
location  Yes No  Yes    No 
MPJ 1         
MPJ2        
MPJ3        
MPJ4        
MPJ 5         
 
Bursitis  Please tick if 
present 
Bursitis presence 
Please mark on the diagram where the bursae are 
Sub met 1   
Inter met 1 / 2   
Sub met 2   
Inter met 2 / 3   
Sub met 3   
Inter met 3 / 4   
Sub met 4   
                
Inter met 4 / 5   
Sub met 5   
Other (please specify) 
                        
Comments: 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Key: MPJ = metatarsophalangeal joint; sub met = plantar metatarsal area; inter met = intermetatarsal capita 
space, M1 = 1
st metatarsal head. 
Plantar View
Plantar aspect
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